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SUMMARY 
 
The objective of this thesis was to develop new azobenzene-based photochromic ligands (PCLs) 
for a variety of transmembrane receptors and ion channels. The main targets being GABAA 
receptors (chapter 2), which are members of the pentameric ligand-gated ion channel family, 
and TRP channels (chapter 3), which are nonselective cation channels that are mainly 
permeable to calcium and sodium ions.  
γ-Aminobutyric acid type A (GABAA) receptors are part of the Cys-loop ligand-gated ion 
channel superfamily and are activated by γ-aminobutyric acid (GABA), the major inhibitory 
neurotransmitter in the mammalian brain. Activation of GABAA receptors by binding of GABA 
leads to opening of the chloride-selective pore, thus hyperpolarizing the postsynaptic neuron. 
Therefore, GABAA receptors are believed to play a major role in anesthesia, although the exact 
mechanism is not fully understood as of today. 
To further interrogate this role, the widely used anesthetics propofol[a] and etomidate[b] were 
converted into photochromic GABAA potentiators. An azobenzene derivative of propofol (AP2, 
Fig. S.1a) was found to be an effective light-dependent potentiator of GABA-induced currents 
in Xenopus oocytes (Fig. S.1c) and moreover acted as a light-dependent anesthetic in Xenopus 
laevis tadpoles. Illumination of tadpoles with propofol itself resulted in a small rightward shift 
in the propofol-dependent loss of righting reflex (LORR) dose-response curve (Fig. S.1d). 
Illumination of tadpoles with AP2, however, i.e. switching to cis-AP2, produced a considerably 
larger rightward shift, i.e. change in efficacy of AP2 (Fig. S.1e). The results of this project have 
been published in Angewandte Chemie International Edition (chapter 2.2).[c] 
In addition, the etomidate derivative AETD2 (Fig. S.1b) was found to act as a potent 
photochromic potentiator of GABAA receptors in Xenopus oocytes (see chapter 2.3). 
 
                                                
[a]  C. Vanlersberghe, F. Camu, Handb. Exp. Pharmacol. 2008, 182, 227–252. 
[b]  E. F. Godefroi, P. A. J. Janssen, C. A. M. Van der Eycken, A. H. M. T. Van Heertum, C. J. E. 
Niemegeers, J. Med. Chem. 1965, 56, 220–223. 
[c] M. Stein, S. J. Middendorp, V. Carta, E. Pejo, D. E. Raines, S. A. Forman, E. Sigel, D. Trauner, 
Angew. Chem. Int. Ed. 2012, 51, 10500–10504. 
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Figure	  S.1.	   a)	   Photoisomerization	   of	   AP2,	   a	   photochromic	   GABAA	   potentiator;	   b)	   molecular	  
structure	   of	  AETD2,	   another	   PCL	   for	  GABAARs;	   c)	   light-­‐dependent	   regulation	   of	  GABAA	   activity	   (single	  
black	  bar:	  application	  of	  1	  µM	  GABA;	  double	  black	  bar:	  co-­‐application	  of	  1	  µM	  GABA	  and	  1.5	  µM	  AP2);	  d)	  
and	  e)	  dose-­‐response	  curve	  of	  light-­‐dependent	  anesthesia	  in	  tadpoles.	  Light	  itself	  produces	  only	  a	  small	  
rightward	   shift	   in	   the	   d)	   propofol-­‐dependent	   loss	   of	   righting	   reflexes	   (LORR;	   circles:	   dark,	   stars:	  
λ	  =	  360−370	  nm)	  whereas	   e)	   light	   in	   the	   presence	   of	  AP2	   results	   in	   a	   large	   rightward	   shift	   (squares:	  
dark,	  crosses:	  λ	  =	  360–370	  nm).	  
 
Another PCL project studied transient receptor potential vanilloid channels 1 (TRPV1 channels) 
which are activated by several chemical and physical stimuli such as heat, voltage, low pH, 
phosphorylation and endogenous as well as exogenous ligands. Being expressed in different 
sorts of nociceptive neurons, its activation results in a sensation of burning and pain. Capsaicin, 
the main ingredient in hot chili peppers, is the most important agonist for TRPV1. Antagonists 
for this channel are of high interest in efforts to alleviate pain. As such, the TRPV1 antagonists 
capsazepine[d] and BCTC[e] were developed and have been widely used in pharmacological 
studies. Based on promising SAR studies for these molecules, photoswitchable azobenzene 
derivatives termed Azo-Capsazepines (ACs) and Azo-BCTC (ABCTC) were developed in 
order to control TRPV1 channel activation with light (Fig. S.2a). Upon voltage-activation of the 
channel, AC4 was found to function as a trans antagonist, i. e. blocking more current in the 
trans state than in the cis state (Fig. S.2b), whereas ABCTC acted as a cis antagonist (Fig. 
S.2c). With AC4, it was also possible to light-dependently counteract capsaicin (CAP)-induced 
                                                
[d] C. S. Walpole, S. Bevan, G. Bovermann, J. Boelsterli , R. Breckenridge, J. W. Davies, G. A. 
Hughes, I. James, L. Oberer, J. Med. Chem. 1994, 37, 1942–1954. 
[e] K. J. Valenzano, E. R. Grant, G. Wu, M. Hachicha, L. Schmid, L. Tafesse, Q. Sun, Y. 
Rotshteyn, J. Francis, J. Limberis, S. Malik, E. R. Whittemore, D. Hodges, J. Pharmacol. Exp. 
Ther. 2003, 306, 377–386. 
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XI 
activation of TRPV1 up to 82% (Fig. S.2d). The results of this project have been published in 
Angewandte Chemie International Edition (chapter 3.2).[f] 
In related work, based on the highly potent synthetic transient receptor potential melastatin 
channel 8 (TRPM8 channel) agonist icilin,[g] azobenzene derivatives termed Azo-Icilins were 
developed in order to control TRPM8 with light (Fig. S.2a; chapter 3.5). This channel is also 
referred to as the “cold receptor” or “menthol receptor”, since cold temperatures and menthol 
activate TRPM8 and result in the perception of coolness. 
 
 
Figure	  S.2.	   a)	  Molecular	  structures	  of	   the	  photochromic	  TRPV1	  antagonists	  AC4,	  ABCTC	  and	  the	  
photochromic	  TRPM8	  agonist	  AI1;	  b)	   light-­‐dependent	  control	  of	  voltage	  activated	  (at	  +200	  mV)	  TRPV1	  
currents	   upon	   application	   of	   100	  µM	  AC4	   (λ	  =	  360	  nm:	   cis-­‐AC4,	   λ	  =	  440	  nm:	   trans-­‐AC4)	   and	   c)	   10	  µM	  
ABCTC,	   respectively	   (λ	  =	  370	  nm:	   cis-­‐ABCTC,	   λ	  =	  470	  nm:	   trans-­‐ABCTC);	   d)	   light-­‐dependent	   control	   of	  
CAP-­‐induced	  activation	  of	  TRPV1	  with	  AC4	  (application	  of	  1	  µM	  AC4	  and	  100	  nM	  CAP,	  holding	  potential	  
−60	  mV).	  
 
Moreover, PCLs were developed for voltage-gated sodium channels (NaV channels, chapter 4), 
the metabotropic glutamate receptor 6 (mGluR6, chapter 5), voltage-gated potassium channels 
(KV channels, chapter 6) and nicotinic acetylcholine receptors (nAChRs, chapter 6). For a 
depiction of all PCLs see figure S.3. 
                                                
[f] M. Stein, A. Breit, T. Fehrentz, T. Gudermann, D. Trauner, Angew. Chem. Int. Ed. 2013, 52, 
9845−9848. 
[g]  E. T. Wei, D. A. Seid, J. Pharm. Pharmacol. 1983, 35, 110–112. 
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Figure	  S.3.	   PCLs	  developed	  for	  NaV	  channels,	  mGluR6,	  nAChRs	  and	  KV	  channels.	  
 
For NaV channels, PCL derivatives were made of the known sodium channel blocking drugs 
lacosamide[h] (ALCM), lamotrigine[i] (ALTG) and crobenetine[j] (ACRO) as well as of a highly 
potent NaV 1.7 inhibitor[k] (MS1). 
PCLs for mGluR6 comprise azobenzene derivatives of 1-benzyl-APDC (Azo-APDC), the only 
mGluR6-selective agonist known to date,[l] and the two phenylglycine derivatives 3C5HPG 
(Azo-3C5HPG) and DCPG (Azo-DCPG).[m] 
                                                
[h] C. Salome, E. Salome-Grosjean, J. P. Stables, H. Kohn, J. Med. Chem. 2010, 53, 3756–3771. 
[i] M. Leach, K. Franzmann, D. Riddall, L. Harbige (University of Greenwich), WO/2011/004195 
A2, 2011. 
[j] M. Grauert, W. D. Bechtel, T. Weiser, W. Stransky, H. Nar, A. J. Carter, J. Med. Chem. 2002, 
45, 3755–3764. 
[k] J. Liang, R. M. Brochu, C. J. Cohen, I. E. Dick, J. P. Felix, M. H. Fisher, M. L. Garcia, G. J. 
Kaczorowski, K. A. Lyons, P. T. Meinke, B. T. Priest, W. A. Schmalhofer, M. M. Smith, J. W. 
Tarpley, B. S. Williams, W. J. Martinc, W. H. Parsons, Bioorg. Med. Chem. Lett. 2005, 15, 
2943–2947. 
[l] W. Tückmantel, A. P. Kozikowski, S. Wang, S. Pshenichkin, J. T. Wroblewski, Bioorg. Med. 
Chem. Lett. 1997, 7, 601–606. 
[m] N. Sekiyama, Y. Hayashi, S. Nakanishi, D. E. Jane, H.-W. Tse, E. F. Birse, J. C. Watkins, Br. J. 
Pharmacol. 1996, 117, 1493–1503. 
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Azo-SEN12333 is a photochromic agonist for α7 nAChRs based on recent SAR studies.[n] For 
KV channels, a red-shifted and non-permanently charged version of QAQ[o] was developed 
(Red DAD) which has already shown very promising results in our efforts toward vision 
restoration (see 6.2). Finally, a new disulfide-containing class of PTLs for KV channels was 
developed based on MAQ[p] in order to hopefully overcome many of the disadvantages related 
to the use of reactive maleimides in biological systems (MS2 and MS3). 
                                                
[n] S. N. Haydar, C. Ghiron, L. Bettinetti, H. Bothmann, T. A. Comery, J. Dunlop, S. La Rosa, I. 
Micco, M. Pollastrini, J. Quinn, R. Roncarati, C. Scali, M. Valacchi, M. Varrone, R. Zanaletti, 
Bioorg. Med. Chem. 2009, 17, 5247–5258. 
[o] A. Mourot, T. Fehrentz, Y. Le Feuvre, C. M. Smith, C. Herold, D. Dalkara, F. Nagy, D. Trauner, 
R. H. Kramer, Nat. Meth. 2012, 9, 396–402. 
[p] M. R. Banghart, K. Borges, E. Y. Isacoff, D. Trauner, R. H. Kramer, Nat. Neurosci. 2004, 7, 
1381–1386. 
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1 
1 INTRODUCTION 
 
1.1 PHOTOSWITCHES – FROM NATURE TO APPLICATION  
 
Photoswitches are small molecules that can undergo photoinduced transformations between two 
(or more) isoforms. Their stable photostationary states generally have different physicochemical 
properties such as refractive index, dielectric constant, oxidation/reduction potential, absorption 
spectra and geometric structure. Therefore, they can be applied to various photonic devices such 
as erasable optical memory media and optical switch components.[1] Moreover, photoswitches 
also play an important role in biological systems, since fundamental biological processes of life 
such as photosynthesis,[2] the conversion of light energy into chemical energy (ATP production) 
and of course vision[3] are essentially controlled by photoinduction. Probably the most popular 
biological photoswitch is the bacteriorhodopsin system of halobacteria. Bacteriorhodopsin is a 
light-driven proton pump that is part of the photosynthetic system of halobacterium, converting 
light energy into ATP controlled by the specific isomerization of all-trans- to 13-cis-retinal. It 
possesses a catalytic cycle period of only 10 ms. Presently, bacteriorhodopsin is the best 
investigated membrane proteine.[4] Although its molecular assembly is rather simple, it has a 
high efficiency, is stable toward chemical and thermal degradation and therefore possibly useful 
for technical applications.  
Since light is unsurpassed in terms of spatial and temporal precision, the development of 
photoswitches for the control of a variety of systems with light has attracted much interest in the 
scientific community. 
Three (main) types of photoswitches exist, classified by their mechanism of function: a) 
molecules that dimerize upon photoexcitation, such as coumarins 1.1 and anthracenes 1.2, b) 
molecules that intramolecularly form bonds upon photoinduction (often cyclization), for 
example spiropyrans 1.3 or spirooxazines 1.4,[5] diarylethenes 1.5[6] or fulgides 1.6,[7] and c) 
molecules that exhibit photoisomerization across double bonds, such as stilbenes 1.7, 
azobenzenes 1.8, or indigo 1.9 and thioindigo derivatives 1.10 (Fig. 1.1).[8] 
1     Introduction 
 
 
 
2 
 
Figure	  1.1.	   Different	  types	  of	  photoswitches,	  classified	  by	  their	  mechanism	  upon	  photoinduction.	  
a)	  Dimerization;	  b)	  intramolecular	  bond	  formation;	  c)	  isomerization	  across	  double	  bonds.	  
 
Within these three types, two subclasses exist: (i) single-cycle photoswitches[9] are used to 
deactivate biomaterial by the attachement of a photosensitive chemical protecting group. Light-
controlled removal of the protecting group reactivates the biomaterial again. By contrast, (ii) 
multi-cycle photoswitches are able to switch reversibly between two different states and 
therefore are considered superior to single-cycle photoswitches in a variety of applications.[8]  
The work of this thesis will focus on azobenzene photoswitches exclusively. Therefore, a brief 
introduction to azobenzenes, a member of the class of multi-cycle photoswitches, is given in the 
following chapter. 
 
 
1.2 PROPERTIES OF AZOBENZENES AND THEIR USE AS PHOTOSWITCHES 
 
Azobenzene (diphenyldiazene) is an aromatic molecule in which a diazo moiety (–N=N–) joins 
two phenyl rings. Owing to their elongated π-conjugated system, azobenzenes show strong 
absorption bands in the UV and/or visible portions of the spectrum. Depending on its 
substituents, azobenzene derivatives can be taylored to absorb at desired wavelengths. Rau 
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therefore classified three types of azobenzenes:[10] a) azobenzene-type molecules, which are 
similar to the unsubstituted azobenzene, b) aminoazobenzene-type molecules, which are ortho- 
or para-substituted with an electron-donating group, and c) pseudo-stilbenes, which are 
substituted at the 4- and 4’-positions with an electron-donating and electron-withdrawing group, 
respectively (Fig. 1.2). 
 
Figure	  1.2.	   Three	   types	   of	   azobenzenes	   according	   to	   Rau.	   a)	   Azobenzene-­‐type	   molecules;	   b)	  
aminoazobenzene-­‐type	  molecules;	   c)	   pseudo-­‐stilbenes.	   For	   each	   of	   the	   three	   types,	   a	   representative	  
example	  is	  shown.	  
 
There are several methods to synthesize azobenzenes of which the most common are shown in 
Scheme 1.1.[11] a) The classic azo coupling is an electrophilic aromatic substitution reaction of 
aryl diazonium salts (typically generated from the corresponding aniline derivatives with 
NaNO2 and HCl) with preferentially electron-rich benzene derivatives.[12] b) Reaction of 
aromatic nitroso compounds and anilines in glacial acetic acid (Mills reaction).[13] The nitroso 
derivatives are often formed from the corresponding anilines with various oxidants. c) 
Reductive coupling of aromatic nitro derivatives and d) oxidative coupling of anilines.[14] 
However, both methods c) and d) only give access to symmetrical azobenzenes in good yields. 
e) More recently, one-pot Buchwald-type coupling reactions of Boc-protected aryl hydrazines 
with aryl iodides and subsequent oxidation was developed as an elegant alternative to obtain 
azobenzenes.[15]  
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Scheme	  1.1.	   Methods	   for	   the	   synthesis	   of	   azobenzenes:	   a)	   Azo	   coupling;	   b)	   Mills	   reaction;	   c)	  
reductive	  coupling	  of	  nitro	  arenes;	  d)	  oxidative	  coupling	  of	  anilines;	  e)	  Buchwald-­‐type	  cross-­‐coupling.	  
 
Since the first observation of the photochemical trans ! cis isomerization of azobenzene 
(Scheme 1.2) by Hartley in 1937,[16] a huge interest has emerged regarding possible applications 
of azobenzenes as bistable photoswitches (see below). 
 
 
Scheme	  1.2.	   Isomerization	  of	  azobenzene	  between	  its	  trans	  and	  cis	  isomers.	  
	  
The thermodynamically more stable trans-azobenzene (by approximately 50 kJ mol-1 [17]) 
isomerizes upon irradiation at λ = 320–350 nm to the metastable cis-azobenzene. The energy 
barrier to the photoexcited state is in the order of 200 kJ mol-1.[18] Although both isomers absorb 
in this wavelength range (symmetry allowed π → π*), the trans isomer has a much higher 
extinction coefficent than the cis isomer.[19] Either irradiation at λ = 400–450 nm (symmetry 
forbidden n → π*; higher absorption of the cis than of the trans isomer) or thermal relaxation 
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leads back to the trans isomer,[20] whereas in the latter case an activation energy of 90 kJ mol-1 
is required for this first-order process.[21] Lifetimes of cis isomers, ranging from less than a 
second up to several years, strongly depend on the following factors: substituents attached to the 
azobenzene scaffold, conformational effects in macrocyclic or ring-like compounds, intra- as 
well as intermolecular interactions, e.g. hydrogen bonds, or even attachement to a surface.[22]   
By fusing the azo moiety into a multiheterocyclic system (˝bridged˝ or ˝cyclic˝ azobenzenes), 
the cis isomers become thermodynamically more stable than the trans isomers. Although 
initially prepared in 1910,[23] 5,6-dihydrodibenzo[c,g][1,2]diazocine (1.11) has just recently 
gained increasing interest when Siewertsen et al.[24] discovered its interesting 
photoisomerization properties in 2009. cis-1.11 can be switched to trans-1.11 with 
λ = 370−400 nm and reverts back to its cis form by λ = 480–550 nm. The cis isomer appears as 
cis-boat conformation, whereas the trans isomer can exist as trans-chair and trans-twist, the 
latter being the more stable conformation (10.27 kcal mol-1 vs. 7.60 kcal mol-1, referred to the 
cis isomer;[25] Scheme 1.3). 
This cis-stability makes diazocines an interesting class of photoswitches for biological 
applications since often the trans isomers are the (more) active ligands. By creating cis-stable 
photoswitches, the desired effect could be triggered by illuminating with light of the respective 
wavelength (“on switch”). After applying the compound in the dark, the molecule would be in 
its inactive (less active) form, avoiding constitutively active ligands. 
 
 
Scheme	  1.3.	   Isomerization	   of	   the	   cis-­‐stable	   bridged	   azobenzene	  1.11.	  Only	   the	  more	   stable	   twist	  
conformation	  is	  shown	  for	  trans-­‐1.11.	  
 
The extremely efficient photoisomerization of azobenzene is one of the cleanest known,[q] 
proceeds very fast (within 1 ps[26]) and is fully reversible. It is therefore considered to be the 
most promising artificial mimic of the retinal-rhodopsin photoswitch involved in the process of 
human vision.[27] 
                                                
[q] Among the few side reactions known, photocyclization to the corresponding benzo[c]cinnolines 
upon irradiation and protonation (e.g. 98% sulphuric acid), complexation (e.g. ferric chloride) or 
photoreduction upon irradiation in protic solvents, such as alcohols, have been observed.[19] 
N N
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N
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Two main mechanisms have been proposed for the isomerization process: by inversion and 
rotation (Scheme 1.4). The inversion pathway occurs after n → π* photoexcitation  (S0 → S1) 
through all-in-plane inversion at one of the two nitrogen atoms (˝lateral shift˝). One N=N–C 
angle increases to ∼180° keeping the C–N=N–C dihedral angle fixed at 0°. This leads to a 
transition state with a sp hybridized nitrogen atom.[28] The rotation pathway involves rupture of 
the N=N double bond to allow free rotation about the N–N single bond. After π → π* 
photoexcitation (S0 → S2), the C−N−N−C dihedral angle changes, keeping the N–N–C angle 
fixed at ∼120°.[29] Due to sterical interactions during the rotation, hindered or constrained 
molecules strongly prefer isomerization by inversion.[30] In addition to these two mechanisms, a 
concerted inversion and an inversion-assisted rotation have also been proposed.[31] 
 
 
Scheme	  1.4.	   Isomerization	  of	  azobenzenes:	  Inversion	  and	  rotation	  mechanisms.	  
 
Trans-azobenzene adopts a planar structure (C2h symmetry), whereas the two phenyl rings of 
the cis isomer are oriented in an out-of-plane fashion with C2 symmetry (as correctly drawn in 
scheme 1.4).[31] However, for the sake of simplicity, cis isomers of azobenzene derivatives are 
drawn in-plane throughout this thesis. 
The trans ! cis isomerization is accompanied by relatively large changes in molecular 
properties such as the length of the molecule (distance between the ends of the molecule 
decreases from 0.99 nm in the trans state to 0.55 nm in the cis state[32]) and molecular volume. 
Depending on the isomerization mechanism (see above), the volume required for isomerization 
from the trans to the cis state rises by 0.12 nm3 in case of an inversion mechanism[33] and even 
by 0.28 nm3 for isomerization by rotation, respectively.[34] In addition, the dipole moment 
increases from essentially 0 in the trans state to 3.1 D in the cis state.[16] 
Because of these remarkable changes of molecular properties, relatively facile syntheses and the 
many advantages of light-induced reactions, azobenzene derivatives have been and are being 
used in a great and growing number of applications. Following the observation by Merian in 
1966[35] that a nylon filament fabric dyed with an azobenzene derivative shrank upon irradiation, 
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the use of azobenzene photoswitches for creating large scale modulations in material properties 
by essentially amplifying the molecular trans ! cis isomerization was proposed and further 
investigated. 
Consequently, azobenzenes have been widely used not only as dyes and pigments, food 
additives and radical inhibitors, but also as therapeutic agents, electronics and for drug delivery 
shuttles.[11] Some examples comprise the application of azobenzene derivatives in liquid crystal 
(LC) systems, initiating a reversible, isothermal phase transition from an ordered LC state to an 
isotropic phase by switching from the trans to the corresponding cis isomers[27] and thus 
providing promising features for potential use in display devices, optical memories[36] and 
electro-optics.[37] In order to obtain suitable optical data storage materials, a stable two-state-
system is required. Hence, efforts are made to stabilize and thus increase the lifetime of the cis 
isomers. In general, it is found that azobenzene derivatives which are covalently bound to the 
surface work better than doped ones because this prevents the molecules from aggregating 
which leads to undesired heterogenous layers and changes in the optical behavior.[15] Another 
possible application of azobenzene photoswitches is their use as filters for gases. For example, 
incorporation of azobenzene derivatives in zeolites can provide light-controlled selective 
membranes for the permeation of certain gas molecules.[38] Interestingly, azobenzene-containing 
liquid-crystalline elastomers (LCE) have been used in efforts to build artificial muscles, since 
the isomerization process of azobenzenes involves motion and thus the generation of a force.[r,22] 
The many advantages of azobenzene photoswitches, including their efficient long-term usage, 
their high spatial and temporal precision as well as their noninvasive regulation, have made 
them also very attractive for biological applications.  
Following the pioneering work of Erlanger who first introduced the use of azobenzenes as 
photochromic ligands in biology in the late 1960s (photoregulation of chymotrypsin,[39] 
acetylcholine receptors[40] and acetylcholinesterase[41]), a vastly increasing number of 
applications in biological contexts has been developed during the last couple of years, among 
which only a brief selection is mentioned here. A good compilation of azobenzene 
photoswitches used for the light-dependent control of biological systems is presented in a recent 
review article by Beharry and Woolley.[42]  
                                                
[r] AFM measurements estimated the mechanical work by trans ! cis isomerization of one 
molecule of azobenzene to 4.5 i 10-20 J: a) T. Hugel, N. B. Holland, A. Cattani, L. Moroder, M. Seitz, H. 
E. Gaub, Science 2002, 296, 1103–1106; b) N. B. Holland, T. Hugel, G. Neuert, A. Cattani-Scholz, C. 
Renner, D. Oesterhelt, L. Moroder, M. Seitz, H. E. Gaub, Macromolecules 2003, 36, 2015–2023.  
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By attaching azobenzene photoswitches to oligopeptides and proteins (either covalently[43] in 
the backbone or as side chains, or by affinity[39,44]), conformational changes can be induced 
upon irradiation. Moreover, DNA conformations can be altered by using azobenzene 
derivatives. Whereas the trans isomer intercalates in and stabilizes the DNA duplex, the cis 
isomer disrupts the duplex.[45] Depending on different interactions with polymerases in the trans 
or cis state, gene expression can be photoinduced by introducing azobenzenes in the promotor 
region of genes.[46] As already mentioned above, azobenzene containing vesicles or micelles are 
also interesting approaches to a light-controlled release of drugs at desired spots in the 
increasingly important field of drug delivery.[47] 
 
 
1.3 OPTOCHEMICAL GENETICS 
 
In 2004, Banghart et al.[48] picked up Erlangers pioneering efforts and applied the concept of 
photochromic ligands to the field of neuroscience by applying azobenzene photoswitches to 
control voltage-dependent potassium channels, thus ultimately regulating neuronal generation 
and transduction of action potentials (“Light-Activated Ion Channels for Remote Control of 
Neuronal Firing”). Focussing on the synthesis and application of biologically and 
photochemically active small molecules rather than genetic engineering, this concept has later 
been established as “optochemical genetics”,[49] evolving from the rapidly increasing field of 
optogenetics.[50]  
Optogenetical approaches aim for regulation of biological systems down to cellular levels with 
light by genetic encoding of (artificial) photoreceptors. The first optogenetic construct was 
“ChARGe”, consisting of rhodopsin, the associated heterotrimeric G protein and arrestin, and 
was based on the vision cascade of Drosophila.[51] With the discovery of channelrhodopsin-2 
(ChR2),[52] which is a natural photoreceptor isolated from the algae Chlamydomonas 
reinhardtii, a powerful new tool for the optical control of neuronal circuits has been 
established.[53] The excitatory, nonspecific cation channel of ChR2 can be controlled with blue 
light (absorption maximum at λ = 480 nm) and is based on the naturally occuring photoswitch 
retinal which is not excised after isomerization (as it is in the mammalian vision cascade). 
Therefore, ChR2 can be used in multiple cycles to optically induce excitation. Since ChR2, 
many other mutants and chimeras have been developed. More recently, red-shifted 
channelrhodopsins have been discovered from the algae Volvox carteri, termed VChRs. VChR1 
has a peak absoption of λ = 589 nm and can be used orthogonally to other ChRs.[54] Beside 
ChRs, other optogenetic tools have been developed such as Natromonas pharaonis 
halorhodopsin (NpHR) which is an inhibitory chloride pump that reacts to yellow light 
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(absorption maximum at λ = 570 nm).[55] More recently, light-driven proton pumps have also 
been discovered that are capable of silencing specific genetically targeted neurons with light to 
investigate their role in neuronal circuits.[56]  
Since the elucidation of the X-ray structure of KcsA, a potassium channel from Streptomycis 
lividans that reacts to changes in pH by MacKinnon in 2002,[57] many more ion channels and 
receptors have been crystallized, revealing new insights into structure, selectivity, gating 
mechanisms and ligand binding at atomic levels. This opens up new possibilities for the rational 
design of small (photoreactive) molecules that selectively target specific receptors (see PCL 
concept). Moreover, specific amino acids can be genetically introduced that are in close 
proximity to the pore region of ion channels or ligand binding sites of receptors in order to 
anchor (photoreactive) molecules that physically block the channel or position a ligand in close 
proximity to the binding site, respectively (PTL concept).  
Optochemical genetics offers three different strategies to control ion channels and receptors in a 
light-dependent fashion with photoreactive small molecules: (photochemically) Caged Ligands 
(CLs), PhotoChromic Ligands (PCLs) and Photoswitchable Tethered Ligands (PTLs). These 
stratgies are depicted in Fig. 1.3 and will be briefly introduced in the next section. 
 
1     Introduction 
 
 
 
10 
 
Figure	  1.3.	   a)	   Schematic	   illustration	  of	   receptor-­‐mediated	  signaling.	  A	   ligand	   (orange)	  binds	   to	  a	  
receptor	  (grey)	  and	  induces	  an	  effect;	  b)	  Caged	  Ligand	  (CL)	  strategy:	  a	  caged	  ligand	  has	  no	  effect	  on	  the	  
receptor,	  whereas	  the	  uncaged	  ligand	  does.	  The	  uncaging	  event	  is	  induced	  by	  light;	  c)	  Example	  for	  the	  
CL	   approach:	   a	   caged	   version	   of	   capsaicin	   (CAP),	   a	   TRPV1	   agonist;	   d)	   PhotoChromic	   Ligand	   (PCL)	  
approach:	  a	  photoswitchable	  ligand	  does	  not	  exhibit	  an	  effect	  on	  the	  receptor	  in	  one	  conformation,	  but	  
does	   affect	   it	   in	   another.	   Both	   conformations	   can	   be	   interconverted	   into	   each	   other	   with	   light	   of	  
different	  wavelengths;	  e)	   4-­‐GluAzo,	   a	   PCL	   version	  of	   glutamate	   for	   ionotropic	   glutamate	   receptors;	   f)	  
Photoswitchable	  Tethered	  Ligand	  (PTL)	  approach:	  a	  photoswitchable	   ligand	  that	   is	  covalently	  attached	  
to	  the	  receptor.	  Only	  one	  conformation	  is	  in	  the	  right	  proximity	  to	  the	  binding	  site	  to	  induce	  an	  effect;	  g)	  
MAG-­‐1,	  an	  unconjugated	  PTL	  for	  ionotropic	  glutamate	  receptors.	  A	  cysteine	  residue	  can	  react	  with	  the	  
maleimide	  moiety	  of	  the	  PTL.	  Illustration	  adapted	  from	  Trauner	  et	  al.,[49]	  reprinted	  with	  permission	  from	  
John	  Wiley	  and	  Sons.	  Copyright	  2011.	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1.3.1 THE CAGED LIGAND (CL) APPROACH 
 
Caged ligands have been used on various receptor types for many years. By attaching a 
photocleavable protecting group to a ligand that renders it inactive, a desired receptor can be 
activated with high spatial and temporal precision through irradiation with light (Fig. 1.3b). This 
concept has been used for example for glutamate receptors,[58] GABA receptors[59] and TRPV1 
channels (caged capsaicin, see Fig. 1.3c).[60] However, certain disadvantages are associated with 
this approach. Most importantly, the uncaging process is an irreversible reaction. Once the 
protecting group is cleaved, the active ligand is released and cannot be “re-caged”, resulting in 
sustained receptor action until the ligand diffuses away. Moreover, toxic side products can be 
released, for example from the remnants of the cleaved protecting group.  
To overcome the above mentioned disadvantages, a reversible “caging” process would be 
desirable which could be achieved by introducing a photoswitchable component onto ligands in 
order to render them light-sensitive and thus create two isoforms of the ligands with differing 
efficacies at the receptor. By attaching azobenzene moieties to ligands, two reversible 
approaches to receptor activation have been created, the PCL and the PTL approach, 
respectively. 
 
1.3.2 THE PHOTOCHROMIC LIGAND (PCL) APPROACH 
 
PCLs combine a biologically active small molecule (agonist, antagonist, allosteric modulator, 
etc.) with a photoswitchable side chain (in this thesis azobenzenes). By switching between the 
two isoforms of the molecule via irradiation with different wavelengths, the efficacy of the 
ligand is modulated. Unlike the uncaging event, this approach is fully reversible (Fig. 1.3d). 
Remarkably, these sometimes rather small changes between the two isoforms have been shown 
to produce relatively large differences in the action of the ligand on the receptor in complex 
cellular and neuronal networks. This finding is underpinned by the “all or nothing” concept of 
action potential (AP) triggering which describes the necessity of reaching a certain threshold for 
an AP to be triggered. Once this threshold is reached, however, the AP is generated in the same 
amplitude, irrelevant of the current that has triggered it.  
Using the PCL approach, various ligand-gated receptors and ion channels have been 
successfully rendered light-responsive, thus turning them into artificial light receptors. For 
voltage-gated potassium channels, photochromic ion channel blockers have been developed by 
attaching a quaternary ammonium ion to an azobenzene moiety. The cationic ammonium ion 
blocks the pore of the channel from the cytosolic side in the trans state of the molecule, but not 
in the cis state.[61] Moreover, photochromic blockers of K+, Na+ and Ca2+ channels have been 
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described to control pain sensation.[62] 4-GluAzo, a PCL version of glutamate, was used to 
optically control ionotropic glutamate receptors (iGluRs; Fig. 1.3e)[63] and ATA-3, a PCL 
version of AMPA, functions as photochromic agonist for AMPA receptors.[64] 
 
1.3.3 THE PHOTOSWITCHABLE TETHERED LIGAND (PTL) APPROACH 
 
In contrast to PCLs, PTLs are covalently attached via a tether to the receptor by introducing a 
reactive electrophilic site to the photoswitch, such as acrylate or maleimide, which can react 
with free cysteine residues on the receptor. Once bound to the receptor, switching between the 
two isoforms of the molecule leads to a change of the local concentration and/or its efficacy on 
the receptor (Fig. 1.3f). PTLs can thus overcome the low affinity of a ligand with its high local 
concentration at the ligand binding site. In principle, they allow for a higher (subtype) 
selectivity for certain receptors since their point of attachment (a reactive cysteine) can be 
genetically introduced. Therefore, the PTL concept preferentially is used as a pharmacological 
tool for the investigation of neuronal circuitries, resembling the original concept of 
optogenetics. 
PTL blockers of K+, Na+ and Ca2+ channels have been used to control heart beat[65] and visual 
responses[66] in a variety of animals with light. PTL versions of glutamate (e.g. MAG-1, Fig. 
1.3g) have also been used to convert ionotropic glutamate receptors (iGluRs) into light-
responsive iGluRs. These so-called LiGluRs have been succesfully applied in vitro and in 
vivo.[67] More recently, this concept has also been applied to metabotropic glutamate receptors 
(LimGluRs[68]) and neuronal nicotinic acetylcholine receptors (nAChR). nAChRs have been 
rendered light-sensitive with a PTL version of acetylcholine, aiming for new methods to study 
the physiological and pathological roles of these receptors in the brain and periphery.[69] 
 
This thesis will focus on new PCL strategies for the optochemical control of ligand-gated 
receptors and ion channels. A great advantage of PCLs over PTLs is their possible application 
on wild-type receptors which opens up the opportunity for their use in clinical treatment. 
More specifically, new PCLs have been designed, synthesized and succesfully applied to the 
light-dependent regulation of γ-aminobutyric acid type A (GABAA) receptors (see chapter 2) 
and transient receptor potential (TRP) channels (chapter 3). Moreover, various PCLs have been 
synthesized for the optical control of voltage-gated sodium channels (NaV channels, chapter 4) 
and the metabotropic glutamate receptor 6 (mGluR6; chapter 5). In addition, PCLs for nAChRs 
and voltage-dependent potassium channels (KV channels), as well as the synthesis of a 
photocleavable protecting group are outlined in chapter 6. 
 
1     Introduction 
 
 
 
13 
1.4 LITERATURE
 
[1]  M. Irie, Chem. Rev. 2000, 100, 1683–1684. 
[2]  G. Feher. J. P. Allen, M. Okamura, D. C. Rees, Nature 1989, 339, 111–116. 
[3] L. Stryer, Ann. Rev. Neurosci. 1986, 9, 87–119.  
[4] a) N. Hampp, Chem. Rev. 2000, 100, 1755–1776; b) N. Vsevolodov, in Biomolecular 
Electronics: An Introduction via photosensitive proteins, Birkhäuser, Boston, 1998. 
[5] G. Berkovic, V. Krongauz, V. Weiss, Chem. Rev. 2000, 100, 1741–1754. 
[6] M. Irie, Chem. Rev. 2000, 100, 1685–1716. 
[7] Y. Yokoyama, Chem. Rev. 2000, 100, 1717–1740. 
[8]  I. Willner, S. Rubin, Angew. Chem. Int. Ed. Engl. 1996, 35, 367–385. 
[9]  a) A. M. Gurney, H. A. Lester. Physiol. Rev. 1987, 67, 583–617; b) I. Willner, B. 
Willner, in Bioorganic Photochemistry, Vol. 2 (Ed.: H. Morrison), Wiley, Weinheim, 
New York, 1993, p. 1. 
[10]  H. Rau, in Photoisomerization of Azobenzenes, (Ed.: J. Rebek), CRC Press, Boca Raton 
FL, 1990. 
[11]  E. Merino, Chem. Soc. Rev. 2011, 40, 3835–3853. 
[12]  K. Haghbeen, W. Tan, J. Org. Chem. 1998, 63, 4503–4505. 
[13]  H. H. Davey, R. D. Lee, T. J. Marks, J. Org. Chem. 1999, 64, 4976–4979. 
[14] S. Wawzoned, T. W. McIntyre, J. Electrochem. Soc. 1972, 119, 1350–1357. 
[15]  K.-Y. Kim, J.-T. Shin, K.-S. Lee, C.-G. Cho, Tetrahedron Lett. 2004, 45, 117–120. 
[16] G. S. Hartley, Nature 1937, 140, 281. 
[17]  F. W. Schulze, H. J. Petrick, H. K. Cammenga, H. Klinge, Z. Phys. Chem. 1977, 107, 
1–19. 
[18]  S. Monti, G. Orlandi, P. Palmieri, Chem. Phys. 1982, 71, 87–99. 
[19]  J. Griffiths, Chem. Soc. Rev. 1972, 1, 481–493. 
[20]  R. Pfister, J. Ihalainen, P. Hamm, C. Kolano, Org. Biomol. Chem. 2008, 6, 3508–3517. 
[21]  P. Haberfield, P. M. Block, M. S. Lux, J. Am. Chem. Soc. 1975, 97, 5804–5806. 
[22]  K. G. Yager, C. J. Barrett, J. Photochem. Photobiol. A 2006, 182, 250–261. 
[23]  H. Duval, Bull. Soc. Chim. Fr. 1910, 7, 727–732. 
[24]  R. Siewertsen, H. Neumann, B. Buchheim-Stehn, R. Herges, C. Näther, F. Renth, F. 
Temps, J. Am. Chem. Soc. 2009, 131, 15594–15595. 
[25] H. Sell, C. Näther, R. Herges, Beilstein J. Org. Chem. 2013, 9, 1–7.  
[26] J. Wachtveitl, T. Nägele, B. Puell, W. Zinth, M. Krüger, S. Rudolph-Böhner, D.  
Oesterhelt, L. Moroder, J. Photochem. Photobiol., A 1997, 105, 283–288.  
[27]  C. J. Barrett, J.-I. Mamiya, K. G. Yager, T. Ikeda, Soft Matter 2007, 3, 1249–1261. 
 
1     Introduction 
 
 
 
14 
 
[28]  D. Y. Curtin, E. J. Grubbs, C. G. McCarty, J. Am. Chem. Soc. 1966, 88, 2775–2786. 
[29]  J. L. Magee, W. Shand Jr., H. Eyring, J. Am. Chem. Soc. 1941, 63, 677–688. 
[30] F. Barigelletti, M. Ghedini, D. Pucci, M. La Deda, Chem. Lett. 1999, 297–298. 
[31] H. M. D. Bandara, S. C. Burdette, Chem. Soc. Rev. 2012, 41, 1809–1825. 
[32]  a) J. J. de Lange, J. M. Robertson, I. Woodward, Proc. Roy. Soc. 1939, A171, 398–410; 
b) C. J. Brown, Acta Crystallogr. 1966, 21, 146–152. 
[33]  T. Naito, K. Horie, I. Mita, Macromolecules 1991, 24, 2907–2911. 
[34]   L. Lamarre, C. S. P. Sung, Macromolecules 1983, 16, 1729–1736. 
[35]  E. Merian, Textile Res. J. 1966, 36, 612–618. 
[36]  a) W. M. Gibbons, P. J. Shannon, S.-T. Sun, B. J. Swetlin, Nature 1991, 351, 49–50; b) 
T. Ikeda, O. Tsutsumi, Science 1995, 268, 1873–1875; c) azobenzene functionalized 
oligopeptides as optical storage: R. H. Berg, S. Hvilsted, P. S. Ramanujam, Nature 
1996, 383, 505–508. 
[37]  Y.-Y. Luk, N. L. Abbott, Science 2003, 301, 623–626. 
[38]  K. Weh, M. Noack, K. Hoffmann, K.-P. Schröder, J. Caro, Microporous Mesoporous 
Mater. 2002, 54, 15–26. 
[39]  H. Kaufmann, S. M. Vratsanos, B. F. Erlanger, Science 1968, 162, 1487–1489. 
[40]  E. Bartels, N. H. Wassermann, B. F. Erlanger, Proc. Natl. Acad. Sci. USA 1971, 68, 
1820−1823. 
[41]  J. Bieth, S. M. Vratsanos, N. Wassermann, B. F. Erlanger, Proc. Natl. Acad. Sci. USA 
1969, 64, 1103–1106. 
[42]  A. A. Beharry, G. A. Woolley, Chem. Soc. Rev. 2011, 40, 4422–4437. 
[43]  T. Inada, T. Terabayashi, Y. Yamaguchi, K. Kato, K.Kikuchi, J. Photochem. Photobiol. 
2005, 175, 100–107. 
[44]  a) D. Fujita, M. Murai, T. Nishioka, H. Miyoshi, Biochemistry 2006, 45, 6581–6586; b) 
J. H. Harvey, D. Trauner, ChemBioChem 2008, 9, 191–193. 
[45]  X. Liang, H. Asanuma, H. Kashida, A. Takasu, T. Sakamoto, G. Kawai, M. Komiyama, 
J. Am. Chem. Soc. 2003, 125, 16408–16415.  
[46]  M. Liu, H. Asanuma, M. Komiyama, J. Am. Chem. Soc. 2006, 128, 1009–1015. 
[47]  a) E. Yoshida, M. Ohta, Colloid Polym. Sci. 2005, 283, 521–531; b) H. Sakai, A. 
Matsumura, T. Saji, M. Abe, Stud. Surf. Sci. Catal. 2001, 132, 505–508; c) X.-M. Liu, 
B. Yang, Y.-L. Wang, J.-Y. Wang, Chem. Mater. 2005, 17, 2792–2795; d) X. Tong, G. 
Wang, A. Soldera, Y. Zhao, J. Phys. Chem. B 2005, 109, 20281–20287. 
[48]  M. R. Banghart, K. Borges, E. Y. Isacoff, D. Trauner, R. H. Kramer, Nat. Neurosci. 
2004, 7, 1381–1386. 
 
1     Introduction 
 
 
 
15 
 
[49]  T. Fehrentz, M. Schönberger, D. Trauner, Angew. Chem. Int. Ed. 2011, 50, 
12156−12182. 
[50]  a) G. Miesenböck, Science 2009, 326, 395–399; b) G. Miesenböck, Annu. Rev. Cell 
Dev. Biol. 2011, 27, 731–758; c) L. Fenno, O. Yizhar, K. Deisseroth, Annu. Rev. Cell 
Dev. Biol. 2011, 34, 389–412.  
[51]  B. V. Zemelmann, G. A. Lee, M. Ng, G. Miesenböck, Neuron 2002, 33, 15–22. 
[52]  G. Nagel, T. Szellas, W. Huhn, S. Kateriya, N. Adeishvili, P. Berthold, D. Ollig, P. 
Hegemann, E. Bamberg, Proc. Natl. Acad. Sci. USA 2003, 100, 13940–13945. 
[53]  E. S. Boyden, F. Zhang, E. Bamberg, G. Nagel, K. Deisseroth, Nat. Neurosci. 2005, 8, 
1263–1268. 
[54] F. Zhang, M. Prigge, F. Beyrière, S. P. Tsunoda, J. Mattis, O. Yizhar, P. Hegemann, K. 
Deisseroth, Nat. Neurosci. 2008, 11, 631–633. 
[55]  F. Zhang, L. P. Wang, M. Brauner, J. F. Liewald, K. Kay, N. Watzke, P. G. Wood, E. 
Bamberg, G. Nagel, A. Gottschalk, K. Deisseroth, Nature 2007, 446, 633–639. 
[56]  B. Y. Chow, X. Han, A. S. Dobry, X. Qian, A. S. Chuong, M. Li, M. A. Henninger, G. 
M. Belfort, Y. Lin, P. E. Monahan, E. S. Boyden, Nature 2010, 463, 98–102. 
[57]  D. A. Doyle, J. Morais Cabral, R. A. Pfützner, A. Kuo, J. M. Gulbis, S. L. Cohen, B. T. 
Chait, R. MacKinnon, Science 1998, 280, 69–77. 
[58]  J. Noguchi, A. Nagaoka, S. Watanabe, G. C. Ellis-Davies, K. Kitamura, M. Kano, M. 
Matsuzaki, H. Kasai, J. Physiol. 2011, 589, 2447–2457.  
[59]  R. Wieboldt, D. Ramesh, B. K. Carpenter, G. P. Hess, Biochemistry 1994, 33, 
1526−1533. 
[60]  B. V. Zemelman, N. Nesnas, G. A. Lee, G. Miesenböck, Proc. Natl. Acad. Sci. USA 
2003, 100, 1352–1357. 
[61]  a) M. R. Banghart, A. Mourot, D. L. Fortin, J. Z. Yao, R. H. Kramer, D. Trauner, 
Angew. Chem. Int. Ed. 2009, 48, 9097–9101; b) A. Mourot, M. A. Kienzler, M. R. 
Banghart, T. Fehrentz, F. M. E. Huber, M. Stein, R. H. Kramer, D. Trauner, ACS Chem. 
Neurosci. 2011, 2, 536–543. 
[62]  A. Mourot, T. Fehrentz, D. Bautista, D. Trauner, R. H. Kramer, Nat. Meth. 2012, 9, 
396−402. 
[63]  M. Volgraf, P. Gorostiza, S. Szobota, M. R. Helix, E. Y. Isacoff, D. Trauner, J. Am. 
Chem. Soc. 2007, 129, 260–261. 
[64]  P. Stawski, M. Sumser, D. Trauner, Angew. Chem. Int. Ed. 2012, 51, 5748–5751. 
 
1     Introduction 
 
 
 
16 
 
[65]  D. L. Fortin, M. R. Banghart, T. D. Dunn, K. Borges, D. A. Wagnaar, Q. Gaudry, M. 
Karakossian, T. W. Otis, W. B. Kristan, D. Trauner, R. H. Kramer, Nat. Meth. 2008, 5, 
331–338. 
[66]  A. Polosukhina, J. Litt, I. Tochitsky, J. Nemargut, Y. Sychey, I. De Kouchkovsky, T. 
Huang, K. Borges, D. Trauner, R. N. Van Gelder, R. H. Kramer, Neuron 2012, 75, 
271−282. 
[67]  a) M. Volgraf, P. Gorostiza, R. Numano, R. H. Kramer, E. Y. Isacoff, D. Trauner, Nat. 
Chem. Bio. 2006, 1, 47–52; b) S. Szobota, P. Gorostiza, F. Del Bene, C. Wyart, D. L. 
Fortin, K. D. Kolstad, O. Tulyathan, M. Volgraf, R. Numano, H. L. Aaron, E. K. Scott, 
R. H. Kramer, J. Flannery, H. Baier, D. Trauner, E. Y. Isacoff, Neuron 2007, 54, 
535−545; c) P. Gorostiza, M. Volgraf, R. Numano, S. Szobota, D. Trauner, E. Y. 
Isacoff, Proc. Natl. Acad. Sci. USA 2007, 104, 10865–10870; d) C. Wyart, F. Del Bene, 
E. Warp, E. K. Scott, D. Trauner, H. Baier, E. Y. Isacoff, Nature 2009, 461, 407–410; 
e) H. Janovjak, S. Szobota, C. Wyart, D. Trauner, E. Y. Isacoff, Nat. Neurosci. 2010, 
13, 1027–1032; f) N. Caporale, K. D. Kolstad, T.  Lee, I. Tochitsky, D. Dalkara, D. 
Trauner, R. H.  Kramer, Y. Dan, E. Y. Isacoff, J. G. Flannery, Mol. Ther. 2011, 19, 
1212–1219. 
[68]  J. Levitz, C. Pantoja, B. Gaub, H. Janovjak, A. Reiner, A. Hoagland, D. Schoppik, B. 
Kane, P. Stawski, A. F. Schier, D. Trauner, E. Y. Isacoff, Nat. Neurosci. 2013, 16, 
507−516. 
[69]  I. Tochitsky, M. R. Banghart, A. Mourot, J. Z. Zhao, B. Gaub, R. H. Kramer, D. 
Trauner, Nat. Chem. 2012, 4, 105–111. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2     PHOTOREGULATION OF GABAA RECEPTORS 
 
 
 
17 
2 PHOTOREGULATION OF GABAA RECEPTORS  
 
2.1 THE GABAA RECEPTOR 
 
Most neuronal inhibition in the brain is mediated by γ-aminobutyric acid (GABA)ergic 
neurons.[1] They are essential for neuronal oscillations in the β- and γ-bands of the 
electroencephalogram (EEG) which are believed to underlie a series of cognitive function such 
as perception, selective attention, working memory and consciousness.[1] Since GABAA 
receptors (GABAARs) are involved in a vast number of different signaling circuits, they exist as 
various subtypes which are encoded by more than a dozen genes. These receptor subtypes vary 
in their subunit composition, in their cellular expression patterns and subcellular concentrations 
as well as in their kinetic properties.[1] The dynamic regulation of receptor function is mediated 
by highly regulated receptor trafficking, chemical modifications (mostly phosphorylation) as 
well as by regulation of subunit expression.[1] Alterations in the subunit composition are often 
involved in chronic diseases, i.e. epilepsy.[2] 
GABAARs are heteropentameric chloride channels and part of the Cys-loop ligand-gated ion 
channel superfamily. They have a pronounced heterogeneity and consist of numerous subunits 
which are divided into three main classes based on their sequence homology: α1-6, β1-3, γ1-3. In 
addition, more specialized and rare subunit forms exist such as δ, ε, π, θ, and ρ1-3.[1] All subunits 
exhibit a similar topology consisting of a large extracellular N-terminal domain (~200 amino 
acids), four α-helical transmembrane helices (TM1–4) and a large intracellular loop connecting 
TM3 and TM4. The extracellular domain consists of mainly β-sheets, whereas the cytoplasmic 
domain comprises α-helices (Fig. 2.1c). Within the N-terminal domain, a 15 amino acid-long 
loop linked via a disulfide bridge between two cysteine residues exists in all subunits which is 
characteristic for the Cys-loop superfamily receptors (Fig. 2.1a, left).[1] The TM2 helices of each 
of the five subunits form the chloride-selective pore of the channel (Fig. 2.1a, right). Although 
there is no high-resolution crystal structure of the receptors available to date, the X-ray structure 
of a soluble acetylcholine binding protein (AChBP) from the snail Lymnaea stagnalis obtained 
in 2001[3] and a more recent, refined electron microscope structure of nAChR from electric fish 
at 4.0 Å resolution[4] serve as templates for the extracellular receptor domains (Fig. 2.1c).  
The ligand binding sites are located on the extracellular domains. In the most abundant (~60%) 
GABAAR, α1β2γ2, also known as α1 GABAAR, the endogenous ligand GABA binds between 
the interface of α1 and β2 subunits, whereas the widely known class of benzodiazepines (BZs), 
which act as allosteric modulators, bind between the γ2 and α1 subunit (Fig. 2.1b). On the 
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contrary, regulation on the intracellular loop occurs by phosphorylation and receptor associated 
proteins.[5]  
 
 
Figure	  2.1.	   a)	  Schematic	  illustration	  of	  GABAARs.	  Illustration	  copied	  from	  Wikipedia.
[6]	  b)	  Model	  of	  
the	   GABAA	   receptor.	   Distribution	   of	   subunits	   is	   shown	   as	   well	   as	   localization	   of	   GABA	   and	  
benzodiazepine	  (BZ)	  binding	  sites.	  Illustration	  copied	  from	  Jacob	  et	  al.,[7]	  reprinted	  with	  permission	  from	  
Macmillan	  Publishers	  Ltd.	  Copyright	  2008.	  c)	  Structure	  of	  nAChR	  from	  the	  Torpedo	  electric	  organ	  with	  
4	  Å	   resolution	  as	  blueprint	   for	  GABAARs.	  The	   two	   front	   subunits	  are	  highlighted	   (α:	   red;	  β:	   blue).	   The	  
grey	   lines	   represent	   the	  plasma	  membrane	   (E	  =	  Extracellular	  space,	   I	  =	   Intracellular	  space).	   Illustration	  
copied	  from	  Unwin,[4]	  reprinted	  with	  permission	  from	  Elsevier.	  Copyright	  2005.	  
 
The many different GABAARs are related to various functions. For instance, α4βnγ/δ (α5) 
GABAARs play a crucial role in learning and memory processes.[1] Sedation is linked to α1β2γ2, 
whereas α2 receptors (α2β3γ2) are responsible for mediating anxiolytic effects.[1] β3-containing 
receptors have been shown to mediate in full the immobilizing action of the two anesthetics 
etomidate and propofol,[8] whereas the hypnotic effects of etomidate are mainly mediated by 
β2-containing GABAARs.[9] Interestingly, the heart rate depressant action and to a large part the 
hypothermic action of propofol and etomidate are linked to other targets.[10] Consequently, a 
β3-selective drug would probably function as an immobilizing anesthetic without undesired 
heart rate depressing side effects.[1] 
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2.2  AZO-PROPOFOLS: PHOTOCHROMIC POTENTIATORS OF GABAA 
RECEPTORS 
 
Propofol is a well-known and clinically widely used anesthetic which functions as a potentiator, 
that is positive allosteric modulator of GABA-induced chloride currents. The resulting 
hyperpolarization leads to a silencing of neuronal activity which is thought to be essential for 
the induction of anesthesia. Propofol recently gained questionable popularity since the famous 
US singer Michael Jackson died of a propofol intoxication in 2009. 
Striving for photocontrol of GABAA receptors, azobenzene derivatives of propofol were 
synthesized and tested in vitro and in vivo for their ability to light-dependently increase or 
decrease GABA-induced chloride currents, respectively. 
 
In the following, the original publication of this work is presented which was published in 
Angewandte Chemie International Edition in 2012.[s] Please note that the numbering of 
schemes, figures as well as compounds in the accompanying Supporting Information was 
adjusted to fit the consecutive numbering of this thesis. 
 
 
 
 
 
 
                                                
[s]  reprinted with permission from John Wiley and Sons. Copyright 2012. 
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General Experimental Details and Instrumentation 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[11] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0).[12] Multiplicities are 
abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, 
sext = sextet, sept = septet, m = multiplet. High resolution mass spectra (EI, ESI) were recorded 
by LMU Mass Spectrometry Service using a Thermo Finnigan MAT 95, a Jeol MStation or a 
Thermo Finnigan LTQ FT Ultra instrument. Melting points were obtained using a Stanford 
Research Systems MPA120 apparatus and are uncorrected. 
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Synthetic Procedures 
 
Synthesis of AP1–3 
 
Scheme	  2.1.	   Synthesis	  of	  AP1–3.	  
 
Synthesis of 2,6-diisopropyl-4-((4-nitrophenyl)diazenyl)phenol (AP1) 
 
 
 
4-Nitroaniline (2.07 g, 15.0 mmol, 1.0 equiv.) was dissolved in MeOH (30 mL) and cooled to 
0 °C. Conc. HCl (4 mL) was added and the mixture was stirred for 5 min. Isoamyl nitrite 
(2.02 mL, 15.0 mmol, 1.0 equiv.) was added slowly in portions and the mixture was stirred for 
30 min at 0 °C. Propofol (2.79 mL, 15.0 mmol, 1.0 equiv.) was dissolved in a separate flask in 
2 M NaOH (28 mL) and H2O (2 mL) and cooled to 0 °C. The diazonium salt of 4-nitroaniline 
was transferred to this solution at 0 °C and the reaction mixture was stirred for 1 h at this 
temperature. The pH was adjusted to pH = 4–6 with 2 M NaOH and the mixture was extracted 
OH
NH2
NO2
1) Isoamyl nitrite, HCl, MeOH, 0 °C, 30 min
2)                         , NaOH, 0 °C, 45 min
OH
N
N
NO2
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N
N
NH2(50%)
(83%)
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1,4-dioxane/H2O, 90 °C, 4 h
AP1 AP2
N
N
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O
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N
N
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O
O
O
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AcAP3
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N
N
NO2
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with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (hexanes/DCM, gradient from 8:2 to 6:4) to give AP1 (2.47 g, 7.54 mmol, 
50%) as a red solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.54. M.p.: 95–98 °C. 1H NMR (CDCl3, 400 MHz, 27 °C): 
δ = 8.39–8.27 (m, 2H, ArH), 8.04–7.87 (m, 2H, ArH), 7.82–7.65 (m, 2H, ArH), 5.30 (s, 1H, 
OH), 3.20 (sept, J = 6.8 Hz, 2H, 2 x CH), 1.34 (d, J = 6.8 Hz, 12H, 4 x CH3) ppm. 13C NMR 
(CDCl3, 100 MHz, 27 °C): δ = 156.2, 154.4, 148.0, 147.0, 134.6, 124.7, 123.0, 119.9, 27.3, 
22.5 ppm. IR (neat, ATR): ṽ = 3509 (w), 2963 (m), 2872 (w), 1590 (m), 1539 (m), 1520 (m), 
1461 (m), 1428 (m), 1404 (w), 1385 (w), 1339 (vs), 1288 (m), 1255 (s), 1196 (m), 1145 (m), 
1104 (m), 1073 (m), 1007 (w), 940 (m), 906 (w), 861 (m), 848 (m), 817 (w), 754 (w), 733 (w), 
716 (w), 691 (w) cm-1. HRMS (EI+): m/z calcd. for [C18H21N3O3]+: 327.1583, found: 327.1576 
([M]+). UV/Vis: λmax = 388 nm. 
 
Synthesis of 4-((4-aminophenyl)diazenyl)-2,6-diisopropylphenol (AP2) 
 
 
 
AP1 (1.40 g, 4.28 mmol, 1.0 equiv.) was dissolved in 1,4-dioxane (75 mL) and water (6.5 mL) 
and Na2S (999 mg, 12.8 mmol, 3.0 equiv.) was added. The reaction mixture was heated to 90 °C 
for 3.75 h. A sat. aqu. solution of NaHCO3 (100 mL) was added and the aqueous phase was 
extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine 
(75 mL), dried over MgSO4 and the solvent was concentrated in vacuo. The crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, gradient from 4:1 to 3:1) 
to give AP2 (1.06 g, 3.56 mmol, 83%) as an orange solid. 
TLC (hexanes/EtOAc, 3:1): Rf = 0.32. M.p.: 159–162 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.70–7.63 (m, 2H, ArH), 7.55 (s, 2H, ArH), 6.79–6.72 (m, 2H, ArH), 3.37 (sept, 
J = 6.9 Hz, 2H, 2 x CH), 1.28 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CD3OD, 
100 MHz, 27 °C): δ = 156.9, 154.9, 150.5, 148.5, 139.6, 127.9, 121.3, 117.9, 30.6, 25.9 ppm. 
IR (neat, ATR): ṽ = 3383 (m), 2962 (m), 2870 (w), 1619 (m), 1600 (vs), 1507 (m), 1462 (m), 
OH
N
N
NH2
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1440 (m), 1280 (m), 1246 (w), 1198 (m), 1160 (m), 1146 (s), 939 (w), 890 (w), 835 (m), 784 
(w) cm-1. HRMS (ESI+): m/z calcd. for [C18H24N3O]+: 298.1919, found: 298.1916 ([M+H]+). 
UV/Vis: λmax = 404 nm. 
 
Synthesis of 4-((4-acetamidophenyl)diazenyl)-2,6-diisopropylphenyl acetate (AcAP3) 
 
 
 
AP2 (400 mg, 1.35 mmol, 1.0 equiv.) was dissolved in DCM (20 mL) and TEA (0.19 mL, 
1.35 mmol, 1.0 equiv.) was added. Acetyl chloride (0.10 mL, 1.4 mmol, 1.0 equiv.) was added 
dropwise at 0 °C and the reaction mixture was stirred for 1 h at this temperature, before it was 
warmed to room temperature and stirred for further 3 h. As TLC analysis indicated remaining 
starting material, another 0.5 equiv. of acetyl chloride (0.050 mL, 0.68 mmol) were added and 
the mixture was stirred for 3 h. TLC analysis indicated still remaining starting material and 
another 0.3 equiv. of acetyl chloride (0.030 mL, 0.41 mmol) were added. The mixture was 
stirred for 12 h at room temperature. H2O (10 mL) was added and the organic phase was 
separated and washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (DCM/MeOH, gradient from 
100:0 to 30:1) to yield bisacetylated AcAP3 (459 mg, 1.20 mmol, 89%) as an orange solid. 
TLC (DCM/MeOH, 20:1): Rf = 0.47. M.p.: 247–249 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.86–7.80 (m, 2H, ArH), 7.71 (s, 2H, ArH), 7.60–7.52 (m, 2H, ArH), 2.98 (sept, 
J = 6.8 Hz, 2H, 2 x CH), 2.41 (s, 3H, CH3), 2.19 (s, 3H, CH3), 1.27 (d, J = 6.8 Hz, 12H, 
4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 169.8, 168.5, 151.1, 149.0, 147.5, 
141.4, 140.4, 123.8, 119.5, 118.7, 28.0, 24.6, 23.2, 20.7 ppm. IR (neat, ATR): ṽ = 2964 (m), 
1758 (m), 1662 (m), 1597 (m), 1554 (m), 1504 (m), 1462 (w), 1408 (w), 1369 (m), 1323 (m), 
1306 (w), 1268 (m), 1200 (vs), 1166 (s), 1149 (m), 1107 (w), 1033 (w), 1006 (w), 909 (m), 853 
(m), 757 (m) cm-1. HRMS (ESI+): m/z calcd. for [C22H28N3O3]+: 382.2131, found: 382.2127 
([M+H]+). 
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Synthesis of N-(4-((4-hydroxy-3,5-diisopropylphenyl)diazenyl)phenyl)acetamide (AP3) 
 
 
 
AcAP3 (450 mg, 1.18 mmol, 1.0 equiv.) was dissolved in MeOH (15 mL) and THF (15 mL) 
and K2CO3 (945 mg, 6.84 mmol, 5.8 equiv.; dissolved in 5 mL H2O) was added. The mixture 
was stirred at room temperature for 16 h. The pH was adjusted to pH = 4–6 with 2 M HCl and 
the mixture was extracted with EtOAc (2 x 30 mL). The combined organic layers were washed 
with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash silica gel chromatography (CHCl3/MeOH, gradient from 100:0 to 40:1), 
yielding AP3 (392 mg, 1.15 mmol, 97%) as a deep red oil. 
TLC (DCM/MeOH 20:1): Rf = 0.31. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 8.10 (br s, 1H, 
NH), 7.92–7.85 (m, 2H, ArH), 7.74–7.63 (m, 4H, ArH), 5.72 (br s, 1H, OH), 3.22 (sept, 
J = 6.9 Hz, 2H, 2 x CH), 2.20 (s, 3H, CH3), 1.31 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 169.0, 153.3, 149.2, 146.8, 139.7, 134.7, 123.4, 120.0, 119.0, 
27.3, 24.6, 22.7 ppm. IR (neat, ATR): ṽ = 3303 (m), 2963 (m), 2870 (w), 1672 (m), 1596 (s), 
1538 (s), 1504 (m), 1462 (m), 1441 (m), 1405 (m), 1372 (m), 1315 (m), 1304 (m), 1266 (m), 
1195 (m), 1161 (m), 1117 (m), 1014 (w), 965 (w), 939 (w), 902 (w), 847 (m), 795 (w), 756 (m), 
700 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C20H26N3O2]+: 340.2025, found: 340.2022 
([M+H]+). UV/Vis: λmax = 378 nm. 
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Synthesis of AP4–14 
 
Scheme	  2.2.	   Synthesis	  of	  AP4–14.	  
 
Typical Procedure (TP) 1: Reaction of propofol with a diazonium salt 
The aniline (3.0 mmol, 1.0 equiv.) was dissolved in H2O (2 mL) and conc. HCl (2 mL) and 
cooled to 0 °C. If the aniline did not dissolve completely in this mixture, MeOH was added until 
a clear solution was obtained. A precooled solution of NaNO2 (228 mg, 3.30 mmol, 1.1 equiv.) 
in H2O (2 mL) was added slowly and the mixture stirred for 30 min at 0 °C. The pH was 
adjusted to pH = 8–9 with a precooled sat. aqu. solution of NaHCO3. To this mixture, propofol 
(0.56 mL, 3.0 mmol, 1.0 equiv.) was added dropwise and the mixture stirred at 0 °C for 12 h. 
The mixture was extracted with CHCl3 (3 x 20 mL), washed with H2O (50 mL) and brine 
(50 mL), dried over MgSO4 and concentrated in vacuo.  
 
Synthesis of 4-((4-hydroxy-3,5-diisopropylphenyl)diazenyl)benzenesulfonic acid (AP4) 
 
 
 
Sulfanilic acid (2.60 g, 15.0 mmol, 1.0 equiv.) was dissolved in 2 M NaOH (9.8 mL) and H2O 
(10 mL) and cooled to 0 °C. NaNO2 (1.04 g, 15.0 mmol, 1.0 equiv.) was added, followed by 
slow addition of conc. HCl (4.5 mL). The mixture was stirred for 30 min at 0 °C. Propofol 
(2.79 mL, 15.0 mmol, 1.0 equiv.) was dissolved in 2 M NaOH (28 mL) and H2O (2 mL) and 
cooled to 0 °C. The diazonium salt of sulfanilic acid was transferred to this solution at 0 °C and 
the reaction mixture was stirred for 2 h at this temperature. The solvent was removed in vacuo 
and the crude product was purified by reversed phase flash silica gel chromatography 
(H2O/MeOH, gradient from 100:0 to 80:20) to give AP4 (2.61 g, 7.20 mmol, 48%) as a deep 
red oil. 
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RP-TLC (H2O/MeOH, 3:1): Rf = 0.24. M.p.: 145 °C (dec.). 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.93–7.89 (m, 2H, ArH), 7.82–7.77 (m, 2H, ArH), 7.63 (s, 2H, ArH), 3.45 (sept, 
J = 6.9 Hz, 2H, 2 x CH), 3.34 (s, 1H, SO3H), 1.25 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 164.9, 154.3, 144.2, 143.2, 137.3, 126.5, 120.9, 119.5, 26.3, 
22.2 ppm. IR (neat, ATR): ṽ = 3428 (m), 2960 (m), 2869 (w), 1653 (m), 1589 (m), 1530 (m), 
1456 (m), 1435 (m), 1413 (w), 1384 (w), 1344 (m), 1290 (s), 1197 (s), 1115 (vs), 1034 (s), 1007 
(m), 943 (w), 907 (w), 843 (w), 820 (w), 740 (w), 663 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C18H23N2O4S]+: 363.1379, found: 363.1375 ([M+H]+). UV/Vis: λmax = 368, 527 nm. 
 
Synthesis of 2,6-diisopropyl-4-(phenyldiazenyl)phenol (AP5) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 50:1 to 20:1) to give AP5 (195 mg, 
0.690 mmol, 23%) as a red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.29. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.92–7.86 
(m, 2H, ArH), 7.74 (s, 2H, ArH), 7.54–7.43 (m, 3H, ArH), 5.20 (br s, 1H, OH), 3.22 (sept, 
J = 6.9 Hz, 2H, 2 x CH), 1.35 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 153.2, 152.9, 146.9, 134.4, 130.0, 129.0, 122.4, 119.1, 27.4, 22.6 ppm. IR (neat, 
ATR): ṽ = 3568 (w), 3361 (m), 3068 (w), 2962 (m), 2931 (m), 2870 (m), 1654 (w), 1591 (m), 
1526 (w), 1463 (s), 1440 (s), 1384 (m), 1364 (m), 1343 (m), 1307 (m), 1278 (s), 1241 (m), 1196 
(s), 1147 (s), 1116 (m), 1071 (m), 1020 (w), 962 (w), 938 (m), 904 (m), 864 (w), 840 (w), 816 
(w), 796 (m), 763 (vs), 732 (s), 688 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C18H23N2O]+: 
283.1810, found: 283.1807 ([M+H]+). UV/Vis: λmax = 362, 450 nm. 
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Synthesis of 4-((4-chlorophenyl)diazenyl)-2,6-diisopropylphenol (AP6) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 20:1 to 10:1) to give AP6 (437 mg, 1.38 mmol, 
46%) as a red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.27. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.89–7.78 
(m, 2H, ArH), 7.72 (s, 2H, ArH), 7.51–7.41 (m, 2H, ArH), 5.20 (s, 1H, OH), 3.20 (sept, 
J = 6.8 Hz, 2H, 2 x CH), 1.34 (d, J = 6.8 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 153.2, 151.3, 146.8, 135.8, 134.4, 129.2, 123.7, 119.2, 27.4, 22.6 ppm. IR (neat, 
ATR): ṽ = 3585 (w), 3421 (w), 2962 (s), 2871 (m), 1589 (m), 1577 (m), 1522 (w), 1483 (m), 
1461 (vs), 1440 (s), 1399 (m), 1385 (m), 1364 (m), 1344 (m), 1277 (s), 1246 (m), 1199 (s), 
1159 (s), 1117 (m), 1088 (vs), 1010 (m), 960 (w), 938 (m), 902 (m), 868 (w), 835 (s), 799 (w), 
768 (w), 727 (m), 710 (w) cm-1. HRMS (ESI+): m/z calcd. for [C18H22N2OCl]+: 317.1421, 
found: 317.1416 ([M+H]+). UV/Vis: λmax = 369 nm. 
 
Synthesis of 2,6-diisopropyl-4-((4-(trifluoromethyl)phenyl)diazenyl)phenol (AP7) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 30:1 to 20:1) to give AP7 (221 mg, 
0.630 mmol, 21%) as a red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.33. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.98–7.89 
(m, 2H, ArH), 7.77–7.69 (m, 4H, ArH), 5.23 (s, 1H, OH), 3.20 (sept, J = 6.9 Hz, 2H, 2 x CH), 
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1.34 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 154.7, 
154.0–153.7 (m), 146.7, 134.6, 131.2 (q, J = 32.2 Hz), 124.0 (q, J = 270.6 Hz), 126.1 (q, 
J = 3.8 Hz), 122.5, 119.6, 27.3, 22.6 ppm. 19F NMR (CDCl3, 376 MHz, 27 °C): δ = –62.4 ppm. 
IR (neat, ATR): ṽ = 3608 (w), 2964 (m), 2873 (w), 1611 (w), 1590 (m), 1527 (w), 1463 (m), 
1441 (m), 1408 (m), 1386 (w), 1364 (w), 1321 (vs), 1280 (m), 1243 (m), 1197 (m), 1164 (m), 
1150 (m), 1127 (s), 1102 (m), 1064 (s), 1014 (m), 960 (w), 938 (m), 904 (m), 848 (m), 818 (w), 
802 (w), 769 (w), 720 (w), 700 (w) cm-1. HRMS (ESI+): m/z calcd. for [C19H22N2OF3]+: 
351.1684, found: 351.1679 ([M+H]+). UV/Vis: λmax = 373 nm. 
 
Synthesis of 2,6-diisopropyl-4-((4-methoxyphenyl)diazenyl)phenol (AP8) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/CHCl3, gradient from 3:1 to 2:8) to give AP8 (262 mg, 0.840 mmol, 
28%) as a red oil. 
TLC (hexanes/CHCl3, 1:1): Rf = 0.16. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.99–7.92 (m, 
2H, ArH), 7.76 (s, 2H, ArH), 7.07–7.00 (m, 2H, ArH), 5.44 (br s, 1H, OH), 3.88 (s, 3H, CH3), 
3.23 (sept, J = 6.9 Hz, 2H, 2 x CH), 1.35 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 161.4, 152.7, 147.2, 147.0, 134.5, 124.3, 118.7, 114.2, 55.5, 27.4, 
22.7 ppm. IR (neat, ATR): ṽ = 2961 (m), 2870 (w), 1600 (m), 1582 (m), 1502 (m), 1460 (m), 
1440 (m), 1385 (w), 1363 (w), 1342 (w), 1314 (m), 1279 (m), 1247 (vs), 1195 (m), 1181 (m), 
1158 (m), 1143 (s), 1116 (m), 1105 (m), 1075 (w), 1029 (m), 986 (w), 960 (w), 937 (w), 905 
(m), 836 (s), 806 (w), 817 (w), 770 (m), 730 (s), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C19H25N2O2]+: 313.1916, found: 313.1914 ([M+H]+). UV/Vis: λmax = 368 nm. 
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Synthesis of 4-((4-(dimethylamino)phenyl)diazenyl)-2,6-diisopropylphenol (AP9) 
 
 
 
The reaction was carried out using TP1. The reaction mixture was concentrated under reduced 
pressure and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 20:1 to 10:1) to give AP9 (615 mg, 1.89 mmol, 63%) as a 
brownish solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.52. M.p.: 157–160 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.89–7.82 (m, 2H, ArH), 7.65 (s, 2H, ArH), 6.80–6.73 (m, 2H, ArH), 5.06 (s, 1H, 
OH), 3.19 (sept, J = 6.9 Hz, 2H, 2 x CH), 3.07 (s, 6H, 2 x CH3), 1.34 (d, J = 6.9 Hz, 12H, 
4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 151.8, 151.7, 147.3, 143.8, 134.1, 
124.4, 118.2, 111.6, 40.4, 27.4, 22.7 ppm. IR (neat, ATR): ṽ = 3337 (m), 2959 (m), 2924 (m), 
2864 (m), 2801 (w), 2723 (w), 2648 (w), 1894 (w), 1598 (s), 1564 (m), 1516 (m), 1459 (m), 
1440 (s), 1399 (m), 1360 (s), 1343 (m), 1278 (s), 1245 (m), 1224 (m), 1199 (m), 1160 (vs), 
1144 (s), 1121 (m), 1107 (m), 1077 (m), 1063 (m), 999 (w), 986 (w), 942 (m), 905 (m), 896 
(w), 885 (w), 870 (w), 819 (vs), 801 (m), 753 (s), 726 (w), 668 (w) cm-1. HRMS (ESI+): m/z 
calcd. for [C20H28N3O]+: 326.2232, found: 326.2229 ([M+H]+). UV/Vis: λmax = 417 nm. 
 
Synthesis of 4-((4-(diethylamino)phenyl)diazenyl)-2,6-diisopropylphenol (AP10) 
 
 
 
The reaction was carried out using TP1. The reaction mixture was concentrated under reduced 
pressure and the crude product was purified by reversed-phase flash silica gel chromatography 
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(H2O/MeOH, gradient from 5:5 to 2:8) to give AP10 (477 mg, 1.35 mmol, 45%) as a brownish 
solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.49. M.p.: 164–165 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.85–7.78 (m, 2H, ArH), 7.63 (s, 2H, ArH), 6.75–6.68 (m, 2H, ArH), 5.01 (s, 1H, 
OH), 3.44 (q, J = 7.0 Hz, 4H, 2 x CH2), 3.19 (sept, J = 6.8 Hz, 2H, 2 x CH), 1.34 (d, J = 6.8 Hz, 
12H, 4 x CH3), 1.22 (t, J = 7.0 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 151.5, 149.5, 147.4, 143.3, 134.0, 124.7, 118.1, 111.0, 44.6, 27.4, 22.7, 12.7 ppm. IR (neat, 
ATR): ṽ = 3288 (w), 2960 (m), 2930 (w), 1593 (s), 1566 (m), 1516 (m), 1459 (m), 1441 (m), 
1397 (m), 1377 (m), 1357 (m), 1269 (m), 1245 (m), 1196 (m), 1163 (m), 1141 (vs), 1094 (m), 
1076 (m), 1013 (m), 986 (w), 938 (w), 904 (w), 893 (w), 884 (w), 819 (m), 788 (m), 770 (w), 
728 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C22H32N3O]+: 354.2545, found: 354.2542 
([M+H]+). UV/Vis: λmax = 425 nm. 
 
Synthesis of 4-((4-fluorophenyl)diazenyl)-2,6-diisopropylphenol (AP11) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 50:1 to 25:1) to give AP11 (249 mg, 
0.830 mmol, 28%) as a red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.26. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.95–7.87 
(m, 2H, ArH), 7.72 (s, 2H, ArH), 7.23–7.14 (m, 2H, ArH), 5.23 (br s, 1H, OH), 3.21 (sept, 
J = 6.8 Hz, 2H, 2 x CH), 1.35 (d, J = 6.8 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 163.9 (q, J = 248 Hz), 153.1, 149.4, 146.8, 134.4, 124.4 (q, J = 8.7 Hz), 119.0, 
115.9 (q, J = 22.7 Hz), 27.4, 22.6 ppm. 19F NMR (CDCl3, 282 MHz, 27 °C): δ = –110.9 ppm. 
IR (neat, ATR): ṽ = 2962 (m), 2863 (w), 1773 (w), 1670 (w), 1589 (m), 1498 (s), 1460 (s), 
1437 (m), 1384 (m), 1362 (m), 1340 (w), 1277 (m), 1223 (s), 1196 (m), 1153 (s), 1133 (s), 1115 
(m), 1086 (m), 1007 (w), 937 (m), 904 (m), 839 (vs), 815 (m), 779 (m), 732 (m) cm-1. HRMS 
(EI+): m/z calcd. for [C18H21FN2O]+: 300.1638, found: 300.1636 ([M]+). UV/Vis: λmax = 363, 
450 nm. 
OH
N
N
F
2     PHOTOREGULATION OF GABAA RECEPTORS 
 
 
 
38 
Synthesis of 4-((4-bromophenyl)diazenyl)-2,6-diisopropylphenol (AP12) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 70:1 to 40:1) to give AP12 (358 mg, 
0.990 mmol, 33%) as a deep red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.39. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.79–7.74 
(m, 2H, ArH), 7.72 (s, 2H, ArH), 7.64–7.60 (m, 2H, ArH), 5.19 (br s, 1H, OH), 3.20 (sept, 
J = 6.9 Hz, 2H, 2 x CH), 1.35 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 153.3, 151.7, 146.8, 134.4, 132.2, 124.2, 124.0, 119.2, 27.4, 22.6 ppm. IR (neat, 
ATR): ṽ = 3578 (w), 3413 (w), 2960 (s), 2928 (m), 2868 (m), 1586 (m), 1573 (m), 1521 (w), 
1459 (vs), 1440 (s), 1394 (m), 1384 (m), 1363 (m), 1344 (m), 1276 (m), 1242 (m), 1198 (s), 
1159 (s), 1149 (s), 1116 (m), 1066 (m), 1006 (m), 960 (w), 937 (m), 902 (m), 866 (w), 831 (m), 
797 (w), 760 (w), 716 (w), 706 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C18H22N2OBr]+: 361.0915, found: 361.0912 ([M+H]+). UV/Vis: λmax = 371, 458 nm. 
 
Synthesis of 4-((4-iodophenyl)diazenyl)-2,6-diisopropylphenol (AP13) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 30:1 to 15:1) to give AP13 (387 mg, 
0.950 mmol, 32%) as a red oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.39. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.86–7.81 
(m, 2H, ArH), 7.72 (s, 2H, ArH), 7.65–7.60 (m, 2H, ArH), 5.21 (br s, 1H, OH), 3.20 (sept, 
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J = 6.9 Hz, 2H, 2 x CH), 1.34 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 153.5, 152.2, 146.8, 138.2, 134.4, 124.1, 119.3, 96.3, 27.4, 22.6 ppm. IR (neat, 
ATR): ṽ = 2959 (m), 2858 (w), 1779 (w), 1670 (w), 1585 (m), 1564 (m), 1515 (m), 1458 (vs), 
1437 (s), 1389 (m), 1362 (m), 1343 (m), 1274 (m), 1239 (m), 1195 (s), 1147 (vs), 1115 (s), 
1072 (m), 1052 (m), 1002 (s), 937 (m), 902 (s), 827 (vs), 796 (m), 767 (m), 732 (s), 710 
(m) cm-1. HRMS (ESI+): m/z calcd. for [C18H22N2OI]+: 409.0777, found: 409.0774 ([M+H]+). 
UV/Vis: λmax = 374, 460 nm. 
 
Synthesis of 4-((4-hydroxy-3,5-diisopropylphenyl)diazenyl)benzonitrile (AP14) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 20:1 to 5:1) to give AP14 (132 mg, 
0.430 mmol, 14%) as an orange solid. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.21. M.p.: 177–178 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 8.04–7.86 (m, 2H, ArH), 7.85–7.67 (m, 4H, ArH), 5.31 (br s, 1H, OH), 3.21 (sept, 
J = 6.8 Hz, 2H, 2 x CH), 1.34 (d, J = 6.8 Hz, 12H, 4 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 154.8, 146.7, 145.8, 134.9, 133.2, 129.8, 129.0, 128.4, 123.5, 122.8, 119.9, 118.7, 
116.3, 112.7 ppm.[t] IR (neat, ATR): ṽ = 3450 (m), 2960 (m), 2869 (w), 2229 (m), 1599 (m), 
1587 (m), 1527 (m), 1459 (s), 1440 (m), 1424 (m), 1401 (m), 1383 (w), 1372 (w), 1347 (w), 
1307 (m), 1289 (m), 1257 (m), 1239 (m), 1191 (m), 1161 (m), 1142 (vs), 1116 (s), 1099 (m), 
1073 (m), 1011 (w), 937 (m), 907 (m), 840 (m), 804 (w), 771 (w), 732 (m) cm-1. HRMS (ESI+): 
m/z calcd. for [C19H22N3O]+: 307.1763, found: 308.1759 ([M+H]+). UV/Vis: λmax = 384 nm. 
 
 
 
                                                
[t]  Additional signals and extensive broadening in the 13C NMR was observed, assumingly due to 
cis/trans-isomerization of AP14. 
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Synthesis of AP15 
 
Scheme	  2.3.	   Synthesis	  of	  AP15.	  
 
Synthesis of 4-(4-nitrophenethyl)morpholine (2.1) 
 
 
 
1-(2-Bromoethyl)-4-nitrobenzene (5.18 g, 22.5 mmol, 1.0 equiv.) was dissolved in DMF 
(40 mL) and morpholine (3.92 mL, 45.0 mmol, 2.0 equiv.) was added. The reaction mixture was 
heated to 80 °C for 16 h. Water (250 mL) was added and the aqueous phase was extracted with 
EtOAc (3 x 50 mL). The combined organic phases were washed with water (250 mL) and brine 
(3 x 250 mL), dried over MgSO4 and concentrated in vacuo to yield tertiary amine 2.1 (5.02 g, 
21.2 mmol, 94%) as an orange oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.34. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 8.19–8.09 
(m, 2H, ArH), 7.40–7.32 (m, 2H, ArH), 3.76–3.68 (m, 4H, 2 x CH2), 2.94–2.85 (m, 2H, CH2), 
2.66−2.59 (m, 2H, CH2), 2.56–2.46 (m, 4H, 2 x CH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 148.1, 146.5, 129.5, 123.6, 66.8, 59.7, 53.6, 33.1 ppm. IR (neat, ATR): ṽ = 2954 (w), 2854 
(w), 2808 (w), 1600 (m), 1515 (s), 1457 (w), 1398 (w), 1343 (vs), 1290 (w), 1274 (w), 1257 
(w), 1208 (w), 1180 (w), 1135 (m), 1116 (s), 1070 (w), 1036 (w), 1008 (m), 916 (w), 875 (m), 
858 (m), 824 (w), 772 (w), 748 (w), 699 (w) cm-1. HRMS (EI+): m/z calcd. for [C12H16N2O3]+: 
236.1161, found: 236.1103 ([M]+). 
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Synthesis of 4-(2-morpholinoethyl)aniline (2.2) 
 
 
 
Nitroarene 2.1 (4.90 g, 20.7 mmol) was dissolved in EtOAc (55 mL) and palladium on charcoal 
(10%; 500 mg) was added under an argon atmosphere. The flask was purged with H2 and 
evacuated (5x). The reaction mixture was then stirred for 3 d under an H2 atmosphere (1 bar). 
The mixture was filtered through Celite and the solvent was removed in vacuo, furnishing 
aniline 2.2 (4.26 g, 20.7 mmol, 100%) as an orange solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.54. M.p.: 81–82 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.04–6.94 (m, 2H, ArH), 6.67–6.56 (m, 2H, ArH), 3.78–3.70 (m, 4H, 2 x CH2), 3.56 (br s, 
2H, NH2), 2.75–2.65 (m, 2H, CH2), 2.59–2.46 (m, 6H, 3 x CH2) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 144.5, 130.0, 129.4, 115.2, 67.0, 61.2, 53.7, 32.4 ppm. IR (neat, ATR): 
ṽ = 3376 (m), 3338 (m), 3241 (m), 3002 (w), 2955 (w), 2925 (m), 2896 (m), 2860 (m), 2812 
(m), 2765 (w), 1646 (m), 1611 (m), 1516 (s), 1447 (w), 1357 (w), 1336 (w), 1276 (m), 1256 
(m), 1210 (w), 1180 (w), 1157 (w), 1136 (m), 1111 (vs), 1070 (m), 1034 (w), 1006 (m), 916 
(m), 866 (s), 825 (m), 789 (w), 773 (w), 739 (w) cm-1. HRMS (EI+): m/z calcd. for 
[C12H18N2O]+: 206.1419, found: 206.1414 ([M]+). 
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Synthesis of 2,6-diisopropyl-4-((4-(2-morpholinoethyl)phenyl)diazenyl)phenol (AP15) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (CHCl3/MeOH, 100:0 → 100:1) to give AP15 (409 mg, 1.03 mmol, 34%) as a 
red solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.46. M.p.: 178–179 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.83–7.78 (m, 2H, ArH), 7.70 (s, 2H, ArH), 7.35–7.30 (m, 2H, ArH), 5.27 (br s, 1H, 
OH), 3.82−3.73 (m, 4H, 2 x CH2), 3.21 (sept, J = 6.9 Hz, 2H, 2 x CH), 2.96–2.85 (m, 2H, CH2), 
3.72−2.64 (m, 2H, CH2), 2.64–2.53 (m, 4H, 2 x CH2), 1.34 (d, J = 6.9 Hz, 12H, 4 x CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 152.9, 151.5, 147.0, 134.3, 129.3, 122.6, 118.9, 66.8, 
60.4, 53.6, 33.0, 27.4, 22.6 ppm. IR (neat, ATR): ṽ = 3358 (m), 2961 (m), 2868 (m), 2813 (m), 
1654 (w), 1590 (m), 1502 (w), 1461 (s), 1441 (m), 1412 (w), 1385 (w), 1361 (w), 1341 (w), 
1305 (w), 1280 (m), 1243 (m), 1199 (m), 1161 (s), 1116 (vs), 1070 (w), 1036 (w), 1005 (w), 
939 (w), 906 (m), 871 (m), 847 (w), 824 (w), 802 (w), 771 (w), 733 (m), 682 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C24H34N3O2]+: 396.2651, found: 396.2643 ([M+H]+). UV/Vis: 
λmax = 365, 460 nm. 
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Synthesis of AP16 
 
Scheme	  2.4.	   Synthesis	  of	  AP16.	  
 
Synthesis of 1-(2-(2-methoxyethoxy)ethoxy)-4-nitrobenzene (2.3) 
 
 
 
4-Nitrophenol (4.87 g, 35.0 mmol, 1.0 equiv.) was dissolved in DMF (65 mL) and K2CO3 
(2.28 g, 16.5 mmol, 0.47 equiv.) and 2-(2-methoxyethoxy)ethyl bromide (4.48 mL, 33.3 mmol, 
0.95 equiv.) were added. The reaction mixture was heated to 70 °C for 16 h. Water (250 mL) 
was added and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined 
organic phases were washed with water (250 mL), 1 M NaOH (3 x 200 mL), and brine 
(2 x 250 mL), dried over MgSO4 and concentrated in vacuo to yield PEG ether 2.3 (6.91 g, 
28.6 mmol, 86%) as a colorless solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.48. M.p.: 79–80 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.23–8.13 (m, 2H, ArH), 7.02–6.92 (m, 2H, ArH), 4.25–4.20 (m, 2H, CH2), 3.91–3.86 (m, 
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2H, CH2), 3.73–3.69 (m, 2H, CH2), 3.59–3.54 (m, 2H, CH2), 3.38 (s, 3H, CH3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 163.8, 141.6, 125.8, 114.6, 71.9, 70.9, 69.4, 68.2, 59.1 ppm. IR 
(neat, ATR): ṽ = 3007 (w), 2914 (w), 2897 (m), 2837 (w), 1608 (m), 1592 (m), 1508 (m), 1498 
(m), 1479 (m), 1460 (m), 1382 (w), 1360 (w), 1340 (s), 1302 (m), 1292 (m), 1259 (vs), 1191 
(m), 1180 (m), 1140 (m), 1124 (m), 1103 (s), 1072 (m), 1052 (m), 1029 (m), 956 (w), 946 (m), 
924 (m), 853 (s), 846 (m), 812 (w), 752 (m), 692 (w), 662 (m) cm-1. HRMS (EI+): m/z calcd. 
for [C11H15NO5]+: 241.0950, found: 241.0944 ([M]+). 
 
Synthesis of 4-(2-(2-methoxyethoxy)ethoxy)aniline (2.4) 
 
 
 
Nitroarene 2.3 (6.80 g, 28.2 mmol) was dissolved in EtOAc (75 mL) and palladium on charcoal 
(10%; 700 mg) was added under an argon atmosphere. The flask was purged with H2 and 
evacuated (5x). The reaction mixture was then stirred for 16 h under an H2 atmosphere (1 bar). 
The mixture was filtered through Celite and the solvent was removed in vacuo, furnishing 
aniline 2.4 (5.96 g, 28.2 mmol, 100%) as an orange oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.19. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 6.77–6.68 
(m, 2H, ArH), 6.63–6.55 (m, 2H, ArH), 4.03 (dd, J = 5.8, 4.1 Hz, 2H, CH2), 3.78 (dd, J = 5.8, 
4.1 Hz, 2H, CH2), 3.72–3.65 (m, 2H, CH2), 3.58–3.51 (m, 2H, CH2), 3.46 (s, 2H, NH2), 3.36 (s, 
3H, CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 151.8, 140.2, 116.3, 115.8, 71.9, 70.6, 
69.9, 68.1, 59.0 ppm. IR (neat, ATR): ṽ = 3428 (w), 3353 (w), 3231 (w), 2919 (w), 2876 (m), 
1628 (m), 1509 (vs), 1456 (m), 1375 (w), 1355 (w), 1330 (w), 1274 (w), 1233 (s), 1174 (w), 
1102 (s), 1062 (m), 1027 (m), 985 (w), 924 (m), 823 (s), 744 (m), 696 (w) cm-1. HRMS (EI+): 
m/z calcd. for [C11H17NO3]+: 211.1208, found: 211.1212 ([M]+). 
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Synthesis of 2,6-diisopropyl-4-((4-(2-(2-methoxyethoxy)ethoxy)phenyl)diazenyl)phenol 
(AP16) 
 
 
 
The reaction was carried out using TP1. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 6:1 to 2:1) to give AP16 (288 mg, 0.720 mmol, 
24%) as a red oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.46. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.89–7.82 
(m, 2H, ArH), 7.67 (s, 2H, ArH), 7.04–6.98 (m, 2H, ArH), 5.13 (s, 1H, OH), 4.25–4.17 (m, 2H, 
CH2), 3.93–3.87 (m, 2H, CH2), 3.76–3.70 (m, 2H, CH2), 3.61–3.57 (m, 2H, CH2), 3.40 (s, 3H, 
CH3), 3.20 (sept, J = 6.8 Hz, 2H, 2 x CH), 1.33 (d, J = 6.8 Hz, 12H, 4 x CH3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 160.5, 152.4, 147.3, 147.0, 134.2, 124.1, 118.6, 114.8, 72.0, 70.8, 
69.7, 67.7, 59.1, 27.4, 22.6 ppm. IR (neat, ATR): ṽ = 3410 (m), 2961 (m), 2928 (m), 2872 (m), 
1598 (m), 1582 (m), 1501 (m), 1459 (m), 1442 (m), 1384 (w), 1361 (w), 1312 (m), 1281 (m), 
1247 (vs), 1199 (m), 1142 (s), 1107 (s), 1062 (m), 938 (w), 902 (w), 838 (m), 780 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C23H33N2O4]+: 401.2440, found: 401.2435 ([M+H]+). UV/Vis: 
λmax = 370, 470 nm. 
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X-ray Structure Discussion of AP2 
 
AP2 crystallizes in the monoclinic P21 space group with four molecules per unit cell. 
Azobenzenes usually favor a planar molecular structure due to its gain in aromatization 
energy.[13] AP2, however, is twisted around the azo bond with dihedral angles of –29.0(3)° 
(C5−C4–N1–N2) and –8.7(3)° (N1–N2–C13–C14), respectively (Fig. 2.2). 
 
 
Figure	  2.2.	   X-­‐ray	  structure	  of	  AP2.	  
	  
The loss of aromaticity is probably overcompensated by the gain of up to six hydrogen bonds 
per molecule. The molecules are oriented head-to-tail in a lattice fashion, with two neighboring 
chains aligning antiparallel. The molecules of one chain are connected by hydrogen bonds 
between the hydroxy and amino groups (N3–H31–O1: D–H 0.86(3) Å, H–A 2.21(3) Å, D–A 
3.022(3) Å, D−H−A 158(2)°). The orthogonal chains are connected via two hydrogen bonds 
between the amino and hydroxy function to each an azo bond nitrogen of two different chains 
((N3–H32–N5: D–H 0.87(3) Å, H–A 2.33(3) Å, D–A 3.194(3) Å, D–H–A 172(2)°, and 
(O1−H1–N2: D–H 0.87(3) Å, H−A 2.40(3) Å, D–A 3.220(3) Å, D–H–A 158(3)°, respectively; 
Fig. 2.3). 
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Figure	  2.3.	   Hydrogen	  bonding	  network	  of	  AP2	  in	  the	  crystal	  lattice.	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NMR Spectra 
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UV/Vis Spectra 
 
UV/Vis spectra of AP1–16 were recorded at concentrations of 50 µM in DMSO (AP2–16) or 
CHCl3 (AP1). Spectra were first recorded in the dark, then again after illumination with the 
absorption maximum wavelength for 1 min unless indicated otherwise.  
AP1 shows solvatochromic behavior which is well known for 4-hydroxy-4’-nitro substituted 
azobenzenes (Fig. 2.3).[14]   
 
 
Figure	  2.3.	   Solvatochromic	  behavior	  of	  AP1.	   Solution	  of	  AP1	   in	   from	   left	   to	   right:	  CHCl3,	  DMSO,	  
1	  M	  NAOH	  (each	  50	  µM	  AP1),	  1	  M	  NaOH	  (500	  µM	  AP1).	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Expression and Functional Characterization in Xenopus Oocytes 
 
Capped cRNAs were synthesized (Ambion, Austin, TX, USA) from the linearized plasmids 
with a cytomegalovirus promotor (pCMV vectors) containing rat α1, β2, or γ2L subunits, 
respectively. A poly-A tail of about 400 residues was added to each transcript using yeast 
poly-A polymerase (United States Biologicals, Cleveland, OH, USA). The concentration of the 
cRNA was quantified on a formaldehyde gel using Radiant Red stain (Bio-Rad) for 
visualization of the RNA. Known concentrations of RNA ladder (Invitrogen) were loaded as 
standard on the same gel. cRNAs were precipitated in ethanol/isoamylalcohol 19 : 1, the dried 
pellet dissolved in water and stored at −80°C. cRNA mixtures were prepared from these stock 
solutions and stored at −80°C. 
Xenopus laevis oocytes were prepared, injected and defolliculated as described previously.[15,16] 
They were injected with 50 nL of the cRNA solution containing wild type α1, β2 and γ2 subunits 
at a concentration of 10 nM : 10 nM : 50 nM,[17] and then incubated in modified Barth’s solution 
(10 mM HEPES-NaOH, pH = 7.5, 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 
0.34 mM Ca(NO3)2, 0.41 mM CaCl2, 100 units/mL penicillin, 100 µg/mL streptomycin) at 
+18°C for at least 24 h before the measurements. 
Electrophysiological experiments were performed by using the two-electrode voltage clamp 
method at a holding potential of −80 mV. The perfusion medium contained 90 mM NaCl, 1 mM 
KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM Na-HEPES (pH = 7.4). Solutions contained a final 
concentration of 0.5% DMSO to ensure solubility of the compounds.  
Concentration-response curves for propofol were measured at a GABA concentration eliciting 
about 0.3% of the maximal GABA current amplitude (EC0.3). GABA was repetitively applied 
until a constant response was obtained. Subsequently, the oocyte was exposed to the same 
concentration of GABA in combination with increasing concentrations of propofol or AP2. 
Relative current potentiation by propofol was calculated using the following equation: 
[(IGABA+Propofol/IGABA) −1] × 100%. The perfusion system was cleaned between drug applications 
by flushing with DMSO to avoid contamination.  
For photoswitching experiments the oocyte was exposed to an Ultrafire® 1 Watt UV LED 
pocket lamp (YonC Trading, Zürich; emission wavelength λ = 390–450 nm according to the 
manufacturer) at a distance of ∼3 cm. The oocytes were continuously perfused at 6 ml/min. 
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Expression and Functional Characterization in HEK 293 Cells 
 
Human embryonic Kidney 293 cells (HEK 293 cells; American Type Culture Collection-CRL-
1573) were maintained in minimum essential medium (Invitrogen) supplemented with 10% 
fetal calf serum, 2 mM glutamine, 50 units/mL penicillin and 50 µg/mL streptomycin at 37 °C in 
5% CO2 – 95% air. For electrophysiological experiments (whole-cell patch clamp), cells were 
plated onto poly-D-lysine (0.01 mg/ml, Sigma) coated culture dishes (Nunc). Equal amounts 
(total of 3 µg DNA/35 mm dish) of plasmids coding for rat α1, β2, γ2, GABAA receptor subunits 
were transfected into HEK 293 cells by the calcium phosphate precipitation method.[18] As a 
marker for successfully transfected cells, cDNA encoding green fluorescent protein was co-
transfected (0.3 µg DNA/35 mm dish) together with the GABAA receptor subunits. After 
overnight incubation, the cells were washed twice with serum free medium and refed with 
medium. 
The kinetics of the action of AP2 were studied using the patch clamp technique in the whole 
cell configuration. HEK 293 cells were bathed in an exernal solution containing (mM): 
140 NaCl, 5 KCl, 4 MgCl2, 1 CaCl2, 10 HEPES and 5 Glucose; pH adjusted to pH = 7.4 with 
NaOH. Patch pipettes were pulled from thin-walled borosilicate glass (GC150TF; Harvard 
Apparatus) using a DMZ universal puller (Zeitz-Instruments). Patch electrodes of a resistance 
of 2.5–3 MΩ were filled with an internal solution containing (mM): 135 CsCl, 2 MgCl2, 
0.5 EGTA, 10 HEPES, 2 MgATP; pH adjusted to pH = 7.2 with CsOH. This combination of 
external and internal solution produced a chloride equilibrium potential of ∼0 mV. 
Measurements were performed using an EPC-10 amplifier (HEKA, Lambrecht/Pfalz, 
Germany). The currents were sampled at 0.5 kHz and filtered with a 0.1 kHz Bessel filter. Cells 
were voltage-clamped at −60 mV and solutions containing either 0.5 µM GABA or 0.5 µM 
GABA in combination with 5 µM AP2 were applied using a perfusion system consisting of 
glass reservoir connected to a Warner Perfusion solenoid mini valve control system (Harvard 
Apparatus). The rate of solution exchange time was ∼5 s. After bath application of AP2 for 5 s, 
the perfusion system was switched off to avoid addition of new trans-AP2. The cells were 
exposed to the UV light as described above. The time course of current amplitudes was fitted 
with a mono-exponentiatal function using the software Kaleidagraph.  
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Anesthetic Effects and Photo-reversibility in Xenopus laevis Tadpoles  
 
Early pre-limb-bud stage albino Xenopus tadpoles were purchased from Xenopus One (Ann 
Arbor, MI, USA). Tadpoles were housed and used in accordance with federal and state 
guidelines and with the approval of the Massachusetts General Hospital Subcommittee on 
Research and Animal Care. Loss of righting reflexes (LORR), a standard measure of hypnotic 
drug effect, was assessed at room temperature (20 to 22 °C) for both propofol and AP2 at 
concentrations ranging from 0.1 to 10 µM. A total of 10 animals were tested at each drug 
concentration by immersion in aqueous solutions of the anesthetics. Control groups of 10 
animals were tested in water without drugs.  In groups of 5 animals, a fire-polished glass rod 
was used to gently reposition animals from their normal prone position into a supine position. 
Animals that did not return to prone position in 5 seconds were deemed to have lost righting 
reflexes. The drug exposure time until steady-state LORR responses was noted. After 
immersion in drug for 30 min, λ = 360–370 nm illumination was provided using a handheld 
LED flashlight (5W handheld LED UV torch with λ = 365 nm peak spectral output, purchased 
from Uveco Gmbh, Bruckmühl, Germany) and a bandpass filter (D365/10x, purchased from 
Chroma Technology Corp., Bellows Falls, VT, USA) at a distance of approximately 5 cm, 
while LORR was reassessed. The center of the illumination beam was aimed at individual 
tadpoles in turn for 5–10 seconds. Following photo-reversal testing, all animals were returned to 
clean water and observed for one hour to confirm reversibility of drug effects.   
Logistic functions of the form Fraction LORR = 1/(1+10^((LogEC50–LogDrug)*nH)) were 
fitted to results (in the absence versus presence of UV light) using GraphPad Prism software 
(v. 5.0, GraphPad Software, La Jolla, CA, USA). EC50 is the half-effect drug concentration for 
LORR and nH is the Hill slope. 
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2.3  PHOTOCHROMIC POTENTIATION OF GABAA RECEPTORS BY 
AZOBENZENE DERIVATIVES OF ETOMIDATE 
 
Etomidate (ETD; also marketed under the name Amidate®) was discovered by Janssen 
Pharmaceutica in 1964.[19] ETD functions as a short acting intravenous anesthetic and sedative. 
Due to its rapid onset of action (< 1 min), easy dosing profile and low likelihood of blood 
pressure decrease it is often used in emergency cases. Like with propofol, induction of 
anesthesia by ETD is not yet fully understood, but it is believed that the anesthetic effect is also 
mediated by potentiation of GABA-induced hyperpolarizing chloride currents.    
Building up on previous results of Azo-Propofol derivatives (see 2.2), photoswitchable 
derivatives of ETD were synthesized in order to optochemically control GABAARs.  
 
2.3.1 AZO-ETOMIDATES AS POTENTIAL PHOTOCHROMIC GABAAR POTENTIATORS 
 
The pentameric ligand-gated GABAA receptor is a chloride-selective ion channel that is 
activated by the major inhibitory neurotransmitter in the mammalian brain, γ-aminobutyric acid 
(GABA).[20] GABA-binding leads to hyperpolarization of the postsynaptic neuron, thus 
decreasing the likelihood of action potential firing. As a consequence, GABAA receptors are 
prominent targets for anesthetic, hypnotic, and anticonvulsant drugs.[21] Most of these drugs, 
such as benzodiazepines, barbiturates, or the clinically widely used propofol, are allosteric 
modulators that potentiate GABA-induced chloride currents (Fig. 2.4).[22] These potentiators 
bind to distinct allosteric sites on GABAA receptors and increase the mean open time of the 
channel or its opening frequency. 
 
	  
Figure	  2.4.	   Structures	  of	  propofol,	  the	  barbiturate	  phenobarbital,	  the	  benzodiazepine	  clonazepam	  
and	  ETD	  (positive	  allosteric	  modulators	  of	  GABAARs).	  
 
Following the recent studies on photoswitchable propofol derivatives for the optochemical 
control of GABAARs, the pharmacology of ETD, another highly potent allosteric potentiator of 
GABAARs, was investigated in more detail. ETD is a general anesthetic drug in clinical use 
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which induces anesthesia with a half effective concentration of ∼2 µM.[23] Due to its easy dosing 
profile and its ability to quickly induce anesthesia without suppressing ventilation, it is often 
used in emergency cases.[24] Moreover, it decreases intracranial pressure while maintaining 
arterial pressure, thus making it a preferred anesthetic for brain surgery.[25] ETD not only 
interacts with GABAARs but also with other members of the Cys-loop receptor family, such as 
glycine, serotonine (5-HT) and acetylcholine (ACh) receptors,[26] and moreover is a potent 
inhibitor of 11β-hydroxylase.[27] However, GABAA is the most sensitive receptor to 
etomidate.[28] Like propofol, ETD also directly activates GABAARs at higher concentrations.[29] 
Although propofol and ETD share a lot of features, some differences between the two drugs do 
exist. ETD mainly acts on GABAARs, containing β2 and β3 subunits, whereas propofol appears 
to act on all GABAARs, regardless of the β subunit type.[30] 
Inspired by binding studies of diazirine-containing derivatives of etomidate that maintained 
their action on GABAARs,[29,31] two classes of photoswitchable azobenzene derivatives of ETD 
were designed (Fig. 2.5). AETD1 bears the azobenzene moiety on the phenyl portion of ETD, 
while AETD2–5 feature the azobenzene on the ester portion of the molecule. 
 
 
Figure	  2.5.	   Structures	  of	  ETD	  and	  AETD1–5.	  
 
AETD1 was synthesized de novo, starting from chiral amine 2.5 in analogy to a literature 
protocol.[26,29a] Boc protection of the amine gave compound 2.6 in 77% yield which was then 
reduced quantitatively with hydrogen and palladium on charcoal to aniline 2.7. Compound 2.7 
was subjected to a Mills reaction with nitrosobenzene to afford azobenzene 2.8 in 75% yield. 
The Boc group was deprotected to give quantitatively primary amine 2.9, followed by 
condensation with ethyl chloroacetate to afford secondary amine 2.10 in 92% yield. Formyl 
protection quantitatively led to 2.11 which was converted in a two-step procedure to 
mercaptoimidazole 2.12. Oxidative desulfurization of 2.12 finally yielded AETD1 (Scheme 
2.5).  
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Scheme	  2.5.	   Synthesis	  of	  AETD1.	  
 
By contrast, AETD2 was synthesized starting from ETD itself. Ester hydrolysis under basic 
conditions afforded carboxylic acid 2.13 in 54% yield which was then reesterified with 
azobenzene alcohol 2.14 to give AETD2 (Scheme 2.6).  
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Scheme	  2.6.	   Synthesis	  of	  AETD2.	  
 
AETD3–5 were synthesized accordingly. Methyl 4-aminobenzoate was diazotated and coupled 
to N,N-diethylaniline to give azobenzene 2.15 in 63% yield. Reduction of the ester using LiAlH4 
gave alcohol 2.16 in excellent yield. Esterification with carboxylic acid 2.13 then yielded 
AETD3 in 63% (Scheme 2.7). 
 
 
Scheme	  2.7.	   Synthesis	  of	  AETD3.	  
 
For the synthesis of AETD4, 4-trifluoromethylaniline was oxidized to the corresponding nitroso 
derivative and subjected to a Mills reaction with (4-aminophenyl)methanol to give azobenzene 
2.17 in 24% yield. Coupling of 2.17 to carboxylic acid 2.13 gave AETD4 in 58% yield (Scheme 
2.8). 
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Scheme	  2.8.	   Synthesis	  of	  AETD4.	  
 
Finally, the synthesis of AETD5 commenced with single Boc protection of 
1,4-phenylenediamine to give compound 2.18 in 90% yield. Methyl 4-aminobenzoate was then 
oxidized to the corresponding nitroso derivative using oxone and subsequently reacted with 
2.18 to give azobenzene 2.19 in 87% yield. Reduction of the ester function with LiAlH4 gave 
alcohol 2.20 which was then coupled to carboxylic acid 2.13 to yield compound 2.21 in 91% 
yield. Deprotection of the Boc group with HCl afforded AETD5 in 86% yield (Scheme 2.9). 
 
 
Scheme	  2.9.	   Synthesis	  of	  AETD5.	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All AETDs were first tested for their ability to potentiate GABA-induced currents mediated by 
α1β2γ2, receptors expressed in Xenopus oocytes (Simon Middendorp, IBMM Bern). Early on, 
AETD2 proved to be the best candidate for further biological evaluation. Whereas AEDT2 
showed a current potentiation of >2000% on α1β2γ2 and α1β3γ2 receptors, AETD3–5 gave 
potentiations of 400–800% (data not shown) and were therefore not further evaluated. 
At low concentrations (corresponding to the therapeutic window of ETD), AETD2 shows 
increased potency compared to ETD (Fig. 2.6). The EC50 values for AETD2 were determined to 
be 0.29 ± 0.08 and 0.33 ± 0.06 µM acting on α1β2γ2 and α1β3γ2 receptors, respectively, compared 
to 3.2 ± 0.7 and 3.5 ± 0.4 µM for ETD, respectively (mean ± SEM, n = 4). However, AETD2 
shows a ~2-fold lower efficacy than ETD. Exchanging the β2/3 subunit with β1 resulted in about 
a 10-fold rightshift of the apparent affinity for ETD which agrees with previously published 
data.[30b] Concentration dependent potentiation in α1β1γ2 receptors by ETD was fitted with an 
EC50 of 35.6 ± 0.7 µM. This fit has to be taken with care as saturation was not reached in this 
experiment. Interestingly, no strong reduction of the apparent affinity for AETD2 on α1β1γ2 
receptors was observed. The EC50 amounted to 0.49 ± 0.09 µM, efficacy however was reduced 
by about 4-fold (Fig. 2.6b). 
In sharp contrast to the results with AEDT2–5, AETD1 proved to be almost inactive in the 
potentiation of GABA-induced currents, suggesting a limited space in the binding pocket in that 
region of the molecule (Fig. 2.6b). Although smaller substituents are tolerated at this 
position,[31] the azo phenyl moiety of AETD1 appears to be too large. 
Having established that AEDT2 functions as a potentiator of GABA currents, it was further 
investigated if it was possible to control this effect in light-dependent manner. Illumination with 
λ = 365 nm, emitted from a UV high power LED pocket lamp (5.2 Watt Uveco GmbH, 
Bruckmühl, Germany) isomerizes AETD2 from its trans state to the cis state. The 
thermodynamically more stable trans isomer is regenerated by thermal relaxation in the dark 
(Fig. 2.6a; see also 2.3.4 for the UV/Vis spectra of all AETDs). Co-application of 2 µM GABA 
with 0.2 µM AETD2 in the absence of light gave a current potentiation of 678 ± 110% 
(mean ± SEM, n = 4) on α1β2γ2 receptors. Illumination with λ = 365 nm light isomerized 
AETD2 to the cis form, leading to a reduction of potentiation of ∼50 % of the potentiation seen 
in the dark, resulting in a residual potentiation of 338 ± 48%. Similar observations were made in 
α1β3γ2 and α1β1γ2 receptors (Fig. 2.6c), whereas ETD did not exhibit any light-dependency in 
the same experiment (data not shown).  
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Figure	  2.6.	  	   a)	   Photodependent	   isomerization	   between	   trans-­‐	   and	   cis-­‐AETD2,	   respectively.	   b)	  
Concentration-­‐dependent	   potentiation	   of	  α1β1γ2,	  α1β2γ2	   and	  α1β3γ2	   receptors	   by	   AETD1,	   AETD2	   and	  
ETD.	  Receptors	  were	  expressed	  in	  Xenopus	  oocytes	  and	  exposed	  to	  a	  GABA	  concentration	  eliciting	  2%	  of	  
the	   maximal	   current	   amplitude	   (EC2)	   in	   combination	   with	   increasing	   concentrations	   of	   the	   drug.	  
Potentiation	  of	  GABA	  currents	  in	  α1β3γ2	  receptors	  by	  AETD2	  is	  not	  shown	  as	  the	  curve	  overlaps	  with	  the	  
curve	   obtained	   in	  α1β2γ2	   receptors.	   Mean	   ±	   SEM	   of	   four	   experiments	   is	   shown.	   c)	   Photodependent	  
potentiation	  of	  chloride	  currents	  in	  α1β2γ2,	  (left),	  α1β3γ2	  (top	  right)	  and	  α1β1γ2	  receptors	  (bottom	  right).	  
First,	  GABA	   (EC0.5-­‐2)	   (single	   bar)	  was	   applied	   alone	   and	   then	   co-­‐applied	  with	   either	   0.2,	   0.1	   or	   0.3	  µM	  
AETD2	   in	   α1β2γ2,	   α1β3γ2	   and	   α1β1γ2	   receptors,	   respectively.	   During	   co-­‐application,	   the	   oocyte	   was	  
exposed	  to	  λ	  =	  365	  nm	  light	  which	  resulted	   in	  a	  reduction	  of	  potentiation.	  When	  the	   light	  was	  turned	  
off,	  the	  current	  amplitude	  increased	  again.	  Experiments	  were	  repeated	  independently	  four	  times	  using	  
different	  oocytes	  (Simon	  Middendorp,	  IBMM	  Bern).	  
2     PHOTOREGULATION OF GABAA RECEPTORS 
 
 
 
88 
Switching off the light reisomerizes AETD2 back to its trans form, thereby increasing the 
current again. This process is fully reversible and occurs in the range of seconds. 
To determine the kinetics of this light-dependent potentiation of GABA-induced currents by 
AETD2, the GABAA receptor was expressed in HEK 293 cells. However, no light-dependent 
change in current potentiation could be observed with none of all AETDs (Simon Middendorp, 
IBMM Bern, data not shown). As of today, it remains unclear if the reversible, light-dependent 
current potentiation in oocytes is derived from different affinities of both trans and cis isomers 
of AETD2, respectively (as shown for Azo-Propofol), or rather from a light-dependent 
solubility of both isomers, resulting in different local concentrations of either isomer. The latter 
hypothesis is supported by the qualitative observation of the Tyndall effect when a solution of 
AETD2 in aqueous buffer was illuminated with λ = 365 nm (Prof. Erwin Sigel, IBMM Bern) 
but could not be proven quantitatively as of today. 
In summary, photochromic GABAA potentiators based on the highly potent anesthetic etomidate 
(ETD) have been developed. The lead compound AETD2 has a >10-fold increased affinity at 
all receptors investigated, when compared to ETD. On all three subtypes, AETD2 potentiates 
GABA-induced currents in the dark in the trans state and significantly reduces this potentiation 
upon illumination with light, isomerizing AETD2 to the cis state. This process is fully 
reversible and could provide a new optochemical tool for investigating the action of etomidate 
on GABAARs. 
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2.3.2     EXPERIMENTAL PROCEDURES AND ANALYTICAL DATA 
 
2.3.2.1 GENERAL EXPERIMENTAL DETAILS AND INSTRUMENTATION 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[32] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0).[12] Multiplicities are 
abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, 
sext = sextet, sept = septet, m = multiplet. High resolution mass spectra (EI, ESI) were recorded 
by LMU Mass Spectrometry Service using a Thermo Finnigan MAT 95, a Jeol MStation or a 
Thermo Finnigan LTQ FT Ultra instrument. Melting points were obtained using a Stanford 
Research Systems MPA120 apparatus and are uncorrected. Optical rotation measurements were 
performed on a Perkin Elmer 241 polarimeter at 22 °C in a 5 cm cell at concentrations 
expressed as g/100 mL. Purity >95% was determined by HPLC with an Agilent Technologies 
1260 Infitinity LC, equipped with an Agilent 1100 Series LC/MSD on a Zorbax XDB-C8 
column, eluting with MeCN/H2O (+ 0.1% formic acid) gradients. 
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2.3.2.2 SYNTHESIS OF AZO-ETOMIDATES 
 
Synthesis of (R)-tert-butyl (1-(4-nitrophenyl)ethyl)carbamate (2.6) 
 
 
 
The HCl salt of amine 2.5 (1.07 g, 5.28 mmol, 1.0 equiv.) was dissolved in THF (20 mL) and 
TEA (0.88 mL, 6.3 mmol, 1.2 equiv.) was added. The mixture was stirred at room temperature 
for 15 min. Then, Boc2O (1.21 g, 5.54 mmol, 1.05 equiv.) and DMAP (65 mg, 0.53 mmol, 
0.1 equiv.) were added and the reaction mixture was stirred for 16 h at room temperature. The 
solvent was removed and the crude product was dissolved in EtOAc (50 mL). The organic layer 
was washed with water (100 mL) and brine (100 mL), dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by flash silica gel column chromatography 
(hexanes/EtOAc, gradient from 10:1 to 3:1) to give Boc-protected amine 2.6 (1.08 g, 
4.06 mmol, 77%) as a colorless oil. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.36. [α]D22: +47.3 (c = 1.0, CHCl3). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 8.23–8.15 (m, 2H, ArH), 7.50–7.41 (m, 2H, ArH), 4.99–4.71 (m, 2H, 
CH, NH), 1.48–1.34 (m, 12H, CH3, C(CH3)3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 154.9, 151.9, 147.0, 126.5, 123.9, 80.1, 50.0, 28.3, 22.6 ppm. IR (neat, ATR): ṽ = 3331 
(w), 2977 (m), 2930 (w), 1686 (s), 1606 (m), 1515 (s), 1454 (m), 1391 (m), 1365 (m), 1343 
(vs), 1316 (m), 1283 (m), 1245 (m), 1164 (s), 1109 (m), 1055 (m), 1014 (m), 1002 (w), 853 (s), 
784 (w), 753 (m), 699 (m) cm-1. HRMS (EI+): m/z calcd. for [C13H18N2O4]+: 266.1267, found: 
266.1267 ([M]+). 
 
Synthesis of (R)-tert-butyl (1-(4-aminophenyl)ethyl)carbamate (2.7) 
 
 
 
Nitroarene 2.6 (1.06 g, 3.98 mmol) was dissolved in MeOH (20 mL) and palladium on charcoal 
(10%; 110 mg) was added under an argon atmosphere. The flask was purged with H2 and 
subsequently evacuated (5x). The reaction mixture was then stirred for 1.5 h under an H2 
atmosphere (1 bar). The mixture was filtered through Celite and the solvent was removed in 
vacuo, yielding aniline 2.7 (940 mg, 3.98 mmol, 100%) as a colorless oil. 
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TLC (hexanes/EtOAc, 4:1): Rf = 0.09. [α]D22: +76.0 (c = 1.0, CHCl3). 1H NMR (CDCl3, 
400 MHz, 27 °C): δ = 7.12–7.05 (m, 2H, ArH), 6.67–6.61 (m, 2H, ArH), 4.85–4.55 (m, 2H, 
CH, NH), 3.58 (br s, 2H, NH2), 1.49–1.33 (m, 12H, CH3, C(CH3)3) ppm. 13C NMR (CDCl3, 
100 MHz, 27 °C): δ = 155.1, 145.4, 134.0, 127.0, 115.1, 79.2, 49.6, 28.4, 22.4 ppm. IR (neat, 
ATR): ṽ = 3352 (w), 2975 (m), 2930 (w), 1688 (s), 1622 (m), 1516 (s), 1453 (m), 1391 (m), 
1365 (m), 1244 (m), 1164 (vs), 1052 (m), 862 (w), 827 (m), 750 (vs), 665 (m) cm-1. HRMS 
(EI+): m/z calcd. for [C13H20N2O2]+: 236.1525, found: 236.1515 ([M]+). 
 
Synthesis of (R)-tert-butyl (1-(4-(phenyldiazenyl)phenyl)ethyl)carbamate (2.8) 
 
 
 
Aniline 2.7 (900 mg, 3.81 mmol, 1.0 equiv.) was dissolved in acetic acid (15 mL) and 
nitrosobenzene (449 mg, 4.19 mmol, 1.1 equiv.) was added in 3 portions over the course of 
10 min. The reaction mixture was stirred for 24 h at room temperature. The mixture was then 
basified to pH = 8–9 with sat. aqu. NaHCO3 and extracted with EtOAc (3 x 30 mL). The 
combined organic layers were washed with sat. aqu. NaHCO3 (100 mL) and brine (100 mL), 
then dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash 
silica gel column chromatography (hexanes/EtOAc, gradient from 10:1 to 5:1) to yield 
azobenzene 2.8 (929 mg, 2.85 mmol, 75%) as an orange solid.  
TLC (hexanes/EtOAc, 4:1): Rf = 0.47. M.p.: 124–126 °C. [α]D22: +105.2 (c = 1.0, CHCl3). 
1H NMR (CDCl3, 300 MHz, 27 °C): δ = 8.00–7.74 (m, 4H, ArH), 7.56–7.30 (m, 5H, ArH), 
4.98−4.64 (m, 2H, CH, NH), 1.54–1.26 (m, 12H, CH3, C(CH3)3) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 155.0, 152.7, 151.8, 147.2, 130.9, 129.0, 126.5, 123.1, 122.8, 79.6, 50.1, 
28.3, 22.7 ppm. IR (neat, ATR): ṽ = 3372 (m), 2966 (w), 1682 (s), 1514 (s), 1481 (w), 1444 
(m), 1391 (w), 1363 (m), 1341 (w), 1307 (m), 1246 (m), 1167 (s), 1093 (w), 1058 (s), 1002 (m), 
922 (w), 861 (w), 846 (s), 771 (s), 737 (w), 686 (vs) cm-1. HRMS (ESI+): m/z calcd. for 
[C19H24N3O2]+: 326.1869, found: 326.1864 ([M+H]+). 
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Synthesis of (R)-1-(4-(phenyldiazenyl)phenyl)ethanamine (2.9) 
 
 
 
Boc-protected amine 2.8 (880 mg, 2.70 mmol) was dissolved in 1,4-dioxane (25 mL) and a 4 M 
solution of HCl in dioxane (25 mL) was added. The mixture was stirred for 16 h at room 
temperature. The solvent was removed under reduced pressure and the residue was taken up in 
water (50 mL). The aqueous layer was washed with Et2O (3 x 50 mL) and then basified with 
sat. aqu. NaHCO3 to pH = 8–9. The aqueous layer was then extracted with CHCl3 (2 x 50 mL) 
and the combined organic layers were washed with brine (70 mL), dried over MgSO4 and 
concentrated in vacuo. Amine 2.9 (608 mg, 2.70 mmol, 100%) was obtained quantitatively as 
orange solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.29. M.p.: 64–65 °C. [α]D22: +12.3 (c = 0.50, CHCl3). 
1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.95–7.84 (m, 4H, ArH), 7.56–7.42 (m, 5H, ArH), 
4.22 (q, J = 6.6 Hz, 1H, CH), 1.94 (br s, 2H, NH2), 1.45 (d, J = 6.6 Hz, 3H, CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 152.7, 151.7, 150.4, 130.8, 129.0, 126.4, 123.1, 122.8, 
51.2, 25.5 ppm. IR (neat, ATR): ṽ = 3377 (w), 3309 (w), 3040 (w), 2962 (w), 2892 (w), 1599 
(m), 1575 (m), 1495 (w), 1482 (w), 1463 (w), 1444 (m), 1414 (m), 1367 (m), 1302 (m), 1272 
(w), 1222 (w), 1187 (m), 1153 (s), 1118 (w), 1101 (m), 1069 (m), 1017 (m), 1008 (m), 999 (m), 
969 (w), 920 (w), 842 (vs), 808 (m), 772 (vs), 734 (m), 686 (vs) cm-1. HRMS (EI+): m/z calcd. 
for [C14H15N3]+: 225.1266, found: 225.1254 ([M]+). 
 
Synthesis of (R)-ethyl 2-((1-(4-(phenyldiazenyl)phenyl)ethyl)amino)acetate (2.10) 
 
 
 
Amine 2.9 (577 mg, 2.56 mmol, 1.0 equiv.) was dissolved in DMF (10 mL) and TEA (0.53 mL, 
3.8 mmol, 1.5 equiv.) was added, followed by ethyl chloroacetate (0.35 mL, 3.3 mmol, 
1.3 equiv.). The mixture was heated to 80 °C for 16 h. To the cooled mixture, EtOAc (50 mL) 
was added and the organic phase was washed with water (2 x 75 mL) and brine (3 x 75 mL), 
then dried over MgSO4 and the solvent removed under reduced pressure. Purification of the 
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crude product by flash silica gel chromatography (hexanes/EtOAc, gradient from 5:1 to 2:1) 
afforded secondary amine 2.10 (736 mg, 2.36 mmol, 92%) as a red oil.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.49. [α]D22: +106.3 (c = 1.0, CHCl3). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.95–7.85 (m, 4H, ArH), 7.55–7.45 (m, 5H, ArH), 4.17 (q, J = 7.2 Hz, 
2H, CH2), 3.92 (q, J = 6.6 Hz, 1H, CH), 3.34 (d, J = 17.4 Hz, 1H, CH), 3.25 (d, J = 17.4 Hz, 
1H, CH), 2.33 (br s, 1H, NH), 1.44 (d, J = 6.6 Hz, 3H, CH3), 1.25 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 172.2, 152.7, 152.1, 147.5, 130.9, 129.0, 127.5, 123.1, 
122.8, 60.8, 57.6, 48.7, 24.1, 14.2 ppm. IR (neat, ATR): ṽ = 3340 (w), 3049 (w), 2977 (m), 
2928 (w), 1735 (vs), 1602 (w), 1582 (w), 1466 (w), 1445 (m), 1416 (w), 1394 (w), 1371 (m), 
1344 (w), 1302 (w), 1194 (vs), 1151 (s), 1097 (m), 1072 (m), 1026 (m), 927 (w), 848 (m), 769 
(m), 737 (w), 688 (m) cm-1. HRMS (ESI+): m/z calcd. for [C18H22N3O2]+: 312.1712, found: 
312.1705 ([M+H]+). 
 
Synthesis of (R)-ethyl 2-(N-(1-(4-(phenyldiazenyl)phenyl)ethyl)formamido)acetate (2.11) 
 
 
 
Diisopropylcarbodiimide (50 µL, 0.32 mmol, 2.0 equiv.) was dissolved in DCM (1 mL) and a 
2 M solution of formic acid in DCM (0.32 mL, 0.64 mmol, 4.0 equiv.) was added dropwise at 
0 °C. The mixture was stirred for 5 min. A precooled to 0 °C solution of glycine ester 2.10 
(50 mg, 0.16 mmol, 1.0 equiv.) in pyridine (1 mL) was added to the DIC and formic acid 
containing solution slowly over a period of 10 min. The mixture was slowly warmed to room 
temperature and stirred for 16 h. The solvent was removed under reduced pressure and the crude 
product was purified by flash silica gel chromatography (CHCl3), giving rise to the N-formyl 
compound 2.11 (55 mg, 0.16 mmol, 100%) as a red oil. Compound 2.11 was obtained as a 
mixture of two isomers in a ratio of approximately 3:1 with respect to the orientation of the 
formyl group. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.19. [α]D22: +66.6 (c = 1.0, CHCl3). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 8.48 (s, 1H, CHO, major isomer), 8.21 (s, 1H, CHO, minor isomer), 
7.96−7.86 (m, 4H, ArH, major isomer; 4H, ArH, minor isomer), 7.57–7.41 (m, 5H, ArH; 5H, 
ArH, minor isomer), 5.90 (q, J = 7.0 Hz, 1H, CH, minor isomer), 4.93 (q, J = 7.0 Hz, 1H, CH, 
major isomer), 4.14 (q, J = 7.2 Hz, 2H, CH2, major isomer), 4.10–4.01 (m, 2H, CH2, minor 
isomer), 3.96 (d, J = 17.3 Hz, 1H, CH, major isomer), 3.83–3.77 (m, 1H, CH, major isomer; 1H, 
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CH, minor isomer), 3.67 (d, J = 17.7 Hz, 1H, CH, minor isomer), 1.73 (d, J = 7.0 Hz, 3H, CH3, 
major isomer), 1.56 (d, J = 7.0 Hz, 3H, CH3, minor isomer), 1.26–1.15 (m, 3H, CH3, major 
isomer; 3H, CH3, minor isomer) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 169.6 (minor 
isomer), 168.5 (major isomer), 163.7 (minor isomer), 162.5 (major isomer), 152.6 (minor 
isomer), 152.5 (major isomer), 152.3 (major isomer), 152.1 (minor isomer), 142.3 (major 
isomer), 142.0 (minor isomer), 131.2 (major isomer), 131.1 (minor isomer), 129.1 (major 
isomer), 129.1 (minor isomer), 128.5 (minor isomer), 127.7 (major isomer), 123.2 (major 
isomer), 122.9 (minor isomer), 122.9 (major isomer), 122.9 (minor isomer), 61.7 (minor 
isomer), 61.3 (major isomer), 56.7 (major isomer), 49.6 (minor isomer), 45.4 (minor isomer), 
43.0 (major isomer), 19.0 (major isomer), 16.2 (minor isomer), 14.0 (major isomer), 14.0 
(minor isomer) ppm. IR (neat, ATR): ṽ = 2981 (w), 2938 (w), 1749 (m), 1672 (vs), 1604 (w), 
1429 (w), 1402 (m), 1374 (w), 1353 (w), 1302 (w), 1256 (w), 1197 (m), 1161 (m), 1116 (w), 
1081 (w), 1029 (w), 1000 (w), 982 (w), 930 (w), 849 (m), 771 (m), 690 (m) cm-1. HRMS 
(ESI+): m/z calcd. for [C19H22N3O3]+: 340.1661, found: 340.1655 ([M+H]+).  
 
Synthesis of (R)-ethyl 1-(1-(4-(phenyldiazenyl)phenyl)ethyl)-1H-imidazole-5-carboxylate 
(AETD1) 
 
 
 
NaOEt (67 µL, 0.18 mmol, 21% in EtOH, 1.1 equiv.) was dissolved in THF (2 mL) and cooled 
to 10 °C. Ethyl formate (39 µL, 0.48 mmol, 3.0 equiv.) was added, followed by a solution of 
N-formyl protected ethyl ester 2.11 (55 mg, 0.16 mmol, 1.0 equiv.) in THF (1.5 mL). The 
reaction mixture was stirred at room temperature for 16 h. The solvent was removed under 
reduced pressure and the crude product was immediately used in the next step. The crude 
product was dissolved in H2O (1 mL) and MeOH (1 mL) and conc. HCl (0.19 mL) was added. 
The mixture was heated to 40 °C for 30 min. A solution of KSCN (23 mg, 0.24 mmol, 
1.5 equiv.) in H2O (1 mL) was added to the mixture and heated to 40 °C for 16 h. The crude 
product was then extracted with CHCl3 (2 x 10 mL) and the combined organic layers were 
washed with brine (30 mL), dried over MgSO4 and the solvent removed under reduced pressure. 
The crude product was used in the next step without further purification. To a solution of 
NaNO2 (0.3 mg, 0.004 mmol, 0.1 equiv.) in H2O (1 mL) and conc. HNO3 (0.2 mL), a solution 
of the crude product in CHCl3 (1 mL) was added at 10 °C. The reaction mixture was then 
slowly warmed to room temperature and stirred for 1.5 h. The crude product was extracted with 
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CHCl3 (2 x 5 mL) and the combined organic layers were washed with sat. aqu. NaHCO3 
(2 x 15 mL) and brine (20 mL), dried over MgSO4 and the solvent removed in vacuo. The crude 
product was purified by flash silica gel chromatography (hexanes/EtOAc, 1:1), yielding 
AETD1 (8.0 mg, 0.023 mmol, 14% over four steps) as a red oil.  
TLC (hexanes/EtOAc, 1:1): Rf = 0.24. [α]D22: +48.4 (c = 0.1, CHCl3). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.94–7.84 (m, 4H, ArH), 7.81 (s, 2H, ArH), 7.56–7.43 (m, 3H, ArH), 
7.33−7.27 (m, 2H, ArH), 6.43 (q, J = 7.2 Hz, 1H, CH), 4.31–4.21 (m, 2H, CH2), 1.92 (d, 
J = 7.2 Hz, 3H, CH3), 1.31 (t, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 160.2, 152.6, 152.1, 144.1, 139.6, 138.3, 131.1, 129.1, 126.9, 123.2, 122.9, 122.7, 60.5, 
55.2, 22.2, 14.2 ppm. IR (neat, ATR): ṽ = 2981 (w), 2914 (w), 1713 (vs), 1604 (w), 1538 (w), 
1466 (m), 1391 (w), 1374 (m), 1349 (m), 1304 (w), 1216 (vs), 1156 (w), 1132 (m), 1107 (m), 
1052 (m), 1011 (w), 980 (w), 921 (w), 844 (m), 766 (m), 716 (w), 690 (w), 666 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C20H21N4O2]+: 349.1665, found: 349.1658 ([M+H]+). UV/Vis: 
λmax = 325, 438 nm.  
 
Synthesis of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid (2.13) 
 
 
 
Etomidate (113 mg, 0.460 mmol, 1.0 equiv.) was dissolved in THF (10 mL) and a 1 M solution 
of LiOH in H2O (1.38 mL, 1.38 mmol, 3.0 equiv.) was added. The mixture was stirred at room 
temperature for 16 h. As TLC analysis indicated still remaining starting material, another 
3.0 equiv. (1.38 mL, 1.38 mmol) was added and the mixture was stirred for another 8 h. Water 
(30 mL) was added to the mixture, followed by basification with 1 M NaOH to pH = 12–14. The 
aqueous phase was washed with EtOAc (2 x 30 mL) and then acidified with 1 M HCl to 
pH = 4−5 and extracted with EtOAc (5 x 20 mL). The combined organic layers were dried over 
MgSO4 and the solvent removed under reduced pressure, affording carboxylic acid 2.13 (55 mg, 
0.25 mmol, 54%) as a colorless foam.  
TLC (DCM/MeOH, 10:1): Rf = 0.05. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 10.51 (br s, 
1H, CO2H), 7.90–7.82 (m, 2H, ArH), 7.37–7.19 (m, 5H, ArH), 6.56 (q, J = 7.0 Hz, 1H, CH), 
1.86 (d, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 162.9, 140.4, 
138.3, 134.7, 128.9, 128.2, 126.6, 124.5, 55.5, 22.0 ppm. IR (neat, ATR): ṽ = 3126 (w), 2983 
(w), 2470 (m), 1898 (m), 1698 (s), 1532 (m), 1495 (m), 1453 (m), 1354 (m), 1278 (m), 1214 
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(vs), 1115 (s), 1070 (m), 1028 (m), 980 (m), 922 (w), 852 (w), 750 (vs), 700 (m), 658 (m) cm-1. 
HRMS (ESI-): m/z calcd. for [C12H11N2O2]-: 215.0821, found: 215.0827 ([M-H]-). 
 
Synthesis of (4-(phenyldiazenyl)phenyl)methanol (2.14) 
 
 
 
Nitrosobenzene (1.86 g, 17.4 mmol, 1.1 equiv.) was dissolved in a mixture of ethanol (13 mL) 
and glacial acetic acid (4.7 mL) with careful heating to 45 °C. The clear green solution was 
cooled to room temperature and 4-aminobenzyl alcohol (1.94 g, 15.8 mmol, 1.0 equiv.) was 
added in 5 portions over the course of 10 min. The mixture was stirred for another 45 min at 
room temperature. Et2O (50 mL) was added and the mixture was washed with sat. aqu. NaHCO3 
(2 x 50 mL; gas evolution!), dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude product was dissolved in a small volume of Et2O and hexanes were added. 
The mixture was then left in a refrigerator for crystallization. The orange crystals were filtered 
and washed with hexanes to obtain azobenzene 2.14. Further crystallization of the mother liquor 
gave an overall yield of 84% (2.83 g, 13.3 mmol).  
TLC (EtOAc): Rf = 0.80. M.p.: 141–142 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.98−7.91 (m, 4H, ArH), 7.58–7.46 (m, 5H, ArH), 4.81 (s, 2H, CH2), 1.83 (br s, 1H, 
OH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 152.7, 152.1, 143.8, 131.0, 129.1, 127.4, 
123.1, 122.9, 64.9 ppm. IR (neat, ATR): ṽ = 3308 (m), 2912 (w), 2860 (w), 1442 (m), 1413 
(m), 1348 (w), 1302 (m), 1150 (m), 1071 (w), 1026 (vs), 1009 (m), 922 (w), 850 (s), 831 (m), 
770 (m), 763 (m), 685 (s), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C13H13N2O]+: 213.1028, 
found: 213.1022 ([M+H]+). 
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Synthesis of (R)-4-(phenyldiazenyl)benzyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate 
(AETD2) 
 
 
 
Carboxylic acid 2.13 (42 mg, 0.19 mmol, 1.0 equiv.), benzylic alcohol 2.14 (102 mg, 
0.480 mmol, 2.5 equiv.) and DMAP (23 mg, 0.19 mmol, 1.0 equiv.) were dissolved in DCM 
(3 mL) and DMF (0.3 mL). Diisopropylcarbodiimide (45 µL, 0.29 mmol, 1.5 equiv.) was added 
and the mixture was stirred at room temperature for 20 h. The solvent was removed under 
reduced pressure and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 5:1 to 2:1), yielding AETD2 (68 mg, 0.17 mmol, 89%) as a red 
oil as a mixture of trans and cis isomers.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.19. [α]D22: +36.0 (c = 0.5, CHCl3). 1H NMR (CDCl3, 
600 MHz, 27 °C): δ = 7.95–7.89 (m, 4H, ArH), 7.88 (s, 1H, ArH), 7.83 (s, 1H, ArH), 7.55–7.46 
(m, 5H, ArH), 7.36–7.29 (m, 3H, ArH), 7.20–7.17 (m, 2H, ArH), 6.36 (q, J = 7.2 Hz, 1H, CH), 
5.35 (d, J = 12.8 Hz, 1H, CH), 5.30 (d, J = 12.8 Hz, 1H, CH), 1.87 (d, J = 7.2 Hz, 3H, 
CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 159.7, 153.3 (cis isomer), 153.1 (cis 
isomer), 152.6, 152.4, 140.8, 139.8, 138.4, 137.9, 134.8, 131.1, 129.1, 128.9, 128.9 (cis isomer), 
128.8 (cis isomer), 128.6, 128.3 (cis isomer), 128.1, 128.1 (cis isomer), 127.5 (cis isomer), 
126.3, 126.2 (cis isomer), 123.1, 122.9, 120.8 (cis isomer), 120.4 (cis isomer), 65.6, 65.3 (cis 
isomer), 55.7, 22.2 ppm. IR (neat, ATR): ṽ = 3416 (w), 3062 (w), 3033 (w), 2982 (w), 1712 
(s), 1605 (w), 1585 (w), 1534 (m), 1495 (w), 1486 (w), 1468 (m), 1450 (m), 1382 (m), 1349 
(m), 1302 (w), 1209 (vs), 1155 (w), 1131 (m), 1103 (s), 1071 (w), 1053 (w), 1028 (w), 1014 
(w), 984 (w), 921 (m), 834 (m), 760 (s), 700 (m), 689 (m), 659 (m) cm-1. HRMS (ESI+): m/z 
calcd. for [C25H23N4O2]+: 411.1821, found: 411.1814 ([M+H]+). UV/Vis: λmax = 325, 435 nm. 
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Synthesis of methyl 4-((4-(diethylamino)phenyl)diazenyl)benzoate (2.15) 
 
 
 
Methyl 4-aminobenzoate (1.23 g, 8.12 mmol, 1.0 equiv.) was dissolved in 4 M HCl (50 mL) and 
cooled to 0 °C. A precooled solution of NaNO2 (616 mg, 8.93 mmol, 1.1 equiv.) in water 
(2 mL) was added dropwise and the mixture was stirred for 30 min at 0 °C. The pH was 
adjusted to pH = 8–10 with an aqu. 10% NaOH solution and N,N-diethyl aniline (1.30 mL, 
8.21 mmol, 1.0 equiv.) was added. The mixture was stirred for 1 h at 0 °C. The aqueous phase 
was extracted with EtOAc (3 x 50 mL) and the combined organic layers were washed with sat. 
aqu. NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure. Purification of the crude product by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 20:1 to 10:1) afforded azobenzene 2.15 (1.60 g, 5.14 mmol, 
63%) as a red solid.  
TLC (hexanes/EtOAc, 4:1): Rf = 0.46. M.p.: 140–141 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 8.21–8.08 (m, 2H, ArH), 7.94–7.78 (m, 4H, ArH), 6.82–6.66 (m, 2H, ArH), 3.94 (s, 
3H, CH3), 3.47 (q, J = 7.0 Hz, 4H, 2 x CH2), 1.24 (t, J = 7.0 Hz, 6H, 2 x CH3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 166.8, 156.1, 150.7, 143.3, 130.5, 129.9, 125.8, 122.9, 111.0, 
52.1, 44.8, 12.7 ppm. IR (neat, ATR): ṽ = 2975 (m), 2948 (w), 2897 (w), 2258 (w), 1711 (s), 
1595 (s), 1554 (m), 1515 (m), 1483 (w), 1469 (w), 1435 (m), 1421 (m), 1407 (m), 1390 (m), 
1377 (m), 1356 (m), 1313 (m), 1270 (vs), 1246 (s), 1192 (m), 1153 (m), 1133 (vs), 1107 (s), 
1094 (s), 1079 (m), 1006 (m), 964 (m), 929 (w), 864 (m), 839 (w), 823 (vs), 810 (w), 793 (w), 
777 (m), 726 (m), 721 (w), 697 (m) cm-1. HRMS (ESI+): m/z calcd. for [C18H22N3O2]+: 
312.1712, found: 312.1703 ([M+H]+). 
 
Synthesis of (4-((4-(diethylamino)phenyl)diazenyl)phenyl)methanol (2.16) 
 
 
 
Methyl ester 2.15 (500 mg, 1.61 mmol, 1.0 equiv.) was dissolved in THF (20 mL) and LiAlH4 
(110 mg, 2.90 mmol, 1.8 equiv.) was added at 0 °C. The mixture was warmed to room 
temperature and stirred for 45 min. A sat. aqu. solution of Rochelle’s salt (30 mL) was added 
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and the mixture was stirred vigorously for 15 min. The crude product was extracted with EtOAc 
(2 x 30 mL) and the combined organic layers were washed with a sat. aqu. solution of 
Rochelle’s salt (50 mL) and brine (100 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure. Purification of the crude product by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 4:1 to 1:1) afforded alcohol 2.16 (450 mg, 1.59 mmol, 99%) as 
a red solid.  
TLC (hexanes/EtOAc, 4:1): Rf = 0.13. M.p.: 99–100 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.93–7.75 (m, 4H, ArH), 7.52–7.41 (m, 2H, ArH), 6.79–6.67 (m, 2H, ArH), 4.75 (d, 
J = 5.7 Hz, 2H, CH2), 3.46 (q, J = 7.2 Hz, 4H, 2 x CH2), 1.72 (t, J = 5.7 Hz, 1H, OH), 1.24 (t, 
J = 7.2 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 152.8, 150.1, 143.1, 
141.8, 127.5, 125.3, 122.3, 111.0, 65.1, 44.7, 12.7 ppm. IR (neat, ATR): ṽ = 3408 (w), 2969 
(w), 2913 (w), 2869 (w), 1592 (vs), 1556 (m), 1513 (m), 1445 (w), 1424 (w), 1388 (m), 1375 
(m), 1346 (s), 1312 (m), 1269 (m), 1250 (m), 1195 (m), 1154 (m), 1136 (vs), 1096 (m), 1078 
(m), 1006 (s), 951 (w), 849 (w), 824 (vs), 790 (m), 734 (w), 700 (w) cm-1. HRMS (ESI+): m/z 
calcd. for [C17H22N3O]+: 284.1763, found: 284.1755 ([M+H]+). 
 
Synthesis of (R)-4-((4-(diethylamino)phenyl)diazenyl)benzyl 1-(1-phenylethyl)-1H-
imidazole-5-carboxylate (AETD3) 
 
 
 
Carboxylic acid 2.13 (42 mg, 0.19 mmol, 1.0 equiv.), primary alcohol 2.16 (136 mg, 
0.480 mmol, 2.5 equiv.) and DMAP (23 mg, 0.19 mmol, 1.0 equiv.) were dissolved in DCM 
(3 mL) and DMF (0.3 mL). Diisopropylcarbodiimide (45 µL, 0.29 mmol, 1.5 equiv.) was added 
and the mixture was stirred at room temperature for 20 h. The solvent was removed under 
reduced pressure and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 4:1 to 1:1), yielding ester AETD3 (58 mg, 0.12 mmol, 63%) as 
an orange solid. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.28. M.p.: 116–117 °C. [α]D22: +50.9 (c = 0.5, CHCl3). 
1H NMR (CDCl3, 600 MHz, 27 °C): δ = 7.88–7.83 (m, 3H, ArH), 7.83–7.80 (m, 2H, ArH), 
7.74 (s, 1H, ArH), 7.46–7.42 (m, 2H, ArH), 7.36–7.31 (m, 2H, ArH), 7.31–7.27 (m, 1H, ArH), 
7.19–7.15 (m, 2H, ArH), 6.75–6.71 (m, 2H, ArH), 6.35 (q, J = 7.2 Hz, 1H, CH), 5.32 (d, 
J = 12.6 Hz, 1H, CH), 5.27 (d, J = 12.6 Hz, 1H, CH), 3.46 (q, J = 7.1 Hz, 4H, 2 x CH2), 1.86 (d, 
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J = 7.2 Hz, 3H, CH3), 1.23 (t, J = 7.1 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 150 MHz, 
27 °C): δ = 160.0, 153.2, 150.2, 143.1, 141.1, 140.0, 138.6, 136.4, 128.8, 128.7, 128.0, 126.2, 
125.4, 122.3, 122.3, 111.0, 65.8, 55.4, 44.7, 22.2, 12.7 ppm. IR (neat, ATR): ṽ = 3124 (w), 
2977 (w), 1690 (m), 1594 (s), 1552 (w), 1514 (m), 1491 (w), 1453 (w), 1424 (w), 1394 (m), 
1380 (m), 1344 (s), 1309 (w), 1273 (m), 1251 (w), 1206 (vs), 1160 (m), 1131 (vs), 1106 (s), 
1050 (m), 1027 (m), 986 (w), 958 (w), 943 (w), 920 (m), 885 (w), 866 (w), 838 (m), 817 (m), 
790 (w), 768 (m), 724 (w), 703 (m), 664 (m) cm-1. HRMS (ESI+): m/z calcd. for [C29H32N5O2]+: 
482.2556, found: 482.2545 ([M+H]+). UV/Vis: λmax = 445 nm. 
 
Synthesis of (4-((4-(trifluoromethyl)phenyl)diazenyl)phenyl)methanol (2.17) 
 
 
 
4-(Trifluoromethyl)aniline (0.56 mL, 4.5 mmol, 1.0 equiv.) was dissolved in DCM (20 mL) and 
oxone (5.47 g, 8.90 mmol, 2.0 equiv.; dissolved in 40 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 16 h at room temperature. The phases were separated, and 
the aqueous phase was extracted with DCM (20 mL). The combined organic phases were 
washed with brine (30 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The resulting green solid was immediately dissolved in HOAc (30 mL) and 
(4-aminophenyl)methanol (548 mg, 4.45 mmol, 1.0 equiv.) was added in 3 portions. The 
mixture was stirred for 24 h at room temperature. The mixture was basified to pH = 8–10 with 
2 M NaOH and the aqueous phase was extracted with EtOAc (2 x 40 mL). The organic phase 
was washed with sat. aqu. NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 5:1 to 2:1), affording azobenzene 2.17 (298 mg, 1.06 mmol, 
24%) as an orange solid.  
TLC (hexanes/EtOAc, 1:1): Rf = 0.57. M.p.: 162–163 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 8.06–8.02 (m, 2H, ArH), 7.96–7.92 (m, 2H, ArH), 7.87–7.83 (m, 2H, ArH), 
7.58−7.54 (m, 2H, ArH), 4.71 (s, 2H, CH2) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 154.6, 151.6, 146.0, 131.7 (q, J = 32.2 Hz), 127.1, 126.0 (q, J = 3.9 Hz), 124.0 (q, 
J = 270 Hz), 122.8, 122.7,  63.2 ppm. 19F NMR (CDCl3, 376 MHz, 27 °C): δ = –64.1 ppm. IR 
(neat, ATR): ṽ = 3250 (m), 2923 (w), 1933 (w), 1601 (m), 1503 (w), 1452 (w), 1410 (m), 1308 
(m), 1222 (w), 1208 (w), 1169 (s), 1120 (vs), 1101 (s), 1064 (s), 1037 (m), 1019 (m), 1009 (s), 
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988 (m), 954 (w), 851 (vs), 828 (m), 795 (m), 754 (m), 741 (w), 720 (w), 710 (w), 664 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C14H12N2OF3]+: 281.0902, found: 281.0893 ([M+H]+). 
 
Synthesis of (R)-4-((4-(trifluoromethyl)phenyl)diazenyl)benzyl 1-(1-phenylethyl)-1H-
imidazole-5-carboxylate (AETD4) 
 
 
 
Carboxylic acid 2.13 (42 mg, 0.19 mmol, 1.0 equiv.), primary alcohol 2.17 (135 mg, 
0.480 mmol, 2.5 equiv.) and DMAP (23 mg, 0.19 mmol, 1.0 equiv.) were dissolved in DCM 
(3 mL) and DMF (0.3 mL). Diisopropylcarbodiimide (45 µL, 0.29 mmol, 1.5 equiv.) was added 
and the mixture was stirred at room temperature for 20 h. The solvent was removed under 
reduced pressure and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, 4:1, increased to 3:1), followed by another reversed-phase flash silica gel 
chromatography (H2O/MeOH, gradient from 10:0 to 1:9). Ester AETD4 was obtained as a red 
oil (53 mg, 0.11 mmol, 58%). 
TLC (hexanes/EtOAc, 1:1): Rf = 0.30. [α]D22: +46.6 (c = 0.1, CHCl3). 1H NMR (CD3OD, 
400 MHz, 27 °C): δ = 8.16 (s, 1H, ArH), 8.07–8.02 (m, 2H, ArH), 7.94–7.90 (m, 2H, ArH), 
7.87−7.83 (m, 2H, ArH), 7.80 (s, 1H, ArH), 7.53–7.49 (m, 2H, ArH), 7.32–7.23 (m, 3H, ArH), 
7.19–7.15 (m, 2H, ArH), 6.35 (q, J = 7.2 Hz, 1H, CH), 5.36–5.30 (m, 2H, CH2), 1.88 (d, 
J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): δ = 159.4, 154.5, 152.0, 
141.6, 140.3, 140.1, 136.9, 131.9 (q, J = 32.2 Hz), 128.4, 128.4, 127.5, 126.1 (q, J = 3.8 Hz), 
125.8, 123.8 (q, J = 270 Hz), 122.9, 122.8, 122.5, 65.0, 59.9, 20.9 ppm. IR (neat, ATR): 
ṽ = 2928 (w), 1716 (s), 1609 (w), 1535 (w), 1491 (w), 1453 (w), 1409 (w), 1384 (w), 1350 (m), 
1323 (vs), 1212 (s), 1168 (m), 1130 (s), 1104 (s), 1064 (m), 1027 (w), 1014 (w), 921 (w), 851 
(m), 764 (w), 701 (w), 659 (w) cm-1. HRMS (ESI+): m/z calcd. for [C26H22N4O2F3]+: 479.1695, 
found: 479.1686 ([M+H]+). UV/Vis: λmax = 318, 435 nm. 
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Synthesis of tert-butyl (4-aminophenyl)carbamate (2.18) 
 
 
 
1,4-Phenylenediamine (3.24 g, 30.0 mmol, 3.0 equiv.) was dissolved in THF (30 mL) and DMF 
(10 mL) and a solution of K2CO3 (1.52 g, 11.0 mmol, 1.1 equiv.; dissolved in 5 mL of H2O) was 
added, followed by Boc2O (2.18 g, 10.0 mmol, 1.0 equiv.). The reaction mixture was stirred at 
room temperature for 16 h. The mixture was then poured onto H2O (40 mL) and extracted with 
CHCl3 (2 x 50 mL). The combined organic layers were dried over MgSO4 and the solvent was 
remover under reduced pressure. The crude product was purified by flash silica gel 
chromatography (DCM/Acetone, 4:1), yielding mono-Boc-protected amine 2.18 (1.88 g, 
9.02 mmol, 90%) as a yellow solid. 
TLC (DCM/Acetone, 4:1): Rf = 0.89. M.p.: 111–112 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.12–7.04 (m, 2H, ArH), 6.67–6.63 (m, 2H, ArH), 1.47 (s, 9H, C(CH3)3) ppm. 
13C NMR (CD3OD, 100 MHz, 27 °C): δ = 154.6, 142.8, 130.0, 120.8, 115.6, 79.0, 27.4 ppm. 
IR (neat, ATR): ṽ = 3374 (m), 3300 (w), 3213 (w), 2988 (w), 2974 (w), 1689 (m), 1599 (w), 
1523 (vs), 1460 (w), 1444 (w), 1429 (m), 1387 (w), 1365 (w), 1306 (m), 1263 (m), 1232 (s), 
1158 (vs), 1096 (w), 1055 (m), 1032 (m), 1014 (w), 926 (w), 904 (w), 852 (w), 829 (m), 771 
(m), 760 (m), 728 (m), 700 (m) cm-1. HRMS (EI+): m/z calcd. for [C11H16N2O2]+: 208.1200, 
found: 208.1212 ([M]+).  
 
Synthesis of methyl 4-((4-((tert-butoxycarbonyl)amino)phenyl)diazenyl)benzoate (2.19) 
 
 
 
Methyl 4-aminobenzoate (1.00 g, 6.62 mmol, 1.0 equiv.) was dissolved in DCM (25 mL) and 
oxone (8.12 g, 13.2 mmol, 2.0 equiv.; dissolved in 50 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 1 h at room temperature. The phases were separated, and the 
aqueous phase was extracted with DCM (20 mL). The combined organic phases were washed 
with brine (30 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
The resulting yellow solid was immediately dissolved in HOAc (50 mL) and DMSO (5 mL) and 
aniline 2.18 (1.31 g, 6.30 mmol, 0.95 equiv.) was added in 2 portions. The mixture was stirred 
for 2 d at room temperature. The mixture was basified to pH = 8–10 with 2 M NaOH and the 
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aqueous phase was extracted with DCM (2 x 40 mL). The combined organic layers were 
washed with sat. aqu. NaHCO3 (100 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (hexanes/EtOAc, gradient from 
20:1 to 2:1), affording azobenzene 2.19 (1.94 g, 5.46 mmol, 87%) as a red solid.  
TLC (hexanes/EtOAc, 4:1): Rf = 0.49. M.p.: 185–187 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 8.20–8.16 (m, 2H, ArH), 7.96–7.89 (m, 4H, ArH), 7.58–7.51 (m, 2H, ArH), 6.75 (s, 
1H, NH), 3.96 (s, 3H, CH3), 1.55 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 166.6, 155.3, 152.2, 148.2, 141.8, 131.3, 130.6, 130.4 (cis isomer), 130.2 (cis isomer), 125.3 
(cis isomer), 124.5, 122.6 (cis isomer), 122.4, 118.2, 81.2, 52.3, 28.3 ppm. IR (neat, ATR): 
ṽ = 3336 (m), 2978 (w), 1712 (vs), 1603 (m), 1535 (s), 1508 (m), 1446 (m), 1436 (m), 1414 
(m), 1394 (w), 1370 (w), 1329 (w), 1304 (m), 1281 (vs), 1233 (vs), 1189 (m), 1160 (m), 1149 
(vs), 1138 (s), 1111 (m), 1051 (m), 1026 (m), 1013 (m), 964 (w), 900 (w), 862 (m), 846 (m), 
832 (w), 770 (m), 748 (w), 724 (w), 690 (m), 678 (m) cm-1. HRMS (ESI-): m/z calcd. for 
[C19H20N3O4]-: 354.1454, found: 354.1469 ([M-H]-).  
 
Synthesis of tert-butyl (4-((4-(hydroxymethyl)phenyl)diazenyl)phenyl)carbamate (2.20) 
 
 
 
Ester 2.19 (923 mg, 2.60 mmol, 1.0 equiv.) was dissolved in THF (20 mL) and LiAlH4 (118 mg, 
3.12 mmol, 1.2 equiv.) was added at 0 °C. The mixture was warmed to room temperature and 
stirred for 5 min. A sat. aqu. solution of Rochelle’s salt (50 mL) was added and the mixture was 
stirred for 1 h. The phases were separated and the aqueous phase was extracted with EtOAc 
(2 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4 
and the solvent was removed under reduced pressure. The crude product was purified by flash 
silica gel chromatography (hexanes/EtOAc, gradient from 3:1 to 1:1), yielding primary alcohol 
2.20 (656 mg, 2.00 mmol, 77%) as an orange solid. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.55. M.p.: 167–168 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.92–7.84 (m, 4H, ArH), 7.54–7.45 (m, 4H, ArH), 6.65 (s, 1H, NH), 4.77 (d, 
J = 5.9 Hz, 2H, CH2), 1.75 (t, J = 5.9 Hz, 1H, OH), 1.54 (s, 9H, C(CH3)3) ppm. 13C NMR 
(CDCl3, 100 MHz, 27 °C): δ = 152.3, 152.2, 148.2, 143.3, 141.0, 127.4, 124.1, 122.8, 118.2, 
81.1, 64.9, 28.3 ppm. IR (neat, ATR): ṽ = 3464 (m), 3434 (m), 3269 (w), 2925 (w), 1723 (m), 
1698 (m), 1602 (m), 1524 (s), 1504 (m), 1451 (w), 1431 (w), 1406 (m), 1365 (m), 1319 (m), 
1310 (m), 1300 (m), 1268 (w), 1229 (m), 1150 (s), 1110 (m), 1052 (m), 1028 (m), 1014 (m), 
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995 (m), 898 (w), 845 (vs), 822 (m), 776 (m), 744 (w), 726 (m) cm-1. HRMS (ESI+): m/z calcd. 
for [C18H22N3O3]+: 328.1661, found: 328.1656 ([M+H]+).  
 
Synthesis of (R)-4-((4-((tert-butoxycarbonyl)amino)phenyl)diazenyl)benzyl 1-(1-phenyl-
ethyl)-1H-imidazole-5-carboxylate (2.21) 
 
 
 
Carboxylic acid 2.13 (97 mg, 0.45 mmol, 1.0 equiv.), primary alcohol 2.20 (147 mg, 
0.450 mmol, 1.0 equiv.) and DMAP (55 mg, 0.45 mmol, 1.0 equiv.) were dissolved in DCM 
(5 mL) and DMF (0.5 mL). Diisopropylcarbodiimide (0.11 mL, 0.68 mmol, 1.5 equiv.) was 
added and the mixture was stirred at room temperature for 8 h. The solvent was removed under 
reduced pressure and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, gradient from 4:1 to 1:1), followed by another reversed-phase flash silica gel 
chromatography (H2O/MeOH, gradient from 20:0 to 1:9), yielding ester 2.21 (215 mg, 
0.410 mmol, 91%) as a red solid.  
TLC (hexanes/EtOAc, 1:1): Rf = 0.44. [α]D22: +36.0 (c = 1.0, CHCl3). M.p.: 179–181 °C. 
1H NMR (CD3OD, 400 MHz, 27 °C): δ = 8.13 (s, 1H, ArH), 7.86–7.81 (m, 4H, ArH), 7.78 (s, 
1H, ArH), 7.61–7.57 (m, 2H, ArH), 7.48–7.44 (m, 2H, ArH), 7.32–7.24 (m, 3H, ArH), 
7.18−7.14 (m, 2H, ArH), 6.34 (q, J = 7.2 Hz, 1H, CH), 5.32–5.28 (m, 2H, CH2), 1.87 (d, 
J = 7.2 Hz, 3H, CH3), 1.53 (s, 9H, C(CH3)3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 159.5, 153.4, 152.4, 147.7, 142.6, 141.5, 140.2, 138.4, 136.9, 128.4, 128.4, 127.5, 125.7, 
123.5, 122.3, 119.8, 118.0, 79.9, 65.2, 55.9, 27.2, 20.9 ppm. IR (neat, ATR): ṽ = 3371 (w), 
2976 (w), 2310 (w), 1715 (s), 1603 (m), 1539 (w), 1506 (m), 1453 (w), 1434 (m), 1387 (vs), 
1367 (s), 1304 (m), 1256 (m), 1217 (vs), 1160 (m), 1132 (m), 1119 (s), 1072 (s), 1028 (w), 
1012 (w), 983 (w), 930 (w), 887 (w), 864 (w), 846 (m), 832 (m), 762 (m), 774 (m), 742 (w), 725 
(w), 708 (w), 694 (w), 660 (w) cm-1. HRMS (ESI+): m/z calcd. for [C30H32N5O4]+: 526.2454, 
found: 526.2446 ([M+H]+). 
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Synthesis of (R)-4-((4-aminophenyl)diazenyl)benzyl 1-(1-phenylethyl)-1H-imidazole-5-
carboxylate (AETD5) 
 
 
 
Boc-protected aniline 2.21 (75 mg, 0.14 mmol) was dissolved in 1,4-dioxane (3 mL) and a 4 M 
solution of HCl in dioxane (3 mL) was added. The mixture was stirred for 16 h at room 
temperature. 1 M HCl (20 mL) was added and the aqueous phase was washed with EtOAc 
(20 mL). The aqueous phase then was basified to pH = 8–10 with 2 M NaOH and extracted with 
CHCl3 (2 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by reversed-phase flash 
silica gel chromatography (H2O/MeOH, gradient from 10:0 to 2:8), yielding ester AETD5 
(52 mg, 0.12 mmol, 86%) as a orange oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.34. [α]D22: +47.3 (c = 1.0, CHCl3). 1H NMR (CD3OD, 
400 MHz, 27 °C): δ = 8.11 (s, 1H, ArH), 7.76–7.68 (m, 5H, ArH), 7.44–7.41 (m, 2H, ArH), 
7.33−7.21 (m, 3H, ArH), 7.17–7.13 (m, 2H, ArH), 6.74–6.70 (m, 2H, ArH), 6.33 (q, J = 7.2 Hz, 
1H, CH), 5.28 (s, 2H, CH2), 1.86 (d, J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (CD3OD, 100 MHz, 
27 °C): δ = 159.5, 152.8, 152.4, 144.2, 141.6, 140.2, 137.1, 136.8, 128.5, 128.4, 127.5, 125.8, 
124.9, 122.6, 121.8, 113.7, 65.4, 55.9, 20.9 ppm. IR (neat, ATR): ṽ = 3344 (m), 3214 (m), 
1714 (m), 1621 (m), 1600 (vs), 1537 (w), 1507 (m), 1456 (w), 1430 (w), 1405 (w), 1383 (w), 
1350 (m), 1306 (m), 1212 (s), 1137 (s), 1107 (m), 1054 (w), 839 (m), 759 (m), 701 (w), 659 
(w) cm-1. HRMS (ESI+): m/z calcd. for [C25H24N5O2]+: 426.1930, found: 426.1923 ([M+H]+). 
UV/Vis: λmax = 410 nm. 
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2.3.3 NMR SPECTRA 
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2.3.4 UV/VIS SPECTRA OF AETD1–5 
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2.3.5 HPLC CHROMATOGRAMS OF AETD2 
 
AETD2 
AETD2 was obtained 98.5% pure as a mixture of trans (Rt = 10.89 min) and cis isomers 
(Rt = 8.68 min). As expected from the UV/Vis spectrum (see above), the cis isomer has almost 
no absorption at λ = 360 nm. Both peaks possess the same mass of 411.1 ([M+H]+).  
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3 PHOTOCONTROL OF TRP CHANNELS 
 
3.1 TRANSIENT RECEPTOR POTENTIAL CHANNELS 
 
The transient receptor potential (TRP) channels form a large superfamily of versatile channels 
that are expressed in every cell type in both vertebrates and invertebrates. They are involved in 
the perception of a broad variety of different physical and chemical stimuli and in the initiation 
of cellular responses therein.[1] All TRP family members are homologues of the first 
characterized Drosophila TRP channel which is involved in the response to bright light.[2] It was 
found that sustained light induced a transient rather than a normal sustained, plateau-like 
receptor potential in photoreceptors of Drosophila which was then described as the trp 
mutation. Cloning of the trp gene revealed that is encodes a Ca2+ permeable channel[3] which 
functions as receptor-operated channel that is activated downstream of the light-induced 
phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2).[4] 
As of today, it remains to be investigated whether TRP channels open upon reduction of PIP2 or 
activation by diacyl glycerol (DAG) or fatty acids derived from DAG.[5]  
Seven subclasses of TRP channels based on their structural homology exist (Fig. 3.1)[6] and 
more than 50 TRP channels have been identified.  
 
 
 
 
 
 
 
 
 
 
 
Figure	  3.1.	   TRP	   Channel	   subfamilies.	   Illustration	   adapted	   from	   Voets	   et	   al.,[6]	   reprinted	   with	  
permission	  from	  Macmillan	  Publishers	  Ltd.	  Copyright	  2005.	  
	  
The TRPC (canonical or classical) subfamily members exhibit the highest homology to 
Drosophila TRP channels.[1] The nomenclature of the other subfamilies originates from their 
first identified members. The TRPV subfamily was named after the vanilloid receptor 1 
(TRPV1), the TRPM subfamily after the tumor suppressor melastatin (TRPM1), the TRPA 
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subfamily after the protein ankyrin-like with transmembrane domains 1 (ANKTM1, now 
TRPA1), the TRPN subfamily after the no mechanoreceptor potential C gene (nompC) from 
Drosophila, the TRPP subfamily after the polycystic kidney disease-related protein 2 (PKD2, 
now TRPP2) and the TRPML subfamily after mucolipin 1 (TRPML1).[1] 
 
 
Figure	  3.2.	   Model	  for	  the	  TRPV6	  pore	  region	  based	  on	  the	  KcsA	  structure.	  Views	  of	  the	  structure	  
are	  shown	  looking	  sideways	  at	  two	  opposite	  subunits	  (left)	  or	  looking	  down	  from	  the	  extracellular	  side	  
on	  the	  homotetrameric	  channel.	  Illustration	  adapted	  from	  Voets	  et	  al.,[7]	  reprinted	  with	  permission	  from	  
the	  American	  Society	  for	  Biochemistry	  and	  Molecular	  Biology.	  Copyright	  2004.	  
 
TRP Channels consist of six transmembrane domains (TM) and a cation-permeable pore region 
between TM5 and TM6. They function either as homo- or heterotetramers.[8] Obtaining 
structural information at the atomic level for any full-length TRP channel is challenging due to 
difficulties encountered in overexpression.[9] In 2009, Moiseenkova-Bell et al.[9] were able to 
obtain a TRPV1 structure at 19 Å resolution from single-particle analysis and electron cryo-
microscopy. In 2007, Lishko et al.[10] were successful in crystallizing ankyrin repeats as part of 
the cytosolic residue of TRPV1. Still, most information about the pore structure has been 
obtained for members of the TRPV subfamily since the TM5–6 linker region shows significant 
sequence homology to the selectivity filter of the prokaryotic potassium channel KcsA.[11] 
Mutations of negatively charged residues in TRPV1 and TRPV4 strongly reduce the 
permeabilities of Ca2+ and Mg2+ and reduce affinity for the TRP channel blocker Ruthenium 
Red.[12] Similar to the KcsA crystal structure, residues preceding these negatively charged 
amino acids show a cyclic pattern of reactivity and thus are believed to form a pore helix.[1] In 
TRPV6, the selectivity filter follows the pore helix with a diameter of approximately 5.4 Å (Fig. 
3.2).[7] The narrowest point of the pore is shaped by D541 which contributes to the selectivity 
filter.[7] 
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Very recently, Liao et al.[13] and Cao et al.[14] managed to obtain mammalian TRPV1 structures 
at a resolution of 3.4 Å by exploiting recent advances in electron cryo-microscopy.  
The intracellular amino and carboxy termini vary in their lengths between the different TRP 
subfamilies and can contain significantly different domains (Fig 3.3).[15] These cytoplasmic 
domains play an important role in the regulation and modulation of channel function but mostly 
remained poorly understood so far.[1] 
 
 
Figure	  3.3.	   Schematic	   structural	   composition	   of	   TRP	   channels.	   The	   subfamilies	   differ	   mostly	   in	  
their	   cytosolic	  N-­‐	  and	  C-­‐termini	   composition.	   Illustration	  adapted	   from	  Moran	  et	  al.,[15]	   reprinted	  with	  
permission	  from	  Macmillan	  Publishers	  Ltd.	  Copyright	  2011.	  
 
Certain TRP channels of different subfamilies play an important role in temperature perception, 
both for heat as well as cooling sensation (Fig. 3.4). Temperatures range from warm (>25 °C for 
TRPV3,[16] >31 °C for TRPV4[17]) to heat (>43 °C for TRPV1[18]), and noxious heat (>52 °C for 
TRPV2[19]). Moreover, TRPM4 and TRPM5[20] are activated upon heating, whereas 
TRPM8[16a,21] and TRPA1[22] are activated upon cooling. Some of these channels are also 
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activated by various ligands, such as capsaicin (TRPV1), menthol (TRPM8), camphor (TRPV3) 
or allyl isothiocyanate (TRPA1). 
 
 
Figure	  3.4.	   Thermosensitive	  TRP	  channels.	  The	  temperature	  spectrum	  ranges	  from	  <8°C	  (TRPA1)	  
to	   >52	  °C	   (TRPV2).	   Illustration	   adapted	   from	  Dhaka	  et	   al.,[23]	   reprinted	  with	  permission	   from	  ANNUAL	  
REVIEWS.	  Copyright	  2006.	  
 
Several hypotheses have been proposed to explain the temperature sensitivity of TRP 
channels.[24] A rather unlikely model proposes that changes in temperature might stimulate 
generation of an endogenous ligand that in turn activates a particular TRP channel. This model 
is contradicted by the finding that most thermosensitive TRP channels (except TRPV4) display 
temperature-sensitivity in cell-free membranes. Another model proposes either a temperature-
dependent phase transition of the lipid membrane or a conformational transition of the channel 
protein which usually happens within a narrow temperature range. A newer hypothesis within 
the model covers the cold activation of TRPM8 and heat activation of TRPV1.[25] Both channels 
are voltage-gated channels that are activated upon membrane depolarization. This voltage-
dependent activation could be shifted by changes in temperature from strongly depolarized 
potentials (voltage for half-maximal activation, V1/2 ≈ 150 mV) to physiological potential. Thus, 
temperature-dependent activation would be rather gradual, unlike a single sharp thermal 
threshold predicted from temperature-induced conformational changes or phase transitions of 
the lipid membrane.[25] 
Arguably, the pharmacologically most relevant among the TRP channel subfamilies is the 
capsaicin receptor TRPV1 which plays a major role in nociception and heat sensation. Contrary 
to TRPV1, the menthol receptor TRPM8 (among others) is responsible for the perception of low 
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temperatures. These two channels were chosen as target receptors for optochemical control with 
azobenzene-based photoswitches in this thesis and will be discussed in detail below. 
 
 
3.2 OPTICAL CONTROL OF TRPV1 CHANNELS 
 
TRPV1 is most abundant in dorsal root ganglion (DRG) and trigeminal ganglion (TG) cells, as 
well as in spinal and peripheral nerve terminals.[1] The channel is mostly located in the plasma 
membrane and in intracellular membranes (e.g. endoplasmic reticulum) where it functions as an 
intracellular Ca2+ release channel.[26] Assembly of the homotetrameric channel seems to require 
the putative TRP-box on the C-terminus of each subunit.[27] Moreover, two calmodulin (CaM) 
binding domains (CaMBDs) determine the CaM-dependent regulation of TRPV1 activity.[1] 
Whereas binding of CaM to the N-terminal CaMBD reduces capsaicin-activated currents,[28] 
binding of capsaicin to CaMBD at the C-terminus results in desensitization of these currents.[29] 
TRPV1 is a nonselective cation channel with a rather low discrimination between mono- and 
divalent cations (PCa/PNa = 1–10).[30] Activation of TRPV1 results in a sensation of burning and 
pain. There are several chemical and physical stimuli that can activate TRPV1 such as heat, 
voltage, phosphorylation by protein kinase C (PKC), low pH (TRPV1 is also permeable to 
H+[31]) and endogenous as well as exogenous ligands. Fig. 3.5 gives an overview of some known 
agonists for TRPV1. Many of these have a vanilline moiety incorporated into their structure 
which is also responsible for the name of this subfamiliy of TRP channels: Transient Receptor 
Potential Vanilloid (TRPV) channel. 
The most common agonist for TRPV1 is capsaicin, the main ingredient in hot chili peppers.[18] 
The cis isomer of capsaicin with respect to the double bond also functions as an agonist and is 
marketed under various names (Zucapsaicin, Civamide, WN-1001).[32] Allyl isothiocyanate, the 
pungent compound in mustard, horseradish and wasabi, activates TRPV1 as well as TRPA1.[33] 
The complex natural product resiniferatoxin (RTX) was isolated from the cactus Euphorbia 
resinifera[34] and is an ultra-potent capsaicin analogue that has a rating of 16,000,000,000 on the 
Scoville Scale,[u,35] making it one of the highest rated substances known. Piperine, which was 
isolated from black pepper,[36] has the two oxygens of vanilline fused into an acetal and is also 
used as an insecticide. There is evidence that the endocannabinoid anandamide also activates 
TRPV1.[37] Although the receptor is mainly found in nociceptive neurons of the peripheral 
nervous system, these receptors have also been found in the brain where their role is far less 
                                                
[u]  The Scoville Scale is a measurement of the spicy heat of chili peppers. Capsaicin itself has a 
value of 16,000,000 SHU (Scoville Heat Units). 
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understood. In 2010, it was discovered that synaptic activation of TRPV1 triggered a form of 
long-term depression mediated by the endocannabinoid anandamide in a type 1 cannabinoid 
receptor–independent manner.[38]  
 
 
Figure	  3.5.	   Overview	  of	  various	  TRPV1	  agonists.	  
 
Moreover, leucotriene B4 was shown to mediate inflammation[39] and histamine-induced 
itching[40] via TRPV1. Olvanil was developed as an orally active analgesic and activates TRPV1 
at the same or slightly stronger potency as capsaicin, albeit exhibiting only weak pungency 
which was thought to be caused by the strong lipophilicity of the compound.[41] Its name 
originates from the two constitutive parts of the molecule, a vanilline core that is esterified with 
oleanolic acid. Arvanil follows the same logic as orvanil with arachidonic acid instead of 
oleanolic acid and was just recently shown to induce cell death of high-grade astrocytomas by 
stimulation of TRPV1.[42]    
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The pharmacological relevance of TRPV1 corresponds to the extensive research effort in 
finding selective antagonists. Fig. 3.6. shows a selection of current highly potent TRPV1 
antagonists. Many of these compounds are in clinical trial phases 1 to 3. Subsequently, not 
much information on them has been published as of today. 
Ruthenium Red very effectively blocks all TRPV channels as well as TRPC1/3, TRPM6 and 
TRPA1.[1,12] Capsazepine (CPZ) was developed by Sandoz in 1994[43] and is described as a very 
specific competitive antagonist for TRPV1. However, it can also inhibit TRPM8 at higher 
concentrations[44] and meanwhile was found to also act on nicotinic acetylcholine receptors 
(nAChRs)[45] as well as voltage-gated Ca2+ channels.[46] To date, BCTC and thio-BCTC are the 
most specific blockers for TRPV1.[44] Both, CPZ and BCTC, will be discussed briefly later (see 
next section). Moreover, iodination of RTX to form 5-iodoresiniferatoxin (I-RTX; structure not 
shown here) turns the ultrapotent agonist RTX into a strong competitive antagonist of 
TRPV1.[47]  
 
 
Figure	  3.6.	   Overview	  of	  TRPV1	  antagonists.	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In 2006, Siemens et al.[48] showed that venom from a tarantula that is native to the West Indies 
contains three inhibitor cysteine knot (ICK) peptides that target TRPV1. Since some 
vanillotoxins also inhibit voltage-gated potassium channels, potential similarities between TRP 
and voltage-gated channel structures are supported by this finding. More recently, Bohlen et 
al.[49] showed that a peptide toxin from the Earth Tiger tarantula selectively and irreversibly 
activates TRPV1. Its high avidity interaction is derived from a unique tandem repeat structure 
of the toxin that endows it with an antibody-like bivalency. Bohlen et al.[49] found that the 
‘double-knot’ toxin traps TRPV1 in the open state by interacting with residues in the 
presumptive pore-forming region of the channel, highlighting the importance of conformational 
changes in the outer pore region of TRP channels during activation.[49] 
In order to be able to control this highly interesting channel with light, photoswitchable 
derivatives of the well-known TRPV1 antagonists CPZ and BCTC were designed and 
synthesized (see below). Based on their molecular structure and published SAR data, these two 
antagonists seemed to be the best candidates for the introduction of a photoswitchable 
azobenzene moiety. On the following pages, the original publication of this work is presented 
which was published in Angewandte Chemie International Edition in 2013.[v] 
Please note that the numbering of schemes and figures in the accompanying Supporting 
Information (but not in the manuscript itself) was adjusted to fit the consecutive numbering of 
this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
[v] reprinted with permission from John Wiley & Sons. Copyright 2013. 
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General Experimental Details and Instrumentation 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[50] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
1H and 13C spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0; DMSO-d6: δH 2.50, 
δC 39.5; acetone-d6: δH 2.05, δC 29.8, 206.6).[51] Multiplicities are abbreviated as follows: 
s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, sept = septet, 
m = multiplet. High resolution mass spectra (EI, ESI) were recorded by LMU Mass 
Spectrometry Service using a Thermo Finnigan MAT 95, a Jeol MStation, or a Thermo 
Finnigan LTQ FT Ultra instrument. Melting points were obtained using a Stanford Research 
Systems MPA120 apparatus and are uncorrected. 
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Synthetic Procedures 
 
Synthesis of Azepine Core 7 from Isovanilline 6 
 
 
Scheme	  3.1.	   Synthesis	  of	  azepine	  core	  7.	  
 
Synthesis of (E)-methyl 3-(3-hydroxy-4-methoxyphenyl)acrylate (10) 
 
 
 
Isovanillin (6; 10.0 g, 65.7 mmol, 1.0 equiv.) and carbmethoxy methylene triphenyl 
phosphorane (24.2 g, 72.3 mmol, 1.1 equiv.) were dissolved in DCM (220 mL) and stirred at 
room temperature for 16 h. The mixture was then heated to reflux for 2 h. After cooling, the 
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solvent was removed in vacuo and the crude product was purified by flash silica gel column 
chromatography (hexanes/EtOAc, 2:1 → 3:2) to yield olefin 10 (13.2 g, 63.5 mmol, 97%) as a 
colorless solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.38. M.p.: 76–78 °C. 1H NMR (CDCl3, 400 MHz, 27 °C): 
δ = 7.60 (d, J = 15.9 Hz, 1H, CH), 7.14 (d, J = 2.1 Hz, 1H, ArH), 7.03 (dd, J = 8.3, 2.1 Hz, 1H, 
ArH), 6.84 (d, J = 8.3 Hz, 1H, ArH), 6.29 (d, J = 15.9 Hz, 1H, CH), 5.63 (s, 1H, OH), 3.93 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 167.7, 148.5, 
145.8, 144.6, 128.0, 121.8, 115.8, 112.9, 110.5, 56.0, 51.6 ppm. IR (neat, ATR): ṽ = 3412 (w), 
1698 (m), 1635 (m), 1613 (m), 1583 (m), 1511 (s), 1456 (w), 1439 (m), 1350 (w), 1314 (m), 
1264 (vs), 1195 (m), 1172 (m), 1160 (m), 1131 (m), 1025 (m), 980 (m), 925 (w), 856 (w), 805 
(m), 762 (w) cm-1. HRMS (EI+): m/z calcd. for [C11H12O4]+: 208.0736, found: 208.0749 ([M]+). 
 
Synthesis of methyl 3-(3-hydroxy-4-methoxyphenyl)propanoate (11) 
 
 
 
Olefin 10 (13.2 g, 63.4 mmol) was dissolved in MeOH (150 mL) and palladium on charcoal 
(2.60 g; 10%) was added. The reaction flask was evacuated and repurged with hydrogen (5x) 
and then stirred at room temperature under a hydrogen atmosphere (1 bar) for 16 h, filtered 
through Celite and washed thoroughly with DCM. The solvent was removed under reduced 
pressure, yielding compound 11 quantitatively (13.3 g, 63.3 mmol, 100%) as a colorless solid.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.67. M.p.: 91–93 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.81–7.76 (m, 2H, ArH), 7.72–7.67 (m, 1H, ArH), 5.57 (s, 1H, OH), 3.88 (s, 3H, OCH3), 
3.69 (s, 3H, OCH3), 2.90–2.83 (m, 2H, CH2), 2.64–2.57 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 173.4, 145.5, 145.0, 133.8, 119.6, 114.5, 110.7, 56.0, 51.6, 35.9, 
30.4 ppm. IR (neat, ATR): ṽ = 3427 (m), 1728 (vs), 1619 (w), 1588 (m), 1514 (m), 1458 (m), 
1442 (m), 1422 (w), 1370 (m), 1301 (m), 1269 (s), 1236 (m), 1220 (m), 1195 (m), 1180 (s), 
1148 (m), 1127 (m), 1054 (w), 1027 (m), 1013 (m), 979 (w), 959 (w), 894 (w), 874 (w), 816 
(m), 810 (m), 786 (w), 762 (w) cm-1. HRMS (EI+): m/z calcd. for [C11H14O4]+: 210.0892, found: 
210.0883 ([M]+). 
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Synthesis of 3-(3-hydroxy-4-methoxyphenyl)propanoic acid (12) 
 
 
 
Methyl ester 11 (13.2 g, 62.8 mmol) was dissolved in THF (100 mL) and a 2 M solution of 
LiOH (35 mL) was added. The mixture was stirred for 16 h at room temperature. Since TLC 
indicated remaining starting material, another 20 mL of 2 M LiOH was added and stirred for 
another 20 h. The mixture was acidified to pH = 2–3 with 2 M HCl and extracted with EtOAc 
(3 x 50 mL). The combined organic phases were washed with brine (75 mL), dried over MgSO4 
and concentrated under reduced pressure to yield free acid 12 (12.1 g, 61.7 mmol, 98%) as a 
colorless solid. 
M.p.: 140–141 °C. 1H NMR (CD3OD, 400 MHz, 27 °C): δ = 6.79 (d, J = 8.2 Hz, 1H, ArH), 
6.66 (d, J = 2.1 Hz, 1H, ArH), 6.62 (dd, J = 8.2, 2.1 Hz, 1H, ArH), 3.79 (s, 3H, OCH3), 
2.79−2.73 (m, 2H, CH2), 2.53–2.48 (m, 2H, CH2) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 175.4, 146.0, 133.7, 120.1, 118.9, 114.9, 111.5, 55.1, 35.6, 30.0 ppm. IR (neat, ATR): 
ṽ = 3307 (m), 1684 (vs), 1518 (m), 1456 (m), 1315 (m), 1211 (m), 1079 (m), 967 (w), 938 (w), 
808 (w), 766 (w), 732 (w) cm-1. HRMS (EI+): m/z calcd. for [C10H13O4]+: 197.0814, found: 
197.0808 ([M+H]+). 
 
Synthesis of N-benzyl-3-(3-hydroxy-4-methoxyphenyl)propanamide (13) 
 
 
 
Carboxylic acid 12 (12.1 g, 61.7 mmol, 1.0 equiv.) was heated together with benzyl amine 
(40.0 mL, 370 mmol, 6.0 equiv.) and 3Å molecular sieves (10.0 g) to 150 °C for 16 h. The 
mixture was cooled, diluted with DCM (300 mL), washed with 1 M HCl (3 x 150 mL), a sat. 
aqu. solution of NaHCO3 (2 x 150 mL), water (100 mL) and brine (100 mL). The organic phase 
was dried over MgSO4 and the solvent removed in vacuo. The crude product was purified by 
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flash silica gel column chromatography (DCM/MeOH, 98:2 → 95:5) to give benzyl amide 13 
(9.65 g, 33.8 mmol, 55%) as a colorless solid. 
TLC (DCM/MeOH, 95:5): Rf = 0.38. M.p.: 112–114 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.32–7.24 (m, 3H, ArH), 7.17–7.13 (m, 2H, ArH), 6.77 (d, J = 2.1 Hz, 1H, ArH), 
6.74 (d, J = 8.2 Hz, 1H, ArH), 6.67 (dd, J = 8.2, 2.1 Hz, 1H, ArH), 5.60 (br m, 2H, OH, NH), 
4.39 (d, J = 5.6, 2.1 Hz, 2H, CH2), 3.86 (s, 3H, OCH3), 2.93–2.87 (m, 2H, CH2), 2.49–2.45 (m, 
2H, CH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 171.9, 145.6, 145.1, 138.1, 134.0, 
128.6, 127.7, 127.4, 119.8, 114.4, 110.7, 56.0, 43.6, 38.6, 31.1 ppm. IR (neat, ATR): ṽ = 3290 
(m), 1643 (s), 1590 (m), 1512 (vs), 1453 (m), 1440 (m), 1355 (w), 1272 (s), 1240 (m), 1176 
(m), 1153 (m), 1130 (m), 1082 (w), 1028 (m), 957 (w), 912 (w), 867 (w), 805 (m), 760 (m), 733 
(m), 698 (m) cm-1. HRMS (EI+): m/z calcd. for [C17H19NO3]+: 285.1365, found: 285.1360 
([M]+). 
 
Synthesis of 5-(3-(benzylamino)propyl)-2-methoxyphenol (14) 
 
 
 
To a solution of amide 13 (9.65 g, 33.8 mmol, 1.0 equiv.) in THF (200 mL) was added slowly a 
suspension of LiAlH4 (2.57 g, 67.6 mmol, 2.0 equiv.) in THF (100 mL) at room temperature 
(gas evolution!). The reaction mixture was heated to reflux for 16 h. A sat. aqu. solution of 
Rochelle’s salt (500 mL) was added and the mixture was stirred vigorously for 1 h. The phases 
were separated and the aqueous layer was extracted with EtOAc (2 x 200 mL). The combined 
organic layers were washed with water (200 mL) and brine (200 mL), dried over MgSO4 and 
the solvent was removed under reduced pressure. The crude product was purified by flash silica 
gel column chromatography (DCM/MeOH, gradient from 20:1 to 10:1) to give secondary amine 
14 (8.52 g, 31.4 mmol, 93%) as a colorless solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.67. M.p.: 115–117 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.39–7.20 (m, 5H, ArH), 6.79–6.75 (m, 2H, ArH), 6.66 (dd, J = 8.2, 2.1 Hz, 1H, 
ArH), 3.88 (s, 3H, OCH3), 3.80 (s, 2H, NCH2), 2.72–2.65 (m, 2H, CH2), 2.62–2.55 (m, 2H, 
CH2), 1.91−1.77 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 145.5, 144.8, 
140.0, 135.4, 128.4, 128.2, 127.0, 119.6, 114.6, 110.6, 56.0, 53.8, 48.7, 33.0, 31.5 ppm. IR 
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(neat, ATR): ṽ = 2932 (m), 2836 (w), 1586 (m), 1509 (s), 1452 (m), 1441 (m), 1349 (w), 1274 
(vs), 1243 (s), 1221 (s), 1178 (m), 1154 (m), 1132 (s), 1071 (w), 1028 (m), 961 (w), 908 (w), 
867 (w), 802 (m), 737 (m), 698 (s) cm-1. HRMS (EI+): m/z calcd. for [C17H21O2N]+: 217.1572, 
found: 271.1568 ([M]+). 
 
Synthesis of 2-benzyl-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-ol (15) 
 
 
 
Amine 14 (5.50 g, 20.3 mmol, 1.0 equiv.) and paraformaldehyde (670 mg, 22.3 mmol, 
1.1 equiv.) were dissolved in acetonitrile (180 mL) and MeSO3H (1.45 mL, 22.3 mL, 1.1 equiv.) 
was added. The mixture was heated to reflux for 16 h. A sat. aqu. solution of NaHCO3 (200 mL) 
was added and the phases were separated. The aqueous phase was extracted with DCM 
(5 x 50 mL) and the combined organic layers were washed with water (150 mL) and brine 
(150 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by flash silica gel column chromatography (DCM/MeOH, 10:1) to give 
benzazepine 15 (5.47 g, 19.3 mmol, 95%) as a pale yellow solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.34. M.p.: 115–117 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.34–7.21 (m, 5H, ArH), 6.75 (s, 1H, ArH), 6.42 (s, 1H, ArH), 5.74 (br s, 1H, OH), 
3.83 (s, 2H, NCH2), 3.79 (s, 3H, OCH3), 3.56 (s, 2H, CH2), 3.17–3.09 (m, 2H, CH2). 2.85–2.77 
(m, 2H, CH2), 1.80–1.67 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 144.0, 
143.9, 139.2, 136.2, 130.6, 129.1, 128.1, 126.9, 115.6, 113.2, 58.9, 58.6, 57.3, 56.0, 35.4, 
25.2 ppm. IR (neat, ATR): ṽ = 3526 (w), 2926 (m), 2841 (w), 1590 (m), 1513 (m), 1495 (m), 
1449 (m), 1332 (m), 1282 (s), 1247 (m), 1205 (m), 1173 (m), 1104 (s), 1079 (w), 1040 (m), 
1028 (w), 970 (m), 909 (m), 886 (w), 850 (m), 794 (w), 760 (m), 731 (vs), 698 (m) cm-1. 
HRMS (EI+): m/z calcd. for [C18H21O2N]+: 283.1572, found: 283.1568 ([M]+). 
 
Synthesis of 8-methoxy-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-ol (16) 
 
 
 
Benzyl protected benzazepine 15 (5.80 g, 20.5 mmol, 1.0 equiv.) was dissolved in MeOH 
(150 mL) and palladium on charcoal (1.5 g; 10%) was added under an argon atmosphere. The 
reaction flask was evacuated and repurged with hydrogen (5x) and then stirred at room 
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temperature overnight under a hydrogen atmosphere (1 bar). The mixture was filtered through 
Celite, washed with MeOH and concentrated in vacuo, affording debenzylated benzazepine 16 
(3.76 g, 19.5 mmol, 95%) as a colorless solid. The crude product was sufficently pure for the 
next step. 
TLC (DCM/MeOH, 10:1): Rf = 0.09. M.p.: 137–138 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 6.75 (s, 1H, ArH), 6.62 (s, 1H, ArH), 3.85 (s, 2H, NCH2), 3.80 (s, 3H, OCH3), 3.34 
(s, 2H, NCH2), 3.15–3.11 (m, 2H, CH2), 2.82–2.77 (m, 2H, CH2), 1.75–1.69 (m, 2H, CH2) ppm. 
13C NMR (CD3OD, 100 MHz, 27 °C): δ = 145.4, 145.3, 133.7, 130.6, 116.5, 113.2, 55.3, 53.1, 
52.2, 34.4, 29.2 ppm. IR (neat, ATR): ṽ = 2933 (m), 2839 (m), 1592 (m), 1516 (s), 1449 (s), 
1334 (m), 1281 (vs), 1243 (m), 1207 (m), 1106 (m), 1079 (w), 1016 (w), 884 (w), 851 (m), 778 
(w) cm-1. HRMS (EI+): m/z calcd. for [C11H15O2N]+: 193.1103, found: 193.1098 ([M]+). 
 
Synthesis of 2,3,4,5-tetrahydro-1H-benzo[c]azepine-7,8-diol hydrobromide (7) 
 
 
 
Methyl ether 16 (1.00 g, 5.17 mmol) was dissolved in aqu. 48% HBr (13 mL) and heated to 
reflux for 20 h. The cooled solution was concentrated in vacuo, resuspended in MeOH (3 mL) 
and sonicated for 30 min. The suspension was centrifuged and the supernatant was removed. 
The grey solid was suspended in Et2O (5 mL), centrifuged and the supernatant was removed 
again. This procedure was repeated five times and the grey solid obtained was dried under high 
vacuum to give HBr salt 7 (650 mg, 2.50 mmol, 48%) as a grey solid. 
M.p.: 210 °C (dec.). 1H NMR (DMSO-d6, 400 MHz, 27 °C): δ = 9.03 (br s, 1H, OH), 8.86 (br 
s, 1H, OH), 8.57 (br s, 2H, NH2), 6.74 (s, 1H, ArH), 6.60 (s, 1H, ArH), 4.15–4.02 (m, 2H, 
NCH2), 3.28–3.22 (m, 2H, CH2), 2.78–2.70 (m, 2H, CH2), 1.82–1.71 (m, 2H, CH2) ppm. 
13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 145.7, 143.4, 134.4, 123.3, 118.9, 117.4, 50.4, 
50.1, 33.0, 25.9 ppm. IR (neat, ATR): ṽ = 3496 (w), 2971 (m), 2843 (m), 1613 (m), 1570 (m), 
1524 (m), 1466 (w), 1440 (w), 1425 (w), 1387 (m), 1358 (w), 1323 (w), 1286 (vs), 1253 (m), 
1203 (m), 1170 (m), 1150 (m), 1101 (m), 1071 (m), 1020 (w), 984 (w), 968 (w), 878 (m), 850 
(s), 773 (m), 739 (w), 661 (w) cm-1. HRMS (EI+): m/z calcd. for [C10H13O2N]+: 179.0946, 
found: 179.0937 ([M-HBr]+). 
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Synthesis of Isothiocyanate 19a 
 
 
Scheme	  3.2.	   Synthesis	  of	  isothiocyanate	  19a.	  
 
Synthesis of tert-butyl 4-aminophenethylcarbamate (2) 
 
 
 
Aminoaniline 1 (4.40 mL, 34.2 mmol, 1.0 equiv.) was dissolved in THF (110 mL) and Boc2O 
(7.92 g, 36.3 mmol, 1.05 equiv.) and DMAP (418 mg, 3.42 mmol, 0.1 equiv.) were added. The 
mixture was stirred for 16 h at room temperature. The solvent was removed and the crude 
product was purified by flash silica gel column chromatography (hexanes/EtOAc, 95:5 → 6:1, 
then gradient to 1:1) to give Boc-protected amine 2 (7.37 g, 31.2 mmol, 91%) as a colorless 
solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.25. M.p.: 68–69 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.01–6.93 (m, 2H, ArH), 6.66–6.60 (m, 2H, ArH), 4.52 (br s, 1H, NH), 3.59 (br s, 2H, NH2), 
3.38–3.24 (m, 2H, CH2), 2.72–2.62 (m, 2H, CH2), 1.43 (s, 9H, C(CH3)3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 155.9, 144.8, 129.6, 128.8, 115.3, 79.1, 42.0, 35.2, 28.4 ppm. IR 
(neat, ATR): ṽ = 3351 (m), 2974 (m), 2934 (w), 1687 (s), 1622 (m), 1581 (w), 1514 (vs), 1451 
(m), 1390 (m), 1364 (m), 1248 (m), 1161 (vs), 1047 (m), 958 (m), 864 (m), 823 (m), 774 (m), 
756 (m), 678 (w) cm-1. HRMS (EI+): m/z calcd. for [C13H20N2O2]+: 236.1525, found: 236.1519 
([M]+). 
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Synthesis of tert-butyl 4-(phenyldiazenyl)phenethylcarbamate (17a) 
 
 
 
Nitrosobenzene (101 mg, 0.940 mmol, 1.1 equiv.) was dissolved in a mixture of ethanol 
(2.1 mL) and glacial acetic acid (0.76 mL) with careful heating to 50 °C. The clear green 
solution was cooled to room temperature again and aniline 2 (200 mg, 0.850 mmol, 1.0 equiv.) 
was added in 3 portions within 5 min. The mixture was stirred for 2 h at room temperature. A 
sat. aqu. solution of NaHCO3 was added (20 mL; gas evolution!) and the aqueous phase was 
extracted with EtOAc (30 mL). The organic phase was carefully washed with sat. aqu. NaHCO3 
(30 mL), and brine (30 mL), then dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash silica gel chromatography (hexanes/EtOAc, gradient from 10:1 to 
7:1), affording azobenzene 17a (192 mg, 0.590 mmol, 69%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.38. M.p.: 116–117 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.94–7.83 (m, 4H, ArH), 7.55–7.44 (m, 3H, ArH), 7.38–7.31 (m, 2H, ArH), 4.54 (br 
s, 1H, NH), 3.48–3.36 (m, 2H, CH2), 2.94–2.83 (m, 2H, CH2), 1.44 (s, 9H, C(CH3)3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 155.8, 152.7, 151.4, 142.4, 130.8, 129.5, 129.0, 123.1, 
122.8, 79.4, 41.7, 36.1, 28.4 ppm. IR (neat, ATR): ṽ = 3379 (m), 2979 (m), 2930 (w), 2877 
(w), 1684 (s), 1602 (w), 1521 (vs), 1468 (m), 1443 (m), 1415 (w), 1389 (m), 1366 (m), 1292 
(m), 1280 (m), 1244 (s), 1164 (s), 1136 (m), 1108 (m), 1070 (m), 1055 (m), 1040 (m), 1031 
(m), 1019 (m), 1012 (m), 1000 (m), 989 (m), 924 (w), 871 (m), 849 (m), 767 (s), 735 (w), 684 
(s), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C15H16N3O2]+: 270.1243, found: 270.1241 
([M-t-Bu+2H]+). 
 
Synthesis of 2-(4-(phenyldiazenyl)phenyl)ethanamine (18a) 
 
 
 
Boc-protected amine 17a (81 mg, 0.25 mmol) was dissolved in 1,4-dioxane (1 mL) and a 4 M 
solution of HCl in dioxane (1 mL) was added. The mixture was stirred for 16 h at room 
temperature. The orange precipitate was diluted with Et2O, filtered off and washed thoroughly 
with Et2O. Amine 18a was obtained as its HCl salt (63 mg, 0.24 mmol, 96%) as orange solid. 
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M.p.: 258 °C (dec.). 1H NMR (CD3OD, 400 MHz, 27 °C): δ = 7.92–7.86 (m, 4H, ArH), 
7.56−7.44 (m, 5H, ArH), 3.26–3.20 (m, 2H, CH2), 3.08–3.02 (m, 2H, CH2) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 152.5, 151.7, 139.9, 130.9, 129.3, 128.8, 122.9, 122.3, 40.2, 
32.9 ppm. IR (neat, ATR): ṽ = 2990 (m), 2971 (m), 1875 (m), 1605 (m), 1584 (w), 1502 (w), 
1475 (m), 1461 (m), 1447 (m), 1418 (w), 1390 (w), 1337 (w), 1307 (w), 1259 (w), 1225 (w), 
1158 (w), 1141 (m), 1114 (m), 1072 (w), 1016 (m), 1001 (w), 972 (w), 960 (w), 937 (m), 924 
(w), 832 (m), 795 (m), 772 (m), 764 (m), 728 (m), 686 (vs) cm-1. HRMS (EI+): m/z calcd. for 
[C14H15N3]+: 225.1266, found: 225.1255 ([M-HCl]+). 
 
Synthesis of 1-(4-(2-isothiocyanatoethyl)phenyl)-2-phenyldiazene (19a) 
 
 
 
The HCl salt of amine 18a (139 mg, 0.530 mmol, 1.0 equiv.) was dissolved in DCM (30 mL) 
and TEA (0.45 mL, 3.2 mmol, 6.0 equiv.) was added. The mixture was stirred for 30 min. 
1,1’-Thiocarbonyldi-2(1H)-pyridone (123 mg, 0.530 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred for 1.5 h. The solvent was removed in vacuo and the crude product 
was purified by flash silica gel column chromatography (hexanes/DCM, gradient from 9:1 to 
7:3) to give isothiocyanate 19a (72 mg, 0.27 mmol, 51%) as orange crystals. 
TLC (hexanes/DCM, 7:3): Rf = 0.34. M.p.: 101–103 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.94–7.86 (m, 4H, ArH), 7.55–7.46 (m, 3H, ArH), 7.40–7.36 (m, 2H, ArH), 
3.81−3.76 (m, 2H, CH2), 3.09–3.05 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): 
δ = 152.6, 151.8, 140.1, 131.0, 129.5, 129.1, 123.3, 122.8, 46.1, 36.4 ppm.[w] IR (neat, ATR): 
ṽ = 2176 (s), 2115 (vs), 1500 (w), 1486 (w), 1436 (m), 1344 (m), 1303 (m), 1185 (w), 1151 (m), 
1108 (w), 1071 (w), 1018 (w), 922 (w), 908 (w), 837 (w), 827 (m), 763 (m), 686 (m), 668 
(w) cm-1. HRMS (EI+): m/z calcd. for [C15H13N3S]+: 267.0830, found: 267.0821 ([M]+). 
 
 
 
 
                                                
[w] Due to extensive broadening, the NCS carbon signal could not be observed in the 13C NMR 
spectrum. 
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Synthesis of AC1 
 
 
Scheme	  3.3.	   Synthesis	  of	  AC1.	  
 
Synthesis of 7,8-dihydroxy-N-(4-(phenyldiazenyl)phenethyl)-4,5-dihydro-1H-benzo[c]-
azepine-2(3H)-carbothioamide (AC1) 
 
 
 
The HBr salt 7 (70 mg, 0.27 mmol, 1.0 equiv.) was suspended in THF (4 mL) and TEA (94 µL, 
0.68 mmol, 2.5 equiv.) was added. The mixture was stirred at room temperature for 30 min. A 
solution of isothiocyanate 19a (72 mg, 0.27 mmol, 1.0 equiv.) in THF (3 mL) was added and 
the reaction mixture was stirred for 4 h. The solution was concentrated in vacuo and water 
(10 mL) was added. The aqueous phase was extracted with EtOAc (3 x 10 mL) and the 
combined organic layers were washed with brine (25 mL), dried over MgSO4 and the solvent 
was removed under reduced pressure. The crude product was purified by flash silica gel column 
chromatography (hexanes/EtOAc, 1:1), affording thiourea AC1 (102 mg, 0.230 mmol, 85%) as 
an orange oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.29. M.p.: 86–88 °C. 1H NMR (CD3OD, 600 MHz, 
27 °C): δ = 7.90–7.85 (m, 2H, ArH), 7.82–7.78 (m, 2H, ArH), 7.54–7.50 (m, 2H, ArH), 
7.50−7.45 (m, 1H, ArH), 7.34–7.30 (m, 2H, ArH), 6.81 (s, 1H, ArH), 6.59 (s, 1H, ArH), 
4.73−4.62 (m, 2H, CH2), 4.10–3.93 (m, 2H, CH2), 3.86–3.79 (m, 2H, CH2), 3.00–2.93 (m, 2H, 
CH2), 2.78−2.73 (m, 2H, CH2), 1.79–1.72 (m, 2H, CH2) ppm. 13C NMR (CD3OD, 100 MHz, 
27 °C): δ = 179.9, 152.6, 151.1, 143.9, 143.3, 142.3, 132.7, 130.6, 129.4, 128.9, 128.8, 128.6, 
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127.4, 122.5, 122.2, 120.6, 120.5, 119.9, 117.0, 116.7, 53.8, 52.7, 46.4, 34.9, 33.3, 27.4 ppm.[x] 
IR (neat, ATR): ṽ = 3325 (m), 3287 (m), 3077 (m), 2929 (m), 1696 (m), 1602 (m), 1517 (vs), 
1416 (m), 1364 (m), 1314 (s), 1296 (m), 1225 (m), 1161 (m), 1116 (m), 1039 (m), 1022 (m), 
969 (w), 824 (w), 766 (w), 737 (w), 695 (m) cm-1. HRMS (ESI-): m/z calcd. for 
[C25H25O2N4S]-: 445.1698, found: 445.1704 ([M-H]-). UV/Vis: λmax = 332, 436 nm. 
 
 
Synthesis of Azobenzene Linkers 19b–d and 5 for AC2–AC5 
 
 
Scheme	  3.4.	   Synthesis	  of	  azobenzene	  linkers	  19b–d	  and	  5	  for	  AC2–AC5.	  
 
Synthesis of tert-butyl 4-((4-methoxyphenyl)diazenyl)phenethylcarbamate (17b) 
 
 
 
Aniline 2 (2.50 g, 10.6 mmol, 1.0 equiv.) was dissolved in DCM (45 mL) and EtOH (10 mL) 
and oxone (13.0 g, 21.2 mmol, 2.0 equiv.; dissolved in 100 mL of H2O) was added. The 
biphasic mixture was stirred vigorously for 12 h at room temperature. The phases were 
                                                
[x] AC1 was obtained as a mixture of trans/cis isomers. Therefore, more signals in the aromatic 
region were observed in the 13C NMR spectrum. 
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separated and the aqueous phase was extracted with DCM (2 x 50 mL). The combined organic 
phases were washed with brine (75 mL), dried over MgSO4 and the solvent was removed under 
reduced pressure. The resulting green oil was immediately dissolved in HOAc (80 mL) and 
aniline 20b (1.31 g, 10.6 mmol, 1.0 equiv.; dissolved in 10 mL of DMSO) was added dropwise. 
The mixture was stirred for 24 h at room temperature. A sat. aqu. solution of NaHCO3 was 
added (300 mL; gas evolution!) and the aqueous phase was extracted with EtOAc (3 x 70 mL). 
The organic phase was washed with brine (5 x 100 mL) to remove remaining DMSO and the 
organic phase was then dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash silica gel chromatography (hexanes/EtOAc, gradient from 10:1 to 3:1), 
affording azobenzene 17b (1.45 g, 4.08 mmol, 38%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.27. M.p.: 111–112 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.94–7.88 (m, 2H, ArH), 7.84–7.79 (m, 2H, ArH), 7.35–7.28 (m, 2H, ArH), 
7.04−6.98 (m, 2H, ArH), 4.58 (br s, 1H, NH), 3.88 (s, 3H, OCH3), 3.47–3.35 (m, 2H, CH2), 
2.92–2.82 (m, 2H, CH2), 1.44 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 161.9, 155.8, 151.5, 147.0, 141.7, 129.5, 124.7, 122.8, 114.2, 79.3, 55.6, 41.6, 36.0, 
28.4 ppm. IR (neat, ATR): ṽ = 3378 (m), 2968 (m), 2932 (m), 2507 (w), 1684 (s), 1600 (m), 
1583 (m), 1524 (s), 1499 (m), 1457 (m), 1443 (m), 1421 (m), 1390 (m), 1366 (m), 1295 (m), 
1282 (m), 1243 (vs), 1167 (s), 1153 (s), 1140 (s), 1106 (m), 1054 (w), 1027 (m), 986 (m), 909 
(m), 871 (m), 842 (vs), 806 (w), 778 (w), 768 (w), 732 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C20H26N3O3]+: 356.1974, found: 356.1967 ([M+H]+). 
 
Synthesis of 1-(4-(2-isothiocyanatoethyl)phenyl)-2-(4-methoxyphenyl)diazene (19b) 
 
 
 
Boc-protected amine 17b (1.31 g, 3.69 mmol) was dissolved in 1,4-dioxane (20 mL) and a 4 M 
solution of HCl in 1,4-dioxane (20 mL) was added. The mixture was stirred at room 
temperature for 16 h. The mixture was basified with 2 M NaOH and the phases were separated. 
The aqueous phase was extracted with DCM (5 x 30 mL) and the combined organic phases 
were washed with brine (100 mL), dried over MgSO4 and the solvent was removed under 
reduced pressure. Amine 18b (907 mg, 3.55 mmol, 96%) was obtained as a red oil and used 
without further purification. 
Amine 18b (200 mg, 0.780 mmol, 1.0 equiv.) was dissolved in DCM (20 mL) and 
1,1’-thiocarbonyldi-2(1H)-pyridone (193 mg, 0.830 mmol, 1.06 equiv.) was added. The reaction 
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mixture was stirred for 36 h. The solvent was removed in vacuo and the crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, 20:1 → 7:1) to give 
isothiocyanate 19b (158 mg, 0.530 mmol, 68%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.42. M.p.: 91–92 °C. 1H NMR (CDCl3, 600 MHz, 27 °C): 
δ = 7.94–7.88 (m, 2H, ArH), 7.87–7.82 (m, 2H, ArH), 7.37–7.31 (m, 2H, ArH), 7.02–6.98 (m, 
2H, ArH), 3.88 (s, 3H, OCH3), 3.78–3.75 (m, 2H, CH2), 3.07–3.02 (m, 2H, CH2) ppm. 
13C NMR (CDCl3, 150 MHz, 27 °C): δ = 162.1, 151.9, 147.0, 139.4, 131.3, 129.5, 124.7, 
123.0, 114.2, 55.7, 46.1, 36.3 ppm. IR (neat, ATR): ṽ = 3007 (w), 2930 (w), 2837 (w), 2178 
(m), 2094 (s), 1600 (m), 1580 (m), 1499 (m), 1454 (m), 1441 (m), 1419 (w), 1411 (w), 1357 
(w), 1325 (w), 1299 (w), 1246 (vs), 1181 (w), 1154 (m), 1142 (m), 1107 (m), 1031 (m), 956 
(w), 842 (s), 762 (w), 730 (w), 673 (w) cm-1. HRMS (ESI+): m/z calcd. for [C16H16N3OS]+: 
298.1014, found: 298.1007 ([M+H]+). 
 
Synthesis of tert-butyl 4-((4-(diethylamino)phenyl)diazenyl)phenethyl-carbamate (17c) 
 
 
 
Aniline 2 (2.66 g, 11.3 mmol, 1.0 equiv.) was dissolved in DCM (45) and EtOH (10 mL) and 
oxone (13.9 g, 22.6 mmol, 2.0 equiv.; dissolved in 100 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 12 h at room temperature. The phases were separated and the 
aqueous phase was extracted with DCM (5 x 50 mL). The combined organic phases were 
washed with brine (200 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The resulting green oil was immediately dissolved in HOAc (80 mL) and aniline 20c 
(1.87 mL, 11.3 mmol, 1.0 equiv.) was added dropwise. The mixture was stirred for 3 d at room 
temperature. A sat. aqu. solution of NaHCO3 was added (300 mL; gas evolution!) and the 
aqueous phase was extracted with EtOAc (3 x 70 mL). The organic phase was carefully washed 
with sat. aqu. NaHCO3 (150 mL) and brine (150 mL). The organic phase was then dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 10:1 to 3:1), affording azobenzene 17c 
(593 mg, 1.50 mmol, 13%) as a red oil. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.24. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.88–7.81 
(m, 2H, ArH), 7.80–7.74 (m, 2H, ArH), 7.32–7.26 (m, 2H, ArH), 6.76–6.67 (m, 2H, ArH), 4.55 
(br s, 1H, NH), 3.51–3.33 (m, 6H, 3 x CH2), 2.90–2.81 (m, 2H, CH2), 1.44 (s, 9H, C(CH3)3), 
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1.22 (t, J = 6.9 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 155.8, 152.0, 
150.0, 143.1, 140.2, 129.4, 125.2, 122.3, 110.9, 79.3, 44.7, 41.7, 36.0, 28.4, 12.7 ppm. IR (neat, 
ATR): ṽ = 3361 (w), 2975 (m), 2928 (w), 1710 (m), 1600 (vs), 1557 (w), 1515 (s), 1450 (w), 
1398 (m), 1357 (m), 1311 (w), 1271 (m), 1250 (m), 1158 (m), 1139 (vs), 1078 (w), 1013 (w), 
956 (w), 825 (m), 784 (w) cm-1. HRMS (ESI+): m/z calcd. for [C23H33N4O2]+: 397.2604, found: 
397.2594 ([M+H]+). 
 
Synthesis of N,N-diethyl-4-((4-(2-isothiocyanatoethyl)phenyl)diazenyl)aniline (19c) 
 
 
 
Boc-protected amine 17c (550 mg, 1.39 mmol) was dissolved in 1,4-dioxane (10 mL) and a 4 M 
solution of HCl in 1,4-dioxane (10 mL) was added. The mixture was stirred at room 
temperature for 16 h. A sat. aqu. solution of NaHCO3 (100 mL) was added and the phases were 
separated. The aqueous phase was extracted with DCM (2 x 20 mL) and the combined organic 
phases were washed with sat. aqu. NaHCO3 (30 mL), dried over MgSO4 and the solvent was 
removed under reduced pressure. Amine 18c (373 mg, 1.26 mmol, 91%) was obtained as a red 
oil and used without further purification. 
Amine 18c (100 mg, 0.340 mmol, 1.0 equiv.) was dissolved in DCM (10 mL) and 
1,1’-thiocarbonyldi-2(1H)-pyridone (86 mg, 0.37 mmol, 1.1 equiv.) was added. The reaction 
mixture was stirred for 12 h. The solvent was removed in vacuo and the crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, 20:1 → 10:1) to give 
isothiocyanate 19c (75 mg, 0.22 mmol, 65%) as red crystals. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.34. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 7.86–7.81 
(m, 2H, ArH), 7.81–7.77 (m, 2H, ArH), 7.32–7.27 (m, 2H, ArH), 6.73–6.69 (m, 2H, ArH), 
3.77–3.72 (m, 2H, CH2), 3.44 (q, J = 7.1 Hz, 4H, 2 x CH2), 3.06–3.01 (m, 2H, CH2), 1.23 (q, 
J = 7.1 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 152.5, 150.1, 143.1, 
137.9, 131.0, 129.3, 125.3, 122.5, 110.9, 46.2, 44.7, 36.3, 12.7 ppm. IR (neat, ATR): ṽ = 2974 
(m), 2931 (w), 2899 (w), 2186 (m), 2110 (m), 1598 (vs), 1559 (m), 1514 (m), 1482 (w), 1469 
(w), 1447 (w), 1426 (w), 1399 (m), 1377 (m), 1356 (m), 1312 (w), 1271 (m), 1250 (w), 1196 
(m), 1156 (m), 1139 (s), 1106 (w), 1096 (w), 1078 (w), 1014 (w), 954 (w), 924 (w), 850 (w), 
824 (m), 788 (w), 673 (w) cm-1. HRMS (ESI+): m/z calcd. for [C19H23N4S]+: 339.1643, found: 
339.1635 ([M+H]+). 
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Synthesis of tert-butyl 4-((4-(trifluoromethyl)phenyl)diazenyl)phenethylcarbamate (3) 
 
 
 
Aniline 2 (1.50 g, 6.35 mmol, 1.0 equiv.) was dissolved in DCM (25 mL) and EtOH (5 mL) and 
oxone (7.81 g, 12.7 mmol, 2.0 equiv.; dissolved in 50 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 16 h at room temperature. The phases were separated and the 
aqueous phase was extracted with DCM (2 x 40 mL). The combined organic phases were 
washed with brine (2 x 75 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The resulting green oil was immediately dissolved in HOAc (50 mL) and aniline 21 
(0.80 mL, 6.35 mmol, 1.0 equiv.; dissolved in 6 mL of DMSO) was added dropwise. The 
mixture was stirred for 24 h at room temperature. A sat. aqu. solution of NaHCO3 was added 
(250 mL; gas evolution!) and the aqueous phase was extracted with DCM (3 x 50 mL). The 
organic phase was washed with sat. aqu. NaHCO3 (100 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash silica gel chromatography 
(hexans/EtOAc, gradient from 20:1 to 8:1), affording azobenzene 3 (272 mg, 0.690 mmol, 11%) 
as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.29. M.p.: 148–149 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 8.01–7.96 (m, 2H, ArH), 7.92–7.87 (m, 2H, ArH), 7.80–7.75 (m, 2H, ArH), 
7.39−7.34 (m, 2H, ArH), 4.57 (br s, 1H, NH), 3.48–3.39 (m, 2H, CH2), 2.93–2.86 (m, 2H, CH2), 
1.45 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 155.8, 154.4 (m), 151.2, 
143.4, 132.1 (q, J = 32.5 Hz), 129.6, 126.3 (q, J = 3.8 Hz), 123.9 (q, J = 406.2 Hz), 123.4, 
122.9, 79.4, 41.6, 36.2, 28.4 ppm. 19F NMR (CDCl3, 376 MHz, 27 °C): δ = –62.6 ppm. IR 
(neat, ATR): ṽ = 3368 (m), 2977 (w), 2934 (w), 2873 (w), 1679 (vs), 1604 (w), 1527 (s), 1463 
(w), 1414 (w), 1392 (w), 1366 (m), 1325 (vs), 1297 (m), 1283 (m), 1251 (m), 1163 (vs), 1125 
(vs), 1102 (m), 1065 (m), 1013 (w), 992 (w), 854 (m), 780 (w), 757 (w), 669 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C20H23N3O2F3]+: 394.1742, found: 394.1742 ([M+H]+). 
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Synthesis of 1-(4-(2-isothiocyanatoethyl)phenyl)-2-(4-(trifluoromethyl)phenyl)diazene (5) 
 
 
 
Boc-protected amine 3 (249 mg, 0.630 mmol) was dissolved in 1,4-dioxane (5 mL) and a 4 M 
solution of HCl in 1,4-dioxane (5 mL) was added. The mixture was stirred at room temperature 
for 16 h. The mixture was basified with sat. aqu. NaHCO3 (40 mL; gas evolution!) and the 
phases were separated. The aqueous phase was extracted with DCM (3 x 10 mL) and the 
combined organic phases were washed with sat. aqu. NaHCO3 (25 mL) and brine (25 mL), 
dried over MgSO4 and the solvent was removed under reduced pressure. Amine 4 (176 mg, 
0.600 mmol, 95%) was obtained as an orange solid and used without further purification. 
Amine 4 (176 mg, 0.600 mmol, 1.0 equiv.) was dissolved in DCM (15 mL) and 
1,1’-thiocarbonyldi-2(1H)-pyridone (153 mg, 0.660 mmol, 1.1 equiv.) was added. The reaction 
mixture was stirred for 16 h. The solvent was removed in vacuo and the crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, 40:1 → 20:1) to give 
isothiocyanate 5 (124 mg, 0.370 mmol, 62%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.57. M.p.: 106–108 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 8.01–7.96 (m, 2H, ArH), 7.95–7.91 (m, 2H, ArH), 7.79–7.75 (m, 2H, ArH), 
7.41−7.37 (m, 2H, ArH), 3.82–3.77 (m, 2H, CH2), 3.11–3.06 (m, 2H, CH2) ppm. 13C NMR 
(CDCl3, 150 MHz, 27 °C): δ = 154.4 (m), 151.7, 141.1, 132.2 (q, J = 32.4 Hz), 131.6, 129.7, 
129.3 (cis isomer), 126.3 (q, J = 3.8 Hz), 123.9 (q, J = 271.2 Hz), 123.6, 123.0, 121.3 (cis 
isomer), 120.3 (cis isomer), 46.0, 36.4 ppm. 19F NMR (CDCl3, 282 MHz, 27 °C): 
δ = −62.6 ppm. IR (neat, ATR): ṽ = 2927 (w), 2854 (w), 2168 (m), 2111 (m), 1601 (w), 1499 
(w), 1436 (m), 1414 (m), 1344 (m), 1318 (vs), 1244 (w), 1220 (m), 1167 (m), 1123 (s), 1108 
(s), 1063 (s), 1007 (m), 910 (m), 851 (s), 826 (m), 741 (m), 722 (w), 656 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C16H13N3F3S]+: 336.0782, found: 336.0771 ([M+H]+). 
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Synthesis of tert-butyl 4-((4-nitrophenyl)diazenyl)phenethylcarbamate (17d) 
 
 
 
4-Nitroaniline 20d (2.07 g, 15.0 mmol, 1.0 equiv.) was dissolved in DCM (60 mL) and oxone 
(18.4 g, 30.0 mmol, 2.0 equiv.; dissolved in 120 mL of H2O) was added. The biphasic mixture 
was stirred vigorously for 12 h at room temperature. The phases were separated and the aqueous 
phase was extracted with DCM (70 mL). The combined organic phases were washed with water 
(75 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The resulting 
green oil was immediately dissolved in HOAc (120 mL) and aniline 2 (3.54 g, 15.0 mmol, 
1.0 equiv.) was added in 4 portions. The mixture was stirred for 2.5 d at room temperature. 
Solid Na2CO3 and a sat. aqu. solution of NaHCO3 was added to set the pH to pH = 8−10 (gas 
evolution!) and the aqueous phase was extracted with EtOAc (2 x 50 mL). The organic phase 
was washed with sat. aqu. NaHCO3 (3 x 200 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash silica gel chromatography (hexanes/EtOAc, gradient 
from 9:1 to 3:1), affording azobenzene 17d (3.56 g, 9.61 mmol, 64%) as a red solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.26. M.p.: 149–150 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 8.36–8.32 (m, 2H, ArH), 8.00–7.96 (m, 2H, ArH), 7.91–7.86 (m, 2H, ArH), 
7.38−7.33 (m, 2H, ArH), 4.60 (br s, 1H, NH), 3.46–3.36 (m, 2H, CH2), 2.92–2.84 (m, 2H, CH2), 
1.42 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 155.8, 155.7, 151.1, 
148.6, 144.2, 129.7, 124.7, 123.6, 123.3, 79.4, 41.5, 36.3, 28.4 ppm. IR (neat, ATR): ṽ = 3371 
(m), 2979 (w), 2934 (w), 2862 (w), 1677 (s), 1605 (m), 1520 (vs), 1456 (m), 1416 (w), 1391 
(w), 1366 (m), 1342 (s), 1277 (m), 1251 (m), 1164 (s), 1107 (m), 1057 (w), 1006 (w), 909 (w), 
860 (s), 795 (w), 782 (w), 754 (w), 732 (m), 688 (m), 592 (w) cm-1. HRMS (ESI+): m/z calcd. 
for [C15H15N4O4]+: 315.1093, found: 315.1085 ([M-t-Bu+H]+). 
 
Synthesis of 1-(4-(2-isothiocyanatoethyl)phenyl)-2-(4-nitrophenyl)diazene (19d) 
 
 
 
Boc-protected amine 17d (2.46 g, 6.64 mmol) was dissolved in 1,4-dioxane (40 mL) and a 4 M 
solution of HCl in 1,4-dioxane (40 mL) was added. The mixture was stirred at room 
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temperature for 16 h. The mixture was basified with 2 M NaOH and the phases were separated. 
The aqueous phase was extracted with EtOAc (3 x 30 mL) and the combined organic phases 
were washed with brine (75 mL), dried over MgSO4 and the solvent was removed under 
reduced pressure. Amine 18d (1.02 g, 3.77 mmol, 57%) was obtained as a red solid and used 
without further purification. 
Amine 18d (600 mg, 2.22 mmol, 1.0 equiv.) was dissolved in DCM (50 mL) and 
1,1’-thiocarbonyldi-2(1H)-pyridone (567 mg, 2.44 mmol, 1.1 equiv.) was added. The reaction 
mixture was stirred for 16 h. The solvent was removed in vacuo and the crude product was 
purified by flash silica gel column chromatography (CHCl3/MeOH, 100:0 → 20:1 → 10:1) to 
give isothiocyanate 19d (488 mg, 1.56 mmol, 70%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.35. M.p.: 153–154 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 8.39–8.35 (m, 2H, ArH), 8.04–8.00 (m, 2H, ArH), 7.97–7.93 (m, 2H, ArH), 
7.43−7.38 (m, 2H, ArH), 3.83–3.78 (m, 2H, CH2), 3.12–3.06 (m, 2H, CH2) ppm. 13C NMR 
(CDCl3, 150 MHz, 27 °C): δ = 155.7, 151.5, 148.7, 141.8, 131.7, 129.8, 124.7, 123.9, 123.4, 
46.0, 36.4 ppm. IR (neat, ATR): ṽ = 2169 (m), 2111 (m), 1609 (m), 1544 (s), 1500 (w), 1483 
(w), 1458 (w), 1436 (w), 1415 (w), 1370 (w), 1349 (vs), 1319 (m), 1245 (w), 1218 (w), 1188 
(w), 1154 (w), 1110 (m), 1073 (w), 1003 (w), 911 (w), 863 (s), 827 (m), 755 (m), 728 (w), 684 
(m), 634 (w) cm-1. HRMS (EI+): m/z calcd. for [C15H12N4O2S]+: 312.0681, found: 312.0670 
([M]+). 
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Synthesis of AC2–AC5 
 
 
Scheme	  3.5.	   Synthesis	  of	  AC2–AC5.	  
 
Synthesis of 7,8-dihydroxy-N-(4-((4-methoxyphenyl)diazenyl)phenethyl)-4,5dihydro-1H-
benzo[c]azepine-2(3H)-carbothioamide (AC2) 
 
 
 
The HBr salt 7 (107 mg, 0.410 mmol, 1.1 equiv.) was suspended in THF (15 mL) and TEA 
(0.13 mL, 0.93 mmol, 2.5 equiv.) was added. A solution of isothiocyanate 19b (110 mg, 
0.370 mmol, 1.0 equiv.) in THF (5 mL) was added and the reaction mixture was stirred for 16 h. 
The solution was concentrated in vacuo and the crude product was purified by flash silica gel 
column chromatography (CHCl3/MeOH, gradient from 100:0 to 80:1), affording thiourea AC2 
(127 mg, 0.270 mmol, 73%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.34. M.p.: 169–170 °C. 1H NMR (CD3OD, 600 MHz, 
27 °C): δ = 7.88–7.85 (m, 2H, ArH), 7.75–7.72 (m, 2H, ArH), 7.30–7.27 (m, 2H, ArH), 
7.05−7.03 (m, 2H, ArH), 6.81 (s, 1H, ArH), 6.59 (s, 1H, ArH), 4.75–4.64 (m, 2H, CH2), 
4.10−3.93 (m, 2H, CH2), 3.86 (s, 3H, OCH3), 3.84–3.78 (m, 2H, CH2), 2.98–2.91 (m, 2H, CH2), 
2.78–2.72 (m, 2H, CH2), 1.77–1.70 (m, 2H, CH2) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
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δ = 179.8, 162.3, 151.2, 146.8, 143.9, 142.4, 142.3, 132.7, 129.3, 127.4, 122.2, 117.0, 116.8, 
113.9, 54.7, 53.8, 52.7, 46.5, 34.8, 33.3, 27.4 ppm. IR (neat, ATR): ṽ = 3292 (m), 2933 (m), 
2839 (w), 2503 (w), 2230 (w), 2070 (w), 1600 (m), 1584 (m), 1500 (s), 1463 (m), 1384 (m), 
1351 (m), 1292 (s), 1252 (vs), 1179 (m), 1154 (m), 1143 (m), 1103 (m), 1066 (w), 1028 (m), 
975 (m), 885 (w), 840 (m), 766 (w), 732 (w), 674 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C26H29O3N4S]+: 477.1960, found: 477.1958 ([M+H]+). UV/Vis: λmax = 353, 442 nm. 
 
Synthesis of N-(4-((4-(diethylamino)phenyl)diazenyl)phenethyl)-7,8-di-hydroxy-4,5-di-
hydro-1H-benzo[c]azepine-2(3H)-carbothioamide (AC3) 
 
 
 
The HBr salt 7 (49 mg, 0.19 mmol, 1.1 equiv.) was suspended in THF (5 mL) and TEA (60 µL, 
0.43 mmol, 2.5 equiv.) was added. The mixture was stirred at room temperature for 30 min. A 
solution of isothiocyanate 19c (59 mg, 0.17 mmol, 1.0 equiv.) in THF (5 mL) was added and the 
reaction mixture was stirred for 12 h. The solution was concentrated in vacuo and the crude 
product was purified by flash silica gel column chromatography (CHCl3/MeOH, gradient from 
100:0 to 70:1), giving thiourea AC3 (81 mg, 0.16 mmol, 94%) as a red oil. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.38. 1H NMR (CD3OD, 600 MHz, 27 °C): δ = 7.80–7.75 
(m, 2H, ArH), 7.70–7.64 (m, 2H, ArH), 7.29–7.23 (m, 2H, ArH), 6.80 (s, 1H, ArH), 6.79–6.75 
(m, 2H, ArH), 6.60 (s, 1H, ArH), 4.75–4.62 (m, 2H, CH2), 4.15–3.88 (m, 2H, CH2), 3.84–3.76 
(m, 2H, CH2), 3.48 (q, J = 7.1 Hz, 4H, 2 x CH2), 2.97–2.89 (m, 2H, CH2), 2.81−2.71 (m, 2H, 
CH2), 1.81–1.68 (m, 2H, CH2), 1.21 (t, J = 7.5 Hz, 6H, 2 x CH3) ppm. 13C NMR (CD3OD, 
150 MHz, 27 °C): δ = 179.8, 151.7, 150.2, 143.9, 142.8, 142.3, 141.0, 132.7, 129.2, 127.4, 
124.8, 121.7, 117.0, 116.8, 110.7, 53.8, 52.7, 46.6, 44.2, 34.8, 33.3, 27.4, 11.5 ppm. IR (neat, 
ATR): ṽ = 3205 (w), 2973 (m), 2929 (m), 1599 (vs), 1517 (s), 1449 (m), 1422 (m), 1397 (m), 
1354 (m), 1314 (m), 1293 (m), 1272 (m), 1194 (m), 1141 (s), 1096 (m), 1077 (m), 1012 (w), 
942 (w), 908 (w), 850 (w), 823 (m), 767 (w), 732 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C29H36O2N5S]+: 518.2590, found: 518.2579 ([M+H]+). UV/Vis: λmax = 430 nm. 
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Synthesis of 7,8-dihydroxy-N-(4-((4-(trifluoromethyl)phenyl)diazenyl)phenethyl)-4,5-di-
hydro-1H-benzo[c]azepine-2(3H)-carbothioamide (AC4) 
 
 
 
The HBr salt 7 (52 mg, 0.20 mmol, 1.1 equiv.) was suspended in THF (6 mL) and TEA (62 µL, 
0.45 mmol, 2.5 equiv.) was added. A solution of isothiocyanate 5 (60 mg, 0.18 mmol, 
1.0 equiv.) in THF (4 mL) was added and the reaction mixture was stirred for 2.5 d. The 
solution was concentrated in vacuo and the crude product was purified by flash silica gel 
column chromatography (CHCl3/MeOH, gradient from 100:0 to 50:1), affording thiourea AC4 
(80 mg, 0.16 mmol, 89%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.38. M.p.: 181–182 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 8.05–7.97 (m, 2H, ArH), 7.87–7.79 (m, 4H, ArH), 7.36–7.30 (m, 2H, ArH), 6.83 (s, 
1H, ArH), 6.60 (s, 1H, ArH), 4.75–4.61 (m, 2H, CH2), 4.17–3.90 (m, 2H, CH2), 3.87–3.78 (m, 
2H, CH2), 3.03–2.93 (m, 2H, CH2), 2.94 (t, J = 7.4 Hz, 2H, CH2), 2.79–2.72 (m, 2H, CH2), 
1.78–1.68 (m, 2H, CH2) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): δ = 179.8, 154.4 (m), 
150.9, 144.3, 144.0, 142.4, 132.7, 131.6 (q, J = 32.3 Hz), 129.5, 129.1 (cis isomer), 127.3, 126.0 
(q, J = 3.8 Hz), 124.1 (q, J = 270.0 Hz), 122.9, 122.7, 120.8 (cis isomer), 120.2 (cis isomer), 
117.0, 116.8, 53.8, 52.9, 46.3, 34.9, 33.4, 27.4 ppm. 19F NMR (CD3OD, 151 MHz, 27 °C): 
δ = –64.1 ppm. IR (neat, ATR): ṽ = 3222 (m), 2939 (w), 1606 (m), 1542 (m), 1520 (m), 1453 
(w), 1408 (w), 1385 (w), 1322 (vs), 1297 (m), 1264 (m), 1243 (m), 1212 (m), 1162 (s), 1126 (s), 
1101 (m), 1064 (s), 1013 (m), 938 (w), 907 (s), 852 (m), 732 (vs), 668 (w) cm-1. HRMS (ESI+): 
m/z calcd. for [C26H26O2N4F3S]+: 515.1729, found: 515.1716 ([M+H]+). UV/Vis: λmax = 334, 
437 nm. 
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Synthesis of 7,8-dihydroxy-N-(4-((4-nitrophenyl)diazenyl)phenethyl)-4,5-dihydro-1H-
benzo-[c]azepine-2(3H)-carbothioamide (AC5) 
 
 
 
The HBr salt 7 (200 mg, 0.770 mmol, 1.1 equiv.) was suspended in THF (40 mL) and TEA 
(0.24 mL, 1.8 mmol, 2.5 equiv.) was added. Isothiocyanate 19d (219 mg, 0.700 mmol, 
1.0 equiv.) was added and the reaction mixture was stirred for 16 h. The solution was 
concentrated in vacuo and the crude product was purified by flash silica gel column 
chromatography (CHCl3/MeOH, gradient from 100:0 to 50:1), yielding thiourea AC5 (302 mg, 
0.610 mmol, 87%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.42. M.p.: 195–197 °C. 1H NMR (Acetone-d6, 400 MHz, 
27 °C): δ = 8.47–8.40 (m, 2H, ArH), 8.14–8.07 (m, 2H, ArH), 7.93–7.87 (m, 2H, ArH), 7.65 (br 
s, 2H, 2 x OH), 7.46–7.39 (m, 2H, ArH), 6.91 (s, 1H, ArH), 6.82 (t, J = 5.6 Hz, 1H, NH), 6.67 
(s, 1H, ArH), 4.74 (s, 2H, CH2), 4.12 (br s, 2H, CH2), 3.92–3.81 (m, 2H, CH2), 3.07–2.99 (m, 
2H, CH2), 2.80–2.77 (m, 2H, CH2), 1.80–1.70 (m, 2H, CH2) ppm. 13C NMR (Acetone-d6, 
100 MHz, 27 °C): δ = 181.1, 155.8, 151.0, 148.8, 145.4, 143.9, 142.4, 133.1, 129.9, 128.2, 
124.8, 123.3, 123.3, 117.2, 117.0, 53.5, 53.1, 46.5, 35.1, 33.7, 27.6 ppm. IR (neat, ATR): 
ṽ = 3480 (w), 3306 (m), 1700 (w), 1598 (m), 1522 (vs), 1448 (m), 1402 (w), 1344 (s), 1288 (s), 
1264 (m), 1232 (m), 1192 (m), 1173 (m), 1153 (m), 1134 (m), 1097 (m), 1013 (w), 969 (m), 
944 (m), 886 (m), 860 (s), 852 (m), 797 (m), 767 (m), 755 (m), 726 (w), 688 (m), 649 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C25H26O4N5S]+: 492.1706, found: 492.1694 ([M+H]+). UV/Vis: 
λmax = 354, 456 nm. 
 
 
 
 
 
 
 
 
NHO
HO
N
H
S
N N
NO2
3     PHOTOCONTROL OF TRP CHANNELS 
 
 
 
170 
Synthesis of AC6 
 
 
Scheme	  3.6.	   Synthesis	  of	  AC6.	  
 
Synthesis of N-(4-((4-aminophenyl)diazenyl)phenethyl)-7,8-dihydroxy-4,5-dihydro-1H-
benzo[c]azepine-2(3H)-carbothioamide (AC6) 
 
 
 
AC5 (40 mg, 0.081 mmol, 1.0 equiv.) was dissolved in 1,4-dioxane (5 mL) and H2O (0.5 mL). 
Sodium sulfide (19 mg, 0.24 mmol, 3.0 equiv.) was added and the reaction mixture was heated 
to 90 °C for 1 h. A sat. aqu. solution of NaHCO3 (20 mL) was added and the phases were 
separated. The aqueous phase was extracted with CHCl3 (3 x 10 mL) and the combined organic 
layers were washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel column chromatography (CHCl3/MeOH, gradient 
from 100:0 to 30:1), yielding aniline AC6 (30 mg, 0.065 mmol, 80%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.40. M.p.: 152–154 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.71–7.64 (m, 4H, ArH), 7.28–7.22 (m, 2H, ArH), 6.80 (s, 1H, ArH), 6.75–6.69 (m, 
2H, ArH), 6.59 (s, 1H, ArH), 4.68 (s, 2H, CH2), 4.02 (br s, 2H, CH2), 3.82–3.76 (m, 2H, CH2), 
2.96–2.89 (m, 2H, CH2), 2.78–2.72 (m, 2H, CH2), 1.77–1.69 (m, 2H, CH2) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 179.8, 151.9, 151.5, 144.3, 143.9, 142.3, 141.3, 132.7, 129.2, 
127.4, 124.6, 121.8, 117.0, 116.8, 113.8, 53.8, 52.7, 46.5, 34.8, 33.3, 27.4 ppm. IR (neat, 
ATR): ṽ = 3335 (m), 3210 (w), 2970 (w), 2930 (w), 1598 (s), 1506 (m), 1427 (m), 1402 (m), 
1381 (m), 1336 (m), 1291 (s), 1234 (m), 1214 (m), 1139 (s), 1097 (m), 1042 (m), 1066 (w), 
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1013 (w), 974 (w), 941 (w), 904 (w), 880 (w), 836 (m), 747 (vs), 665 (m), 644 (m) cm-1. HRMS 
(ESI+): m/z calcd. for [C25H28O2N5S]+: 462.1964, found: 462.1952 ([M+H]+). UV/Vis: 
λmax = 407 nm. 
 
 
Synthesis of ABCTC 
 
 
Scheme	  3.7.	   Synthesis	  of	  ABCTC.	  
 
Synthesis of 4-nitrophenyl (4-(phenyldiazenyl)phenyl)carbamate (9) 
 
 
 
4-Aminoazobenzene (8; 250 mg, 1.27 mmol, 1.1 equiv.) was dissolved in DCM (4 mL) and 
pyridine (1 mL). 4-Nitrophenyl chloroformate (232 mg, 1.15 mmol, 1.0 equiv.) was added at 
0 °C. Immediately, precipitate was formed and more DCM (4 mL) was added. The slurry was 
warmed to room temperature and stirred for 1.5 h. The mixture was diluted with DCM (20 mL) 
and washed with 0.6 M HCl, 0.02 M HCl, H2O, and sat. aqu. NaHCO3 (20 mL each). The 
organic layer was dried over MgSO4 and concentrated in vacuo. Carbamate 9 (361 mg, 
1.00 mmol, 87%) was obtained sufficiently pure for the next step as an orange solid. 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.91. M.p.: 168–169 °C. 1H NMR 
(CDCl3, 600 MHz, 27 °C): δ = 8.33–8.28 (m, 2H, ArH), 7.98–7.95 (m, 2H, ArH), 7.93–7.87 
(m, 2H, ArH), 7.65–7.58 (m, 2H, ArH), 7.53–7.49 (m, 2H, ArH), 7.49–7.45 (m, 1H, ArH), 
7.44–7.39 (m, 2H, ArH), 7.17 (br s, 1H, NH) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): 
δ = 155.1, 152.6, 149.8, 149.2, 145.2, 139.0, 130.9, 129.1, 128.9, 125.3, 125.1, 124.2, 122.8, 
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122.3, 122.1, 118.9 ppm.[y] IR (neat, ATR): ṽ = 3326 (m), 1729 (s), 1601 (m), 1518 (vs), 1488 
(m), 1438 (m), 1409 (m), 1342 (m), 1325 (m), 1305 (m), 1197 (vs), 1155 (m), 1108 (m), 840 
(w), 857 (m), 841 (s), 769 (m), 749 (m), 719 (w), 687 (m) cm-1. HRMS (EI+): m/z calcd. for 
[C19H14N4O4]+: 362.1015, found: 362.1008 ([M]+). 
 
Synthesis of 4-(3-chloropyridin-2-yl)-N-(4-(phenyldiazenyl)phenyl)piperazine-1-
carboxamide (ABCTC) 
 
 
 
Carbamate 9 (200 mg, 0.550 mmol, 1.05 equiv.) and 1-(3-chloropyridin-2-yl)piperazine  
(103 mg, 0.520 mmol, 1.0 equiv.) were dissolved in CHCl3 (1 mL) and TEA (0.08 mL, 
0.6 mmol, 1.1 equiv) was added at room temperature. The reaction mixture was stirred for 1.5 h 
and then diluted with CHCl3 (10 mL) and washed with 2 M K2CO3 (2 x 20 mL). The combined 
aqueous phases were extracted with CHCl3 (10 mL) and the organic phase was washed with 
brine (20 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash silica gel column chromatography (DCM/MeOH, 100:0 → 10:1), yielding ABCTC 
(192 mg, 0.460 mmol, 88%) as an orange solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.38. M.p.: 176–178 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 8.19 (dd, J = 4.8, 1.2 Hz, 1H, ArH), 7.93–7.86 (m, 4H, ArH), 7.61 (dd, J = 7.8, 
1.2 Hz, 1H, ArH), 7.56–7.53 (m, 2H, ArH), 7.51–7.47 (m, 2H, ArH), 7.45–7.43 (m, 1H, ArH), 
6.88 (dd, J = 7.8, 4.8 Hz, 1H, ArH), 6.60 (br s, 1H, NH), 3.71–3.68 (m, 4H, 2 x CH2), 3.46–3.42 
(m, 4H, 2 x CH2) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 157.9, 154.5, 152.7, 148.3, 
145.9, 141.7, 138.9, 130.5, 129.0, 124.0, 122.8, 122.6, 119.4, 119.3, 118.5, 48.7, 44.1 ppm.[z] IR 
(neat, ATR): ṽ = 3308 (w), 3059 (w), 2998 (w), 2893 (w), 2851 (w), 1641 (m), 1592 (m), 1578 
(m), 1526 (m), 1505 (m), 1461 (m), 1434 (s), 1414 (s), 1380 (m), 1337 (m), 1300 (m), 1288 
(m), 1231 (vs), 1152 (m), 1142 (m), 1123 (m), 1071 (w), 1032 (m), 1019 (w), 995 (m), 937 (m), 
                                                
[y]  Due to trans/cis isomerization, more signals than expected were observed in the 13C NMR 
spectrum. 
[z] Due to trans/cis isomerization, more signals than expected were observed in the 13C NMR 
spectrum. 
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842 (m), 789 (w), 753 (s), 722 (w), 688 (m), 666 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C22H22ON6Cl]+: 421.1544, found: 421.1540 ([M+H]+). UV/Vis: λmax = 370, 446 nm. 
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NMR Spectra 
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UV/Vis Spectra 
 
UV/Vis spectra of AC1–AC6 and ABCTC were each recorded at a concentration of 100 µM in 
DMSO. Spectra were first recorded in the dark, then again after illumination with the absorption 
maximum wavelength for 1 min (and 10 min in some cases) unless indicated otherwise.  
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Determination of Antagonistic Potencies of AC1–3 and AC5–6 upon Activation of 
TRPV1 with CAP 
 
Antagonistic potencies were determined by aequorin-based calcium measurements. TRPV1 was 
activated by addition of 1 µM CAP to increasing concentrations of antagonists. Figure 3.7 
displays the dose-response curves of AC1–3 and AC5–6 (n = 3–4). IC50 values are summarized 
in Table 3.1. 
 
 
Figure	  3.7.	   Dose-­‐response	  curves	  of	  a)	  –	  c)	  AC1–3	  and	  d)	  –	  e)	  AC5–6	  upon	  TRPV1	  activation	  with	  
1	  µM	  CAP,	  compared	  to	  CPZ	  (n	  =	  3–4).	  
 
Table	  3.1.	   Determination	  of	  IC50	  values	  of	  AC	  derivatives	  upon	  TRPV1	  activation	  with	  1	  µM	  CAP.	  
Antagonist IC50 (1 µ M CAP) 
AC1 > 50 µM 
AC2 > 50 µM 
AC3 > 50 µM 
AC5 > 50 µM 
AC6 > 50 µM 
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Cell Culture 
 
HEK 293T cells were cultured under standard conditions (Dulbecco’s modified Eagle medium 
(DMEM) containing 10% FBS; 37 °C, 10% CO2). Cells were plated on poly-L-lysine 
(0.1 mg/ml) treated coverlips in a density of 20,000 cells per cm2 for electrophysiological 
measurements.  
HEK 293 cells were transfected with TRPV1-YFP[52] (kindly provided by Dr. Tim D. Plant, 
Institute for Pharmacology and Toxicology, Marburg, Germany) using PromoFectin® 
transfection agent according to the manufacturers instructions and measured after 12–24 h.  
 
Whole-cell Electrophysiology 
 
Patch clamp recordings of HEK 293T cells were carried out using a HEKA Patch Clamp EPC10 
USB amplifier in whole cell mode and were performed at room temperature. Cells were 
voltage-clamped at –60 mV. Pipettes (Science Products GB200-F-8P with filament) were pulled 
with a Narishige PC-10 pipette puller and had resistances of 4–6 MΩ. The Bath solution 
contained 150 mM NaCl, 6.0 mM CsCl, 1.0 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES and 
10 mM glucose, adjusted to pH = 7.4. Pipette solution contained 150 mM NaCl, 3.0 mM MgCl2, 
10.0 mM HEPES and 5.0 mM EGTA, adjusted to pH = 7.2.[25] Data was recorded using the 
HEKA PatchMaster software (V2x60). The sampling rate was 20–50 kHz and the currents were 
digitally filtered at 2.9 kHz. Cells were illuminated with a Polychrome V monochromator (Till 
Photonics), as described previously.[53] 
 
Aequorin-based Calcium Measurements 
 
Total luminescence in HEK 293 cells, co-transfected with the aequorin encoding plasmid 
G5α[54] and TRPV1-YFP,[52] was measured using a FLUOstar® Omega plate reader at 37 ºC 
after labelling of the cells with coelenterazine H (5 µM) for 30 min at room temperature. HBS as 
a control was automatically injected 5 s after starting the measurement. In intervals of 1 s total 
emission was monitored and the area under the curve (AUC) determined. AUC of calcium 
signals induced by 1 µM CAP in the absence of any antagonist was set to 100% and effects of 
various antagonist concentrations determined in %. Data were analyzed using Prism4.0 
(GraphPad Software Inc., San Diego, CA).  
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3.3 AZO-CAPSAZEPINES IN THE RETINA  
 
Capsazepine is known to act also as an antagonist on TRPM1 channels[55] which are involved in 
the ON-pathway in the vision cascade (see 5.1). Therefore, the most promising of all 
Azo-Capsazepine derivatives, AC4, and the red-shifted AC3 were tested for light-dependent 
modulation of retinal activity in dissected blind mouse retinae (rho-/-, cngA3-/-, opn4-/-; Laura 
Laprell, LMU). Application of both compounds resulted in increased spiking. However, neither 
AC3 (20 µM) nor AC4 (10−20 µM) showed significant pattern changes when illuminated with 
different wavelengths according to their absorption spectra (AC3: dark/480 nm; AC4: 
360/480 nm). 
 
 
Figure	  3.8.	   No	   photodependent	   activity	   of	   a)	  AC3	   (20	  µM)	   and	   b)	  AC4	   (10–20	  µM)	   in	   dissected	  
blind	   mouse	   retina	   recordings	   (black:	   darkness;	   blue:	   λ	  =	  480	  nm;	   purple:	   λ	  =	  360	  nm;	   Laura	   Laprell,	  
LMU).	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3.4 THE MENTHOL RECEPTOR TRPM8 
 
The functions of TRPM channels are highly diverse and comprise Mg2+ homeostasis (TRPM6, 
TRPM7),[56] taste detection (TRPM5),[57] cell proliferation (TRPM7)[56a] as well as detection of 
warm temperatures (TRPM5)[20] and noxious cold (TRPM8).[21a] TRPM1 was moreover shown 
to be part of the ON bipolar pathway of the human vision cascade, being involved in the 
inversion of the mGluR6 signal in ON bipolar cells.[55] The detailed mechanism of this sign 
inversion, however, is not yet fully understood. Among all TRP channels, TRPM4 and TRPM5 
appear to be the only members of this large family that are impermeable to Ca2+.[1,58] 
The so-called cold or menthol receptor TRPM8 was first discovered by McKemy et al. in 
2002[21a] and was found to respond to cold temperatures as well as to the cooling agents menthol 
and eucalyptol (Fig. 3.9).[21a,21b] 
 
	  
Figure	  3.9.	   Structures	  of	  TRPM8	  agonists	  (–)-­‐menthol	  and	  eucalyptol.	  	  
 
TRPM8 was originally identified in prostate cancer, followed by many other non-prostatic 
tumors.[59] It is also found in the bladder and in various tissues of the male genital tract.[60] 
Attributing to its temperature and pain perception function, TRPM8 is also located in sensory 
neurons.[1] The cold activation of TRPM8 is hypothesized to occur – similar to TRPV1 
channels – via a temperature-dependent shift of the voltage activation of the channel.[25] 
The pleasant perception of coolness is transduced mainly by low-threshold thermoceptors 
expressing TRPM8 channels, whereas high-threshold nociceptors are responsible for the 
perception of cold pain. The latter is mediated also by TRPM8 channels and the voltage-gated 
sodium channel NaV 1.8. Moreover, TRPA1 channels in sensitized nociceptors may contribute 
to the perception of noxious cold but their exact role and specific temperature dependence is 
still under debate (Fig. 3.10).[61] For example, in a recent study TRPA1 was observed to be 
insensitive to cold temperatures but cold did amplify agonist evoked TRPA1 currents.[62] 
TRPA1 activation is now speculated to lead to cold hypersensitivity, possibly transduced via 
TRPM8.[61]   
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Figure	  3.10.	   TRPM8	  mediates	  the	  perception	  of	  cold	  temperatures	  and	  cold	  pain,	  whereas	  TRPA1	  is	  
believed	   to	   be	   related	   to	   pain	   perception	   only.	   Illustration	   copied	   from	   McKemy,[61]	   reprinted	   with	  
permission	  from	  the	  American	  Chemical	  Society.	  Copyright	  2013.	  
 
 
3.5 AZO-ICILIN 
 
Icilin is a synthetic super-agonist of TRPM8 channels with an EC50 value of 0.2 µM.[21] 
Although structurally not related to menthol, it produces an extreme sensation of cold both in 
humans and animals. It is ~200 times more potent than menthol and 2.5 times more 
efficacious.[63]  
Although there is little information published on the structure–activity relationship of icilin, one 
derivative bearing a chlorine atom instead of the nitro group is known to retain agonistic effects 
on TRPM8. Consequently, the m-NO2 group was chosen as an anchor for an azobenzene 
moiety, leading to the photoswitchable analogue Azo-Icilin 1 (AI1; Fig. 3.11). 
 
 
Figure	  3.11.	   Structures	  of	  icilin	  and	  AI1.	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Synthesis of Azo-Icilin 1 
 
The synthesis of AI1 was based on the original synthesis of icilin by Delmar Chemicals Ltd.[64] 
Starting from m-nitroacetophenone, a Mannich reaction with paraformaldehyde and diethyl 
amine yielded 3.1 in 70% as the hydrochloride salt.[65] Unfortunately, using the reported 
conditions[64] for the next step, reaction of 3.1 with the unprotected o-hydroxy aniline did not 
lead to the desired substitution product. However, replacing the unprotected phenol with methyl 
or benzyl protected derivatives led to the desired secondary amines 3.2 and 3.3 in 62% and 82% 
yield, respectively. Ring closure with potassium cyanate afforded methyl (3.4) and benzyl 
protected icilin (3.5) in excellent yields (Scheme 3.8). 
 
 
Scheme	  3.8.	   Synthesis	  of	  phenol	  protected	  icilin	  derivatives	  3.4	  and	  3.5.	  	  
 
In order to introduce the azobenzene moiety, several attempts to reduce the nitro group of 3.4 to 
the corresponding aniline 3.6 were undertaken, leading to different results (Scheme 3.9, Table 
3.2). 
 
 
Scheme	  3.9.	   Attempted	  conditions	  for	  the	  reduction	  of	  3.4	  to	  the	  aniline	  3.6.	  	  
 
Hydrogen and palladium on charcoal quantitatively yielded 3.7, in which in addition to the nitro 
functionality the benzylic double bond was reduced (Table 3.2, entry 1). Attempts with sodium 
sulfide gave the desired product in 34–40% yield with no other isolated side products (entry 2). 
Using the rather harsh conditions with tin(II) chloride in concentrated hydrochloric acid led to 
decomposition of the starting material (entry 3). Zinc in glacial acetic acid afforded 3.6 in 70% 
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yield (entry 5) but the best results were obtained with iron and ammonium chloride in a 
refluxing ethanol/water mixture, yielding 3.6 reliably in 80–90% (entry 4).  
 
Table	  3.2.	   Conditions	  for	  the	  reduction	  of	  3.4	  to	  3.6.	  	  
Entry Reagent Conditions Yield 3.6 [%]  Yield other products [%]  
1 H2, Pd/C MeOH, rt, 1.5 h 0 
 
3.7, 100 
2 Na2S 1,4-dioxane/H2O, 
90 °C, 1 h 
34–40 - 
3 SnCl2, HCl rt, 3.5 h 0 - 
4 Fe, NH4Cl EtOH/H2O, Δ, 3 h 80–90 - 
5 Zn, HOAc 50 °C, 3 h 70 - 
 
However, since it was not possible to purify 3.6 completely, the so obtained aniline was used 
crude for the next step (Scheme 3.10). Aniline 3.6 was stirred under Mills conditions with 
nitrosobenzene, leading to two yellow to orange products which after isolation and 
characterization turned out to be undesired compounds 3.8 (35% yield) and 3.9 (10%), 
respectively. The desired Mills product was not observed. 
 
 
Scheme	  3.10	   Undesired	  enamine	  attack	  of	  3.6	  to	  nitrosobenzene.	  	  
 
A proposed reaction mechanism for the formation of 3.8 is given in Scheme 3.11. The enamine 
portion of 3.6 nucleophilically attacks the nitrogen of the nitrosobenzene, leading to 
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intermediate 3.10 which, after proton transfer, gives hydroxylamine 3.11. Acid catalyzed 
dehydration leads to imine 3.12 which is converted into enamine 3.8 through imine-enamine 
tautomerism. The full aromatization and therefore high stability of 3.8 might be an important 
feature in this reaction pathway. In a following, second reaction sequence, a regular Mills 
reaction with a second equivalent of nitrosobenzene then presumably furnishes 3.9. 
 
 
Scheme	  3.11.	   Proposed	  reaction	  mechanism	  of	  3.6	  and	  nitrosobenzene	  to	  3.8.	  	  
 
Subsequently, a new route was developed introducing the azobenzene moiety early on in the 
synthesis (Scheme 3.12). Mannich precursor 3.13 was synthesized by a Mills reaction of 
m-aminoacetophenone and nitrosobenzene in 61% yield. Ketone 3.13 was then submitted to 
Mannich conditions (paraformaldehyde, diethylamine, acid catalysis) to provide HCl salt 3.14 
in excellent yield (93%). Having obtained poor results with unprotected o-hydroxy aniline in the 
previous route toward AI1, 3.14 was first condensed with benzyl protected o-hydroxy aniline to 
give 3.16 in 83% yield. Reaction with KOCN yielded benzyl protected Azo-Icilin 3.17 
quantitatively. However, attempts to remove the benzyl ether using BBr3 or HBr in HOAc, 
respectively, led to decomposition of the starting material (Scheme 3.13).  
In another attempt to condense the Mannich product 3.14 with unprotected o-hydroxy aniline, 
the desired product 3.15 was obtained in a good yield of 64%. Formation of the heterocycle 
with KOCN finally gave rise to AI1 in 60% yield (Scheme 3.12). 
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Scheme	  3.12.	   Synthesis	  of	  Azo-­‐Icilin	  1.	  	  
 
 
 
Scheme	  3.13.	   Attempted	  removal	  of	  the	  benzyl	  ether	  of	  3.17.	  	  
	  
Biological Evaluation of Azo-Icilin 1 
 
The absorption maxima of AI1 were determined to be λ = 320 nm and λ = 435 nm, respectively 
(Fig. 3.12a). Subsequent testing in transiently TRPM8 transfected HEK 293 cells was carried 
out to determine whether AI1 remained an agonist for the channel. Expression of TRPM8 was 
assured in control experiments by cold activation of the channel with cold buffer solution (not 
shown). AI1 at various concentrations (0.1–10 µM) was applied via a puff pipette to the cells, 
leading to a robust inward current, proving the agonistic activity of AI1 (Fig. 3.12b). The 
current, however, appeared to be steadily increasing, reaching no baseline current which might 
attribute to the relatively high hydrophobicity of the compound. Application of light of different 
wavelengths did not lead to light-dependent changes of current. In a different experiment, 
additional activation of the channel with a voltage step to +200 mV did result in 
photoswitchable currents when AI1 was applied at a concentration of 5 µM. Switching between 
λ = 350 nm and λ = 440 nm led to changes in current of  >1 nA (Fig. 3.12c).   
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Figure	  3.12.	   a)	   UV/Vis	   spectrum	   of	   AI1	   (DMSO)	   with	   peak	   absorptions	   at	   λ	  =	  320	  nm	   and	  
λ	  =	  435	  nm.	  b)	  Puff	  application	  of	  AI1	  (2	  µM)	  to	  HEK	  293	  cells,	  transiently	  transfected	  with	  TRPM8.	  The	  
current	  steadily	  increased	  but	  no	  changes	  upon	  irradiation	  with	  either	  λ	  =	  440	  nm	  (blue)	  or	  λ	  =	  350	  nm	  
(purple)	  were	   observed	   (holding	   potential	   –60	  mV).	   c)	   Voltage	   activation	   of	   TRPM8	   (+200	  mV)	   during	  
application	  of	  AI1	  (5	  µM)	  resulted	  in	  photoswitchable	  currents	  of	  ∼2	  nA.	  
	  
Taken together, the results obtained with AI1 proved the tolerance of icilin toward substitution 
with meta-azobenzenes on the dihydropyrimidone moiety, since AI1 still acts as agonist on 
TRPM8. The photoswitchable currents upon voltage activation of the channel indicate the 
potential of photoswitchable icilin derivatives. These findings prompted the development of 
further azobenzene derivatives of icilin which is described in the following section. 
 
Synthesis of AI2 and AI3 
 
Initial attempts to synthesize a red-shifted, p-diethylamino substituted Azo-Icilin derivative 
failed. Mannich precursor 3.18 was synthesized in 95% yield from 3-aminoacetophenone by 
diazotization and subsequent coupling to N,N-diethylaniline. Ketone 3.18 was then subjected to 
Mannich conditions as previously established but the desired product 3.19 could not be isolated, 
probably owing to the influence of the basic nitrogen of the diethylamino group (Scheme 3.14). 
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Scheme	  3.14.	   Attempted	  synthesis	  of	  a	  p-­‐diethylamino	  substituted	  Azo-­‐Icilin	  derivative.	  	  
 
The synthesis of a trifluoromethyl analogue, termed AI2, was more successful. Firstly, 
4-trifluoromethylaniline was oxidized to the corresponding nitroso compound and then 
condensed with 3-aminoacetophenone in a Mills reaction, furnishing azobenzene 3.20 in 54% 
yield. A Mannich reaction of 3.20 with paraformaldehyde and diethyl amine under acidic 
catalysis led to Mannich product 3.21 in 88% yield which was further reacted with 
2-hydroxyaniline to yield 3.22 in 52% yield. Finally, formation of the dihydropyrimidone ring 
was achieved by reaction of 3.22 with potassium cyanate (52% yield; Scheme 3.15). 
 
 
Scheme	  3.15.	   Synthesis	  of	  AI2.	   
The synthesis of AI3, a p-methoxy analogue of Azo-Icilin, commenced with oxidation of 
3-aminoacetophenone to the corresponding nitroso derivative using oxone, followed by 
condensation with p-anisidine to give azobenzene 3.23 in 56% yield. Reaction of ketone 3.23 
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with paraformaldehyde and diethyl amine gave Mannich product 3.24 in 92% yield. 
Substitution with 2-hydroxyaniline then led to secondary amine 3.25 in 56% yield. Finally, ring 
closure with potassium cyanate afforded AI3 in 63% yield (Scheme 3.16). 
 
Scheme	  3.16.	   Synthesis	  of	  AI3.	  	  
 
The absorption maxima of AI2 and AI3 were determined to be at λ = 314 nm and λ = 428 nm 
(AI2, Fig. 3.13a), as well as at λ = 355 nm and λ = 440 nm (AI3, Fig. 3.13b). Both derivatives 
AI2 and AI3 were tested in transiently TRPM8 transfected HEK 293 cells on their ability to 
directly activate the channel in a light-dependent fashion. However, neither AI2 nor AI3 
showed direct activation of TRPM8 at concentrations up to 10 µM (data not shown). Voltage 
activation of TRPM8 (+200 mV) in the presence of 10 µM AI2 resulted in a small 
photoswitchable current (∼40 pA compared to ∼2 nA for AI1; data not shown). 
 
 
Figure	  3.13.	   UV/Vis	   spectra	   of	   a)	   AI2	   (DMSO,	   λmax	  =	  314	  nm,	   428	  nm)	   and	   b)	   AI3	   (DMSO,	  
λmax	  =	  355	  nm,	  440	  nm).	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3.6 EXPERIMENTAL PROCEDURES AND ANALYTICAL DATA 
 
3.6.1 GENERAL EXPERIMENTAL DETAILS AND INSTRUMENTATION 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[50] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0; DMSO-d6: δH 2.50, 
δC 39.5).[51] Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, 
q = quartet, quint = quintet, sext = sextet, sept = septet, m = multiplet. High resolution mass 
spectra (EI, ESI) were recorded by LMU Mass Spectrometry Service using a Thermo Finnigan 
MAT 95, a Jeol MStation or a Thermo Finnigan LTQ FT Ultra instrument. Melting points were 
obtained using a Stanford Research Systems MPA120 apparatus and are uncorrected. 
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3.6.2 SYNTHESIS OF AZO-ICILINS 
	  
Synthesis of N,N-diethyl-3-(3-nitrophenyl)-3-oxopropan-1-aminium chloride (3.1) 
 
 
 
Diethylamine (3.43 mL, 33.3 mmol, 1.0 equiv.) was dissolved in MeCN (270 mL) and conc. 
HCl (2.98 mL) was added. Paraformaldehyde (3.00 g, 100 mmol, 3.0 equiv.) was added, 
followed by m-nitroacetophenone (16.5 g, 100 mmol, 3.0 equiv.). The mixture was heated to 
reflux for 2.5 d. The solvent was removed under reduced pressure and the residue was triturated 
with Et2O (2 x 250 mL). The colorless solid was recrystallized from acetone (150 mL) and dried 
overnight under high vacuum. The HCl salt of Mannich product 3.1 was obtained in 70% yield 
(6.69 g, 23.3 mmol) as colorless needles. 
M.p.: 119–121 °C. 1H NMR (DMSO-d6, 400 MHz, 27 °C): δ = 10.46 (br s, 1H, NH), 8.70 (dd, 
J = 2.0, 2.0 Hz, 1H, ArH), 8.49 (ddd, J = 8.2, 2.4, 1.2 Hz, 1H, ArH), 8.41 (ddd, J = 8.2, 2.4, 
1.2 Hz, 1H, ArH), 7.85 (dd, J = 8.2, 8.2 Hz, 1H, ArH), 3.73–3.66 (m, 2H, CH2), 3.42–3.35 (m, 
2H, CH2), 3.16 (dq, J = 7.2, 2.4 Hz, 4H, 2 x CH2), 1.22 (t, J = 7.2 Hz, 6H, 2 x CH3) ppm. 
13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 195.7, 148.5, 137.7, 134.6, 131.1, 128.2, 122.9, 
46.8, 45.9, 32.3, 9.0 ppm. IR (neat, ATR): ṽ = 2444 (m), 1692 (s), 1612 (w), 1530 (s), 1478 
(m), 1441 (m), 1387 (w), 1352 (vs), 1213 (m), 1170 (w), 1154 (w), 1109 (w), 1088 (w), 1065 
(w), 1046 (w), 1005 (w), 965 (w), 924 (w), 880 (w), 845 (m), 811 (m), 784 (m), 732 (vs), 692 
(m), 676 (m) cm-1. HRMS (ESI+): m/z calcd. for [C13H19N2O3]+: 251.1396, found: 251.1390 
([M-Cl]+). 
 
Synthesis of 3-((2-methoxyphenyl)amino)-1-(3-nitrophenyl)propan-1-one (3.2) 
 
 
 
The HCl salt of amine 3.1 (1.43 g, 5.00 mmol, 1.1 equiv.) and o-anisidine (0.51 mL, 4.6 mmol, 
1.0 equiv.) were dissolved in ethanol (7.5 mL) and water (7.5 mL) and heated to reflux for 3 h. 
The mixture was cooled and a sat. aqu. solution of NaHCO3 was added (50 mL). The aqueous 
phase was extracted with EtOAc (50 mL). The organic phase was washed with sat. aqu. 
NaHCO3 (50 mL) and concentrated under reduced pressure. The crude product was purified by 
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flash silica gel column chromatography (hexanes/EtOAc, gradient from 6:1 to 4:1) to give 
secondary amine 3.2 (854 mg, 2.84 mmol, 62%) as a red solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.55. M.p.: 95–96 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.78–8.73 (m, 1H, ArH), 8.45–8.36 (m, 1H, ArH), 8.30–8.23 (m, 1H, ArH), 7.66 (dd, 
J = 8.0, 8.0 Hz, 1H, ArH), 6.92–6.84 (m, 1H, ArH), 6.79–6.73 (m, 1H, ArH), 6.72–6.64 (m, 2H, 
ArH), 4.54 (br s, 1H, NH), 3.81 (s, 3H, CH3), 3.71–3.65 (m, 2H, CH2), 3.39–3.31 (m, 2H, 
CH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 196.9, 148.4, 147.1, 138.0, 137.3, 133.5, 
129.9, 127.4, 122.9, 121.2, 116.9, 109.7, 109.6, 53.4, 38.3, 38.2 ppm. IR (neat, ATR): ṽ = 3413 
(w), 3081 (w), 2939 (w), 2902 (w), 2869 (w), 2836 (w), 1689 (m), 1613 (m), 1601 (m), 1525 
(s), 1511 (vs), 1476 (m), 1456 (m), 1432 (m), 1347 (vs), 1319 (m), 1248 (m), 1221 (vs), 1178 
(m), 1128 (m), 1097 (m), 1050 (m), 1027 (m), 1001 (m), 903 (w), 807 (w), 732 (vs), 698 (w), 
672 (m) cm-1. HRMS (ESI+): m/z calcd. for [C16H17N2O4]+: 301.1188, found: 301.1183 
([M+H]+). 
 
Synthesis of 3-((2-(benzyloxy)phenyl)amino)-1-(3-nitrophenyl)propan-1-one (3.3) 
 
 
 
The HCl salt of amine 3.1 (2.00 g, 6.97 mmol, 1.1 equiv.) and 2-benzyloxyaniline (1.26 g, 
6.34 mmol, 1.0 equiv.) were dissolved in ethanol (12 mL) and water (12 mL) and heated to 
reflux for 3 h. The mixture was cooled and a sat. aqu. solution of NaHCO3 was added (70 mL). 
The aqueous phase was extracted with EtOAc (2 x 50 mL). The organic phase was washed with 
sat. aqu. NaHCO3 (70 mL) and concentrated under reduced pressure. The crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, gradient from 10:1 to 5:1) 
to give secondary amine 3.3 (1.97 g, 5.23 mmol, 82%) as a red oil. 
TLC (Hexane/EtOAc, 2:1): Rf = 0.64. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 8.77–8.73 (m, 
1H, ArH), 8.41 (ddd, J = 7.8, 2.4, 1.2 Hz, 1H, ArH), 8.25 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 
7.65 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.42–7.36 (m, 4H, ArH), 7.35–7.31 (m, 1H, ArH), 6.91 
(ddd, J = 7.8, 7.8, 1.2 Hz, 1H, ArH), 6.84 (dd, J = 8.4, 1.2 Hz, 1H, ArH), 6.72 (dd, J = 8.4, 
1.2 Hz, 1H, ArH), 6.67 (ddd, J = 7.8, 7.8, 1.2 Hz, 1H, ArH), 5.05 (s, 2H, CH2), 4.66 (br s, 1H, 
NH), 3.72–3.67 (m, 2H, CH2), 3.36–3.31 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 150 MHz, 
27 °C): δ = 196.9, 148.4, 146.3, 138.0, 137.6, 137.0, 133.5, 129.9, 128.6, 128.0, 127.5, 127.5, 
122.9, 121.7, 116.9, 111.4, 110.1, 70.5, 38.3, 38.2 ppm. IR (neat, ATR): ṽ = 3414 (w), 3061 
(w), 2871 (w), 1689 (m), 1601 (m), 1523 (s), 1511 (s), 1473 (m), 1441 (m). 1378 (m), 1347 
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(vs), 1314 (m), 1249 (m), 1206 (s), 1162 (w), 1128 (m), 1093 (m), 1015 (m), 918 (w), 853 (w), 
808 (w), 731 (vs), 697 (m), 671 (m) cm-1. HRMS (ESI+): m/z calcd. for [C22H21N2O4]+: 
377.1501, found: 377.1494 ([M+H]+). 
 
Synthesis of 3-(2-methoxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one (3.4) 
 
 
 
Secondary amine 3.2 (775 mg, 2.30 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 1,4-dioxane 
(15 mL) and concentrated under reduced pressure. The so obtained HCl salt was then dissolved 
in glacial acetic acid (20 mL) and potassium cyanate (673 mg, 8.3 mmol, 3.6 equiv.) was added. 
The mixture was heated to 60 °C for 2 h. Water (20 mL) and sat. aqu. NaHCO3 (50 mL) were 
added and the aqueous phase was extracted with CHCl3 (2 x 30 mL). The combined organic 
phases were washed with sat. aqu. NaHCO3 (2 x 30 mL), dried over MgSO4 and concentrated 
under reduced pressure, yielding tricycle 3.4 (678 mg, 2.08 mmol, 90%) as a yellow solid. An 
analytical sample was purified by flash silica gel column chromatography (CHCl3/MeOH, 
gradient from 100:0 to 80:1). 
TLC (CHCl3/MeOH, 40:1): Rf = 0.23. M.p.: 243–245 °C. 1H NMR (DMSO-d6, 400 MHz, 
27 °C): δ = 8.93 (s, 1H, ArH), 8.34 (dd, J = 1.6, 1.6 Hz, 1H, ArH), 8.17 (dd, J = 8.0, 1.6 Hz, 
1H, ArH), 7.98 (d, J = 8.4 Hz, 1H, ArH), 7.65 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 7.30–7.21 (m, 2H, 
ArH), 7.07 (d, J = 7.6 Hz, 1H, ArH), 6.94 (ddd, J = 7.6, 7.6, 1.2 Hz, 1H, ArH), 5.40 (dd, 
J = 5.7, 3.6 Hz, 1H, CH), 4.22 (d, J = 3.6 Hz, 1H, CH), 3.77 (s, 3H, CH3) ppm. 13C NMR 
(DMSO-d6, 100 MHz, 27 °C): δ = 155.7, 153.0, 148.3, 135.9, 135.3, 132.2, 130.4, 129.8, 
128.9, 123.5, 121.1, 120.5, 112.8, 97.8, 56.0, 49.7 ppm. IR (neat, ATR): ṽ = 3198 (w), 3085 
(w), 2934 (w), 2834 (w), 1653 (vs), 1598 (m), 1525 (m), 1504 (s), 1466 (m), 1345 (m), 1300 
(m), 1264 (m), 1230 (m), 1207 (m), 1180 (m), 1164 (w), 1119 (m), 1048 (m), 1026 (m), 976 
(m), 927 (w), 890 (w), 862 (w), 845 (w), 800 (m), 757 (s), 743 (s), 730 (m), 664 (m) cm-1. 
HRMS (ESI+): m/z calcd. for [C17H16N3O4]+: 326.1141, found: 326.1136 ([M+H]+). 
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Synthesis of 3-(2-(benzyloxy)phenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one 
(3.5) 
 
 
 
Secondary amine 3.3 (783 mg, 1.97 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 1,4-dioxane 
(20 mL) and concentrated under reduced pressure. The so obtained HCl salt was then dissolved 
in glacial acetic acid (25 mL) and potassium cyanate (799 mg, 9.85 mmol, 5.0 equiv.) was 
added. The mixture was heated to 60 °C for 2 h. Water (30 mL) and sat. aqu. NaHCO3 (70 mL) 
were added and the aqueous phase was extracted with CHCl3 (2 x 50 mL). The combined 
organic phases were washed with sat. aqu. NaHCO3 (2 x 50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash silica gel column 
chromatography (CHCl3/MeOH, gradient from 100:0 to 70:1) to give tricycle 3.5 (609 mg, 
1.52 mmol, 77%) as a yellow solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.35. M.p.: 69–70 °C. 1H NMR (CDCl3, 600 MHz, 27 °C): 
δ = 8.32 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 8.18 (ddd, J = 7.8, 1.8, 0.6 Hz, 1H, ArH), 7.80–7.77 (m, 
1H, ArH), 7.50 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.35–7.27 (m, 6H, ArH), 7.05–7.00 (m, 2H, 
ArH), 5.27–5.21 (m, 1H, CH), 5.14 (s, 2H, CH2), 4.55–4.25 (br s, 2H, CH2) ppm. 13C NMR 
(CDCl3, 150 MHz, 27 °C): δ = 154.5, 153.6, 148.5, 136.9, 136.0, 135.2, 130.6, 130.6, 129.8, 
129.0, 128.5, 127.8, 127.0, 123.4, 121.5, 120.2, 113.9, 97.2, 70.4, 49.8 ppm. IR (neat, ATR): 
ṽ = 3219 (w), 3090 (w), 1656 (s), 1618 (m), 1597 (m), 1528 (m), 1500 (m), 1449 (m), 1378 (w), 
1345 (m), 1287 (m), 1214 (m), 1162 (w), 1120 (m), 1046 (w), 1022 (m), 903 (w), 862 (w), 808 
(w), 790 (w), 734 (vs), 696 (m), 667 (m) cm-1. HRMS (ESI+): m/z calcd. for [C23H20N3O4]+: 
402.1454, found: 402.1447 ([M+H]+). 
 
Synthesis of 4-(3-aminophenyl)-1-(2-methoxyphenyl)tetrahydropyrimidin-2(1H)-one (3.7) 
 
 
 
Nitroalkene 3.4 (20 mg, 0.061 mmol) was dissolved in MeOH (3 mL) and palladium on 
charcoal (10%; 1 spatula) was added under an argon atmosphere. The flask was evacuated and 
N NH
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purged with hydrogen (3x). The mixture was stirred at room temperature for 1.5 h under a 
hydrogen atmosphere (1 bar). The mixture was filtered over Celite and washed with CHCl3. The 
solvent was removed under reduced pressure, yielding aminoalkane 3.7 (17 mg, 0.058 mmol, 
95%) as a colorless solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.38. M.p.: 213–215 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.28–7.24 (m, 3H, ArH), 7.16 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 6.99–6.94 (m, 2H, 
ArH), 6.80−6.76 (m, 2H, ArH), 6.63 (ddd, J = 7.8, 1.8, 0.6 Hz, 1H, ArH), 4.95 (br s, 1H, NH), 
4.65–4.59 (m, 1H, CH), 3.87 (s, 3H, CH3), 3.80–3.67 (m, 2H, CH2), 2.34–2.25 (m, 1H, CH), 
2.13–2.05 (m, 1H, CH) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 155.6, 155.5, 146.8, 
144.0, 131.7, 129.8, 129.6, 128.4, 120.9, 116.3, 114.4, 112.6, 112.1, 55.7, 55.5, 46.5, 31.1 ppm. 
IR (neat, ATR): ṽ = 3323 (w), 3224 (w), 2923 (w), 1653 (vs), 1602 (s), 1557 (m), 1539 (m), 
1506 (vs), 1457 (s), 1319 (m), 1299 (m), 1272 (m), 1245 (m), 1180 (w), 1162 (w), 1117 (m), 
1046 (w), 1024 (w), 871 (w), 790 (m), 751 (s), 697 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C17H20N3O2]+: 298.1556, found: 298.1549 ([M+H]+). 
 
Synthesis of 4-(3-aminophenyl)-1-(2-methoxyphenyl)-5-(phenylamino)pyrimidin-2(1H)-
one (3.8) 
 
 
 
Nitroarene 3.4 (68 mg, 0.17 mmol, 1.0 equiv.) was dissolved in EtOH (3.6 mL) and water 
(0.9 mL) and Fe (76 mg, 1.4 mmol, 8.0 equiv.) and NH4Cl (5.0 mg, 0.090 mmol, 0.5 equiv.) 
were added. The reaction mixture was heated to reflux for 3 h. The cooled solution was filtered 
over Celite and washed with EtOAc. The organic phase was washed with brine (20 mL), dried 
over MgSO4 and concentrated under reduced pressure.  
The crude aniline 3.6 was then dissolved in glacial acetic acid (2 mL) and nitrosobenzene 
(18 mg, 0.17 mmol, 1.0 equiv.) was added. The mixture was stirred at room temperature for 
16 h. The mixture was then basified with sat. aqu. NaHCO3 and extracted with EtOAc 
(2 x 10 mL). The combined organic layers were washed with sat. aqu. NaHCO3 (20 mL), brine 
(20 mL), then dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash silica gel column chromatography (CHCl3/MeOH, gradient from 100:0 to 30:1) to yield 
aromatic enamine 3.8 (23 mg, 0.060 mmol, 35%). As a side product, the double adduct of 
nitrosobenzene, azo enamine 3.9 (8.0 mg, 0.017 mmol, 10%) was obtained. 
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TLC (DCM/MeOH, 10:1): Rf = 0.34. 1H NMR (CD3OD, 400 MHz, 27 °C): δ = 7.90 (s, 1H, 
ArH), 7.50 (ddd, J = 8.4, 7.5, 1.6 Hz, 1H, ArH), 7.44 (dd, J = 7.8, 1.6 Hz, 1H, ArH), 7.23 (dd, 
J = 8.4, 1.0 Hz, 1H, ArH), 7.19 (dd, J = 2.0, 2.0 Hz, 1H, ArH), 7.16 (ddd, J = 7.6, 2.0, 2.0 Hz, 
1H, ArH), 7.13–7.08 (m, 4H, ArH), 6.80 (ddd, J = 7.9, 2.0, 1.1 Hz, 1H, ArH), 6.70–6.66 (m, 
3H, ArH), 3.90 (s, 3H, CH3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): δ = 174.7, 155.4, 
154.0, 148.3, 147.5, 146.7, 136.3, 130.7, 128.9, 128.4, 128.1, 127.7, 120.6, 120.4, 118.3, 118.2, 
117.5, 115.1, 113.5, 112.3, 55.1 ppm. IR (neat, ATR): ṽ = 3338 (m), 3007 (w), 1654 (vs), 1621 
(m), 1599 (s), 1497 (s), 1474 (m), 1436 (m), 1412 (m), 1358 (m), 1305 (m), 1286 (m), 1266 
(m), 1220 (w), 1180 (w), 1159 (w), 1119 (w), 1042 (w), 1024 (w), 994 (w), 877 (w), 786 (m), 
748 (s), 693 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C23H21N4O2]+: 385.1665, found: 
385.1656 ([M+H]+). 
 
Synthesis of 1-(3-(phenyldiazenyl)phenyl)ethanone (3.13) 
 
 
 
3-Aminoacetophenone (6.76 g, 50.0 mmol, 1.0 equiv.) was dissolved in glacial acetic acid 
(50 mL) and nitrosobenzene (5.36 g, 50.0 mmol, 1.0 equiv.) was added in 5 portions over 
10 min. The reaction mixture was stirred at room temperature for 2.5 d and then extracted with 
CHCl3 (5 x 20 mL). The combined organic layers were washed with sat. aqu. NaHCO3 
(3 x 50 mL), dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by flash silica gel column chromatography (CHCl3/hexanes, gradient from 2:8 to 
5:5) to yield azobenzene 3.13 (6.85 g, 30.5 mmol, 61%) as a red solid. 
TLC (CHCl3/hexanes, 4:6): Rf = 0.41. M.p.: 89–90 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.47 (dd, J = 1.8, 1.8, 1H, ArH), 8.14–8.05 (m, 2H, ArH), 7.98–7.92 (m, 2H, ArH), 7.62 
(ddd, J = 7.8, 7.8, 0.6 Hz, 1H, ArH), 7.58–7.47 (m, 3H, ArH), 2.69 (s, 3H, CH3) ppm. 13C NMR 
(CDCl3, 75 MHz, 27 °C): δ = 197.5, 152.7, 152.4, 138.1, 131.5, 130.2, 129.4, 129.2, 127.0, 
123.0, 122.9, 26.8 ppm. IR (neat, ATR): ṽ = 3064 (w), 1687 (vs), 1586 (w), 1491 (w), 1473 
(w), 1425 (w), 1358 (m), 1309 (w), 1290 (m), 1266 (m), 1208 (m), 1153 (m), 1072 (w), 1017 
(w), 998 (w), 956 (w), 926 (w), 898 (w), 801 (m), 768 (m), 726 (w), 689 (s) cm-1. HRMS (EI+): 
m/z calcd. for [C14H12N2O]+: 224.0950, found: 224.0946 ([M]+). 
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Synthesis of N,N-diethyl-3-oxo-3-(3-(phenyldiazenyl)phenyl)propan-1-aminium chloride 
(3.14) 
 
 
 
Diethylamine (1.03 mL, 10.0 mmol, 1.0 equiv.) was dissolved in MeCN (50 mL) and conc. HCl 
(0.89 mL) was added. Paraformaldehyde (601 mg, 20.0 mmol, 2.0 equiv.) was added, followed 
by ketone 3.13 (4.49 g, 20.0 mmol, 2.0 equiv.). The mixture was heated to reflux for 2.5 d. The 
solvent was removed under reduced pressure and the residue was triturated with Et2O 
(3 x 50 mL). The colorless solid was recrystallized from acetone (30 mL) and dried under high 
vacuum. The HCl salt of Mannich product 3.14 was obtained in 93% yield (3.21 g, 9.30 mmol) 
as a red solid. 
M.p.: 129–130 °C. 1H NMR (DMSO-d6, 400 MHz, 27 °C): δ = 10.62 (br s, 1H, NH), 8.45 (dd, 
J = 1.8, 1.8 Hz, 1H, ArH), 8.18 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 8.14 (ddd, J = 7.8, 1.8, 
1.2 Hz, 1H, ArH), 7.95–7.88 (m, 2H, ArH), 7.77 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.63–7.56 (m, 
3H, ArH), 3.77–3.66 (m, 2H, CH2), 3.44–3.38 (m, 2H, CH2), 3.21–3.12 (m, 4H, 2 x CH2), 1.23 
(t, J = 7.2 Hz, 6H, 2 x CH3) ppm. 13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 196.7, 152.4, 
152.2, 137.7, 132.5, 131.0, 130.5, 130.0, 127.0, 123.2, 122.7, 46.8, 46.1, 33.2, 9.0 ppm. IR 
(neat, ATR): ṽ = 3360 (w), 2977 (w), 2448 (m), 1687 (s), 1600 (m), 1581 (m), 1477 (m), 1461 
(m), 1438 (m), 1397 (m), 1380 (m), 1361 (w), 1311 (m), 1242 (w), 1200 (m), 1169 (w), 1152 
(m), 1135 (w), 1115 (w), 1082 (w), 1070 (m), 1012 (m), 979 (w), 964 (w), 930 (w), 906 (w), 
864 (w), 842 (w), 802 (m), 778 (m), 693 (vs), 668 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C19H24N3O]+: 310.1919, found: 310.1910 ([M-Cl]+). 
 
Synthesis of 3-((2-(benzyloxy)phenyl)amino)-1-(3-(phenyldiazenyl)phenyl)propan-1-one 
(3.16) 
 
 
 
The HCl salt of amine 3.14 (200 mg, 0.580 mmol, 1.1 equiv.) and 2-benzyloxyaniline (106 mg, 
0.530 mmol, 1.0 equiv.) were dissolved in ethanol (1 mL) and water (1 mL) and heated to reflux 
for 2 h. The mixture was cooled and a sat. aqu. solution of NaHCO3 was added (10 mL). The 
aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic phases were 
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washed with sat. aqu. NaHCO3 (15 mL) and brine (15 mL) and concentrated under reduced 
pressure. The crude product was purified by flash silica gel column chromatography 
(hexanes/EtOAc, gradient from 20:1 to 8:1) to give secondary amine 3.16 (191 mg, 
0.440 mmol, 83%) as an orange oil. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.50. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 8.46 (dd, 
J = 1.8, 1.8 Hz, 1H, ArH), 8.11 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 8.06 (ddd, J = 7.8, 1.8, 
1.2 Hz, 1H, ArH), 7.99–7.91 (m, 2H, ArH), 7.66 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 8.25 (ddd, 
J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 7.57–7.47 (m, 3H, ArH), 7.44–7.28 (m, 5H, ArH), 6.91 (ddd, 
J = 7.8, 7.8, 1.2 Hz, 1H, ArH), 6.84 (dd, J = 7.8, 1.2 Hz, 1H, ArH), 6.75 (dd, J = 7.8, 1.2 Hz, 
1H, ArH), 6.66 (ddd, J = 7.8, 7.8, 1.2 Hz, 1H, ArH), 5.06 (s, 2H, CH2), 4.75 (br s, 1H, NH), 
3.73–3.67 (m, 2H, CH2), 3.41–3.35 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): 
δ = 198.5, 152.6, 152.4, 146.3, 137.8, 137.1, 131.5, 130.0, 129.4, 129.2, 128.5, 127.9, 127.5, 
127.1, 123.0, 122.5, 121.7, 120.4, 116.8, 111.4, 110.2, 70.5, 38.6, 38.1 ppm. IR (neat, ATR): 
ṽ = 3726 (w), 3419 (w), 3063 (w), 3035 (w), 2898 (w), 2869 (w), 1684 (s), 1601 (m), 1511 (vs), 
1444 (m), 1380 (m), 1344 (w), 1316 (m), 1252 (s), 1207 (s), 1151 (m), 1125 (m), 1072 (w), 
1050 (w), 1019 (m), 912 (w), 856 (w), 796 (w), 768 (w), 737 (vs), 691 (vs), 668 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C28H26N3O2]+: 436.2025, found: 436.2015 ([M+H]+). 
 
Synthesis of 3-(2-(benzyloxy)phenyl)-6-(3-(phenyldiazenyl)phenyl)-3,4-dihydropyrimidin-
2(1H)-one (3.17) 
 
 
 
Secondary amine 3.16 (162 mg, 0.370 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 
1,4-dioxane (4 mL) and concentrated under reduced pressure. The so obtained HCl salt was then 
dissolved in glacial acetic acid (4 mL) and potassium cyanate (150 mg, 1.85 mmol, 5.0 equiv.) 
was added. The mixture was heated to 60 °C for 2 h. Water (10 mL) and sat. aqu. NaHCO3 
(30 mL) were added and the aqueous phase was extracted with CHCl3 (2 x 20 mL). The 
combined organic phases were washed with sat. aqu. NaHCO3 (2 x 30 mL), dried over MgSO4 
and concentrated under reduced pressure. The crude product was purified by flash silica gel 
column chromatography (CHCl3/hexanes, 1:1 → 1:0) to give tricycle 3.17 (172 mg, 
0.370 mmol, 100%) as an orange oil. 
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TLC (hexanes/EtOAc, 1:1): Rf = 0.60. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 8.00 (dd, 
J = 1.8, 1.8 Hz, 1H, ArH), 7.97–7.89 (m, 3H, ArH), 7.57–7.48 (m, 5H, ArH), 7.47–7.42 (m, 2H, 
ArH), 7.37–7.24 (m, 5H, ArH), 7.05–6.99 (m, 2H, ArH), 6.66 (br s, 1H, NH), 5.23 (td, J = 3.8, 
1.9 Hz, 1H, CH), 5.14 (s, 2H, CH2), 4.49–4.28 (br s, 2H, CH2) ppm. 13C NMR (CDCl3, 
100 MHz, 27 °C): δ = 154.6, 153.5, 152.9, 152.5, 137.0, 136.3, 135.4, 131.3, 131.0, 129.6, 
129.4, 129.1, 128.7, 128.5, 127.7, 127.1, 126.9, 124.1, 123.0, 121.6, 118.3, 114.1, 95.8, 70.4, 
49.9 ppm. IR (neat, ATR): ṽ = 3225 (w), 3066 (w), 1657 (vs), 1598 (m), 1502 (m), 1481 (m), 
1449 (m), 1382 (w), 1289 (m), 1214 (m), 1159 (w), 1120 (w), 1048 (w), 1023 (w), 908 (w), 841 
(w), 801 (w), 750 (m), 692 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C29H25N4O2]+: 
461.1978, found: 461.1966 ([M+H]+). 
 
Synthesis of 3-((2-hydroxyphenyl)amino)-1-(3-(phenyldiazenyl)phenyl)propan-1-one (3.15) 
 
 
 
The HCl salt of amine 3.14 (1.50 g, 4.34 mmol, 1.1 equiv.) and 2-hydroxyaniline (431 mg, 
3.95 mmol, 1.0 equiv.) were dissolved in ethanol (10 mL) and water (10 mL) and heated to 
reflux for 2.5 h. The mixture was cooled and a sat. aqu. solution of NaHCO3 was added 
(75 mL). The aqueous phase was extracted with EtOAc (2 x 30 mL). The organic phase was 
washed with sat. aqu. NaHCO3 (50 mL) and brine (50 mL) and concentrated under reduced 
pressure. The crude product was purified by flash silica gel column chromatography 
(hexanes/EtOAc, gradient from 10:1 to 6:1) to give secondary amine 3.15 (869 mg, 2.52 mmol, 
64%) as an orange solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.44. M.p.: 137–138 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C)[aa]: δ = 8.44 (dd, J = 1.7, 1.7 Hz, 1H, ArH), 8.35 (dd, J = 1.7, 1.7 Hz, 0.5H, ArH, cis 
isomer), 8.09 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 8.07–8.03 (m, 1.5H, ArH), 7.98–7.94 (m, 
0.5H, ArH, cis isomer), 7.94–7.89 (m, 3H, ArH), 7.60 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 7.57–7.47 
(m, 5H, ArH), 7.26–7.24 (m, 1H, ArH, cis isomer), 6.91–6.70 (m, 5H, ArH), 3.66–3.61 (m, 2H, 
CH2), 3.47–3.38 (m, 3H, trans-CH2, cis-CH2), 3.20–3.13 (m, 1H, CH2, cis isomer) ppm. 
13C NMR (CDCl3, 100 MHz, 27 °C)[aa]: δ = 198.6, 198.5, 152.6, 152.6, 152.4, 145.6, 137.5, 
134.4, 131.5, 131.4, 130.0, 130.0, 129.5, 129.4, 129.1, 129.1, 127.4, 126.9, 123.0, 122.7, 122.5, 
121.3, 120.6, 120.1, 115.2, 50.3, 40.7, 37.7, 36.5 ppm. IR (neat, ATR): ṽ = 3333 (m), 3065 
                                                
[aa] In the 1H and 13C NMR spectrum, a 2:1 mixture of trans : cis isomers of 3.15 was observed. 
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(m), 2683 (vs), 1608 (m), 1513 (m), 1492 (m), 1447 (m), 1391 (w), 1356 (w), 1311 (w), 1260 
(m), 1197 (m), 1152 (m), 1116 (w), 1068 (w), 1042 (w), 1019 (w), 996 (w), 911 (w), 839 (w), 
797 (w), 743 (m), 690 (s) cm-1. HRMS (ESI+): m/z calcd. for [C21H20N3O2]+: 346.1556, found: 
346.1546 ([M+H]+). 
 
Synthesis of 3-(2-hydroxyphenyl)-6-(3-(phenyldiazenyl)phenyl)-3,4-dihydropyrimidin-
2(1H)-one (AI1) 
 
 
 
Secondary amine 3.15 (860 mg, 2.49 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 
1,4-dioxane (20 mL) and concentrated under reduced pressure. The so obtained HCl salt was 
then dissolved in glacial acetic acid (40 mL) and potassium cyanate (1.01 g, 12.5 mmol, 
5.0 equiv.) was added. The mixture was heated to 60 °C for 2 h. Water (40 mL) and sat. aqu. 
NaHCO3 (100 mL) were added and the aqueous phase was extracted with CHCl3 (2 x 30 mL). 
The combined organic phases were washed with sat. aqu. NaHCO3 (3 x 70 mL), dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash silica 
gel column chromatography (CHCl3/MeOH, 100:0) to give AI1 (564 mg, 1.52 mmol, 61%) as 
an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.43. M.p.: 177–178 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.99 (s, 1H, ArH), 7.96–7.91 (m, 3H, ArH), 7.56–7.49 (m, 5H, ArH), 7.38 (br s, 1H, 
OH), 7.25−7.23 (m, 1H, ArH), 7.20–7.17 (m, 1H, ArH), 7.07–6.96 (m, 3H, 2 x ArH, NH), 
5.33−5.26 (m, 1H, CH), 4.54 (d, J = 3.8 Hz, 2H, CH2) ppm. 13C NMR (CDCl3, 150 MHz, 
27 °C): δ = 154.2, 152.9, 152.4, 151.2, 136.0, 134.4, 131.4, 130.4, 129.8, 129.1, 128.1, 127.1, 
124.3, 124.2, 123.0, 121.3, 120.1, 118.6, 95.6, 50.3 ppm. IR (neat, ATR): ṽ = 3241 (m), 1642 
(vs), 1597 (m), 1496 (s), 1449 (m), 1333 (w), 1298 (m), 1243 (w), 1212 (w), 1154 (w), 1108 
(w), 1056 (w), 1022 (w), 995 (w), 964 (w), 908 (w), 840 (w), 827 (w), 800 (w), 754 (s), 690 
(m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C22H19N4O2]+: 371.1508, found: 371.1498 
([M+H]+). UV/Vis: λmax = 320, 435 nm. 
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Synthesis of 1-(3-((4-(diethylamino)phenyl)diazenyl)phenyl)ethanone (3.18) 
 
 
 
3-Aminoacetophenone (1.35 g, 10.0 mmol, 1.0 equiv.) was dissolved in 1 M HCl (32 mL) and 
cooled to 0 °C. A precooled solution of sodium nitrite (720 mg, 10.5 mmol, 1.05 equiv.) in 
water (5.3 mL) was added dropwise and the resulting mixture was stirred for 30 min at 0 °C. A 
precooled solution of N,N-diethylaniline (1.68 mL, 10.5 mmol, 1.05 equiv.) in 1 M HCl (24 mL) 
was added slowly, followed by a precooled solution of sodium acetate (5.74 g) in water 
(40 mL). The reaction mixture was stirred vigorously for 2 h at 0 °C. The mixture was extracted 
with DCM (2 x 50 mL) and the combined organic layers were washed with sat. aqu. NaHCO3 
(100 mL), dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash silica gel column chromatography (DCM/hexanes, gradient from 1:1 to 100% 
DCM) to yield azobenzene 3.18 (2.80 g, 9.48 mmol, 95%) as a deep red oil. 
TLC (DCM): Rf = 0.52. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 8.38 (dd, J = 1.8, 1.8 Hz, 
1H, ArH), 8.02 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 7.97 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 
7.92−7.84 (m, 2H, ArH), 7.55 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 3.46 (q, J = 7.1 Hz, 4H, 2 x CH2), 
2.68 (s, 3H, CH3), 1.24 (t, J = 7.1 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 197.9, 153.4, 150.5, 143.0, 138.0, 129.2, 128.4, 126.3, 125.6, 122.3, 111.0, 44.8, 26.8, 
12.6 ppm. IR (neat, ATR): ṽ = 2971 (m), 2929 (w), 1684 (s), 1596 (vs), 1561 (m), 1515 (m), 
1469 (w), 1446 (w), 1431 (w), 1395 (s), 1353 (s), 1310 (w), 1270 (m), 1240 (m), 1195 (w), 
1178 (w), 1153 (m), 1136 (vs), 1093 (w), 1077 (m), 1011 (w), 954 (w), 913 (w), 860 (w), 822 
(m), 796 (w), 744 (w), 726 (w), 686 (m) cm-1. HRMS (ESI+): m/z calcd. for [C18H21N3O]+: 
296.1763, found: 296.1759 ([M+H]+). 
 
Synthesis of 1-(3-((4-(trifluoromethyl)phenyl)diazenyl)phenyl)ethanone (3.20) 
 
 
 
4-(Trifluoromethyl)aniline (1.35 mL, 10.7 mmol, 1.0 equiv.) was dissolved in DCM (25 mL) 
and oxone (13.2 g, 21.4 mmol, 2.0 equiv.; dissolved in 50 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 4 h at room temperature. The phases were separated and the 
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aqueous phase was extracted with DCM (30 mL). The combined organic phases were washed 
with brine (50 mL), dried over MgSO4 and the solvent was removed under reduced pressure. 
The resulting green oil was immediately dissolved in HOAc (60 mL) and 3-aminoacetophenone 
(1.45 g, 10.7 mmol, 1.0 equiv.) was added in small portions over the course of 10 min. The 
mixture was stirred for 3 d at room temperature. The mixture was basified with 2 M NaOH and 
extracted with DCM (2 x 30 mL). The combined organic phases were washed with sat. aqu. 
NaHCO3 (2 x 50 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash silica gel column chromatography (DCM/hexanes, gradient from 2:1 to 1:2) to 
yield azobenzene 3.20 (1.69 g, 5.78 mmol, 54%) in the form of red crystals. 
TLC (DCM/hexanes, 1:1): Rf = 0.35. M.p.: 57–58 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.50 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 8.18–8.09 (m, 2H, ArH), 8.06–8.00 (m, 2H, ArH), 
7.83−7.77 (m, 2H, ArH), 7.65 (ddd, J = 7.8, 7.8, 0.3 Hz, 1H, ArH), 2.70 (s, 3H, CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 197.3, 154.1 (q, J = 1.4 Hz), 152.4, 138.2, 132.7 (q, 
J = 32.6 Hz), 131.0, 129.5, 127.2, 126.4 (q, J = 3.8 Hz), 123.8 (q, J = 270.1 Hz), 123.2, 123.1, 
26.8 ppm. 19F NMR (CDCl3, 282 MHz, 27 °C): δ = –62.7 ppm. IR (neat, ATR): ṽ = 1683 (m), 
1609 (w), 1586 (w), 1507 (w), 1472 (w), 1432 (w), 1412 (w), 1358 (m), 1313 (s), 1279 (m), 
1261 (m), 1213 (w), 1205 (w), 1165 (m), 1132 (vs), 1101 (s), 1060 (s), 1010 (m), 971 (w), 919 
(m), 849 (s), 805 (m), 771 (w), 726 (w), 682 (m), 671 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C15H12F3N2O]+: 293.0902, found: 293.0898 ([M+H]+). 
 
Synthesis of 3-((2-hydroxyphenyl)amino)-1-(3-((4-(trifluoromethyl)phenyl)diazenyl)-
phenyl)-propan-1-one (3.22)[bb] 
 
 
 
Diethylamine (0.31 mL, 3.0 mmol, 1.0 equiv.) was dissolved in MeCN (14 mL) and conc. HCl 
(0.25 mL) was added. Paraformaldehyde (159 mg, 5.30 mmol, 1.75 equiv.) was added, followed 
by ketone 3.20 (1.55 g, 5.30 mmol, 1.75 equiv.). The mixture was heated to reflux for 16 h. The 
solvent was removed under reduced pressure and the residue was triturated with Et2O 
(3 x 30 mL). The colorless solid was recrystallized from acetone (25 mL) and dried under high 
                                                
[bb] Compound 3.22 appeared as a mixture of isomers in the NMR spectra. Even NMR spectra taken 
at elevated temperatures could not be interpreted due to overlapping signals and isomer peaks. 
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vacuum. The HCl salt of Mannich product 3.21 was obtained in 88% yield (1.10 g, 2.66 mmol) 
as orange crystals and directly used in the next step. 
The HCl salt of amine 3.21 (1.09 g, 2.63 mmol, 1.1 equiv.) and 2-aminophenol (261 mg, 
2.39 mmol, 1.0 equiv.) were dissolved in ethanol (6 mL) and water (6 mL) and heated to reflux 
for 2 h. The mixture was cooled and a sat. aqu. solution of NaHCO3 was added (20 mL). The 
aqueous phase was extracted with EtOAc (2 x 20 mL). The organic phase was washed with sat. 
aqu. NaHCO3 (30 mL) and brine (30 mL) and concentrated under reduced pressure. The crude 
product was purified by flash silica gel column chromatography (hexanes/EtOAc, gradient from 
10:1 to 2:1) to give secondary amine 3.22 (515 mg, 1.25 mmol, 52%) as an orange solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.48. M.p.: 124–125 °C. IR (neat, ATR): ṽ = 2925 (w), 
1685 (m), 1598 (w), 1486 (m), 1411 (w), 1370 (w), 1321 (vs), 1253 (w), 1226 (m), 1168 (m), 
1126 (s), 1064 (s), 1012 (m), 894 (w), 850 (m), 799 (w), 736 (m), 681 (w) cm-1. HRMS (ESI+): 
m/z calcd. for [C22H19N3O2F3]+: 414.1429, found: 414.1430 ([M+H]+). 
 
Synthesis of 3-(2-hydroxyphenyl)-6-(3-((4-(trifluoromethyl)phenyl)diazenyl)phenyl)-3,4-
di-hydropyrimidin-2(1H)-one (AI2) 
 
 
 
Secondary amine 3.22 (180 mg, 0.440 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 
1,4-dioxane (4 mL) and concentrated under reduced pressure. The so obtained HCl salt was then 
dissolved in glacial acetic acid (7 mL) and potassium cyanate (178 mg, 2.20 mmol, 5.0 equiv.) 
was added. The mixture was heated to 60 °C for 2.5 h. A sat. aqu. solution of NaHCO3 in water 
(20 mL) was added and the aqueous phase was extracted with EtOAc (2 x 20 mL). The 
combined organic phases were washed with sat. aqu. NaHCO3 (30 mL) and brine (30 mL), 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash silica gel column chromatography (hexanes/EtOAc, 2:1) to give tricycle AI2 (100 mg, 
0.230 mmol, 52%) as an orange solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.14. M.p.: 199–201 °C. 1H NMR (DMSO-d6, 600 MHz, 
27 °C): δ = 9.57 (s, 1H, NH), 8.83 (s, 1H, OH), 8.12 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 8.10–8.07 
(m, 2H, ArH), 8.01–7.98 (m, 2H, ArH), 7.93 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H, ArH), 7.81 (ddd, 
J = 7.8, 1.8, 1.0 Hz, 1H, ArH), 7.65 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.19 (dd, J = 7.8, 1.8 Hz, 
1H, ArH), 7.13–7.10 (m, 1H, ArH), 6.91 (dd, J = 8.2, 1.4 Hz, 1H, ArH), 6.81 (ddd, J = 7.2, 7.2, 
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1.2 Hz, 1H, ArH), 5.36 (td, J = 3.8, 2.0 Hz, 1H, CH), 4.27 (d, J = 3.8 Hz, 2H, CH2) ppm. 
13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 154.4, 153.9, 153.2, 152.3, 136.3, 135.9, 131.4 
(q, J = 31.2 Hz), 130.2, 129.9, 129.8, 129.4, 128.5, 127.2 (q, J = 3.8 Hz), 124.4 (q, 
J = 270.8 Hz), 123.6, 123.4, 120.1, 119.7, 117.0, 96.7, 49.6 ppm. 19F NMR (DMSO-d6, 
376 MHz, 27 °C): δ = –61.1 ppm. IR (neat, ATR): ṽ = 3369 (m), 2411 (m), 2342 (w), 2075 
(w), 1682 (w), 1618 (m), 1588 (m), 1576 (m), 1496 (s), 1447 (m), 1412 (w), 1390 (w), 1314 
(vs), 1301 (m), 1271 (w), 1225 (w), 1167 (m), 1152 (m), 1108 (s), 1102 (s), 1062 (vs), 1013 
(m), 969 (m), 934 (w), 887 (w), 846 (s), 818 (w), 787 (w), 752 (s), 746 (s), 723 (w), 714 (w), 
685 (m), 671 (w), 654 (w) cm-1. HRMS (ESI+): m/z calcd. for [C23H18N4O2F3]+: 439.1382, 
found: 439.1381 ([M+H]+). UV/Vis: λmax = 314, 428 nm. 
 
Synthesis of 1-(3-((4-methoxyphenyl)diazenyl)phenyl)ethan-1-one (3.23) 
 
 
 
3-Aminoacetophenone (1.35 g, 10.0 mmol, 1.0 equiv.) was dissolved in DCM (25 mL) and 
oxone (12.3 g, 20.0 mmol, 2.0 equiv.; dissolved in 50 mL of H2O) was added. The biphasic 
mixture was stirred vigorously for 3.5 h at room temperature. The phases were separated and 
the aqueous phase was extracted with DCM (30 mL). The combined organic phases were 
washed with brine (50 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The resulting green oil was immediately dissolved in HOAc (50 mL) and p-anisidine 
(1.23 g, 10.0 mmol, 1.0 equiv.) was added in small portions over the course of 10 min. The 
mixture was stirred for 16 h at room temperature. The mixture was basified with 2 M NaOH and 
extracted with DCM (3 x 25 mL). The combined organic phases were washed with sat. aqu. 
NaHCO3 (2 x 50 mL) and brine (50 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel column chromatography (hexanes/EtOAc, 
gradient from 10:1 to 3:1) to yield azobenzene 3.23 (1.42 g, 5.58 mmol, 56%) as orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.37. M.p.: 99–100 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 8.45–8.41 (m, 1H, ArH), 8.07 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 8.04 (ddd, 
J = 7.8, 1.8, 1.2 Hz, 1H, ArH), 7.98–7.92 (m, 2H, ArH), 7.59 (ddd, J = 7.8, 7.8, 1.2 Hz, 1H, 
ArH), 7.06–6.99 (m, 2H, ArH), 7.65 (ddd, J = 7.8, 7.8, 0.8 Hz, 1H, ArH), 3.90 (s, 3H, CH3), 
2.69 (s, 3H, CH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 197.7, 162.5, 152.8, 146.8, 
138.0, 129.6, 129.3, 126.8, 125.0, 122.6, 114.3, 55.6, 26.8 ppm. IR (neat, ATR): ṽ = 1686 (s), 
1600 (m), 1584 (m), 1502 (s), 1454 (w), 1416 (w), 1357 (m), 1313 (w), 1296 (w), 1252 (vs), 
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1215 (w), 1181 (w), 1152 (m), 1141 (m), 1105 (w), 1028 (m), 956 (w), 913 (w), 839 (m), 805 
(w), 787 (w), 724 (w), 685 (m) cm-1. HRMS (ESI+): m/z calcd. for [C15H15N2O2]+: 255.1134, 
found: 255.1132 ([M+H]+). 
 
Synthesis of 3-((2-hydroxyphenyl)amino)-1-(3-((4-methoxyphenyl)diazenyl)phenyl)-
propan-1-one (3.25) 
 
 
 
Diethylamine (0.16 mL, 1.6 mmol, 1.0 equiv.) was dissolved in MeCN (15 mL) and conc. HCl 
(0.13 mL) was added. Paraformaldehyde (83 mg, 2.8 mmol, 1.75 equiv.) was added, followed 
by ketone 3.23 (700 mg, 2.75 mmol, 1.75 equiv.). The mixture was heated to reflux for 16 h. 
The solvent was removed under reduced pressure and the residue was triturated with Et2O 
(3 x 20 mL). The colorless solid was recrystallized from acetone (20 mL) and dried under high 
vacuum. The HCl salt of Mannich product 3.24 was obtained in 92% yield (533 mg, 1.42 mmol) 
as a red solid. 
The HCl salt of amine 3.24 (100 mg, 0.270 mmol, 1.0 equiv.) and 2-aminophenol (30 mg, 
0.27 mmol, 1.0 equiv.) were dissolved in ethanol (1 mL) and water (1 mL) and heated to reflux 
for 3 h. The mixture was cooled and a sat. aqu. solution of NaHCO3 was added (10 mL). The 
aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic phases were 
washed with sat. aqu. NaHCO3 (20 mL) and brine (20 mL) and concentrated under reduced 
pressure. The crude product was purified by flash silica gel column chromatography (CHCl3, 
100%) to give secondary amine 3.25 (55 mg, 0.15 mmol, 56%) as an orange solid. 
TLC (CHCl3/MeOH, 19:1): Rf = 0.47. M.p.: 132–133 °C. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 8.36 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 8.02 (dd, J = 7.8, 1.8 Hz, 2H, ArH), 7.92–7.87 
(m, 2H, ArH), 7.59 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.06–7.03 (m, 2H, ArH), 6.75–6.71 (m, 2H, 
ArH), 6.69−6.64 (m, 1H, ArH), 6.58–6.51 (m, 1H, ArH), 3.86 (s, 3H, CH3), 3.58–3.53 (m, 2H, 
CH2), 3.39–3.32 (m, 2H, CH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 199.4, 162.8, 
152.7, 146.6, 145.2, 137.8, 136.3, 129.3, 129.2, 126.3, 124.6, 121.6, 119.9, 117.8, 114.0, 113.5, 
111.8, 54.7, 39.1, 37.6 ppm. IR (neat, ATR): ṽ = 3395 (w), 1682 (m), 1601 (s), 1584 (m), 1502 
(s), 1447 (w), 1415 (w), 1364 (w), 1315 (w), 1297 (w), 1253 (vs), 1205 (w), 1182 (w), 1148 (s), 
1119 (w), 1080 (w), 1028 (m), 999 (w), 916 (w), 839 (m), 805 (w), 743 (w), 683 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C22H22N3O3]+: 376.1661, found: 376.1654 ([M+H]+). 
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Synthesis of 3-(2-hydroxyphenyl)-6-(3-((4-methoxyphenyl)diazenyl)phenyl)-3,4-dihydro-
pyrimidin-2(1H)-one (AI3) 
 
 
 
Secondary amine 3.25 (119 mg, 0.320 mmol, 1.0 equiv.) was dissolved in 4 M HCl in 
1,4-dioxane (10 mL) and concentrated under reduced pressure. The so obtained HCl salt was 
then dissolved in glacial acetic acid (15 mL) and potassium cyanate (130 mg, 1.60 mmol, 
5.0 equiv.) was added. The mixture was heated to 60 °C for 3.5 h. A sat. aqu. solution of 
NaHCO3 (50 mL) was added and the aqueous phase was extracted with EtOAc (2 x 20 mL). 
The combined organic phases were washed with sat. aqu. NaHCO3 (40 mL) and brine (40 mL), 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash silica gel column chromatography (CHCl3, 100%) to give AI3 (80 mg, 0.20 mmol, 63%) 
as an orange solid. 
TLC (CHCl3/MeOH, 19:1): Rf = 0.34. M.p.: 175–176 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.95–7.92 (m, 3H, ArH), 7.90 (ddd, J = 7.2, 1.8, 1.8 Hz, 1H, ArH), 7.55–7.49 (m, 
2H, ArH), 7.38 (s, 1H, OH), 7.26–7.24 (m, 1H, ArH), 7.21–7.18 (m, 1H, ArH), 7.07 (dd, 
J = 7.2, 1.8 Hz, 1H, ArH), 7.03–7.01 (m, 2H, ArH), 6.98 (ddd, J = 7.2, 7.2, 1.8 Hz, 1H, ArH), 
6.84 (s, 1H, OH), 5.29 (td, J = 3.9, 2.2 Hz, 1H, CH), 4.55 (d, J = 3.9 Hz, 2H, CH2), 3.89 (s, 3H, 
CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 162.4, 154.1, 153.0, 151.1, 146.8, 136.1, 
134.3, 130.4, 129.8, 128.1, 126.4, 125.0, 124.2, 124.1, 121.3, 120.2, 118.1, 114.3, 95.5, 55.6, 
50.3 ppm. IR (neat, ATR): ṽ = 3238 (m), 1643 (s), 1599 (s), 1584 (m), 1500 (vs), 1450 (m), 
1416 (w), 1297 (m), 1252 (vs), 1216 (m), 1182 (w), 1146 (m), 1106 (m), 1059 (w), 1029 (m), 
964 (w), 902 (w), 839 (m), 803 (w), 752 (vs), 686 (w), 667 (w) cm-1. HRMS (ESI+): m/z calcd. 
for [C23H21N4O3]+: 401.1614, found: 401.1608 ([M+H]+). UV/Vis: λmax = 355, 440 nm. 
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3.6.3 BIOLOGICAL METHODS 
 
Cell Culture 
 
HEK 293T cells were cultured under standard conditions (Dulbecco’s modified Eagle medium 
(DMEM) containing 10% FBS; 37 °C, 10% CO2). Cells were plated on poly-L-lysine 
(0.1 mg/ml) treated coverlips in a density of 20,000 cells per cm2 for electrophysiological 
measurements.  
HEK 293T cells were transfected with TRPM8 (kindly provided by Dr. V. Chubanov, Walther-
Straub-Institute of Pharmacology and Toxicology, Munich) using Lipofectamine® transfection 
agent according to the manufacturers instructions and measured after 12–24 h.  
 
Whole-cell Electrophysiology 
 
Patch clamp recordings of HEK 293T cells were carried out using a HEKA Patch Clamp EPC10 
USB amplifier in whole cell mode and were performed at room temperature. Cells were 
voltage-clamped at –60 mV. Pipettes (Science Products GB200-F-8P with filament) were pulled 
with a Narishige PC-10 pipette puller and had resistances of 4–6 MΩ. The Bath solution 
contained 150 mM NaCl, 6.0 mM CsCl, 1.0 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES and 
10 mM glucose, adjusted to pH = 7.4. Pipette solution contained 150 mM NaCl, 3.0 mM MgCl2, 
10.0 mM HEPES and 5.0 mM EGTA, adjusted to pH = 7.2.[25] Data was recorded using the 
HEKA PatchMaster software (V2x60). The sampling rate was 20–50 kHz and the currents were 
digitally filtered at 2.9 kHz. Cells were illuminated with a Polychrome V monochromator (Till 
Photonics), as described previously.[66] 
 
 
 
 
 
 
 
 
 
 
3     PHOTOCONTROL OF TRP CHANNELS 
 
 
 
236 
3.7 NMR SPECTRA 
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4 PHOTOCHROMIC LIGANDS FOR VOLTAGE-GATED 
SODIUM CHANNELS 
 
4.1 VOLTAGE-GATED SODIUM CHANNELS 
 
Voltage-gated sodium (NaV) channels initiate electrical signaling in neurons through the 
generation of action potentials. NaV channels are rapidly activated, have a high selectivity and 
contribute to a variety of diseases. Mutations of NaV channels are involved in inherited epilepsy, 
migraine, periodic paralysis, cardiac arrhythmia and chronic pain syndromes.[1] Therefore, NaV 
channels are a prominent target of drug development in local anesthesia and in the treatment of 
NaV channelopathies in the brain, skeletal muscle and heart.[2] Although many subtypes of 
voltage-gated sodium channels exist (NaV 1.1 – NaV 1.9), their tetrameric structures are highly 
conserved.  
In 2011, Payandeh et al. have obtained the first crystal structure of a voltage-gated sodium 
channel (NaV of Arcobacter butzleri, NaVAb) at a resolution of 2.7 Å,[3] shedding light on the 
structural details of NaV channels. Each of the four subunits consists of six transmembrane 
(TM) helices and two additional pore (P) helices. TM1–4 form the voltage-sensing domain 
(VSD), whereas TM5–6 constitute the pore domain (Fig 4.1a). The selectivity filter of the pore 
is formed by the four Glu177 residues of the four subunits. Unlike K+ ions, which pass the 
selectivity filter of KV channels without their hydration sphere, Na+ ions remain fully hydrated 
at that stage. Having passed the selectivity filter, the hydrophobic inner cavity allows for fast 
diffusion of ions (Fig. 4.1b+c).[3] 
Interestingly, the crystal structure revealed strong interactions of the channel with the ambient 
lipid membrane. Four lateral openings allow for lipid penetration into the inner cavity and ion 
conduction pathway of the channel. Yet, the role of these fenestrations still remains to be 
investigated but they could play an important role in the delivery of small hydrophobic drugs, as 
these openings were found to lead to important drug binding sites.[3] 
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Figure	  4.1.	   a)	   Crystal	   structure	   of	   NaVAb.	   Only	   two	   of	   four	   subunits	   are	   shown	  with	   one	   being	  
highlighted.	  TM1–4	   (blue	   to	  green)	   constitute	   the	  VSD	  and	  TM5–6	   (yellow,	   red)	   form	  the	  pore	  of	   the	  
channel.	  b)	  Architecture	  of	  the	  pore	  of	  NaVAb.	  The	  pore	  volume	  is	  shaded	  in	  grey,	  the	  Glu177	  side	  chains	  
are	   highlighted	   in	   purple.	   c)	   Side	   view	   of	   the	   selectivity	   filter.	   Four	   putative	   cations	   or	  molecules	   of	  
water	   (red)	   are	   shown	   above	   the	   four	   Glu177	   residues	   and	   one	   putative	   water	   molecule	   at	   Leu176	  
(grey).	  Illustrations	  copied	  from	  Payandeh	  et	  al.,[3]	  reprinted	  with	  permission	  from	  Macmillan	  Publishers	  
Ltd.	  Copyright	  2011.	  
 
As NaV channels are involved in many neuropathic disorders, strong efforts have been 
undertaken to develop (subtype-selective) drugs for the treatment of a variety of diseases. 
Taking advantage of the many published studies including detailed structure–activity 
relationships, a selection of promising small molecules has been made to develop photochromic 
ligands for the optical control of voltage-gated sodium channels. These include (but are not 
limited to) the clinically established drugs lacosamide (UCB) and lamotrigine 
(GlaxoSmithKline) as well as crobenetine, a drug candidate developed by Boehringer Ingelheim 
that has made it into clinical trials (see below). 
 
 
4.2 AZO-LACOSAMIDE 
 
Lacosamide (LCM) is a medication developed by UCB for the adjunctive treatment of partial-
onset seizures and diabetic neuropathic pain marketed under the trade name Vimpat®. LCM is a 
functionalized amino acid that, like most antiepileptic drugs, acts through NaV channels.[4] 
However, LCM appears to act by enhancing the slow inactivation of NaV channels rather than 
stabilizing fast inactivation.[5] Whereas the latter proceeds via a “ball and chain” mechanism that 
involves occluding the pore of the channel by binding of a cytoplasmatic portion,[6] the 
mechanism of slow inactivation is not fully understood yet. It is hypothesized that it results 
from a structural rearrangement of the pore.[7]  
Extensive SAR studies on LCM with various bulky aromatic substituents for the benzyl group 
have been carried out.[8] Lacosamide itself has an ED50 value of 4.5 mg/kg, as determined by 
maximal electroshock seizure test (MES) on mice.[8] Fig. 4.2 shows examples of comparably 
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potent analogues of LCM that strongly resemble azobenzene modifications on the benzyl 
moiety. Derivatives bearing an ethyl bridge between the two phenyl rings possess an ED50 value 
between 10 and 30 mg/kg. Several phenyl benzyl ethers or amines are in the same range or 
possess even lower ED50 values. Linear derivatives bearing a triple bond between the two 
phenyl rings have an ED50 value between 30 and 100 mg/kg. The most promising, i.e. strongest 
azobenzene resembling derivative, however, is the stilbene version of LCM, ranging between 
30 and 100 mg/kg for its ED50 value.  
	  
	  
Figure	  4.2.	   Structure–activity	   relationship	   of	   LCM.	   1)	   ED50	   values	   were	   determined	   by	   maximal	  
electroshock	  seizure	  (MES)	  test.	  
 
Altogether, the flexible substitution pattern on the benzyl moiety of LCM and the 
pharmacologically established function of the drug prompted the derivatization of LCM into 
Azo-Lacosamide (ALCM; Fig. 4.3). 
 
 
 
Figure	  4.3.	   Structures	  of	  lacosamide	  and	  Azo-­‐Lacosamide.	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Synthesis of Azo-Lacosamide 
 
Firstly, the azobenzylic amine 4.1 was synthesized starting from 4-aminobenzylamine which 
was Boc-protected with Boc2O and DMAP in 95% yield. Compound 4.1 then underwent a Mills 
reaction with nitrosobenzene to give azobenzene 4.2 in 83% yield. Deprotection of the Boc 
group with HCl eventually gave the azobenzylic amine 4.3 as its hydrochloride salt in 99% 
yield (Scheme 4.1). 
 
 
Scheme	  4.1.	   Synthesis	  of	  the	  azobenzylic	  amine	  linker	  4.3.	  	  
 
Compound 4.3 was then reacted with Boc-protected D-serine in a HATU-mediated amide 
coupling reaction to form amide 4.4 in 68% yield. Methylation of the hydroxy group using 
dimethyl sulfate furnished 4.5 in 94% yield. Boc deprotection under acidic conditions afforded 
the free amine 4.6 in 84% yield which was then acetylated using acetic anhydride and 
triethylamine, giving rise to ALCM in 65% yield (Scheme 4.2). 
 
 
Scheme	  4.2.	   Synthesis	  of	  ALCM.	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The maximum absorption wavelengths of ALCM were determined to be at λ = 328 nm and 
λ = 440 nm (Fig. 4.4a). The action of ALCM on slow inactivation of NaV channels was tested 
using HEK 293 cells, stably transfected with human NaV 1.7 (hNaV 1.7; Dr. Angelika Lampert, 
Friedrich-Alexander University Erlangen-Nürnberg). In order to distinguish the transfected 
currents from endogenous tetrodotoxin-sensitive (TTXs) sodium channels occuring in HEK 293 
cells,[9] hNaV 1.7 was mutated to be TTX resistant[10] and 500 nM TTX was added to the external 
bath solution to block those endogenous currents.  
To assess steady-state slow inactivation, a stimulus protocol was applied (Fig. 4.4b, top) and 
sodium currents were recorded using whole-cell patch-clamp experiments with and without 
illumination with light (λ = 340–380 nm). The relative current decline due to slow inactivation 
(calculated as ratio of I2/I1) was determined. Exemplary traces of ALCM (100 µM; added to 
the internal solution) indicate a smaller decrease in relative currents I2/I1 after illumination with 
λ = 340–380 nm (blue trace “post”) compared to the same experiment in the dark (black trace 
“pre”; Fig. 4.4b, bottom). Statistical analysis (n = 9) revealed that trans-ALCM (100 µM) 
reduced hNaV 1.7 currents by slow inactivation in the same range as LCM (100 µM) compared 
to control experiments with DMSO or EtOH (Fig. 4.4c). Illumination of ALCM with 
λ = 340−380 nm light, leading to cis-ALCM, resulted in significantly increased relative Na+ 
currents (I2/I1light = 0.67) than obtained for trans-ALCM in the dark (I2/I1dark = 0.58), 
indicating that trans-ALCM is enhancing slow inactivation of hNaV 1.7 more efficaciously than 
cis-ALCM. No light-dependent changes in efficacy were found for LCM (Fig. 4.4c). By 
comparison of the relative Na+ currents prior and after illumination with light, a photoswitching 
index (PI) can be calculated (as determined by the ratio of (I2/I1light – I2/I1dark) / I2/I1dark) of 
PI = 16%. Further experiments of light-dependent actions of ALCM in DRG neurons are 
currently on the way (Dr. Angelika Lampert, Friedrich-Alexander University Erlangen-
Nürnberg). 
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Figure	  4.4.	   a)	   UV/Vis	   spectrum	   of	  ALCM	   (DMSO).	   The	   peak	   absorptions	   are	   at	  λ	  =	  328	  nm	   and	  
λ	  =	  440	  nm.	  Photoisomerization	  from	  the	  trans	  to	  the	  cis	  form	  was	  achieved	  by	  applying	  λ	  =	  350	  nm.	  b)	  
Pulse	  protocol	  for	  slow-­‐type	  inactivation	  of	  hNaV	  1.7	  (top)	  and	  representative	  traces	  of	  recordings	  with	  
ALCM	   (100	  µM)	   added	   to	   the	   pipette	   solution	   in	   the	   dark	   (pre)	   and	   after	   illumination	   with	   λ	  =	  340–
380	  nm	  (post).	  A	  short	  depolarizing	  test	  pulse	  (I1)	  from	  −100	  mV	  to	  +20	  mV	  was	  followed	  by	  a	  60	  s	  pulse	  
to	   –70	  mV,	   followed	   by	   a	   100	  ms	   step	   to	  −100	  mV	   to	   remove	   fast	   inactivation	   and	   a	   test	   pulse	   I2	   to	  
+20	  mV	   for	  40	  ms,	  at	  which	  available	   channels	  were	  assessed.	  This	  protocol	  was	   repeated	  with	   (post)	  
and	   without	   (pre)	   illumination	   with	   light	   (λ	  =	  340−380	  nm).	   c)	   Statistical	   analysis	   of	   light-­‐dependent	  
slow-­‐type	   inactivation	   of	   hNaV	   1.7	  with	  ALCM	   (100	  µM)	   and	   LCM	   (100	  µM,	   control),	   respectively.	   The	  
difference	   in	   current	   change	   with	   ALCM	   in	   the	   dark	   versus	   with	   λ	  =	  340−380	  nm	   light	   is	   significant.	  
Additional	  control	  experiments	  with	  DMSO	  or	  EtOH	  revealed	  no	  significant	  light-­‐dependent	  effects	  (Dr.	  
Angelika	  Lampert,	  Friedrich-­‐Alexander	  University	  Erlangen-­‐Nürnberg).	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4.3 AZO-LAMOTRIGINE 
 
Lamotrigine (LTG), marketed under the trade name Lamictal® by GlaxoSmithKline, is an 
anticonvulsant drug that is used for the treatment of epilepsy, bipolar disorder, depression[11] 
and neuropathic pain.[12] It significantly reduces the frequency of Lennox-Gastaut syndrome 
seizures, a severe form of epilepsy.[13] LTG also functions as a mood stabilizer and was the first 
drug since lithium salts which the U.S. Food and Drug Administration (FDA) has approved for 
this purpose. It acts presynaptically on NaV channels and belongs to the class of sodium channel 
blocking antiepileptic drugs.[14] Other members of this class of drugs are carbamazepine or 
phenytoin (Fig. 4.5). Lamotrigine, however, belongs to a different compound class 
(phenyltriazine) and has a broader spectrum of action. For instance, it is also effective in the 
treatment of the depressed phase in bipolar disorder, whereas the above-mentioned drugs are 
not. Belonging to a different class of compounds, it moreover does not share the same side 
effects as other antiepileptic drugs, thus providing unique properties which can be advantageous 
in certain treatment cases.[15] LTG decreases the release of neurotransmitters aspartate and 
glutamate and inhibits neuronal α2β2 nAChR.[16] It blocks sustained repetitive firing in cultured 
mouse spinal cord neurons in a concentration-dependent manner in the treatment of human 
seizures.[17] However, it also inhibits voltage-activated calcium channels which might contribute 
to its broader spectrum of action.[18] 
 
 
Figure	  4.5.	   Structures	  of	  sodium	  channel	  blocking	  antiepileptic	  drugs.	  	  
 
Extensive SAR have been carried out on LTG, not only investigating its affinity or efficacy on 
sodium channels, but also other properties such as L-type calcium channel affinity and 
microsome stability.[19] Several candidates possess large extended aryl substituents in the 
6-position of the triazine core with comparable or even better IC50 values than lamotrigine itself. 
A composition of benzyloxyphenyl-substituted derivatives is shown in Fig. 4.6 which best 
resemble the structure of an azobenzene moiety. Substitution of the C6-attached phenyl ring in 
the meta position with respect to the triazine core appears to be superior over para substitution.  
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Figure	  4.6.	   Selected	   examples	   from	   SAR	   studies	   of	   LTG.[19]	   1)	   IC50	   values	   were	   measured	   with	  
respect	  to	  [14C]	  guanidine	  flux	  as	  an	  indicator	  of	  sodium	  channel	  opening/blockade.	  
 
Consequently, Azo-Lamotrigine (ALTG), the meta-azobenzene derivative of lamotrigine was 
chosen as target molecule (Fig. 4.7). 
 
 
Figure	  4.7.	   Structures	  of	  lamotrigine	  and	  Azo-­‐Lamotrigine.	  	  
 
Synthesis of Azo-Lamotrigine 
 
In the initially planned route, nitrosobenzene was first condensed with 3-aminobenzoic acid in a 
Mills reaction to give azobenzene 4.7 in 73% yield. The acid was then first converted to the 
corresponding acid chloride 4.8 with oxalyl chloride and DMF in 90% yield. The acid chloride 
proved to be very stable, surviving basic workup and even column chromatography. This 
stability might be the reason for the following problems in the attempted replacement of the 
chloride with cyanide nucleophiles (Scheme 4.3). 
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Scheme	  4.3.	   1st	  route	  toward	  ALTG.	  	  
 
Literature-known methods for this reaction and variations thereof were applied but did not lead 
to the desired product 4.9 (Table 4.1). Normant’s method[20] comprises refluxing the acid 
chloride with copper cyanide in acetonitrile (entry 1). However, no traces of 4.9 were observed. 
Modifications by the addition of Celite (entry 2) or NaI (entry 3) were not successful. Using 
TMSCN instead (method by Olah[21]) neither resulted in the formation of 4.9 (entry 4). The 
addition of SnCl4 as a Lewis acid resulted in decomposition of the starting material (entry 5).  
 
Table	  4.1.	   Applied	  conditions	  for	  the	  reaction	  of	  acid	  chloride	  4.8	  to	  4.9.	  	  
Entry Reagent Conditions Yield 4.9 [%]  
1 CuCN MeCN, Δ, 1 h 0 
2 CuCN, Celite MeCN, rt to reflux, 24 h 0 
3 CuCN, NaI MeCN, rt, 16 h 0 
4 TMSCN MeCN, rt, 16 h 0 
5 TMSCN, SnCl4 MeCN, rt, 16 h decomp. 
 
As indicated above, due to the surprising stability of acid chloride 4.8, a new route toward 
Azo-Lamotrigine was designed involving a more reactive aldehyde intermediate for the 
introduction of the cyanide (Scheme 4.4).  
First, azobenzene 4.10 was obtained from a Mills reaction of (3-aminophenyl)methanol and 
nitrosobenzene in excellent yield. Alcohol 4.10 was oxidized with MnO2 to the corresponding 
aldehyde 4.11 in 97% yield. The aldehyde was then reacted with TMSCN in 4 h at room 
temperature to cyanohydrin 4.12 in excellent yield (91%). Compound 4.12 was oxidized using 
MnO2 but the resulting product could not be isolated in pure form. Subsequently, crude 4.13 
was reacted with aminoguanidine bismesylate, which had previously been obtained from 
aminoguanidine bicarbonate and MsOH according to a literature procedure.[19] Cyanohydrazone 
4.14 was obtained in 46% yield over two steps. The triazine ring was finally closed under basic 
conditions by the addition of NaOEt to an ethanolic solution of 4.14 and heating to reflux for 
1.5 h, affording ALTG in 76% yield.  
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Scheme	  4.4.	   Synthesis	  of	  ALTG:	  2nd,	  successful	  route.	  	  
  
The photochemical properties of ALTG were investigated by UV/Vis spectrometry (Fig. 4.8). 
The maximum absorption wavelengths of ALTG were determined to be λ = 323 nm and 
λ = 421 nm, respectively. Its potential as photochromic NaV blocker is currently investigated in 
collaboration with Prof. Heinz Beck (Rheinische Friedrich-Wilhelms-University Bonn).  
 
	  
Figure	  4.8.	   	   UV/Vis	   spectrum	   of	   ALTG	   (DMSO)	   with	   maximum	   absorption	   wavelengths	   of	  
λ = 323	  nm	  and	  λ = 421	  nm.	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4.4 AZO-CROBENETINE 
 
Voltage-gated sodium channels are thought to play a key role in excitotoxic damage. Sodium 
channel blockers could be helpful to protect from excitotoxic damage since they inhibit 
neuronal depolarization, glutamate release and Na+ influx, thereby reducing Ca2+ influx by 
means of Ca2+ channels.[22] Crobenetine (BIII 890 CL) was developed by Boehringer Ingelheim 
from SAR studies of 6,7-benzomorphans[23] and reported as a potent, selective and highly use-
dependent sodium channel blocker to protect brain tissue from ischemia[24] and function as 
analgesic.[25]  
It was found that the IC50 value of Crobenetine for sodium channels in their inactivated states 
was much lower (IC50 = 77 nM) than for sodium channels in the resting state (IC50 = 18 µM)[24] 
which is desired for neuroprotective drugs since they would preferentially block sodium 
channels in depolarized tissue without inhibiting normal physiological functions.[24]   
Two point mutations (F1764A and Y1771A) in transmembrane segment S6 in domain IV of the 
α subunit reduced the voltage- and frequency-dependent block which suggests that BIII 890 CL 
binds to the local anesthetic receptor site in the pore.[24] Crobenetine crosses the blood−brain 
barrier in rats and is effective at reversing joint hyperalgesia in rats with adjuvant-induced 
mono-arthritis and also in decreasing spontaneous pain-related behavioural changes evoked by 
mono-arthritis.[25] 
 
Starting from Crobenetine, the syntheses of azo analogues p-Azo-Crobenetine (p-ACRO) and 
m-Azo-Crobenetine (m-ACRO) were planned (Fig. 4.9).   
 
 
Figure	  4.9.	   Structures	  of	  crobenetine	  and	  its	  azo	  analogues	  p-­‐ACRO	  and	  m-­‐ACRO.	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Synthesis of Azo-Crobenetines 
 
1st Generation Route toward Azo-Crobenetines 
 
Firstly, the phenolic hydroxy group of crobenetine (4.15; generously provided by Boehringer 
Ingelheim) was TBS protected using TBSCl and imidazole, giving rise to 4.16 in 73% yield. 
The benzyl ether was cleaved by Pd-catalyzed hydrogenation, affording secondary alcohol 4.17 
in 75% yield. Unfortunately, in the attempted etherification using bromide 4.18 and NaH as 
base the phenolic TBS group was cleaved, giving rise to the phenolic ether 4.19 in 38% yield 
(Scheme 4.5). The reaction was repeated with meta-azobromide 4.21 which also led to phenolic 
ether formation, affording ether 4.22 in 41% yield (Scheme 4.8). 
 
Scheme	  4.5.	   1st	  generation	  route	  toward	  p-­‐ACRO.	  
Para-bromide 4.18 was obtained by an Appel reaction from the corresponding para-alcohol 
4.20 (Scheme 4.6) which has been previously described (compound 10 in chapter 2.3). The 
corresponding meta-bromide 4.21 was synthesized accordingly from meta-alcohol 4.10 
(Scheme 4.7). 
	  
Scheme	  4.6.	   Synthesis	  of	  para-­‐bromide	  4.18.	  
	  
	  
Scheme	  4.7.	   Synthesis	  of	  meta-­‐bromide	  4.21.	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Scheme	  4.8.	   1st	  generation	  route	  toward	  m-­‐ACRO.	  
 
A series of other conditions was investigated to form the desired aliphatic ethers (Scheme 4.9 
and Table 4.2).  
 
Scheme	  4.9.	   Attempted	  etherification	  of	  alcohol	  4.17	  and	  electrophiles	  X	  to	  Y.	  
 
Table	  4.2.	  	  	  	  	  	  	  	  	  	  	  	  	  Ether	  formation	  attempts	  toward	  p-­‐ACRO	  and	  m-­‐ACRO.	  
Entry X Reagent Conditions Equiv. 4.17 / X Yield Y 
1 Br 1) NaH, 
Bu4NI 
THF/DMF,  
0 °C to rt, 16 h 
1.0 / 1.25 0%  
(38% 4.19) 
2 Br 1) Ag2O 2) DCM, rt, 16 h 1.0 / 3.0 0% 
3 Br 1) Ag2O 2) Et2O, Δ, 16 h 1.0 / 2.0 traces 
4 Br 1) Ag2O 2) PhMe, 90 °C, 4 d 1.0 / 5.0 0% 
5 Br 1) KO-tBu THF, rt, 16 h 1.0 / 1.6 traces 
6 OTf 3) 2,6-lutidine DCM,  
–78 °C to rt, 16 h 
1.0 / 1.1 recovered 
SM 
7 NH(CO)CCl3 1) BF3 • OEt2 DCM,  
–20 °C to rt, 16 h 
1.0 / 3.0 recovered 
SM 
8 NH(CO)CCl3 1) TMSOTf DCM,  
0 °C to rt, 2 d 
1.0 / 10 recovered 
SM 
9 OMs 4) TEA THF,  
0 °C to rt, 2 h 
1.0 / 2.0 0% 
1) isolated and fully characterized. 2) freshly prepared. 3) prepared in situ from the corresponding alcohol 
and Tf2O, 2,6-lutidine. 4) prepared in situ from the corresponding alcohol and MsCl, TEA. 
Entry 1 shows the above reported results with undesired phenol alkylation. Exchanging the base 
for KO-tBu gave only traces of the desired product (entry 5). For etherifications with an 
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adjacent stereocenter on the alcohol, a common literature protocol is to react the alcohol and the 
bromide with Ag2O instead of using a base to generate the alcoholate.[26] However, only traces 
of Y were obtained by heating 4.17 together with bromide 4.18 and freshly prepared Ag2O in 
refluxing Et2O (Table 4.2, entry 3), whereas stirring the mixture at room temperature in DCM 
did not yield any product (entry 2). Heating the mixture up to 90 °C in toluene led to 
decomposition of the starting material (entry 4). Other than bromide, also the corresponding 
triflate (entry 6), mesylate (entry 9) and trichloroacetimidate (entries 7 and 8, synthesized from 
alcohol 4.20 with NaH and trichloroacetontrile in 53% yield;[27] see Scheme 4.10) were 
synthesized as electrophiles. By using the triflate, only starting material could be recovered, 
whereas the mesylate led to decomposition. No reaction was observed for the 
trichloroacetimidate 4.23 with the addition of BF3 • OEt2 or TMSOTf as Lewis acids, 
respectively (entries 7 and 8).  
 
 
Scheme	  4.10.	   Synthesis	  of	  trichloroacetimidate	  4.23	  from	  alcohol	  4.20.	  
	  
In addition to the para-substituted azobenzene electrophiles, meta-iodide 4.24 was synthesized 
from alcohol 4.10 under Appel conditions in 70% yield (Scheme 4.11).  
 
	  
Scheme	  4.11.	   Synthesis	  of	  iodide	  4.24	  from	  alcohol	  4.10.	  
 
Alkylation of alcohol 4.17 was also attempted using iodide 4.24 as electrophile (Scheme 4.12 
and Table 4.3). Heating at 90 °C with freshly prepared Ag2O for 4 d led to decomposition (entry 
1). KHMDS at low temperatures allowed for the recovery of the starting material (entry 2), 
whereas KHMDS with 18-crown-6 at high temperatures led to decomposition (entry 3). With 
n-BuLi as base, no conversion was obtained (entry 4). 	  
	  
Scheme	  4.12.	   Attempted	  etherification	  of	  alcohol	  4.17	  and	  iodide	  4.24	  to	  Y.	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Table	  4.3.	  	  	  	  	  	  	  	  	  	  	  	  	  Ether	  formation	  attempts	  of	  alcohol	  4.17	  and	  iodide	  4.24.	  
Entry Reagent Conditions Equiv. 4.17 / 4.24 Yield Y 
1 Ag2O 1) PhMe, 90 °C, 4 d 1.0 / 5.0 0% 
2 KHMDS THF, –78 °C to rt, 16 h 1.0 / 2.0 recovered SM 
3 KHMDS,  
18-crown-6 
DME, 0 °C to 90 °C, 16 h 1.0 / 2.0 0% 
4 n-BuLi THF, –78 °C to 50 °C, 16 h 1.0 / 2.0 recovered SM 
1) freshly prepared.  
 
Unfortunately, none of the alkylation attempts of alcohol 4.17 proved successful. Consequently, 
a new route toward ACRO was developed. 
 
2nd Generation Route toward Azo-Crobenetines 
 
In a new approach toward p-ACRO, the azolinker was planned to be introduced via an amide 
coupling between amine 4.25 (generously provided by Boehringer Ingelheim) and azo lactate 
4.26. The amide could then be reduced in the next step to the desired p-ACRO (Scheme 4.13). 
The same strategy was applied to the synthesis of the corresponding meta-derivative m-ACRO. 
 
Scheme	  4.13.	   2nd	  generation	  route	  toward	  p-­‐ACRO.	  
 
Accordingly, para-azo lactate 4.26 was synthesized. Still, ether formation between (−)-methyl 
L-lactate and bromide 4.18 proved to be challenging, suggesting a strong influence of the 
neighboring methyl group. Attempts with NaH and the corresponding azo bromide, as well as 
azo trichloroacetimidate and CSA (no reaction) or TfOH (decomposition), respectively, did not 
give the desired product. Finally, freshly prepared Ag2O in refluxing Et2O furnished ether 4.28 
in modest yield (27%). Saponification of the methyl ester with LiOH yielded azo lactate 4.26 in 
91% yield (Scheme 4.14).  
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Scheme	  4.14.	   Synthesis	  of	  para-­‐azo	  lactate	  4.26.	  
 
HATU-mediated coupling of 4.26 and 4.25 provided amide 4.27 in 37% yield, but best results 
(77% yield) were achieved by converting the acids to the corresponding acid chlorides with 
oxalyl chloride and catalytic amounts of DMF first, followed by coupling to the secondary 
amine 4.25. Amide 4.27 was then reduced with LiAlH4 in 75% yield to the final product 
p-ACRO (Scheme 4.15). 
 
Scheme	  4.15.	   Synthesis	  of	  p-­‐ACRO	  from	  4.26	  and	  4.25.	  
 
Following the same protocol, meta-azo lactate ester 4.29 was synthesized from (−)-methyl 
L-lactate and bromide 4.21 with Ag2O in 40% yield. Basic hydrolysis of the methyl ester with 
LiOH quantitatively yielded acid 4.30 (Scheme 4.16). 
 
Scheme	  4.16.	   Synthesis	  of	  meta-­‐azo	  lactate	  4.30.	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Acid 4.30 was converted into the corresponding acid chloride using oxalyl chloride and DMF 
and then reacted with amine 4.25 to give amide 4.31 in 86% yield. Reduction with LiAlH4 
afforded m-ACRO in 64% yield (Scheme 4.17). 
	  
Scheme	  4.17.	   Synthesis	  of	  m-­‐ACRO	  from	  4.30	  and	  4.25.	  
 
The photochemical properties of both isomers of Azo-Crobenetine were investigated using 
UV/Vis spectrometry. The maximum absorption wavelengths of p-ACRO were determined to 
be λ = 328 nm and λ = 435 nm, respectively (Fig. 4.10a). As expected, m-ACRO differs only 
slightly from p-ACRO with absorption maxima of λ = 325 nm and λ = 435 nm, respectively 
(Fig. 4.10b). Its potential as photochromic NaV blocker is currently investigated in collaboration 
with Dr. Angelika Lampert (Friedrich-Alexander University Erlangen-Nürnberg).  
 
 
 
Figure	  4.10.	   UV/Vis	   spectra	   (DMSO)	   of	   a)	   p-­‐ACRO	   with	   maximum	   absorption	   wavelengths	   of	  
λ = 328	  nm	  and	  λ = 435	  nm,	  and	  b)	  m-­‐ACRO	  (λmax = 325,	  435	  nm).	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 4.5 ATTEMPTS TOWARD PHOTOCONTROL OF NAV 1.7 
 
The voltage-gated sodium channel type 1.7 is preferentially expressed at high levels in two 
types of neurons: nociceptive dorsal root ganglion (DRG) neurons and sympathetic ganglion 
neurons which are part of the involuntary nervous system.[28] NaV 1.7 is deployed at the endings 
of pain-sensing nerves (the nociceptors) close to areas where the impulse is initiated.[28] The role 
of NaV 1.7 as pain sensing channel was discovered from different observations.[29] Firstly, DRG 
neurons in animal models of inflammatory pain show increased expression of NaV 1.7. 
Secondly, genetically engineered mice lacking NaV 1.7 expression (specifically in their 
nociceptors) showed markedly reduced responses to inflammatory pain.[30] 
In 2006, Cox et al.[31] discovered mutations of the NaV 1.7 encoding gene SCN9A that cause a 
loss of NaV 1.7 function in three families from Pakistan. Interestingly, the people described in 
this study have no apparent deficits in non-nociceptive sensory functions, such as the ability to 
perceive touch, warmth, cold, tickle, pressure, or the position of their limbs (proprioception).[31] 
These findings suggest that it may be possible to ameliorate pain by blocking NaV 1.7 without 
suffering significant side-effects. Hence, great efforts have been undertaken by the 
pharmaceutical industry to develop selective NaV 1.7 blockers for the treatment of inflammatory 
and chronic pain.[32] However, up to date, to the knowledge of the author no satisfyingly NaV 1.7 
selective small molecule blocker has been developed which might attribute to the great 
structural resemblance of the NaV type 1 subfamily. The tarantula venom peptide ProTx-II is 
one of the rare NaV 1.7-selective toxins inhibiting NaV 1.7 with an IC50 value of 0.3 nM, 
compared with IC50 values of 30 to 150 nM for other heterologously expressed NaV 1 
subtypes.[33]  
In a recent study by Merck, compound 4.32 was discovered as a potent and use-dependent 
sodium channel blocker for treatment of chronic pain which exhibits a high potency on NaV 1.7 
channels (IC50 = 4.0 µM).[34] Further development led to the replacement of the azocane moiety 
with a pyrrolidine ring. Various derivatives of this general structure have been synthesized and 
tested on their activity on NaV 1.7 (Fig. 4.11). The p-(t-butyl)benzyl ether has a slightly 
increased IC50 value of 9.0 µM, whereas the biphenyl derivative possesses the same IC50 value 
as 4.32. By replacing the first phenyl ring with a heterocyclic five-membered ring (i.e. thiazole, 
1,2,4-oxadiazole), the IC50 values decrease significantly to 1.3 µM or even 0.86 µM, 
respectively. 
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Figure	  4.11.	   Selected	  examples	  from	  structure–activity	  relationship	  studies	  of	  4.32.	  	  
 
Due to its close structural resemblance, the azobenzene derivative MS1 was designed as a 
potential photodependent NaV 1.7 blocker on the basis of 4.33 (Fig. 4.12). 
 
 
Figure	  4.12.	   Structures	  of	  a	  NaV	  1.7	  blocker	  4.33	  and	  its	  azobenzene	  derivative	  MS1.	  	  
 
Synthesis of MS1 
 
Following a protocol by Katritzky[35] for direct amide coupling of unprotected 
o-hydroxybenzoic acids, 2-hydroxy-3-methoxybenzoic acid was first converted into its 
benzotriazole ester using thionyl chloride and benzotriazole. The active ester was then in situ 
reacted with pyrrolidine to yield amide 4.34 in unexpectedly low yield (26%). Next, the 
azobenzene linker was introduced by etherification of the phenolic hydroxy group under basic 
conditions with bromide 4.18 to yield MS1 in 99% yield (Scheme 4.18). 
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Scheme	  4.18.	   Synthesis	  of	  MS1,	  a	  potential	  NaV	  1.7	  blocker.	  
	  
The maximum absorption wavelengths of MS1 were determined by UV/Vis spectromerty to be 
λ = 328 nm and λ = 440 nm, respectively (Fig. 4.13). In collaboration with Dr. Angelika 
Lampert (Friedrich-Alexander University Erlangen-Nürnberg), the selectivity of MS1 on 
NaV 1.7 as well as its light-dependent actions on this subtype of voltage-gated sodium channels 
are currently investigated. 
	  
	  
	  
Figure	  4.13.	   UV/Vis	   spectrum	  of	  MS1	  with	  maximum	  absorption	  wavelengths	  of	  λ = 328	  nm	  and	  
λ = 440	  nm	  (DMSO).	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4.6 EXPERIMENTAL PROCEDURES AND ANALYTICAL DATA 
 
4.6.1 GENERAL EXPERIMENTAL DETAILS AND INSTRUMENTATION 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[36] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0; DMSO-d6: δH 2.50, 
δC 39.5).[37] Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, 
q = quartet, quint = quintet, sext = sextet, sept = septet, m = multiplet. High resolution mass 
spectra (EI, ESI) were recorded by LMU Mass Spectrometry Service using a Thermo Finnigan 
MAT 95, a Jeol MStation or a Thermo Finnigan LTQ FT Ultra instrument. Melting points were 
obtained using a Stanford Research Systems MPA120 apparatus and are uncorrected. Optical 
rotation measurements were performed on a Perkin Elmer 241 polarimeter at 22 °C in a 5 cm 
cell at concentrations expressed as g/100 mL. 
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4.6.2 SYNTHESIS OF AZO-LACOSAMIDE 
 
Synthesis of tert-butyl 4-aminobenzylcarbamate (4.1) 
 
 
 
4-Aminobenzylamine (4.52 mL, 40.0 mmol, 1.0 equiv.) was dissolved in THF (130 mL) and 
Boc2O (9.17 g, 42.0 mmol, 1.05 equiv.) and DMAP (489 mg, 4.00 mmol, 0.100 equiv.) were 
added. The mixture was stirred for 3 h at room temperature. The solvent was removed in vacuo 
and the crude product was purified by flash silica gel column chromatography (hexanes/EtOAc, 
gradient from 3:1 to 1:1) to give Boc-protected amine 4.1 (8.40 g, 37.8 mmol, 95%) as a 
yellowish solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.30. M.p.: 82–83 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.09–7.02 (m, 2H, ArH), 6.66–6.59 (m, 2H, ArH), 4.73 (br s, 1H, NH), 4.17 (d, J = 5.6 Hz, 
2H, CH2), 3.60 (br s, 2H, NH2), 1.45 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 155.8, 145.7, 128.8, 128.7, 115.1, 79.2, 44.3, 28.4 ppm. IR (neat, ATR): ṽ = 3367 
(m), 1688 (vs), 1623 (m), 1513 (vs), 1457 (m), 1391 (w), 1363 (m), 1325 (w), 1304 (w), 1245 
(s), 1161 (s), 1119 (m), 1046 (m), 1027 (m), 937 (w), 931 (w), 864 (w), 821 (m), 784 (w), 758 
(w), 666 (w) cm-1. HRMS (EI+): m/z calcd. for [C12H18N2O2]+: 222.1368, found: 222.1375 
([M]+). 
 
Synthesis of tert-butyl 4-(phenyldiazenyl)benzylcarbamate (4.2) 
 
 
 
Nitrosobenzene (3.94 g, 36.8 mmol, 1.0 equiv.) was dissolved in a mixture of glacial acetic acid 
(250 mL) and DMSO (10 mL). Aniline 4.1 (8.18 g, 36.8 mmol, 1.0 equiv.) was added in 
4 portions within 10 min. The mixture was stirred for 2.5 d at room temperature. Solid Na2CO3 
was added in portions (gas evolution!), followed by a sat. aqu. solution of NaHCO3 and the 
aqueous phase was extracted with DCM (3 x 70 mL). The organic phase was carefully washed 
with 2 M NaOH (100 mL) and sat. aqu. NaHCO3 (100 mL), then dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash silica gel chromatography 
NHBoc
H2N
NHBoc
N
N
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(hexanes/EtOAc, gradient from 20:1 to 5:1), affording azobenzene 4.2 (9.48 g, 30.4 mmol, 
83%) as an orange solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.40. M.p.: 129–130 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.92–7.86 (m, 4H, ArH), 7.53–7.48 (m, 2H, ArH), 7.48–7.44 (m, 1H, ArH), 
7.43−7.39 (m, 2H, ArH), 4.93 (br s, 1H, NH), 4.39 (d, J = 5.2 Hz, 2H, CH2), 1.47 (s, 9H, 
C(CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 155.9, 152.6, 151.9, 142.0, 130.9, 
129.0, 128.0, 123.1, 122.8, 79.7, 44.4, 28.4 ppm. IR (neat, ATR): ṽ = 3324 (m), 2978 (w), 
2924 (w), 1682 (vs), 1652 (w), 1602 (w), 1558 (w), 1522 (s), 1485 (w), 1447 (w), 1431 (w), 
1391 (m), 1365 (m), 1285 (vs), 1244 (m), 1221 (w), 1167 (m), 1155 (s), 1134 (m), 1106 (w), 
1072 (w), 1039 (w), 1021 (m), 1012 (m), 955 (m), 862 (m), 846 (m), 831 (m), 790 (m), 763 (m), 
730 (w), 717 (w), 691 (s), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C18H22O2N3]+: 
312.1712, found: 312.1706 ([M+H]+). 
 
Synthesis of 4-(phenyldiazenyl)phenyl)methanaminium chloride (4.3) 
 
 
 
Boc-protected amine 4.2 (9.36 g, 30.1 mmol) was dissolved in 1,4-dioxane (150 mL) and a 4 M 
solution of HCl in dioxane (150 mL) was added. The mixture was stirred for 16 h at room 
temperature. The orange precipitate was filtered off and washed thoroughly with Et2O (3x). 
Amine 4.3 was obtained as its HCl salt (7.39 g, 29.8 mmol, 99%) as an orange solid. 
M.p.: 244–247 °C. 1H NMR (DMSO-d6, 400 MHz, 27 °C): δ = 8.55 (br s, 3H, NH3+), 
7.92−7.83 (m, 4H, ArH), 7.73–7.66 (m, 2H, ArH), 7.61–7.52 (m, 3H, ArH), 4.10 (s, 2H, 
CH2) ppm. 13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 154.1 (cis isomer), 153.9 (cis isomer), 
152.3, 152.1, 137.9, 133.3 (cis isomer), 132.2, 130.5, 129.9, 129.9 (cis isomer), 129.4 (cis 
isomer), 127.7 (cis isomer), 123.0, 123.0, 120.4 (cis isomer), 120.2 (cis isomer), 42.2 ppm. IR 
(neat, ATR): ṽ = 2963 (m), 2880 (m), 2686 (w), 2576 (w), 1593 (m), 1525 (w), 1502 (w), 1480 
(s), 1465 (m), 1443 (m), 1419 (w), 1378 (m), 1333 (w), 1301 (w), 1215 (m), 1187 (w), 1157 
(w), 1114 (m), 1074 (m), 1018 (m), 969 (m), 955 (m), 930 (w), 917 (w), 881 (m), 847 (s), 837 
(s), 774 (m), 756 (s), 726 (m), 681 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C13H14N3]+: 
212.1188, found: 212.1181 ([M-Cl]+). 
 
 
NH2
N
N
HCl
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Synthesis of (R)-tert-butyl (3-hydroxy-1-oxo-1-((4-(phenyldiazenyl)benzyl)-amino)propan-
2-yl)carbamate (4.4) 
 
 
 
Boc-protected D-serine (257 mg, 1.25 mmol, 1.0 equiv.) was dissolved in DCM (15 mL). The 
HCl salt of amine 4.3 (372 mg, 1.50 mmol, 1.2 equiv.) and TEA (0.26 mL, 1.9 mmol, 
1.5 equiv.) were added, followed by HATU (570 mg, 1.50 mmol, 1.2 equiv.). The reaction 
mixture was stirred at room temperature for 16 h. The solvent was removed under reduced 
pressure and the residue was suspended in CHCl3 (20 mL) and washed with 10% aqu. citric acid 
(2 x 30 mL). The organic phase was washed with sat. aqu. NaHCO3 (2 x 30 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (CHCl3/MeOH, gradient from 100:0 to 30:1), affording amide 4.4 (339 mg, 
0.850 mmol, 68%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.27. [α]D22: +0.88 (c = 1.0, CHCl3). M.p.: 137–138 °C. 
1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.94–7.82 (m, 4H, ArH), 7.55–7.43 (m, 2H, ArH), 
7.48−7.44 (m, 1H, ArH), 7.41–7.36 (m, 2H, ArH), 7.21 (br s, 1H, NH), 5.64 (br s, 1H, NH), 
4.62−4.53 (m, 1H, CH), 4.50–4.40 (m, 1H, CH), 4.23–4.11 (m, 2H, 2 x CH), 3.75–3.64 (m, 1H, 
CH), 3.22 (br s, 1H, OH), 1.43 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): 
δ = 171.6, 156.4, 152.6, 152.0, 140.8, 131.0, 129.1, 128.0, 123.2, 122.8, 80.7, 62.7, 54.7, 43.0, 
28.3 ppm. IR (neat, ATR): ṽ = 3325 (m), 2965 (w), 1684 (s), 1627 (vs), 1556 (m), 1530 (vs), 
1465 (m), 1444 (m), 1418 (m), 1388 (m), 1363 (m), 1352 (m), 1303 (m), 1243 (s), 1171 (s), 
1103 (m), 1069 (m), 1039 (m), 1012 (m), 977 (m), 957 (w), 919 (w), 872 (w), 835 (m), 794 (w), 
766 (m), 722 (w), 683 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C21H27N4O4]+: 
399.2032, found: 399.2026 ([M+H]+). 
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Synthesis of (R)-tert-butyl (3-methoxy-1-oxo-1-((4-(phenyldiazenyl)benzyl)-amino)propan-
2-yl)carbamate (4.5) 
 
 
 
To a solution of alcohol 4.4 (306 mg, 0.770 mmol, 1.0 equiv.) in DCM (10 mL) were added 
Bu4NI (55 mg, 0.15 mmol, 0.2 equiv.) and H2O (1 mL). The solution was cooled to 10 °C and a 
solution of NaOH (185 mg, 4.62 mmol, 6.0 equiv.) in H2O (0.2 mL) was added dropwise. 
Subsequently, Me2SO4 (0.32 mL, 3.4 mmol, 4.4 equiv.) was added dropwise at 10 °C and the 
mixture was stirred at this temperature for 1 h and warmed slowly to room temperature 
overnight. H2O (30 mL) was added and the phases were separated. The organic phase was 
washed with sat. aqu. NaHCO3 (2 x 30 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (CHCl3/MeOH, gradient from 
100:0 to 40:1), affording methyl ether 4.5 (297 mg, 0.720 mmol, 94%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.51. [α]D22: –5.3 (c = 0.5, CHCl3). M.p.: 88–89 °C. 
1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.91–7.83 (m, 4H, ArH), 7.52–7.42 (m, 3H, ArH), 
7.41–7.36 (m, 2H, ArH), 6.84 (t, J = 5.4 Hz, 1H, NH), 5.43 (br s, 1H, NH), 4.54 (t, J = 5.8 Hz, 
2H, CH2), 4.35−4.23 (m, 1H, CH), 3.84 (dd, J = 9.2, 3.9 Hz, 1H, CH), 3.50 (dd, J = 9.2, 6.2 Hz, 
1H, CH), 3.37 (s, 3H, CH3), 1.43 (s, 9H, C(CH3)3) ppm. 13C NMR (CDCl3, 100 MHz, 
27 °C)[cc]: δ = 170.4, 155.5, 152.6, 151.9, 141.1, 137.4 (cis isomer), 131.0, 129.0, 128.7 (cis 
isomer), 128.0, 127.5 (cis isomer), 127.3 (cis isomer), 123.1, 122.8, 120.9 (cis isomer), 120.3 
(cis isomer), 80.4, 72.0, 59.1, 54.0, 43.1, 28.2 ppm. IR (neat, ATR): ṽ = 3294 (m), 2931 (w), 
1684 (m), 1652 (vs), 1529 (m), 1457 (m), 1391 (m), 1364 (m), 1346 (w), 1312 (m), 1280 (w), 
1242 (m), 1165 (s), 1121 (m), 1106 (m), 1082 (m), 1046 (m), 1018 (m), 958 (w), 913 (m), 864 
(w), 826 (m), 767 (m), 729 (m), 703 (w), 686 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C22H29N4O4]+: 413.2189, found: 413.2182 ([M+H]+). 
 
 
 
 
 
 
 
 
                                                
[cc] Compound 4.5 was obtained as a mixture of cis/trans isomers. 
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Synthesis of (R)-2-amino-3-methoxy-N-(4-(phenyldiazenyl)benzyl)propanamide (4.6) 
 
 
 
Boc-protected amine 4.5 (225 mg, 0.550 mmol) was dissolved in 1,4-dioxane (5 mL) and a 4 M 
solution of HCl in 1,4-dioxane (5 mL) was added. The reaction mixture was stirred at room 
temperature for 16 h. A sat. aqu. solution of NaHCO3 (20 mL) was added and the phases were 
separated. The aqueous phase was extracted with EtOAc (20 mL) and the combined organic 
layers were washed with sat. aqu. NaHCO3 (15 mL), dried over MgSO4 and concentrated in 
vacuo, affording amine 4.6 (143 mg, 0.460 mmol, 84%) as an orange solid. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.29. [α]D22: +5.6 (c = 1.0, CHCl3). M.p.: 95–97 °C. 
1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.92–7.86 (m, 4H, ArH), 7.55–7.44 (m, 3H, ArH), 
7.43–7.39 (m, 2H, ArH), 4.53 (d, J = 6.1 Hz, 2H, CH2), 3.68–3.60 (m, 3H, CH, CH2), 3.38 (s, 
3H, CH3), 1.72 (br s, 2H, NH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 172.7, 152.6, 
151.9, 141.5, 131.0, 129.0, 128.2, 123.1, 122.8, 74.5, 58.9, 54.9, 42.8 ppm. IR (neat, ATR): 
ṽ = 3337 (w), 3269 (m), 2890 (w), 1644 (vs), 1599 (m), 1525 (s), 1483 (m), 1464 (m), 1442 (m), 
1412 (w), 1355 (w), 1333 (w), 1302 (w), 1221 (m), 1181 (w), 1152 (m), 1129 (m), 1107 (s), 
1070 (m), 1017 (w), 1010 (w), 970 (w), 923 (m), 876 (m), 849 (m), 829 (m), 787 (w), 769 (s), 
705 (w), 683 (s), 668 (m) cm-1. HRMS (ESI+): m/z calcd. for [C17H21N4O2]+: 313.1665, found: 
313.1659 ([M+H]+). 
 
Synthesis of (R)-2-acetamido-3-methoxy-N-(4-(phenyldiazenyl)benzyl)propanamide 
(ALCM) 
 
 
 
Amine 4.6 (124 mg, 0.400 mmol, 1.0 equiv.) was dissolved in DCM (7 mL) and cooled to 0 °C. 
TEA (83 µL, 0.60 mmol, 1.5 equiv.) was added, followed by acetyl chloride (34 µL, 0.48 mmol, 
1.2 equiv.). The reaction mixture was warmed to room temperature and stirred for 3.5 h. As 
TLC analysis indicated incomplete reaction, more acetyl chloride (10 µL, 0.14 mmol, 
0.35 equiv.) was added and the mixture was stirred for further 15 min. 10% aqu. citric acid 
(20 mL) was added and the phases were separated. The aqueous layer was extracted with DCM 
H
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(20 mL). The combined organic layers were washed with sat. aqu. NaHCO3 (25 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (CHCl3/MeOH, gradient from 100:0 to 40:1), affording ALCM (93 mg, 
0.26 mmol, 65%) as an orange solid. 
TLC (CHCl3/MeOH, 10:1): Rf = 0.46. [α]D22: –15.2 (c = 0.1, CHCl3). M.p.: 201–202 °C. 
1H NMR (CDCl3, 600 MHz, 27 °C): δ = 7.92–7.86 (m, 4H, ArH), 7.53–7.44 (m, 3H, ArH), 
7.41−7.37 (m, 2H, ArH), 6.88–6.81 (m, 1H, NH), 6.45–6.40 (m, 1H, NH), 4.60–4.50 (m, 3H, 
CH, CH2), 3.83 (dd, J = 9.0, 4.2 Hz, 1H, CH), 3.47–3.43 (m, 1H, CH), 3.40 (s, 3H, CH3), 2.04 
(s, 3H, CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C)[dd]: δ = 170.3, 170.1, 170.0, 152.6, 
152.0, 140.9, 140.9, 131.0, 129.1, 128.0, 128.0, 123.2, 122.8, 71.5, 59.1, 52.4, 52.4, 43.2, 43.1, 
23.2, 23.2 ppm. IR (neat, ATR): ṽ = 3274 (m), 3067 (w), 2971 (w), 2923 (w), 2876 (w), 2818 
(w), 1783 (w), 1626 (vs), 1544 (s), 1483 (w), 1444 (m), 1371 (m), 1341 (w), 1300 (w), 1278 
(w), 1222 (w), 1202 (w), 1138 (m), 1122 (m), 1107 (m), 1055 (w), 1012 (w), 980 (w), 933 (w), 
891 (w), 832 (m), 805 (w), 769 (m), 745 (m), 724 (m), 684 (s) cm-1. HRMS (ESI+): m/z calcd. 
for [C19H23N4O3]+: 355.1770, found: 355.1763 ([M+H]+). UV/Vis: λmax = 328, 440 nm. 
 
 
4.6.3 SYNTHESIS OF AZO-LAMOTRIGINE 
 
Synthesis of 3-(phenyldiazenyl)benzoic acid (4.7) 
 
 
 
Nitrosobenzene (10.7 g, 100 mmol, 1.0 equiv.) was dissolved in glacial acetic acid (100 mL) 
and DCM (50 mL). 3-Aminobenzoic acid (13.7 g, 100 mmol, 1.0 equiv.) was added in several 
portions within 10 min. The mixture was stirred at room temperature for 16 h. The solvent was 
removed under reduced pressure and residual solvent was coevaporated with toluene 
(3 x 40 mL). Recrystallization from ethyl acetate afforded azobenzene 4.7 (16.5 g, 72.8 mmol, 
73%) as an orange solid. 
M.p.: 168–169 °C. 1H NMR (CD3OD, 400 MHz, 27 °C): δ = 8.49 (ddd, J = 1.6, 1.6, 0.4 Hz, 
1H, ArH), 8.14 (ddd, J = 8.0, 1.6, 1.2 Hz, 1H, ArH), 8.12 (ddd, J = 8.0, 2.0, 1.2 Hz, 1H, ArH), 
7.95−7.90 (m, 2H, ArH), 7.64 (ddd, J = 8.0, 8.0, 0.4 Hz, 1H, ArH), 7.57–7.50 (m, 3H, 
                                                
[dd] A mixture of rotamers of ALCM was observed in the 13C NMR. 
N
N CO2H
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ArH) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): δ = 167.6, 152.5, 152.4, 131.9, 131.5, 131.2, 
129.1, 128.9, 126.5, 123.3, 122.5 ppm. IR (neat, ATR): ṽ = 3353 (s), 2504 (m), 1678 (vs), 
1597 (m), 1586 (m), 1472 (w), 1447 (m), 1425 (w), 1354 (m), 1343 (m), 1302 (m), 1274 (w), 
1215 (m), 1173 (w), 1159 (w), 1116 (w), 1079 (w), 1019 (w), 996 (w), 923 (w), 821 (w), 765 
(m), 682 (m) cm-1. HRMS (ESI-): m/z calcd. for [C13H9N2O2]-: 225.0664, found: 225.0670 
([M-H]-). 
 
Synthesis of 3-(phenyldiazenyl)benzoyl chloride (4.8) 
 
 
 
Carboxylic acid 4.7 (200 mg, 0.880 mmol, 1.0 equiv.) was dissolved in DCM (5 mL) and DMF 
(0.5 mL). Oxalyl chloride (0.71 mL, 1.4 mmol, 1.6 equiv.) was added dropwise within 15 min. 
The reaction mixture was stirred at room temperature for 1 h, followed by removal of the 
solvent in vacuo. The crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, 50:1) to yield acid chloride 4.8 (194 mg, 0.790 mmol, 90%) as an orange 
solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.89. M.p.: 69–70 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.65 (ddd, J = 2.1, 2.1, 0.6 Hz, 1H, ArH), 8.25–8.18 (m, 2H, ArH), 8.00–7.94 (m, 2H, ArH), 
7.67 (ddd, J = 7.8, 7.8, 0.6 Hz, 1H, ArH), 7.58–7.51 (m, 3H, ArH) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 168.0, 152.8, 152.3, 134.4, 132.8, 131.9, 129.7, 129.2, 129.0, 125.7, 
123.2 ppm. IR (neat, ATR): ṽ = 3087 (w), 3060 (w), 1747 (vs), 1673 (w), 1590 (m), 1584 (m), 
1489 (m), 1468 (w), 1445 (m), 1415 (w), 1319 (w), 1301 (w), 1279 (w), 1233 (m), 1191 (m), 
1169 (w), 1149 (m), 1117 (m), 1082 (w), 1070 (w), 1017 (w), 1000 (w), 970 (w), 921 (w), 912 
(m), 889 (m), 816 (s), 767 (s), 694 (s), 684 (vs), 653 (m) cm-1. HRMS (EI+): m/z calcd. for 
[C13H9N2OCl]+: 244.0403, found: 244.0399 ([M]+). 
 
 
 
 
 
 
 
 
N
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Synthesis of (3-(phenyldiazenyl)phenyl)methanol (4.10) 
 
 
 
Nitrosobenzene (4.50 g, 42.0 mmol, 1.1 equiv.) was dissolved in a mixture of ethanol (30 mL) 
and glacial acetic acid (11.4 mL) with careful heating to 45 °C. The clear green solution was 
cooled to room temperature again and 3-aminobenzyl alcohol (4.71 g, 38.2 mmol, 1.0 equiv.) 
was added in 5 portions within 10 min. The mixture was stirred for 1 h at room temperature. 
The solvent was removed under reduced pressure and Et2O (100 mL) was added. The organic 
phase was carefully washed with sat. aqu. NaHCO3 (100 mL; gas evolution!), then dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (hexanes/EtOAc, gradient from 4:1 to 2:1), affording azobenzene 5.11 (7.76 g, 
36.6 mmol, 96%) as red crystals. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.66. M.p.: 35–36 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.98–7.90 (m, 3H, ArH), 7.90–7.84 (dddd, J = 7.2, 1.8, 1.8, 0.3  Hz, 1H, ArH), 7.59–7.45 
(m, 5H, ArH), 4.78 (s, 2H, CH2), 2.25 (br s, 1H, OH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 152.8, 152.6, 142.1, 131.1, 129.4, 129.3, 129.1, 122.9, 122.6, 120.6, 64.9 ppm. IR (neat, 
ATR): ṽ = 3314 (m), 1585 (w), 1447 (m), 1304 (w), 1238 (w), 1195 (w), 1150 (w), 1125 (w), 
1019 (m), 922 (w), 884 (w), 838 (w), 793 (s), 768 (s), 690 (vs) cm-1. HRMS (ESI+): m/z calcd. 
for [C13H13N2O]+: 213.1028, found: 213.1022 ([M+H]+). 
 
Synthesis of 3-(phenyldiazenyl)benzaldehyde (4.11) 
 
 
 
To a solution of alcohol 4.10 (1.89 g, 8.90 mmol, 1.0 equiv.) in DCM (100 mL), MnO2 (7.74 g, 
89.0 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered through Celite and washed thoroughly with 
DCM. The filtrate was concentrated under reduced pressure to give the aldehyde 4.11 (1.82 g, 
8.66 mmol, 97%) as a red solid which could be used without further purification. An analytical 
sample was obtained by preparative TLC (100% CHCl3). 
TLC (hexanes/EtOAc, 2:1): Rf = 0.83. M.p.: 62–63 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 10.14 (s, 1H, CHO), 8.41 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 8.19 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H, 
N
N OH
N
N H
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ArH), 7.98–7.93 (m, 2H, ArH), 7.70 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.59–7.50 (m, 3H, 
ArH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 191.7, 153.0, 152.4, 137.3, 131.6, 131.1, 
129.8, 129.2, 128.7, 123.8, 123.1 ppm. IR (neat, ATR): ṽ = 3057 (w), 2845 (w), 2746 (w), 
1688 (vs), 1607 (m), 1580 (m), 1492 (w), 1471 (w), 1435 (m), 1389 (m), 1302 (w), 1271 (w), 
1229 (m), 1194 (m), 1143 (m), 1114 (m), 1107 (m), 1070 (m), 1018 (m), 997 (w), 976 (w), 957 
(m), 920 (w), 904 (m), 882 (w), 838 (w), 807 (s), 778 (m), 765 (s), 683 (vs), 668 (s) cm-1. 
HRMS (ESI+): m/z calcd. for [C13H11N2O]+: 211.0871, found: 211.0865 ([M+H]+). 
 
Synthesis of 2-hydroxy-2-(3-(phenyldiazenyl)phenyl)acetonitrile (4.12) 
 
 
 
Aldehyde 4.11 (500 mg, 2.38 mmol, 1.0 equiv.) was dissolved in THF (60 mL) and TMSCN 
(1.20 mL, 9.56 mmol, 9.6 equiv.) was added dropwise. The reaction mixture was stirred at room 
temperature for 4 h. The solvent was removed under reduced pressure and the crude product 
was taken up in EtOAc (20 mL). The organic phase was washed with sat. aqu. NaHCO3 
(30 mL) and brine (30 mL), dried over MgSO4 and concentrated in vacuo. Purification of the 
crude product by flash silica gel chromatography (hexanes/EtOAc, gradient from 20:1 to 2:1) 
afforded cyanohydrin 4.12 (521 mg, 2.16 mmol, 91%) as an orange oil. 
TLC (CHCl3): Rf = 0.13. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 8.05 (ddd, J = 1.8, 1.8, 
0.6 Hz, 1H, ArH), 7.97–7.94 (m, 1H, ArH), 7.93–7.90 (m, 2H, ArH), 7.64–7.61 (m, 1H, ArH), 
7.58 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 7.54–7.49 (m, 3H, ArH), 5.64 (d, J = 5.4 Hz, 1H, CH), 3.21 
(d, J = 5.4 Hz, 1H, OH) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 152.9, 152.3, 136.3, 
131.6, 130.0, 129.2, 128.7, 124.6, 123.0, 120.5, 118.5, 63.3 ppm. IR (neat, ATR): ṽ = 3407 
(m), 3062 (w), 2917 (w), 1700 (w), 1585 (w), 1479 (w), 1448 (m), 1377 (m), 1308 (w), 1215 
(w), 1194 (w), 1150 (m), 1129 (w), 1070 (m), 1046 (m), 1000 (w), 927 (w), 899 (w), 851 (w), 
803 (m), 766 (m), 692 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C14H12N3O]+: 238.0980, found: 
238.0974 ([M+H]+). 
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Synthesis of (Z)-N'-(diaminomethylene)-3-phenyldiazenyl)benzohydrazonoyl cyanide 
(4.14) 
 
 
 
To a solution of cyanohydrin 4.12 (464 mg, 1.96 mmol, 1.0 equiv.) in DCM (35 mL), MnO2 
(1.70 g, 19.6 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at 
room temperature for 16 h. The mixture was filtered through Celite and washed thoroughly with 
DCM. The filtrate was concentrated under reduced pressure to give compound 4.13 which was 
directly used in the next step.  
To a solution of aminoguanidine bismesylate[ee] (940 mg, 3.53 mmol, 1.8 equiv.) in MsOH 
(18 mL) at 70 °C, a solution of compound 4.13 in MeCN (30 mL) was added over 15 min. The 
reaction mixture was stirred at 70 °C for 5 h. The hot solution was then poured onto ice water 
and neutralized with 2 M NaOH to pH = 8–9. The aqueous layer was extracted with DCM 
(3 x 30 mL) and the combined organic layers were washed with sat. aqu. NaHCO3 (100 mL), 
brine (100 mL), then dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by flash silica gel chromatography (DCM/MeOH, 10:0 → 2:1), yielding 
cyanohydrazone 4.14 (144 mg, 0.490 mmol, 25% over two steps) as a red solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.30. M.p.: 178–180 °C. 1H NMR (DMSO-d6, 600 MHz, 
27 °C): δ = 8.23 (ddd, J = 1.8, 1.8, 0.6 Hz, 1H, ArH), 8.04 (ddd, J = 7.8, 1.8, 0.6 Hz, 1H, ArH), 
7.92–7.88 (m, 2H, ArH), 7.77 (ddd, J = 7.8, 1.8, 0.6 Hz, 1H, ArH), 7.62–7.56 (m, 4H, ArH), 
6.75 (br s, 4H, 2 x NH2) ppm. 13C NMR (DMSO-d6, 150 MHz, 27 °C): δ = 163.6, 152.7, 
152.4, 136.1, 132.1, 130.2, 129.9, 127.6, 123.1, 121.6, 119.4, 117.5, 114.3 ppm. IR (neat, 
ATR): ṽ = 3448 (m), 3322 (m), 3185 (m), 2214 (m), 1652 (m), 1609 (m), 1558 (s), 1475 (vs), 
1441 (m), 1414 (s), 1314 (m), 1276 (m), 1211 (w), 1150 (s), 1083 (m), 1034 (w), 1018 (s), 998 
(w), 972 (m), 926 (w), 915 (w), 887 (m), 867 (w), 798 (m), 762 (m), 740 (w), 678 (vs), 656 
(w) cm-1. HRMS (EI+): m/z calcd. for [C15H13N7]+: 291.1232, found: 291.1231 ([M]+). 
 
 
 
                                                
[ee]  Aminoguanidine bismesylate was synthesized from aminoguanidine bicarbonate in quantitative 
yield according to a literature procedure: M. Leach, K. Franzmann, D. Riddall, L. Harbige (University of 
Greenwich), WO/2011/004195 A2, 2011. 
N
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Synthesis of 6-(3-(phenyldiazenyl)phenyl)-1,2,4-triazine-3,5-diamine (ALTG) 
 
 
 
To a solution of cyanohydrazone 4.14 (50 mg, 0.17 mmol, 1.0 equiv.) in EtOH (10 mL), NaOEt 
(0.25 mL, 21% solution in EtOH) was added in one portion. The reaction mixture was heated to 
reflux for 1.75 h. The mixture was cooled to room temperature and the solvent was removed 
under reduced pressure. The crude product was purified by flash silica gel chromatography 
(DCM/MeOH, gradient from 100:0 to 15:1 ), affording triazine ALTG (39 mg, 0.13 mmol, 
76%) as an orange solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.25. M.p.: 225–226 °C. 1H NMR (DMSO-d6, 600 MHz, 
27 °C): δ = 8.02 (ddd, J = 1.8, 1.8, 0.6 Hz, 1H, ArH), 7.92–7.89 (m, 3H, ArH), 7.72 (ddd, 
J = 7.8, 1.8, 0.6 Hz, 1H, ArH), 7.66 (ddd, J = 7.8, 7.8, 0.6 Hz, 1H, ArH), 7.61–7.54 (m, 3H, 
ArH), 6.80 (br s, 2H, NH2), 6.40 (br s, 2H, NH2) ppm. 13C NMR (DMSO-d6, 100 MHz, 
27 °C): δ = 161.9, 154.8, 152.4, 152.3, 138.9, 137.2, 132.1, 131.4, 130.2, 129.9, 123.0, 122.9, 
122.1 ppm. IR (neat, ATR): ṽ = 3488 (w), 3404 (w), 3319 (m), 3193 (m), 1664 (m), 1624 (s), 
1520 (vs), 1432 (m), 1418 (m), 1322 (m), 1307 (w), 1285 (w), 1263 (w), 1209 (w), 1093 (w), 
1069 (w), 1020 (w), 915 (w), 901 (m), 858 (w), 808 (m), 759 (m), 722 (m), 699 (m), 683 
(s) cm-1. HRMS (ESI+): m/z calcd. for [C15H14N7]+: 292.1311, found: 292.1303 ([M+H]+). 
UV/Vis: λmax = 323, 441 nm. 
 
 
4.6.4 SYNTHESIS OF AZO-CROBENETINES 
 
Synthesis of (2R,6S)-3-((S)-2-(benzyloxy)propyl)-10-((tert-butyldimethylsilyl)-oxy)-6,11,11-
trimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocine (4.16) 
 
 
 
To a solution of the HCl salt of crobenetine 4.15 (150 mg, 0.360 mmol, 1.0 equiv.) in DMF 
(6 mL) were added TBSCl (109 mg, 0.720 mmol, 2.0 equiv.), imidazole (98 mg, 1.4 mmol, 
4.0 equiv.) and DMAP (5.0 mg, 0.040 mmol, 0.1 equiv.) at 0 °C. The reaction mixture was 
N
N
N
NN
H2N NH2
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warmed to room temperature and stirred for 16 h. The mixture then was poured into H2O 
(100 mL), extracted with Et2O (3 x 30 mL) and the combined organic layers were washed with 
H2O (5 x 100 mL). The combined aqueous layers were again extracted with Et2O (3 x 30 mL) 
and the combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
product was used without further purification for the next step. An analytical sample was 
obtained by flash silica gel chromatography (hexanes/EtOAc, 10:1), affording TBS ether 4.16 
(176 mg, 0.360 mmol, 100%) as a colorless oil. 
TLC (hexanes/EtOAc, 10:1): Rf = 0.47. [α]D22: –81.2 (c = 0.33, DCM). 1H NMR (CDCl3, 
400 MHz, 27 °C): δ = 7.40–7.30 (m, 4H, ArH), 7.29–7.26 (m, 1H, ArH), 7.03 (dd, J = 8.0, 
8.0 Hz, 1H, ArH), 6.91 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 6.63 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 
4.67–4.60 (m, 2H, CH2), 3.68–3.58 (m, 1H, CH), 2.92 (d, J = 18.8 Hz, 1H, CH), 2.71 (dd, 
J = 13.2, 6.0 Hz, 1H, CH), 2.55 (d, J = 6.0 Hz, 1H, CH), 2.50–2.42 (m, 2H, 2 x CH), 2.28 (dd, 
J = 13.2, 5.6 Hz, 1H, CH), 2.12 (d, J = 13.4 Hz, 1H, CH), 2.06 (d, J = 13.4 Hz, 1H, CH), 1.29 
(s, 3H, CH3), 1.28 (s, 3H, CH3), 1.22 (d, J = 6.0 Hz, 3H, CH3), 1.04 (s, 9H, C(CH3)3), 1.02–0.98 
(m, 1H, CH), 0.79 (s, 3H, CH3), 0.23 (s, 3H, SiCH3), 0.22 (s, 3H, SiCH3) ppm. 13C NMR 
(CDCl3, 100 MHz, 27 °C): δ = 151.4, 145.8, 139.3, 128.6, 128.3, 127.5, 127.3, 126.0, 118.0, 
115.3, 73.4, 70.9, 62.5, 61.1, 46.4, 39.0, 37.9, 36.5, 25.9, 23.6, 23.3, 20.7, 20.5, 18.9, 18.4, –4.0, 
–4.0 ppm. IR (neat, ATR): ṽ = 2958 (m), 2927 (s), 2856 (m), 1579 (m), 1464 (s), 1389 (m), 
1372 (m), 1346 (w), 1313 (w), 1271 (s), 1252 (vs), 1208 (w), 1168 (m), 1102 (m), 1035 (m), 
980 (s), 967 (s), 938 (w), 909 (w), 865 (m), 837 (s), 827 (s), 813 (m), 778 (s), 737 (m), 718 (m), 
695 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C31H48NO2Si]+: 494.3454, found: 
494.3449 ([M+H]+). 
 
Synthesis of (S)-1-((2R,6S)-10-((tert-butyldimethylsilyl)oxy)-6,11,11-tri-methyl-1,2,5,6-
tetrahydro-2,6-methanobenzo[d]azocin-3(4H)-yl)propan-2-ol (4.17) 
 
 
 
Palladium on charcoal (100 mg, 10%) was added to a solution of crude benzyl ether 4.16 
(170 mg, 0.340 mmol, 1.0 equiv.) in EtOH (8 mL) and EtOAc (4 mL) in an autoclave. The 
autoclave was purged with H2 (4 bar) and evacuated (5x). The reaction mixture was then stirred 
for 20 h under an H2 atmosphere (4 bar). As TLC indicated still remaining starting material, 
palladium on charcoal (50 mg, 10%) were added and the autoclave was purged again with H2 
(4 bar) and evacuated (5x). The reaction mixture was then stirred for another 7 h under an H2 
OTBS N OH
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atmosphere (4 bar). The mixture was filtered through Celite and the solvent was removed in 
vacuo. The crude product was purified by flash silica gel chromatography (DCM/MeOH, 20:1), 
giving alcohol 4.17 (126 mg, 0.310 mmol, 91%) as a colorless oil. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.48. [α]D22: –41.9 (c = 0.15, MeOH). 1H NMR (CD3OD, 
600 MHz, 27 °C): δ = 7.03 (dd, J = 7.8, 7.8 Hz, 1H, ArH), 6.93 (dd, J = 7.8, 1.2 Hz, 1H, ArH), 
6.65 (dd, J = 7.8, 1.2 Hz, 1H, ArH), 3.81–3.74 (m, 1H, CH), 2.95–2.86 (m, 1H, CH), 2.59–2.51 
(m, 3H, 3 x CH), 2.33–2.29 (m, 2H, 2 x CH), 2.15–2.04 (m, 2H, 2 x CH), 1.31 (s, 6H, 2 x CH3), 
1.13 (d, J = 6.0 Hz, 3H, CH3), 1.05 (s, 9H, C(CH3)3), 1.04–1.02 (m, 1H, CH), 0.82 (s, 3H, CH3), 
0.23 (s, 3H, SiCH3), 0.22 (s, 3H, SiCH3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 151.3, 145.3, 127.9, 126.0, 117.9, 115.2, 64.4, 63.7, 63.0, 44.4, 38.6, 37.5, 36.3, 24.9, 22.3, 
22.2, 21.7, 19.4, 19.1, 17.8, –5.2, –5.3 ppm. IR (neat, ATR): ṽ = 3410 (m), 2960 (m), 2928 (s), 
2857 (m), 1628 (s), 1580 (s), 1465 (vs), 1408 (m), 1390 (m), 1325 (m), 1270 (vs), 1251 (s), 
1221 (w), 1190 (w), 1167 (w), 1084 (w), 1036 (w), 981 (m), 967 (m), 941 (w), 864 (m), 838 (s), 
827 (s), 814 (m), 780 (m), 719 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C24H42NO2Si]+: 404.2985, found: 404.2980 ([M+H]+). 
 
Synthesis of 1-(4-(bromomethyl)phenyl)-2-phenyldiazene (4.18) 
 
 
 
To a solution of alcohol 4.20 (1.77 g, 8.30 mmol, 1.0 equiv.) in THF (50 mL) were added CBr4 
(3.18 g, 9.60 mmol, 1.15 equiv.) and PPh3 (2.52 g, 9.60 mmol, 1.15 equiv.) at 0 °C. The 
reaction mixture was stirred for 16 h at room temperature and then concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (hexanes/DCM, gradient from 
4:1 to 1:1), affording bromide 4.18 (1.95 g, 7.10 mmol, 86%) as orange crystals.  
TLC (hexanes/EtOAc, 20:1): Rf = 0.51. M.p.: 118–119 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.95–7.87 (m, 4H, ArH), 7.56–7.45 (m, 5H, ArH), 4.55 (s, 2H, CH2) ppm. 
13C NMR (CDCl3, 100 MHz, 27 °C): δ = 152.6, 152.3, 140.5, 131.2, 129.9, 129.1, 123.3, 
123.0, 32.8 ppm. IR (neat, ATR): ṽ = 1438 (w), 1302 (w), 1221 (w), 1194 (w), 1150 (m), 1090 
(w), 922 (w), 851 (m), 780 (m), 764 (s), 668 (m), 683 (s) cm-1. HRMS (ESI+): m/z calcd. for 
[C13H12BrN2]+: 275.0184, found: 275.0179 ([M+H]+). 
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Synthesis of (S)-1-((2R,6S)-6,11,11-trimethyl-10-((4-phenyldiazenyl)benzyl)oxy)-1,2,5,6-
tetrahydro-2,6-methanobenzo[d]azocin-3(4H)-yl)propan-2-ol (4.19) 
 
 
 
NaH (10 mg, 0.42 mmol, 3.5 equiv.) was suspended in DMF (3 mL) at 0 °C. To this, a solution 
of alcohol 4.17 (50 mg, 0.12 mmol, 1.0 equiv.) in THF (3 mL) was added and stirred at 0 °C for 
1 h. Bu4NI (4.4 mg, 0.012 mmol, 0.1 equiv.) and bromide 4.18 (66 mg, 0.24 mmol, 2.0 equiv.) 
were added. The reaction mixture was warmed to room temperature and stirred for 16 h. A sat. 
aqu. solution of NH4Cl (10 mL) was added and the mixture was extracted with DCM 
(2 x 15 mL). The combined organic phases were washed with H2O (3 x 20 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude product was purified 
by flash silica gel column chromatography (hexanes/CHCl3, gradient from 4:1 to 1:1), followed 
by a second column chromatography (hexanes/EtOAc, 1% TEA, 10:1) to yield phenolic ether 
4.19 (22 mg, 0.045 mmol, 38%) as a yellow oil. 
TLC (hexanes/EtOAc, 2:1, 1% TEA): Rf = 0.37. [α]D22: –48.0 (c = 0.10, DCM). 1H NMR 
(CDCl3, 600 MHz, 27 °C): δ = 7.97–7.94 (m, 2H, ArH), 7.94–7.91 (m, 2H, ArH), 7.61 (d, 
J = 8.6 Hz, 2H, ArH), 7.55–7.51 (m, 2H, ArH), 7.50–7.47 (m, 1H, ArH), 7.16 (dd, J = 7.8, 
7.8 Hz, 1H, ArH), 6.97 (d, J = 7.8 Hz, 1H, ArH), 6.77 (d, J = 7.8 Hz, 1H, ArH), 5.18 (s, 2H, 
OCH2), 3.88 (br s, 1H, OH), 3.78–3.74 (m, 1H, CH), 2.94 (d, J = 19.0 Hz, 1H, CH), 2.72 (dd, 
J = 19.0, 6.1 Hz, 1H, CH), 2.59–2.56 (m, 2H, 2 x CH), 2.46 (dd, J = 12.3, 2.9 Hz, 1H, CH), 
2.18–2.04 (m, 3H, 3 x CH), 1.34–1.30 (s, 6H, 2 x CH3), 1.15–1.10 (m, 4H, CH, CH3), 0.85 (s, 
3H, CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 154.1, 152.6, 152.2, 145.2, 140.5, 
131.0, 129.1, 127.7, 126.5, 126.1, 123.0, 122.8, 117.9, 108.2, 69.3, 65.6, 63.9, 62.7, 43.6, 39.0, 
37.5, 36.8, 23.6, 23.2, 21.7, 20.4, 19.9 ppm. IR (neat, ATR): ṽ = 3436 (w), 2966 (m), 2924 (m), 
1579 (m), 1468 (m), 1454 (m), 1412 (m), 1374 (m), 1329 (m), 1261 (s), 1248 (s), 1221 (m), 
1208 (m), 1190 (m), 1167 (m), 1134 (w), 1102 (m), 1055 (s), 1020 (m), 970 (w), 918 (w), 830 
(m), 778 (m), 766 (s), 735 (s), 719 (s), 687 (vs) cm-1. HRMS (ESI+): m/z calcd. for 
[C31H38N3O2]+: 484.2964, found: 484.2958 ([M+H]+). 
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Synthesis of 1-(3-(bromomethyl)phenyl)-2-phenyldiazene (4.21) 
 
 
 
To a solution of alcohol 4.10 (5.00 g, 23.6 mmol, 1.0 equiv.) in THF (150 mL) were added CBr4 
(9.02 g, 27.2 mmol, 1.15 equiv.) and PPh3 (7.13 g, 27.2 mmol, 1.15 equiv.) at 0 °C. The 
reaction mixture was warmed to room temperature and stirred for 16 h. The solvent was 
removed in vacuo and the crude product was purified by flash silica gel chromatography 
(hexanes/DCM, 5:1 → 3:1), yielding bromide 4.21 (6.06 g, 22.0 mmol, 93%) as an orange solid.  
TLC (hexanes/EtOAc, 10:1): Rf = 0.70. M.p.: 43–44 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.97–7.93 (m, 3H, ArH), 7.90–7.86 (m, 1H, ArH), 7.56–7.48 (m, 1H, ArH), 4.59 (s, 
2H, CH2) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 152.8, 152.5, 138.9, 131.4, 131.3, 
129.6, 129.1, 123.4, 123.0, 122.9, 32.8 ppm. IR (neat, ATR): ṽ = 1585 (w), 1481 (w), 1444 
(m), 1293 (w), 1249 (w), 1212 (m), 1149 (m), 1070 (m), 1020 (w), 999 (w), 922 (m), 903 (m), 
796 (m), 762 (s), 688 (vs) cm-1. HRMS (EI+): m/z calcd. for [C13H12BrN2]+: 274.0105, found: 
274.0096 ([M]+). 
 
Synthesis of (S)-1-((2R,6S)-6,11,11-trimethyl-10-((3-phenyldiazenyl)benzyl)oxy)-1,2,5,6-
tetrahydro-2,6-methanobenzo[d]azocin-3(4H)-yl)propan-2-ol (4.22) 
 
 
 
NaH (8.5 mg, 0.35 mmol, 3.5 equiv.) was suspended in DMF (2.5 mL) at 0 °C. To this, a 
solution of alcohol 4.17 (40 mg, 0.099 mmol, 1.0 equiv.) in THF (2.5 mL) was added and 
stirred at 0 °C for 1 h. Bu4NI (4.0 mg, 0.010 mmol, 0.1 equiv.) and bromide 4.21 (55 mg, 
0.20 mmol, 2.0 equiv.) were added. The reaction mixture was warmed to room temperature and 
stirred for 16 h. A sat. aqu. solution of NH4Cl (10 mL) was added and the mixture was extracted 
with DCM (2 x 15 mL). The combined organic phases were washed with H2O (3 x 20 mL), 
dried over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, 1% TEA, gradient from 
10:1 to 1:1), followed by a second column chromatography (hexanes/EtOAc, 1% TEA, gradient 
from 20:1 to 5:1), affording phenolic ether 4.22 (20 mg, 0.041 mmol, 41%) as a yellow oil. 
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TLC (hexanes/EtOAc, 2:1, 1% TEA): Rf = 0.62. [α]D22: –56.0 (c = 0.10, DCM). 1H NMR 
(CDCl3, 600 MHz, 27 °C): δ = 8.02 (s, 1H, ArH), 7.94–7.88 (m, 3H, ArH), 7.59–7.48 (m, 5H, 
ArH), 7.16 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 6.96 (d, J = 8.0 Hz, 1H, ArH), 6.78 (d, J = 8.0 Hz, 
1H, ArH), 5.20 (s, 2H, OCH2), 3.93 (br s, 1H, OH), 3.78–3.73 (m, 1H, CH), 2.95 (d, 
J = 19.0 Hz, 1H, CH), 2.72 (dd, J = 19.0, 6.1 Hz, 1H, CH), 2.61–2.53 (m, 2H, 2 x CH), 2.47 
(dd, J = 12.3, 2.9 Hz, 1H, CH), 2.20–2.02 (m, 3H, 3 x CH), 1.35–1.31 (m, 6H, 2 x CH3), 
1.15−1.06 (m, 4H, CH, CH3), 0.84 (s, 3H, CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): 
δ = 154.2, 152.8, 152.6, 145.2, 138.7, 131.2, 129.5, 129.3, 129.1, 126.5, 126.1, 122.8, 122.6, 
121.2, 117.9, 108.2, 69.4, 65.6, 63.9, 62.7, 43.6, 39.0, 37.5, 36.8, 23.6, 23.2, 21.7, 20.4, 
19.9 ppm. IR (neat, ATR): ṽ = 3431 (w), 2966 (m), 2924 (m), 2822 (w), 1580 (m), 1468 (m), 
1455 (s), 1410 (m), 1374 (m), 1329 (m), 1282 (m), 1262 (s), 1209 (m), 1190 (w), 1167 (m), 
1150 (w), 1134 (w), 1076 (m), 1055 (s), 1022 (m), 971 (w), 923 (w), 886 (w), 843 (w), 784 (m), 
766 (m), 720 (m), 693 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C31H38N3O2]+: 484.2964, found: 
484.2958 ([M+H]+). 
 
Synthesis of 4-(phenyldiazenyl)benzyl 2,2,2-trichloroacetimidate (4.23) 
 
 
 
NaH (12.5 mg, 0.520 mmol, 1.1 equiv.) was suspended in THF (10 mL) and cooled to 0 °C. 
Alcohol 4.20 (100 mg, 0.470 mmol, 1.0 equiv.) was added and the mixture was stirred for 
30 min at 0 °C. Trichloroacetonitrile (0.23 mL, 2.4 mmol, 5.0 equiv.) was added and the 
mixture was warmed to room temperature and stirred for 1 h. A sat. aqu. solution of NH4Cl  
(50 mL) was added and the aqueous phase extracted with DCM (3 x 20 mL). The combined 
organic layers were washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash silica gel chromatography (hexanes/DCM, 5:1 → 3:1), 
affording trichloroacetimidate 4.23 (89 mg, 0.25 mmol, 53%) as orange crystals.  
TLC (hexanes/DCM, 2:1): Rf = 0.29. M.p.: 124–125 °C. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 8.44 (s, 1H, NH), 7.95–7.89 (m, 4H, ArH), 7.60–7.56 (m, 2H, ArH), 7.54–7.43 (m, 
2H, ArH), 7.49–7.45 (m, 1H, ArH), 5.42 (s, 2H, CH2) ppm. 13C NMR (CDCl3, 150 MHz, 
27 °C): δ = 162.4, 152.6, 152.4, 138.3, 131.1, 129.1, 128.3, 123.0, 122.9, 91.2, 70.1 ppm. IR 
(neat, ATR): ṽ = 3340 (m), 1664 (s), 1489 (w), 1467 (w), 1445 (m), 1409 (m), 1370 (m), 1302 
(m), 1290 (m), 1154 (w), 1066 (vs), 1002 (m), 988 (m), 909 (w), 854 (m), 838 (m), 825 (m), 
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797 (s), 788 (s), 773 (m), 732 (w), 685 (m) cm-1. HRMS (EI+): m/z calcd. for [C15H12Cl3N3O]+: 
355.0046, found: 355.0048 ([M]+). 
 
Synthesis of 1-(3-(iodomethyl)phenyl)-2-phenyldiazene (4.24) 
 
 
 
PPh3 (147 mg, 0.560 mmol, 1.2 equiv.) and imidazole (48 mg, 0.71 mmol, 1.5 equiv.) were 
dissolved in THF (10 mL) and alcohol 4.10 (100 mg, 0.470 mmol, 1.0 equiv.) was added, 
followed by iodine (142 mg, 0.560 mmol, 1.2 equiv.). The mixture was stirred at room 
temperature for 1 h. H2O (100 mL) was added and the aqueous phase extracted with DCM 
(3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by quick flash silica gel 
chromatography (hexanes/DCM, 5:1 → 3:1), affording iodide 4.24 (107 mg, 0.330 mmol, 70%) 
as orange crystals.  
TLC (hexanes/DCM, 5:1): Rf = 0.35. M.p.: 121 °C (dec.). 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.93–7.89 (m, 2H, ArH), 7.87–7.82 (m, 2H, ArH), 7.55–7.47 (m, 5H, ArH), 4.53 (s, 
2H, CH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 152.6, 151.9, 142.3, 131.1, 129.5, 
129.1, 123.3, 122.9, 4.7 ppm. IR (neat, ATR): ṽ = 1596 (w), 1580 (w), 1498 (w), 1484 (w), 
1465 (w), 1441 (w), 1407 (w), 1302 (m), 1222 (w), 1213 (m), 1146 (s), 1116 (m), 1072 (m), 
1018 (m), 1008 (w), 922 (w), 850 (s), 822 (m), 779 (m), 764 (s), 730 (m), 682 (vs) cm-1. HRMS 
(EI+): m/z calcd. for [C13H10IN2]+: 320.9889, found: 320.9887 ([M-H]+). 
 
Synthesis of (S)-methyl 2-((4-(phenyldiazenyl)benzyl)oxy)propanoate (4.28) 
 
 
 
Freshly prepared Ag2O (840 mg, 3.63 mmol, 2.0 equiv.) was added to a solution of (−)-methyl 
L-lactate (0.17 mL, 1.8 mmol, 1.0 equiv.) and bromide 4.18 (1.00 g, 3.63 mmol, 2.0 equiv.) in 
Et2O (30 mL). The reaction mixture was heated to reflux for 24 h and then filtered through 
Celite and thoroughly washed with DCM. The solvent was removed under reduced pressure and 
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the crude product was purified by flash silica gel column chromatography (hexanes/EtOAc, 
gradient from 50:1 to 10:1), affording ether 4.28 (149 mg, 0.500 mmol, 27%) as a red oil.  
TLC (hexanes/EtOAc, 10:1): Rf = 0.25. [α]D22: –78.0 (c = 0.20, CHCl3). 1H NMR (CDCl3, 
400 MHz, 27 °C): δ = 7.94–7.88 (m, 4H, ArH), 7.54–7.46 (m, 5H, ArH), 4.77 (d, J = 12.2 Hz, 
1H, CH), 4.54 (d, J = 12.2 Hz, 1H, CH), 4.11 (q, J = 6.8 Hz, 1H, CH), 3.77 (s, 3H, OCH3), 1.48 
(d, J = 6.8 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 173.5, 152.6, 152.2, 
140.6, 131.0, 129.1, 128.4, 122.9, 122.8, 74.2, 71.5, 52.0, 18.7 ppm. IR (neat, ATR): ṽ = 2989 
(w), 2952 (w), 2872 (w), 1748 (vs), 1606 (w), 1485 (w), 1446 (m), 1415 (w), 1392 (w), 1372 
(w), 1300 (w), 1274 (w), 1207 (m), 1142 (vs), 1121 (s), 1070 (m), 1014 (m), 975 (w), 924 (w), 
831 (m), 767 (m), 688 (m) cm-1. HRMS (ESI+): m/z calcd. for [C17H19N2O3]+: 299.1396, found: 
299.1391 ([M+H]+). 
 
Bromide 4.18 was recovered in 48% yield (475 mg, 1.74 mmol) and aldehyde 4.35 was 
obtained as a side product (63 mg, 0.30 mmol, 16%). 
 
 
 
TLC (hexanes/EtOAc, 10:1): Rf = 0.29. M.p.: 106–108 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 10.11 (s, 1H, CHO), 8.04 (s, 4H, ArH), 7.98–7.95 (m, 2H, ArH), 7.57–7.52 (m, 3H, 
ArH) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 191.6, 155.9, 152.5, 137.4, 132.0, 130.7, 
129.2, 123.3, 123.2 ppm. IR (neat, ATR): ṽ = 1699 (vs), 1598 (m), 1486 (w), 1465 (w), 1442 
(w), 1379 (w), 1305 (m), 1263 (w), 1197 (s), 1149 (m), 1071 (m), 1000 (w), 920 (w), 841 (m), 
794 (m), 766 (m), 732 (w), 715 (w), 682 (m) cm-1. HRMS (EI+): m/z calcd. for [C13H10N2O]+: 
210.1793, found: 210.1791 ([M]+). 
 
Synthesis of (S)-2-((4-(phenyldiazenyl)benzyl)oxy)propanoic acid (4.26) 
 
 
 
Methyl ester 4.28 (7.0 mg, 0.023 mmol, 1.0 equiv.) was dissolved in THF (0.5 mL) and a 1 M 
solution of LiOH in H2O (0.07 mL, 0.07 mmol, 3.0 equiv.) was added. The reaction mixture 
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was stirred for 16 h at room temperature. The mixture was diluted with H2O (10 mL) and 
washed with EtOAc (15 mL). The aqueous phase was then acidified to pH = 2–3 with 1 M HCl 
and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. Pure carboxylic acid 4.26 was obtained in 91% yield (6.0 mg, 
0.021 mmol) as an orange solid.  
[α]D22: –85.0 (c = 0.20, CHCl3). 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.97–7.89 (m, 4H, 
ArH), 7.55–7.46 (m, 5H, ArH), 4.79 (d, J = 12.0 Hz, 1H, CH), 4.63 (d, J = 12.0 Hz, 1H, CH), 
4.16 (q, J = 6.9 Hz, 1H, CH), 1.54 (d, J = 6.9 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 100 MHz, 
27 °C): δ = 176.3, 152.6, 152.4, 139.9, 131.1, 129.1, 128.5, 123.0, 122.9, 73.8, 71.6, 18.2 ppm. 
IR (neat, ATR): ṽ = 2992 (m), 1731 (s), 1710 (vs), 1457 (w), 1446 (w), 1415 (w), 1333 (w), 
1304 (w), 1283 (w), 1219 (m), 1141 (vs), 1118 (m), 1066 (m), 1022 (m), 919 (w), 856 (w), 836 
(m), 768 (m), 726 (w), 686 (m), 666 (w) cm-1. HRMS (EI+): m/z calcd. for [C16H16N2O3]+: 
284.1161, found: 284.1157 ([M]+). 
 
Synthesis of (S)-1-((2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-2,6-methano-
benzo[d]azocin-3(4H)-yl)-2-((4-phenyldiazenyl)benzyl)oxy)-propan-1-one (4.27)[ff] 
 
 
 
Carboxylic acid 4.26 (75 mg, 0.26 mmol, 1.0 equiv.) was dissolved in DCM (7.5 mL) and 
oxalyl chloride (0.65 mL, 2 M in DCM, 1.3 mmol, 5.0 equiv.) and DMF (5 drops) were added. 
The mixture was stirred at room temperature for 1 h and then concentrated in vacuo. Residual 
solvent was coevaporated with toluene (2 x 5 mL) and the residue was dissolved in DCM 
(7.5 mL) and cooled to 0 °C. This solution was added to a solution of the HBr salt of amine 4.25 
(162 mg, 0.520 mmol, 2.0 equiv.) and DIPEA (0.22 mL, 1.3 mmol, 5.0 equiv.) in DCM 
(7.5 mL) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. A 
sat. aqu. solution of NH4Cl (30 mL) was added and the aqueous layer was extracted with EtOAc 
                                                
[ff]  Compound 4.27 was obtained as an approx. 2:1 mixture of two isomers, probably due to the 
sterically biased amide bond, as temperature-dependent NMR experiments and the literature (see Grauert 
et al.[23]) suggested. Thus, two sets of signals were observed in the NMR spectra of 4.27. Whereas the 
signals of the major isomer could be clearly assigned in the 1H NMR spectrum, the 13C NMR could not be 
interpreted. Therefore, all peaks of both isomers are provided. 
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(3 x 15 mL). The combined organic phases were washed with NH4Cl (3 x 30 mL) and brine 
(30 mL), dried over MgSO4 and the solvent was removed under reduced pressure. The crude 
product was purified by flash silica gel column chromatography (hexanes/EtOAc, 2:1 → 3:2) to 
give amide 4.27 (80 mg, 0.16 mmol, 62%) as a mixture of trans/cis isomers as a red oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.50. [α]D22: –102.0 (c = 0.10, DCM). 1H NMR (CDCl3, 
600 MHz, 27 °C; major isomer): δ = 7.93–7.88 (m, 3H, ArH), 7.87–7.84 (m, 2H, ArH), 
7.51−7.49 (m, 3H, ArH), 7.46–7.44 (m, 3H, ArH), 7.08–7.06 (m, 1H, ArH), 6.90–6.88 (m, 1H, 
ArH), 6.66 (dd, J = 7.9, 0.9 Hz, 1H, ArH), 5.51 (br s, 1H, OH), 4.76 (d, J = 6.7 Hz, 1H, CH), 
4.62 (d, J = 12.2 Hz, 1H, CH), 4.54–4.51 (m, 1H, CH), 4.39–4.36 (m, 1H, CH), 3.87 (dd, 
J = 14.0, 5.1 Hz, 1H, CH), 3.06 (dd, J = 18.7, 6.8 Hz, 1H, CH), 2.84 (dd, J = 13.6, 3.8 Hz, 1H, 
CH), 2.57–2.54 (m, 1H, CH), 2.02−1.98 (m, 1H, CH), 1.63 (s, 3H, CH3), 1.44 (d, J = 6.8 Hz, 
3H, CH3), 1.11 (s, 3H, CH3), 1.09−1.06 (m, 1H, CH), 0.87–0.86 (m, 3H, CH3) ppm. 13C NMR 
(CDCl3, 150 MHz, 27 °C): δ = 171.3, 170.6, 152.6, 152.2, 152.0, 151.9, 144.1, 143.9, 140.8, 
140.7, 131.0, 131.0, 129.1, 129.1, 128.7, 128.5, 128.4, 128.2, 127.1, 127.1, 122.9, 122.9, 122.8, 
122.1, 121.9, 120.7, 120.4, 117.6, 117.5, 112.4, 112.3, 75.4, 73.6, 70.7, 70.1, 56.7, 52.5, 40.8, 
39.2. 38.9, 38.8, 36.7, 36.2 36.0 35.9, 35.7, 28.5, 28.4, 27.3, 23.8, 22.7, 22.5, 22.3, 21.7, 20.8, 
20.4, 20.1, 17.9, 17.8, 17.5, 17.3, 14.6, 7.9 ppm. IR (neat, ATR): ṽ = 3261 (m), 2978 (m), 2928 
(m), 1622 (vs), 1584 (s), 1466 (s), 1392 (m), 1374 (m), 1342 (m), 1282 (m), 1257 (m), 1230 
(m), 1206 (w), 1154 (m), 1109 (m), 1071 (m), 1014 (w), 982 (w), 970 (w), 947 (w), 922 (w), 
833 (m), 787 (m), 766 (m), 735 (m), 689 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C31H36N3O3]+: 498.2757, found: 498.2750 ([M+H]+).  
 
Synthesis of (2R,6S)-6,11,11-trimethyl-3-((S)-2-((4-(phenyldiazenyl)benzyl)oxy)-propyl)-
1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocin-10-ol (p-ACRO) 
 
 
 
Amide 4.27 (80 mg, 0.16 mmol, 1.0 equiv.) was dissolved in THF (6 mL) and LiAlH4 (12.1 mg, 
0.320 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room temperature for 
1 h. A  sat. aqu. solution of Rochelle’s salt was added (5 mL) and vigorously stirred for 30 min. 
The phases were separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The 
combined organic phases were washed with brine (20 mL), dried over MgSO4 and the solvent 
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was removed under reduced pressure. The crude product was purified by flash silica gel column 
chromatography (hexanes/EtOAc, 3:1 → 2:1), yielding amine p-ACRO (60 mg, 0.12 mmol, 
75%) as a red oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.76. [α]D22: –48.0 (c = 0.10, DCM). 1H NMR (CDCl3, 
600 MHz, 27 °C): δ = 7.92–7.88 (m, 4H, ArH), 7.53–7.48 (m, 4H, ArH), 7.48–7.43 (m, 1H, 
ArH), 7.04 (dd, J = 7.9, 7.9 Hz, 1H, ArH), 6.89 (d, J = 7.2 Hz, 1H, ArH), 6.62 (dd, J = 7.9, 
1.0 Hz, 1H, ArH), 4.72 (s, 2H, OCH2), 4.63 (br s, 1H, OH), 3.68–3.65 (m, 1H, CH), 2.86 (d, 
J = 18.0 Hz, 1H, CH), 2.71 (dd, J = 13.3, 6.6 Hz, 1H, CH), 2.65 (d, J = 6.0 Hz, 1H, CH), 
2.53−2.46 (m, 2H, 2 x CH), 2.35 (dd, J = 13.3, 4.8 Hz, 1H, CH), 2.14–2.07 (m, 2H, 2 x CH), 
1.32–1.29 (m, 6H, 2 x CH3), 1.23 (d, J = 6.2 Hz, 3H, CH3), 1.07–1.01 (m, 1H, CH), 0.81 (s, 3H, 
CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 152.7, 152.0, 151.2, 145.9, 142.6, 130.8, 
129.0, 127.9, 126.5, 123.4, 122.8, 122.8, 117.7, 111.6, 73.6, 70.5, 62.7, 61.6, 46.1, 38.9, 37.8, 
36.6, 23.6, 23.2, 20.4, 19.4, 18.8 ppm. IR (neat, ATR): ṽ = 3345 (m), 2966 (m), 2924 (s), 2814 
(m), 1605 (w), 1584 (m), 1485 (w), 1465 (vs), 1415 (w), 1388 (m), 1372 (m), 1338 (m), 1277 
(s), 1256 (m), 1220 (m), 1201 (m), 1165 (m), 1153 (m), 1131 (m), 1098 (s), 1072 (vs), 1034 
(m), 1014 (m), 972 (w), 944 (w), 921 (w), 909 (m), 829 (m), 786 (m), 766 (m), 731 (m), 720 
(m), 688 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C31H38N3O2]+: 484.2964, found: 
484.2959 ([M+H]+). UV/Vis: λmax = 328, 435 nm. 
 
Synthesis of (S)-methyl 2-((3-(phenyldiazenyl)benzyl)oxy)propanoate (4.29) 
 
 
 
Freshly prepared Ag2O (0.84 g, 3.6 mmol, 1.0 equiv.) was added to a solution of (−)-methyl 
L-lactate (0.69 mL, 7.3 mmol, 2.0 equiv.) and bromide 4.21 (1.00 g, 3.63 mmol, 1.0 equiv.) in 
THF (30 mL). The reaction mixture was heated to 50 °C for 16 h and then filtered through 
Celite and thoroughly washed with DCM. The solvent was removed under reduced pressure and 
the crude product was purified by flash silica gel column chromatography (hexanes/EtOAc, 
gradient from 50:1 to 10:1), affording ether 4.29 (433 mg, 1.45 mmol, 40%) as a red oil.  
TLC (hexanes/EtOAc, 10:1): Rf = 0.26. [α]D22: –79.0 (c = 0.20, CHCl3). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.97–7.83 (m, 4H, ArH), 7.58–7.48 (m, 5H, ArH), 4.83 (d, J = 12.2 Hz, 
1H, CH), 4.58 (d, J = 12.2 Hz, 1H, CH), 4.15 (q, J = 6.8 Hz, 1H, CH), 3.80 (s, 3H, OCH3), 1.50 
(d, J = 6.8 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 173.6, 152.8, 152.6, 
138.8, 131.0, 130.3, 129.2, 129.1, 122.9, 122.5, 122.0, 74.3, 71.6, 52.0, 18.7 ppm. IR (neat, 
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ATR): ṽ = 1747 (s), 1586 (w), 1447 (m), 1395 (w), 1371 (w), 1272 (m), 1205 (m), 1140 (s), 
1118 (s), 1067 (m), 1021 (m), 975 (w), 923 (w), 890 (w), 834 (w), 795 (m), 764 (m), 692 
(vs) cm-1. HRMS (EI+): m/z calcd. for [C17H18N2O3]+: 298.1317, found: 298.1311 ([M]+). 
 
Synthesis of (S)-2-((3-(phenyldiazenyl)benzyl)oxy)propanoic acid (4.30) 
 
 
 
Methyl ester 4.29 (380 mg, 1.27 mmol, 1.0 equiv.) was dissolved in THF (25 mL) and a 1 M 
solution of LiOH in H2O (3.81 mL, 3.81 mmol, 3.0 equiv.) was added. The reaction mixture 
was stirred for 20 h at room temperature. The mixture was diluted with H2O (10 mL) and 
washed with EtOAc (15 mL). The aqueous phase was then acidified to pH = 2–3 with 1 M HCl 
and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. Pure carboxylic acid 4.30 was obtained in 100% yield (361 mg, 
1.27 mmol) as a red oil.  
[α]D22: –58.0 (c = 0.20, CHCl3). 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 10.10 (br s, 1H, 
CO2H), 7.96–7.84 (m, 4H, ArH), 7.56–7.44 (m, 5H, ArH), 4.83 (d, J = 11.7 Hz, 1H, CH), 4.63 
(d, J = 11.7 Hz, 1H, CH), 4.18 (q, J = 6.9 Hz, 1H, CH), 1.55 (d, J = 6.9 Hz, 3H, CH3) ppm. 
13C NMR (CDCl3, 100 MHz, 27 °C): δ = 178.0, 152.8, 152.6, 138.3, 131.1, 130.3, 129.3, 
129.1, 122.9, 122.7, 122.0, 73.8, 71.7, 18.4 ppm. IR (neat, ATR): ṽ = 3060 (w), 2987 (w), 2878 
(w), 1717 (s), 1462 (w), 1447 (m), 1372 (w), 1327 (w), 1306 (w), 1234 (m), 1197 (w), 1114 (s), 
1064 (m), 1020 (m), 909 (m), 795 (m), 764 (m), 731 (m), 691 (vs) cm-1. HRMS (EI+): m/z 
calcd. for [C16H16N2O3]+: 284.1161, found: 284.1156 ([M]+). 
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Synthesis of (S)-1-((2R,6S)-10-hydroxy-6,11,11-trimethyl-1,2,5,6-tetrahydro-2,6-methano- 
benzo[d]azocin-3(4H)-yl)-2-((3-(phenyldiazenyl)benzyl)oxy)propan-1-one (4.31)[gg] 
 
 
 
Carboxylic acid 4.30 (100 mg, 0.350 mmol, 1.0 equiv.) was dissolved in DCM (10 mL) and 
oxalyl chloride (0.88 mL, 2 M in DCM, 1.8 mmol, 5.0 equiv.) and DMF (5 drops) were added. 
The mixture was stirred at room temperature for 1 h and then concentrated in vacuo. The crude 
residue was coevaporated with toluene (2 x 5 mL), dissolved in DCM (10 mL) and cooled to 
0 °C. This solution was added to a solution of the HBr salt of amine 4.25 (219 mg, 0.700 mmol, 
2.0 equiv.) and DIPEA (0.30 mL, 1.8 mmol, 5.0 equiv.) in DCM (10 mL) at 0 °C. The reaction 
mixture was warmed to room temperature and stirred for 2 h. A sat. aqu. solution of NH4Cl 
(30 mL) was added and the aqueous layer was extracted with EtOAc (3 x 15 mL). The 
combined organic phases were washed with NH4Cl (3 x 30 mL) and brine (30 mL), dried over 
MgSO4 and the solvent was removed under reduced pressure. The crude product was purified 
by flash silica gel column chromatography (hexanes/EtOAc, 2:1 → 3:2) to give amide 4.31 
(149 mg, 0.300 mmol, 86%) as a mixture of trans/cis isomers as a red oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.40. [α]D22: –90.0 (c = 0.10, DCM). 1H NMR (CDCl3, 
400 MHz, 27 °C; major isomer): δ = 7.93–7.86 (m, 4H, ArH), 7.53–7.46 (m, 5H, ArH), 
7.06−7.02 (m, 1H, ArH), 6.90–6.86 (m, 1H, ArH), 6.64 (dd, J = 7.9, 1.0 Hz, 1H, ArH), 5.63 (s, 
1H, OH), 4.78 (d, J = 6.6 Hz, 1H, CH), 4.66 (d, J = 12.2 Hz, 1H, CH), 4.57 (d, J = 12.2 Hz, 1H, 
CH), 4.41–4.37 (m, 1H, CH), 3.85 (dd, J = 14.4, 5.6 Hz, 1H, CH), 3.08 (dd, J = 18.7, 6.7 Hz, 
1H, CH), 2.85 (td, J = 14.0, 3.6 Hz, 1H, CH), 2.57 (d, J = 18.6 Hz, 1H, CH), 2.05–1.97 (m, 1H, 
CH), 1.66 (s, 1H, CH), 1.45 (d, J = 6.8 Hz, 3H, CH3), 1.13 (s, 3H, CH3), 0.87 (s, 3H, CH3) ppm. 
13C NMR (CDCl3, 100 MHz, 27 °C): δ = 171.2, 170.6, 152.8, 152.7, 152.6, 152.5, 152.1, 
152.0, 144.1, 143.9, 138.9, 138.9, 131.1, 130.4, 129.2, 129.1, 128.8, 128.7, 127.1, 127.0, 122.9, 
122.9, 122.6, 122.5, 122.2, 122.1, 122.0, 121.8, 121.8, 120.5, 117.5, 117.5, 112.4, 112.3, 77.2, 
                                                
[gg] Compound 4.31 was obtained as an approx. 2:1 mixture of two isomers, probably due to the 
sterically biased amide bond, as temperature-dependent NMR experiments and the literature (see Grauert 
et al.[23]) suggested. Thus, two sets of signals were observed in the NMR spectra of 4.31. Whereas the 
signals of the major isomer could be clearly assigned in the 1H NMR spectrum, the 13C NMR could not be 
interpreted. Therefore, all peaks of both isomers are provided. 
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75.0, 73.5, 70.7, 70.1, 56.8, 52.5, 39.2, 38.9, 38.8, 36.7, 36.2, 36.0, 35.9, 35.7, 28.5, 27.4, 22.7, 
22.5, 22.3, 21.8, 20.4, 20.1, 17.7 ppm. IR (neat, ATR): ṽ = 3235 (w), 2979 (w), 2935 (w), 1619 
(s), 1583 (s), 1466 (s), 1392 (w), 1374 (m), 1342 (m), 1281 (m), 1256 (m), 1230 (m), 1205 (m), 
1149 (m), 1105 (m), 1071 (m), 1023 (m), 981 (w), 969 (w), 946 (w), 909 (m), 835 (w), 787 (m), 
764 (m), 730 (vs), 693 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C31H36N3O3]+: 498.2757, found: 
498.2749 ([M+H]+).  
 
Synthesis of (2R,6S)-6,11,11-trimethyl-3-((S)-2-((3-phenyldiazenyl)benzyl)oxy)-propyl)-
1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocin-10-ol (m-ACRO) 
 
 
 
Amide 4.31 (137 mg, 0.280 mmol, 1.0 equiv.) was dissolved in THF (10 mL) and LiAlH4 
(21 mg, 0.56 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room 
temperature for 1 h. The mixture was quenched with H2O and a sat. aqu. solution of Rochelle’s 
salt was added (10 mL) and vigorously stirred for 30 min. The phases were separated and the 
aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic phases were 
washed with brine (20 mL), dried over MgSO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash silica gel column chromatography 
(hexanes/EtOAc, 3:1 → 2:1), yielding amine m-ACRO (87 mg, 0.18 mmol, 64%) as a red oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.73. [α]D22: –46.0 (c = 0.10, DCM). 1H NMR (CDCl3, 
400 MHz, 27 °C): δ = 7.95–7.90 (m, 3H, ArH), 7.86–7.81 (m, 1H, ArH), 7.55–7.45 (m, 5H, 
ArH), 7.05 (dd, J = 7.9, 7.9 Hz, 1H, ArH), 6.88 (d, J = 6.9 Hz, 1H, ArH), 6.62 (dd, J = 7.9, 
1.1 Hz, 1H, ArH), 4.80–4.70 (m, 2H, OCH2), 3.74–3.67 (m, 1H, CH), 2.87 (d, J = 18.2 Hz, 1H, 
CH), 2.73 (dd, J = 13.3, 6.7 Hz, 1H, CH), 2.68 (d, J = 5.9 Hz, 1H, CH), 2.54–2.45 (m, 2H, 
2 x CH), 2.37 (dd, J = 13.3, 4.7 Hz, 1H, CH), 2.15–2.07 (m, 2H, 2 x CH), 1.34–1.27 (m, 6H, 
2 x CH3), 1.24 (d, J = 6.2 Hz, 3H, CH3), 1.08–0.99 (m, 1H, CH), 0.80 (s, 3H, CH3) ppm. 
13C NMR (CDCl3, 100 MHz, 27 °C): δ = 152.7, 152.6, 151.3, 145.8, 140.4, 131.0, 130.1, 
129.1, 126.5, 123.4, 122.8, 122.0, 121.8, 120.5, 117.6, 111.6, 73.5, 70.6, 62.6, 61.5, 46.2, 38.9, 
37.8, 36.5, 23.6, 23.3, 20.4, 19.4, 18.8 ppm. IR (neat, ATR): ṽ = 3356 (w), 2967 (w), 2925 (w), 
1585 (m), 1490 (w), 1465 (m), 1373 (m), 1338 (m), 1269 (s), 1221 (w), 1198 (s), 1154 (s), 1129 
(m), 1110 (m), 1098 (m), 1034 (m), 1006 (m), 988 (w), 944 (w), 922 (w), 909 (w), 843 (w), 788 
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(s), 762 (m), 735 (m), 721 (m), 694 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C31H38N3O2]+: 
484.2964, found: 484.2960 ([M+H]+). UV/Vis: λmax = 325, 435 nm. 
 
 
4.6.5 SYNTHESIS OF MS1 
 
Synthesis of (2-hydroxy-3-methoxyphenyl)(pyrrolidin-1-yl)methanone (4.34) 
 
 
 
Benzotriazole (1.88 g, 15.8 mmol, 3.15 equiv.) was dissolved in THF (30 mL) and SOCl2 
(0.36 mL, 5.0 mmol, 1.0 equiv.) was added. The mixture was stirred at room temperature for 
45 min. A solution of 2-hydroxy-3-methoxybenzoic acid (841 mg, 5.00 mmol, 1.0 equiv.) in 
THF (20 mL) was added rapidly and the mixture stirred for 2 h at room temperature. In a 
separate flask, pyrrolidine (0.61 mL, 7.5 mmol, 1.5 equiv.) and TEA (1.04 mL, 7.50 mmol, 
1.5 equiv.) were dissolved in THF (5 mL). To this flask was added the supernatant of the 
2-hydroxy-3-methoxybenzoic acid benzotriazole amide containing flask rapidly via a syringe. 
The remaining solid was washed with THF (12.5 mL) and the supernatant was again transferred 
to the reaction flask. The reaction mixture was stirred for 30 min at room temperature. The 
solvent was removed under reduced pressure and the residue was taken up in EtOAc (30 mL). 
The organic layer was washed with water (50 mL), 1 M HCl (3 x 50 mL) and brine (50 mL), 
then dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash silica gel column chromatography (hexanes/EtOAc, gradient from 4:1 to 2:3) 
to give amide 4.34 (286 mg, 1.29 mmol, 26%) as a colorless oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.29. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.05 (dd, 
J = 8.0, 1.5 Hz, 1H, ArH), 6.93 (dd, J = 8.0, 1.5 Hz, 1H, ArH), 6.78 (dd, J = 8.0, 8.0 Hz, 1H, 
ArH), 3.89 (s, 3H, CH3), 3.71–3.63 (m, 4H, 2 x CH2), 1.99–1.88 (m, 4H, 2 x CH2) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 169.7, 149.3, 148.6, 119.8, 118.5, 117.8, 113.8, 
56.1 ppm.[hh] IR (neat, ATR): ṽ = 3209 (w), 2966 (w), 2880 (w), 1604 (s), 1576 (s), 1480 (s), 
1446 (vs), 1428 (vs), 1361 (w), 1340 (w), 1250 (vs), 1187 (w), 1071 (m), 1033 (w), 973 (w), 
                                                
[hh] Due to extensive broadening, the two pyrrolidine carbon atoms of 4.34 could not be observed in 
the 13C NMR spectrum. 
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948 (w), 913 (w), 838 (w), 819 (w), 793 (w), 749 (w), 720 (w), 664 (w) cm-1. HRMS (EI+): m/z 
calcd. for [C12H15NO3]+: 221.1052, found: 221.1036 ([M]+). 
 
Synthesis of (3-methoxy-2-((4-(phenyldiazenyl)benzyl)oxy)phenyl)(pyrrolidin-1-yl)-
methanone (MS1) 
 
 
 
Phenol 4.34 (267 mg, 1.21 mmol, 1.0 equiv.) and K2CO3 (669 mg, 4.84 mmol, 4.0 equiv.) were 
dissolved in DMF (12 mL). Bromide 4.18 (666 mg, 2.42 mmol, 2.0 equiv.) was added and the 
mixture was stirred for 30 min at room temperature, then heated to 60 °C for 4 h. The solvent 
was removed in vacuo and the residue taken up in DCM (30 mL). The organic layer was 
washed with water (2 x 50 mL) and brine (3 x 50 mL), then dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by flash silica gel column 
chromatography (CHCl3/MeOH, 100:0 → 100:1) to give MS1 (500 mg, 1.20 mmol, 99%) as a 
red oil. 
TLC (CHCl3/MeOH, 20:1): Rf = 0.53. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.93–7.87 
(m, 4H, ArH), 7.60–7.55 (m, 2H, ArH), 7.53–7.42 (m, 3H, ArH), 7.10 (dd, J = 8.2, 7.6 Hz, 1H, 
ArH), 6.94 (dd, J = 8.2, 1.4 Hz, 1H, ArH), 6.90 (dd, J = 7.6, 1.4 Hz, 1H, ArH), 5.10 (s, 2H, 
CH2), 3.87 (s, 3H, CH3), 3.60 (t, J = 7.0 Hz, 2H, CH2), 3.28–3.18 (m, 2H, CH2), 1.90–1.82 (m, 
2H, CH2), 1.77−1.73 (m, 2H, CH2) ppm.[ii] 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 167.2, 
152.8, 152.6, 152.2, 143.8, 140.7, 133.3, 130.9, 129.0, 128.7, 125.1, 122.8, 122.8, 119.1, 112.9, 
75.4, 55.8, 47.8, 45.6, 25.7, 24.6 ppm. IR (neat, ATR): ṽ = 2971 (w), 2874 (w), 1670 (w), 1619 
(m), 1472 (m), 1442 (m), 1425 (m), 1371 (w), 1340 (w), 1302 (w), 1266 (m), 1214 (m), 1183 
(w), 1153 (w), 1103 (w), 1070 (m), 1010 (m), 986 (m), 950 (w), 926 (w), 831 (w), 798 (w), 783 
(w), 746 (vs), 687 (m), 663 (m) cm-1. HRMS (ESI+): m/z calcd. for [C25H26N3O3]+: 416.1974, 
found: 416.1965 ([M+H]+). UV/Vis: λmax = 328, 444 nm. 
 
 
 
 
                                                
[ii] MS1 was obtained as a 10:1 mixture of trans : cis isomers as indicated by 1H NMR spectrum. 
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4.7 NMR SPECTRA 
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5 STUDIES TOWARD PHOTOSWITCHABLE MGLUR6 
AGONISTS AS A POTENTIAL APPROACH TO VISION 
RESTORATION 
 
5.1 THE METABOTROPIC GLUTAMATE RECEPTOR 6 
 
The metabotropic glutamate receptor 6 (mGluR6) is a G-protein coupled receptor (GPCR) that 
belongs to the group III mGluRs. It consists of a large (500–600 amino acids) N-terminal 
extracellular domain, a seven transmembrane (TM) domain and a C-terminal intracellular 
domain (Fig. 5.1a).[1] Its natural agonist glutamate  binds to the extracellular domain according 
to the so-called “venus flytrap”-model[2]  and has an EC50 value of 20 µM.[3] mGluR6 is believed 
to be expressed solely in ON bipolar cells in the retina, although recent studies revealed that 
mGluR6 might have different expression patterns in zebrafish.[4] It is responsible for the 
synaptic transmission and mediation from the photoreceptors to the ganglion cells of the ON 
response in the ON pathway of the vertebrate retina. On the contrary, in OFF bipolar cells 
located AMPA receptors mediate the OFF response. These two pathways respond oppositely to 
the absorption of light by the photoreceptors which leads to a decrease of glutamate release to 
the bipolar cells. Whereas this decrease of glutamate leads to less excitation in the 
AMPA-mediated OFF bipolar pathway, another (yet not fully understood) sign inversion occurs 
in the mGluR6-mediated ON bipolar cells, leading to an increase in excitation. It is important to 
note that in the ON pathway the signal of light absorption is transduced with double sign 
inversion, whereas for the OFF pathway only one inversion occurs. As a consequence, an 
agonist for mGluR6 would mimic the response to darkness (Fig. 5.1b).[5] A more detailed plan 
of the retina and its function can be found elsewhere.[6] 
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Figure	  5.1.	  	   Schematic	   illustration	  of	  a)	  the	  structure	  of	  mGluR6	  and	  b)	  signal	  transduction	  in	  the	  
ON-­‐	  and	  OFF-­‐pathways	  in	  the	  vertebrate	  retina,	  respectively.	  Illustrations	  copied	  from	  Nakanishi	  et	  al.,[5]	  
reprinted	  with	  permission	  from	  Elsevier.	  Copyright	  1998.	  	  
	  
Since mGluR6 is thought to be expressed solely in the retina, it is an ideal target receptor for the 
optochemical approach toward vision restoration. Undesired side effects could be reduced 
significantly by naturally avoiding drug distribution problems as well as receptor selectivity 
problems with an mGluR6-selective photoswitch. To date, no crystal structure of mGluR6 has 
been published. Hence, a literature search for known agonists and antagonists and their 
structure–activity relationships was conducted in order to identify promising target molecules 
which could be turned into possible photoswitches to control mGluR6 by introduction of an 
azobenzene moiety to the molecules. The azobenzene linkers could in principle be attached not 
only in the para, but also in meta or even ortho position with respect to the azo moiety. An 
overview of these is given in figures 5.2 and 5.3 with only the para-substituted azobenzenes 
shown for simplicity reasons. All of these compounds mimic the structure of the endogenous 
ligand glutamate with slight alterations in the molecule’s geometry (e.g. sp2 centers, ring fusion) 
or replacement of a functional group by a similar one (e.g. phosphate). 1-Benzyl-APDC is the 
most promising compound since it is the only selective mGluR6 agonist known and has a EC50 
value of 20 µM.[7] Moreover, some phenylglycine derivatives are known as agonists for 
mGluR6: the carboxy derivative (S)-3,4-DCPG[8] as well as the hydroxy derivatives 
3C5HPG,[8b] 4Cl-3,5-DHPG,[8b] and (S)-3,5-DHPG.[8b] As a highly potent agonist, the phosphate 
derivative L-AP4 was identified (EC50 = 0.2 µM).[8b,9] 
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Figure	  5.2.	   	  Structures	  of	  mGluR6	  agonists	  and	  their	  possible	  azobenzene	  derivatives.	  
 
Furthermore, Homo-AMPA (EC50 = 82 µM),[10] the elongated analogue of the iGluR agonist 
AMPA,[11] could be modified on two positions to introduce the azobenzene unit, either by 
C-alkylation on the isoxazole ring, or by O-alkylation of the hydroxy group.[12] More interesting 
agonists include the cyclopropylphosphate PPCG-2[13] and the tricarboxylic acid ACPT-I (Fig. 
5.3)[14] 
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Figure	  5.3.	   Structures	   of	   mGluR6	   agonists	   Homo-­‐AMPA,	   PPCG-­‐2,	   ACPT-­‐I	   and	   their	   possible	  
azobenzene	  derivatives.	  
 
 
5.2 AZO-APDC 
 
As described above, 1-benzyl-APDC was reported by Tückmantel et al.[7] to be a selective 
agonist for mGluR6. For this reason and in addition for its ideal molecular anchor point for an 
azobenzene moiety at the pyrrolidine nitrogen atom thereby replacing the benzyl group, it was 
chosen as the prime candidate for the approach toward optochemical control of mGluR6. 
Therefore, both para- as well as meta-Azo-APDC were synthesized and biologically evaluated. 
 
Synthesis of Azo-APDCs 
 
Both Azo-APDC derivatives were synthesized starting from cis-4-hydroxy-D-proline (5.1) 
which was first converted to its ethyl ester using thionyl chloride in ethanol, followed by benzyl 
protection of the secondary amine yielding 5.2 in 77% over two steps. Oxidation of the 
secondary alcohol under Swern conditions gave ketone 5.3 in 92% yield. A Bucherer-Bergs 
reaction with potassium cyanide and ammonium carbonate led to hydantoin 5.4 as a mixture of 
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diastereomers in 51% yield. Hydantoin cleavage with sodium hydroxide, followed by 
reesterification with thionyl chloride in methanol gave a mixture of two amino diester 
diastereomers. The desired major diastereomer 5.5 could be separated at that stage and was 
obtained in 24% yield over two steps (Scheme 5.1).  
 
Scheme	  5.1.	   Synthesis	  of	  protected	  amino	  acid	  5.5	  via	  a	  Bucherer-­‐Bergs	  reaction	  as	  the	  key	  step.	  
 
The diastereoselectivity of the Bucherer-Bergs reaction of 4-oxoprolines can be explained by 
the model studies by Tanaka et al.[15] which are illustrated in Fig 5.4. The hydantoin is formed 
as a mixture of two diastereomers A and B. Depending on the steric bulk provided by the ester 
function shielding the upper face of the molecule, formation of transition state A is favored over 
B due to steric interaction of the ester and the imine functions. Whereas the combined yield of 
A and B for this reaction stays in the same range (70–75%), the ratio of A to B steadily 
increases from 75 : 25 for the sterically less demanding methyl ester up to 96 : 4 for the bulky 
tert-butyl ester. 
 
Figure	  5.4.	   Model	   studies	   explain	   the	   diastereoselectivity	   of	   the	   Bucherer-­‐Bergs	   reaction	   of	  
4-­‐oxoproline	  derivatives.	  Bulky	  ester	  groups	  shield	  the	  upper	  face	  of	  the	  molecule	  and	  therefore	  favor	  
hydantoin	  formation	  from	  the	  bottom	  face.	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Having obtained 5.5, the primary amino group was Boc protected yielding 5.6 in 99% yield, 
followed by benzyl deprotection of the tertiary amine using palladium on charcoal and 
ammonium formate as hydrogen source. Secondary amine 5.7 was obtained in 98% yield 
(Scheme 5.2). 
 
 
Scheme	  5.2.	   Synthesis	  of	  secondary	  amine	  5.7.	  
 
Amine 5.7 was then reacted with bromide 4.18 to give tertiary amine 5.10 in 77% yield. 
Saponification of the methyl ester using LiOH, followed by deprotection of the Boc group with 
HCl in ethyl acetate gave p-Azo-APDC in 62% over two steps (Scheme 5.3). 
 
 
Scheme	  5.3.	   Synthesis	  of	  p-­‐Azo-­‐APDC	  from	  amine	  5.7	  and	  para-­‐azobenzene	  bromide	  4.18. 
 
Accordingly, 5.9 was synthesized from amine 5.7 and meta-bromide 4.21 in 63% yield. Global 
deprotection afforded m-Azo-APDC in 93% yield over two steps (Scheme 5.4). 
 
 
Scheme	  5.4.	   Synthesis	  of	  m-­‐Azo-­‐APDC	  from	  amine	  5.7	  and	  meta-­‐azobenzene	  bromide	  4.21. 
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Biological Evaluation of Azo-APDCs 
 
The peak absorption wavelengths and photoswitching properties of both Azo-APDCs were 
determined by UV/Vis spectroscopy in DMSO (Fig. 5.5a+b). Both Azo-APDCs are non-red-
shifted azobenzenes and thus show peak absorptions for the trans→cis transition in the UV 
range at λ = 323 nm (p-Azo-APDC) and λ = 324 nm (m-Azo-APDC). The trans→cis transition 
peaks are found at λ = 420 nm (p-Azo-APDC) and λ = 440 nm (m-Azo-APDC), respectively. 
The trans→cis isomerization process appears to proceed faster for m-Azo-APDC than for the 
para derivative. 
 
 
Figure	  5.5.	   a)	  UV/Vis	  spectrum	  of	  p-­‐Azo-­‐APDC	  (DMSO).	  The	  absorption	  maxima	  are	  at	  λ	  =	  323	  and	  
λ	  =	  420	  nm	  for	  the	  trans→cis	  and	  cis→trans	  transition,	  respectively.	  b)	  UV/Vis	  spectrum	  of	  m-­‐Azo-­‐APDC	  
(λmax	  =	  324,	   440	  nm;	   DMSO).	   c)	   Electrophysiolocigal	   trace	   of	   GIRK-­‐coupled	   mGluR6	   in	   HEK	   293	   cells.	  
Stimulation	   of	   saturated	   glutamate	   (Glu;	   1	  mM),	   followed	   by	   100	   µM	   p-­‐Azo-­‐APDC	   in	   its	   trans	  
conformation	   leading	   to	   a	   current	   increase	   of	  ∼40%	   compared	   to	   Glu	   (Benjamin	   Gaub,	   University	   of	  
California,	  Berkeley).	  
	  
Figure 5.5c shows an electrophysiological trace of GIRK-coupled mGluR6 in HEK 293 cells 
(Benjamin Gaub, University of California, Berkeley). 100 µM p-Azo-APDC elicits ~40% of 
saturated glutamate (1mM) current, proving moderate agonist activity of the azo derivative. 
However, the kinetics were determined to be rather slow compared to glutamate. Moreover, no 
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significant photoswitching effects could be observed in related experiments (data not shown). 
The meta derivative did not show any agonist activity (no data shown). 
 
 
5.3 AZO-3C5HPG 
 
In their structure–activity relationship of different mGluRs, Sekiyama et al.[8b] report (racemic) 
3C5HPG as a good agonist for mGluR6 in CHO cells. 3C5HPG (which stands for 
3-carboxy-5-hydroxyphenylglycine) has the glutamate backbone incorporated into a benzene 
ring with an additional hydroxy function that could be used as an anchor point for the 
attachment of an azobenzene linker. Accordingly, both the para- and meta-azobenzene 
derivatives were synthesized and tested for their activity on mGluR6. 
 
Synthesis of Azo-3C5HPGs 
 
The synthesis of p-Azo-3C5HPG is illustrated in Scheme 5.5. The azobenzene linker was 
introduced early on in the synthesis: Dimethyl 5-hydroxyisophthalate was etherified using 
azobenzene bromide 4.18 and potassium carbonate, yielding 5.10 in 98% yield. Monoreduction 
of the symmetric diester 5.10 with LiAlH4 gave primary alcohol 5.11 in 61% yield (81% brsm), 
recovering 25% of the starting material (the doubly reduced diol was obtained as a side product 
in 5%). Benzylic oxidation with MnO2 gave aldehyde 5.12 in 89% yield which was then 
converted to aminonitrile 5.13 under Strecker conditions using TMSCN and ammonia in very 
good yield (77%). Compound 5.13 was then subjected to Pinner conditions affording amino 
acid methyl ester 5.14 in 52% yield. p-Azo-3C5HPG was finally obtained after saponification 
of the two esters with LiOH in 54% yield. 
During this synthesis it was observed that conversion of aldehyde 5.12 into aminonitrile 5.13 
required relatively long reaction times. In first attempts the reaction was stopped after 1 h as 
TLC analysis indicated full conversion of the starting material into a new product which turned 
out to be cyanohydrin 5.15 which was obtained in 74% yield (Scheme 5.6). Apparently, attack 
of the cyanide at the carbonyl group is relatively fast but reversible. Hence, the thermodynamic 
product 5.13 is formed after first reaction of the aldehyde with ammonia to the corresponding 
imine and subsequent nucleophilic attack of cyanide.  
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Scheme	  5.5.	  	   Synthesis	  of	  p-­‐Azo-­‐3C5HPG.	  
 
	  
	  
Scheme	  5.6.	  	   Conversion	  of	  aldehyde	  5.12	  into	  cyanohydrin	  5.15.	  
 
Crucial for the success of the synthesis was the relatively mild conversion of aldehyde 5.12 via 
aminonitrile 5.13 to the corresponding amino methyl ester 5.14 through a Pinner reaction with 
HCl in MeOH. Other attempts to install the amino acid moiety requiring harsher conditions 
(Strecker synthesis, Bucherer-Bergs reaction) failed. Fig. 5.6 gives an overview of classical 
methods to install amino acid functions. In the classical Strecker synthesis a carbonyl 5.16 is 
converted to an aminonitrile 5.17 using ammonia and a cyanide source. The nitrile is then 
hydrolyzed usually with refluxing conc. HCl to give the amino acid 5.18. Another method 
CO2Me
CO2MeHO
CO2Me
CO2MeO
NN
CO2Me
O
NN
OH
CO2Me
O
NN
O
CO2H
O
NN NH2
CO2H
p-Azo-3C5HPG
acetone, rt, 16 h
MnO2 TMSCN, NH3
MeOH/DCM, rt, 36 h
LiAlH4
THF, rt, 4 h
(98%) (81% brsm)
DCM, rt, 16 h
(89%) (77%)
CO2Me
O
NN
CN
NH2
CO2Me
O
NN
CO2Me
NH21) HCl, MeOH, 0 °C, 1 h
2) H2O, rt, 12 h
(52%)
LiOH
THF, rt, 16 h
(54%)
5.13 5.14
5.10
4.18, K2CO3, BU4NI
5.11 5.12
H
CO2Me
O
NN
O
CO2Me
O
NN
CN
OH
5.12 5.15
TMSCN, NH3
MeOH/DCM, rt, 1 h
(74%)
H
5     STUDIES TOWARD PHOTOSWITCHABLE MGLUR6 AGONISTS AS A POTENTIAL 
        APPROACH TO VISION RESTORATION 
 
 
 
351 
avoiding acidic conditions is the Bucherer-Bergs reaction in which 5.16 is reacted first with 
ammonium carbonate and cyanide to form hydantoin 5.19 which then can be cleaved using 
strongly basic conditions and high temperatures to give amino acid 5.18. The Pinner reaction 
proceeds over the same aminonitrile 5.17 as in the Strecker synthesis. However, instead of harsh 
hydrolysis conditions, 5.17 is converted to the so-called Pinner salt with HCl in low 
concentration in anhydrous alcohols at 0 °C within 30 min. 
 
 
Figure	  5.6.	   Methods	   for	   amino	   acid	   synthesis:	   Strecker	   synthesis,	   Bucherer-­‐Bergs	   and	   Pinner	  
reaction.	  
 
The Pinner salt is a versatile starting material to access a variety of functional groups. By 
adding K2CO3 to Pinner salts imidates can be obtained. Hydrolysis gives rise to esters, whereas 
H2S and pyridine give thioesters. Addition of ammonia in alcohols leads to the corresponding 
amidinium salts (Fig. 5.7).  
In case of α-amino-substituted Pinner salts oligomerization and eventual dealkylations can 
occur as side reactions which possibly explains the yields in the range between 50 and 60% 
reliably obtained in these syntheses. 
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Figure	  5.7.	   Possible	   reactions	   of	   Pinner	   salts:	   Syntheses	   of	   imidates,	   esters,	   thioesters	   or	  
amidinium	  salts. 
 
Having obtained cyanohydrin 5.15 accidentally during the synthesis, 5.15 was used as a model 
system for the Pinner reaction. Compound 5.15 was treated with HCl in methanol at 0 °C for 
45 min, followed by aqueous workup to yield methyl ester 5.20 in 17% (Scheme 5.7). Later, the 
yields of this reaction were improved by prolonged reaction times after the addition of water. 
 
 
Scheme	  5.7.	  	   Pinner	  reaction	  of	  model	  system	  5.15.	  
 
In earlier attempts to install the amino acid function, the simpler aldehyde 5.23 was synthesized 
(Scheme 5.8). First, dimethyl 5-hydroxyisophthalate was TBS-protected in 94% yield using 
TBSCl and imidazole. Compound 5.21 was then reduced with LiAlH4 to alcohol 5.22 in 56% 
yield (81% brsm). Benzylic oxidation with MnO2 gave aldehyde 5.23 in 93% yield. However, 
neither Strecker nor Bucherer-Bergs conditions afforded amino acid derivative 5.24.   
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Scheme	  5.8.	   Attempted	   synthesis	   of	   5.24	   by	   Strecker	   or	   Bucherer-­‐Bergs	   conditions.	   R	  =	  TBS	   for	  
Bucherer-­‐Bergs	  reaction,	  R	  =	  H	  for	  Strecker	  reaction.	  
	  
The meta-derivative m-Azo-3C5HPG was synthesized according to the route shown above for 
p-Azo-3C5HPG by using the meta-azobromide 4.21 instead. Ether formation of bromide 4.21 
and dimethyl 5-hydroxyisophthalate yielded 5.25 in 86% yield. Reduction with LiAlH4 gave 
alcohol 5.26 in 59% yield, followed by MnO2-mediated oxidation to aldehyde 5.27 in 94% 
yield. Aminonitrile 5.28 was synthesized by a Strecker reaction in 31% yield (39% brsm), 
followed by a Pinner reaction, affording aminoacid methyl ester 5.29 in 60% yield. 
Saponification using LiOH finally gave rise to m-Azo-3C5HPG in 63% yield (Scheme 5.9). 
 
Scheme	  5.9.	   Synthesis	  of	  m-­‐Azo-­‐3C5HPG.	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Again, cyanohydrin 5.30 was obtained as a side product in the conversion of aldehyde 5.27 to 
aminonitrile 5.28. Even with 36 h reaction time, 5.30 was obtained in 40% yield (50% brsm). 
Compound 5.30 was then again used as a model system for a subsequent Pinner reaction, giving 
the desired product 5.31 reliably in 61% yield (Scheme 5.10). 
 
Scheme	  5.10.	   Synthesis	  of	  5.31.	  
 
 
Biological Evaluation of Azo-3C5HPGs 
 
The absorption maxima and photoswitching properties of both Azo-3C5HPGs were determined 
by UV/Vis spectroscopy (Fig. 5.8a+b; p-Azo-3C5HPG: λmax = 322, 425 nm; m-Azo-3C5HPG: 
λmax = 335, 433 nm). In electrophysiological experiments on GIRK-coupled mGluR6 in HEK 
293 cells, application of the cis isomer of p-Azo-3C5HPG (100 µM; generated by 
preillumination of the compound with UV light) lead to 10-20% of the saturated glutamate 
response (Fig. 5.8c, enlarged window; Benjamin Gaub, University of California, Berkeley). In 
the same experiment, m-Azo-3C5HPG as well as both Azo-APDCs were also tested and did not 
show significant mGluR6 agonist activity, neither in their trans nor in their cis configurations.  
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Figure	  5.8.	   a)	  UV/Vis	   spectrum	  of	  p-­‐Azo-­‐3C5HPG	  with	  absorption	  maxima	  at	  λmax	  =	  322,	  425	  nm	  
(DMSO).	  The	  transition	  between	  dark	  and	  UV	  light	  appeared	  to	  be	  relatively	  slow,	  therefore	  switching	  
between	   λ	  =	  322	  nm	   and	   λ	  =	  425	  nm	   is	   shown.	   b)	   UV/Vis	   spectrum	   of	   m-­‐Azo-­‐3C5HPG	   (λmax	  =	  335,	  
433	  nm;	  DMSO).	  c)	  Electrophysiolocigal	  trace	  of	  GIRK-­‐coupled	  mGluR6	  in	  HEK	  293	  cells	  (Benjamin	  Gaub,	  
University	   of	   California,	   Berkeley).	   Application	   of	   both	   Azo-­‐3C5HPGs	   as	   well	   as	   both	   Azo-­‐APDCs	   is	  
shown.	  Only	  cis-­‐p-­‐Azo-­‐3C5HPG	  showed	  weak	  agonist	  activity	  of	  10-­‐20%	  of	  sat.	  Glu	  (enlarged	  window).	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5.4 AZO-DCPG 
 
Synthesis of Azo-DCPG 
 
Thomas et al.[8a] reported (S)-3,4-DCPG as agonist for mGluR6 (and mGluR8a) in 2001. 
3,4-DCPG (3,4-dicarboxyphenylglycine) is another phenylglycine derivative which features the 
glutamate structure fused into a benzene backbone. The additional free 4-carboxy function 
could be used to install an azobenzene linker via an amide.  
 
 
Scheme	  5.11.	   Synthesis	  of	  regioisomers	  5.37	  and	  5.38.	  
	  
Firstly, 1,2,4-tricarboxylic anhydride was selectively reduced at the 4-position by borane and 
subsequently esterified under Fischer conditions with H2SO4 in MeOH. This literature known 
procedure[16] afforded compound 5.32 in 51% yield over two steps which was then oxidized to 
aldehyde 5.33 in 90% yield using MnO2. The aldehyde was protected at that stage by acetal 
formation with ethylene glycol and catalytic amounts of p-TsOH to afford 5.34 quantitatively. 
Saponification with LiOH gave dicarboxylic acid 5.35 in 96% yield. Acid 5.35 was then 
converted quantitatively to its anhydride 5.36 by acetic anhydride and then further reacted with 
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4-aminoazobenzene, followed by acidic acetal deprotection to yield the two regioisomers 5.37 
and 5.38 (Scheme 5.11).  
Unfortunately, only analytical quantities of the pure regioisomers could be obtained by multiple 
recrystallization efforts from different solvents. Analysis of the (2D) NMR spectra of both 
isomers allowed for identification and assignment of the two isomers. In the 1H NMR spectra, 
the aldehyde protons A of 5.37 and 5.38 have the same chemical shift of 10.12 ppm. However, 
the aromatic protons B, C and D can be used to distinguish between the two isomers. For 
compound 5.38, B, C and D appear close together between 8.0 and 8.2 ppm (Fig 5.9a. bottom), 
whereas for 5.37 the singlet of proton B is shifted downfield to 8.40 ppm and the doublet of D is 
shifted upfield to 7.80 ppm (Fig 5.9a, top). As indicated by the same chemical shifts of proton 
A, carbon atoms 2 also possess very similar chemical shifts in the 13C NMR spectra (137.0 ppm 
vs. 138.0 ppm). Carbons 1, 3 and 4, which also share the same direct environment for both 
regioisomers, appear for both compounds relatively close together a ~130 ppm (5.38: 129.5 
(C1), 130.6 (C3), 130.8 (C4) vs. 5.37: 129.4 (C4), 131.2 (C1), 132.6 ppm (C3)). Due to the 
neighboring acid and amide function, respectively, the chemical shifts for C1(5.37) and 
C4(5.38), as well as C4(5.37) and C1(5.38) are very similar. As expected, the biggest 
differences can be observed for carbon atoms 5 and 6 which are directly attached to the 
carboxylic acid and amide functions, respectively. C6 next to the carboxylic acid in isomer 5.38 
has a chemical shift of 138.7 ppm, whereas the corresponding C5 of isomer 5.37 is significantly 
downfield shifted (143.5 ppm). The C6 signal for 5.37 unfortunately could not be clearly 
identified, probably due to extensive broadening as can be seen also for the corresponding C5 
signal for compound 5.38 (Fig 5.9b). 
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Figure	  5.9.	   Regioisomers	   of	   aldehydes	   5.37	   and	   5.38.	   Signal	   assignment	   of	   the	   aromatic	   core	  
structure	  for	  both	  regioisomers	  in	  the	  a)	  1H	  NMR	  (top:	  5.37,	  bottom:	  5.38)	  and	  b)	  13C	  NMR	  spectra	  (top:	  
5.37,	  bottom:	  5.38). 
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Due to separation problems on large scale (even on HPLC), both regioisomers 5.37 and 5.38 
were used as a mixture for all further reactions in order to hopefully be able to separate them at 
a later stage. 500 mg of the mixture of regioisomeric aldehydes 5.37 and 5.38 were converted to 
the aminonitriles with TMSCN and ammonia and further reacted to the corresponding methyl 
ester via its Pinner salt using HCl in methanol. Saponification with LiOH gave the final 
products which at that stage could be separated by preparative HPLC, affording a 3:1 mixture of 
Azo-DCPG and its regioisomer 5.39 (Scheme 5.12).  
 
 
Scheme	  5.12.	   Synthesis	   of	  Azo-­‐DCPG	   and	   its	   regioisomer	   5.39	   from	   regioisomeric	   aldehydes	   5.37	  
and	  5.38.	  
Their identity was confirmed by NMR and HRMS, although unfortunately the regioisomers 
could not be assigned as no relevant cross peaks were visible in the 2D NMR spectra. 
Crystallization efforts as well as attempts to convert the major isomer to the dimethyl ester 5.40 
with TMSCHN2 in order to obtain relevant cross peaks in the 2D NMR spectra for structural 
assignment purposes have failed (Scheme 5.13). 
 
 
Scheme	  5.13.	   Attempted	  conversion	  of	  major	  isomer	  of	  Azo-­‐DCPG/5.39	  to	  the	  dimethyl	  ester	  5.40.	  
 
Nonetheless, the two regioisomers were tested individually in a biological assay similar to the 
previously described Azo-APDCs and Azo-3C5HPGs on potential activity on mGluR6. 
Unfortunately, none of the two isomers showed any activity on GIRK-coupled mGluR6 (data 
not shown). 
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5.5 EXPERIMENTAL PROCEDURES AND ANALYTICAL DATA 
 
5.5.1 GENERAL EXPERIMENTAL DETAILS AND INSTRUMENTATION 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[17] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0; DMSO-d6: δH 2.50, 
δC 39.5; D2O: δH 4.79).[18] Multiplicities are abbreviated as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, quint = quintet, sext = sextet, sept = septet, m = multiplet. High 
resolution mass spectra (EI, ESI) were recorded by LMU Mass Spectrometry Service using a 
Thermo Finnigan MAT 95, a Jeol MStation or a Thermo Finnigan LTQ FT Ultra instrument. 
Melting points were obtained using a Stanford Research Systems MPA120 apparatus and are 
uncorrected. Optical rotation measurements were performed on a Perkin Elmer 241 polarimeter 
at 22 °C in a 5 cm cell at concentrations expressed as g/100 mL. 
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5.5.2 SYNTHESIS OF AZO-APDCS 
 
Synthesis of (2R,4R)-ethyl 1-benzyl-4-hydroxypyrrolidine-2-carboxylate (5.2) 
 
 
 
Thionyl chloride (3.34 mL, 46.1 mmol, 1.2 equiv.) was added dropwise to a mixture of 
cis-4-hydroxy-D-proline (5.1) (5.00 g, 38.1 mmol, 1.0 equiv.) in ethanol (80 mL) at 0 °C. The 
solution was heated to reflux for 16 h and cooled to room temperature. The solution was diluted 
with Et2O and the resulting white solid was filtered, washed with Et2O and dried in vacuo to 
yield (2R,4R)-ethyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride (6.22 g, 31.8 mmol, 
83%). This material was directly used for the next reaction without further purification.  
Benzyl chloride (5.35 mL, 46.5 mmol, 1.5 equiv.) was added to a mixture of (2R,4R)-ethyl 
4-hydroxypyrrolidine-2-carboxylate hydrochloride (6.22 g, 31.8 mmol, 1.0 equiv.) and TEA 
(10.0 mL, 71.9 mmol, 2.3 equiv.) in DCM (60 mL). The reaction mixture was heated to reflux 
for 36 h. After cooling, 1 M NaOH (50 mL) was added and the phases were separated. The 
aqueous phase was extracted with DCM (2 x 50 mL) and the combined organic phases were 
washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by silica gel chromatography (hexanes/EtOAc, 1:1) to give the N-benzylated ethyl 
ester 5.2 (7.27 g, 29.2 mmol, 92%; 77% over two steps) as a colorless oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.37. [α]D22: +57.3 (c = 0.37, DCM). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.35–7.21 (m, 5H, ArH), 4.28–4.20 (m, 1H, CH), 4.08 (qd, J = 7.2, 
2.4 Hz, 2H, CH2), 3.88 (d, J = 13.1 Hz, 1H, CH), 3.70 (d, J = 13.1 Hz, 1H, CH), 3.39–3.25 (m, 
2H, CH, OH), 3.01 (dt, J = 9.8, 1.5 Hz, 1H, CH), 2.63 (dd, J = 9.8, 4.1 Hz, 1H, CH), 2.37 (ddd, 
J = 14.1, 9.9, 5.8 Hz, 1H, CH), 2.00–1.88 (m, 1H, CH), 1.22 (t, J = 7.2 Hz, 3H, CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 175.1, 138.1, 129.0, 128.2, 127.2, 70.9, 63.5, 61.8, 
61.0, 58.1, 39.1, 14.1 ppm. IR (neat, ATR): ṽ = 3412 (m), 1728 (s), 1496 (w), 1454 (m), 1376 
(m), 1340 (w), 1271 (w), 1194 (vs), 1085 (m), 1050 (m), 1028 (m), 974 (w), 747 (m), 700 
(s) cm-1. HRMS (EI+): m/z calcd. for [C14H19NO3]+: 249.1365, found: 249.1364 ([M]+). 
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Synthesis of (R)-ethyl 1-benzyl-4-oxopyrrolidine-2-carboxylate (5.3) 
 
 
 
Oxalyl chloride (3.67 mL, 42.8 mmol, 1.5 equiv.) was added dropwise to a solution of DCM 
(100 mL) and DMSO (4.05 mL, 57.0 mmol, 2.0 equiv.) at –78 °C. The reaction mixture was 
allowed to equilibrate for 10 min, followed by dropwise addition of a solution of alcohol 5.2 
(7.10 g, 28.5 mmol, 1.0 equiv.) in DCM (30 mL). Upon complete addition, the reaction mixture 
was stirred for 2 h at –78 °C. Then TEA (11.9 mL, 85.5 mmol, 3.0 equiv.) was added dropwise 
and the reaction mixture was allowed to warm to room temperature. The pH was adjusted to 
pH = 10 with sat. aqu. NaHCO3, the phases were separated and the aqueous phase was extracted 
with Et2O (2 x 75 mL). The combined organic phases were washed with brine (100 mL), dried 
over MgSO4 and evaporated to dryness. The crude product was purified by silica gel 
chromatography (hexanes/EtOAc, 4:1), affording ketone 5.3 (6.50 g, 26.3 mmol, 92%) as an 
orange oil. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.43. [α]D22: +32.1 (c = 0.75, DCM). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.37–7.28 (m, 5H, ArH), 4.23 (q, J = 7.1 Hz, 2H, CH2), 3.98 (d, 
J = 13.1 Hz, 1H, CH), 3.85 (dd, J = 7.7, 5.7 Hz, 1H, CH), 3.76 (d, J = 13.1 Hz, 1H, CH), 3.38 
(d, J = 17.2 Hz, 1H, CH), 3.03 (d, J = 17.2 Hz, 1H, CH), 2.74 (dd, J = 18.0, 7.7 Hz, 1H, CH), 
2.57 (dd, J = 18.0, 5.7 Hz, 1H, CH), 1.32 (t, J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 211.0, 172.0, 137.0, 128.8, 128.5, 127.6, 62.3, 61.1, 58.9, 57.4, 41.8, 
14.3 ppm. IR (neat, ATR): ṽ = 1760 (vs), 1729 (s), 1454 (w), 1374 (w), 1345 (w), 1244 (w), 
1195 (s), 1176 (s), 1132 (m), 1075 (w), 1029 (m), 753 (w), 700 (m) cm-1. HRMS (ESI+): m/z 
calcd. for [C14H18NO3]+: 248.1287, found: 248.1281 ([M+H]+). 
 
Synthesis of (2R,4R)-dimethyl 4-amino-1-benzylpyrrolidine-2,4-dicarboxylate (5.5) 
 
 
 
KCN (2.64 g, 40.5 mmol, 2.5 equiv.) was added in one portion to a solution of ketone 5.3 
(4.00 g, 16.2 mmol, 1.0 equiv.) and ammonium carbonate (4.67 g, 48.6 mmol, 3.0 equiv.) in 
ethanol (120 mL) and water (120 mL). The resulting reaction mixture was heated to 55 °C for 
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24 h. The mixture was cooled to room temperature, diluted with water (150 mL) and extracted 
with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (75 mL), dried 
over MgSO4 and the solvent was removed in vacuo to yield a mixture of both hydantoin 
diastereomers (2.63 g, 8.29 mmol, 51%) as colorless gum. 
 
An analytical sample of diastereomeric pure hydantoin 5.4 (main isomer) was obtained by flash 
silica gel chromatography (CHCl3/MeOH, 60:1) as colorless gum. 
 
 
 
TLC (CHCl3/MeOH, 50:1): Rf = 0.16. [α]D22: +63.5 (c = 0.40, DMSO-d6). 1H NMR 
(DMSO-d6, 600 MHz, 27 °C): δ = 10.63 (s, 1H, NH), 8.17 (s, 1H, NH), 7.31–7.25 (m, 4H, 
ArH), 7.24–7.18 (m, 1H, ArH), 4.10–4.01 (m, 2H, CH2), 3.93 (d, J = 13.2 Hz, 1H, CH), 3.46 (d, 
J = 13.2 Hz, 1H, CH), 3.40 (t, J = 7.8 Hz, 1H, CH), 2.89 (d, J = 10.1 Hz, 1H, CH), 2.65 (d, 
J = 10.1, 1H, CH), 2.43 (dd, J = 13.2, 7.8 Hz, 1H, CH), 2.05 (dd, J = 13.2, 9.0 Hz, 1H, CH), 
1.25 (t, J = 7.1, 3H, CH3) ppm. 13C NMR (DMSO-d6, 150 MHz, 27 °C): δ = 178.0, 172.0, 
156.6, 138.4, 129.1, 128.6, 127.5, 65.7, 65.0, 61.9, 60.9, 57.8, 40.5, 14.5 ppm. IR (neat, ATR): 
ṽ = 3242 (m), 1775 (m), 1712 (vs), 1397 (m), 1286 (m), 1190 (m), 1101 (m), 1028 (m), 749 (s), 
700 (m) cm-1. HRMS (ESI+): m/z calcd. for [C16H20N3O4]+: 318.1454, found: 318.1446 
([M+H]+). 
 
A mixture of both hydantoin diastereomers (2.40 g, 7.56 mmol, 1.0 equiv.) was dissolved in 2 M 
NaOH (50 mL) and the reaction mixture was heated to reflux for 16 h. The reaction mixture was 
then cooled to 0 °C, acidified to pH = 1 with conc. HCl and concentrated in vacuo. Methanol 
(50 mL) was added to the crude amino diacid mixture and then concentrated to dryness (5x). 
The resulting anhydrous amino diacid was then reconstituted in methanol (100 mL), cooled to 
0 °C and treated with thionyl chloride (2.20 mL, 30.3 mmol, 4.0 equiv.). Upon complete 
addition, the reaction mixture was heated to reflux for 36 h. The solids were filtered and the 
filtrate was concentrated in vacuo. The crude product was reconstituted in water (50 mL) and 
basified to pH = 8 with 1 M NaOH. The aqueous phase was then extracted with EtOAc 
(3 x 40 mL). The combined organic layers were washed with brine (75 mL), dried over MgSO4 
and evaporated to dryness to give both diastereomers in 59% yield (1.30 g, 4.45 mmol).  
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The desired diastereomeric pure methyl ester 5.5 was then obtained by flash silica gel 
chromatography (DCM/MeOH/HOAc/H2O, 95:5:0.6:0.6 → 90:10:0.6:0.6) in a total yield over 
two steps of 24% (539 mg, 1.84 mmol) as a colorless gum. 
TLC (hexanes/EtOAc, 1:4): Rf = 0.09. [α]D22: +68.7 (c = 0.21, DCM). 1H NMR (CDCl3, 
600 MHz, 27 °C): δ = 7.33–7.27 (m, 4H, ArH), 7.25–7.22 (m, 1H, ArH), 3.95 (d, J = 13.2 Hz, 
1H, CH), 3.73 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 3.58 (d, J = 13.2 Hz, 1H, CH), 3.46 (dd, 
J = 9.6, 5.4 Hz, 1H, CH), 2.90 (d, J = 9.0 Hz, 1H, CH), 2.83 (d, J = 9.0 Hz, 1H, CH), 2.77 (dd, 
J = 13.2, 9.6 Hz, 1H, CH), 2.14 (br s, 2H, NH2), 1.99 (dd, J = 13.2, 5.4 Hz, 1H, CH) ppm. 
13C NMR (CDCl3, 150 MHz, 27 °C): δ = 174.5, 173.8, 137.8, 129.0, 128.3, 127.3, 64.9, 64.3, 
63.0, 58.0, 52.5, 52.0, 42.6 ppm. IR (neat, ATR): ṽ = 3376 (w), 2952 (w), 1734 (vs), 1496 (w), 
1436 (m), 1203 (s), 1119 (m), 1028 (w), 753 (m), 702 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C15H21N2O4]+: 293.1501, found: 293.1492 ([M+H]+). 
 
Synthesis of (2R,4R)-dimethyl 1-benzyl-4-((tert-butoxycarbonyl)amino)-pyrrolidine-2,4-
dicarboxylate (5.6) 
 
 
 
Boc2O (1.15 g, 5.25 mmol, 3.0 equiv.) was added to a solution of amine 5.5 (513 mg, 
1.75 mmol, 1.0 equiv.) in DCM (12 mL). The reaction mixture was stirred at room temperature 
for 16 h. The solvent was removed in vacuo and the crude product was purified by flash silica 
gel chromatography (hexanes/EtOAc, 99:1 → 4:1 → 1:1), affording Boc-protected amine 5.6 
(677 mg, 1.73 mmol, 99%) as a colorless solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.25. M.p.: 124–125 °C. [α]D22: +29.1 (c = 0.23, DCM). 
1H NMR (CDCl3, 600 MHz, 27 °C): δ = 7.33–7.24 (m, 5H, ArH), 5.37 (br s, 1H, NH), 4.01 (br 
s, 1H, CH), 3.72 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.64–3.54 (m, 1H, CH), 3.54–3.45 (m, 1H, 
CH), 3.07 (br s, 1H, CH), 2.95–2.77 (m, 2H, CH2), 2.27 (br s, 1H, CH), 1.40 (s, 9H, 
(CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 173.2, 172.4, 155.1, 137.3, 129.0, 
128.4, 127.4, 80.1, 63.8, 63.3, 61.7, 57.9, 52.7, 52.1, 39.8, 28.2 ppm. IR (neat, ATR): ṽ = 3378 
(w), 2953 (w), 1733 (s), 1712 (vs), 1496 (m), 1367 (m), 1251 (s), 1169 (vs), 1075 (m), 749 (w), 
702 (w) cm-1. HRMS (ESI+): m/z calcd. for [C20H29N2O6]+: 393.2026, found: 393.2018 
([M+H]+). 
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Synthesis of (2R,4R)-dimethyl 4-((tert-butoxycarbonyl)amino)pyrrolidine-2,4-
dicarboxylate (5.7) 
 
 
 
Ammonium formate (523 mg, 8.30 mmol, 5.0 equiv.) was added to a solution of benzyl 
protected amine 5.6 (650 mg, 1.66 mmol, 1.0 equiv.) and Pd/C (10%, 70 mg) in methanol 
(17 mL). The resulting reaction mixture was heated to reflux for 2 h. The mixture was cooled to 
room temperature and filtered through Celite. The filtrate was concentrated in vacuo and the 
residue was purified by flash silica gel chromatography (hexanes/EtOAc, 1:4 → 0:1) to give 
amine 5.7 (490 mg, 1.62 mmol, 98%) as a colorless gum. 
TLC (EtOAc): Rf = 0.25. [α]D22: –22.9 (c = 0.11, DCM). 1H NMR (CDCl3, 600 MHz, 27 °C): 
δ = 5.18 (br s, 1H, NH), 4.00 (dd, J = 9.6, 5.4 Hz, 1H, CH), 3.75 (s, 6H, 2 x OCH3), 3.65 (br s, 
1H, NH), 3.36 (d, J = 12.0 Hz, 1H, CH), 3.33–3.27 (m, 1H, CH), 2.76 (dd, J = 13.8, 9.6 Hz, 1H, 
CH), 2.41–2.31 (m, 1H, CH), 1.40 (s, 9H, (CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): 
δ = 173.9, 172.9, 155.0, 80.3, 65.6, 59.7, 57.0, 52.8, 52.5, 40.9, 28.2 ppm. IR (neat, ATR): 
ṽ = 3360 (w), 2956 (w), 1732 (vs), 1711 (vs), 1514 (m), 1453 (m), 1392 (w), 1367 (m), 1243 
(s), 1165 (vs), 1112 (m), 1074 (m), 1031 (m), 870 (w), 830 (w), 682 (w) cm-1. HRMS (ESI+): 
m/z calcd. for [C13H23N2O6]+: 303.1556, found: 303.1549 ([M+H]+). 
 
Synthesis of (2R,4R)-dimethyl 4-((tert-butoxycarbonyl)amino)-1-(4-phenyldiazenyl)-
benzyl)pyrrolidine-2,4-dicarboxylate (5.8) 
 
 
 
To a solution of amine 5.7 (130 mg, 0.430 mmol, 1.0 equiv.) in DCM (10 mL) were added 
DIPEA (0.15 mL, 0.85 mmol, 2.0 equiv.) and a solution of bromide 4.18 (233 mg, 0.850 mmol, 
2.0 equiv.) in DCM (7 mL). Bu4NI (159 mg, 0.430 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred at room temperature for 16 h. 1 M NaOH (10 mL) was added and 
the phases were separated. The aqueous phase was extracted with Et2O (5 x 20 mL) and the 
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combined organic layers were washed with brine (25 mL), dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash silica gel chromatography (hexanes/EtOAc, gradient 
from 4:1 to 2:1), affording tertiary amine 5.8 (162 mg, 0.330 mmol, 77%) as orange crystals. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.38. M.p.: 154–155 °C. [α]D22: –18.5 (c = 0.09, DCM). 
1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.93–7.82 (m, 4H, ArH), 7.55–7.43 (m, 5H, ArH), 
5.40 (br s, 1H, NH), 4.09 (d, J = 13.2 Hz, 1H, CH), 3.73 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 
3.68–3.64 (m, 1H, CH), 3.54 (dd, J = 9.2, 6.0 Hz, 1H, CH), 3.17–3.05 (m, 1H, CH), 2.97–2.80 
(m, 2H, 2 x CH), 2.29 (dd, J = 13.2, 5.4 Hz, 1H, CH), 1.39 (s, 9H, (CH3)3) ppm. 13C NMR 
(CDCl3, 100 MHz, 27 °C): δ = 173.3, 172.5, 155.1, 152.6, 152.0, 140.8, 130.9, 129.6, 129.1, 
122.9, 122.8, 80.1, 63.9, 63.3, 61.8, 57.6, 52.7, 52.2, 39.9, 28.2 ppm. IR (neat, ATR): ṽ = 3394 
(w), 1741 (s), 1707 (s), 1508 (m), 1393 (w), 1364 (w), 1301 (m), 1269 (m), 1250 (m), 1168 (vs), 
1075 (m), 1050 (m), 829 (w), 765 (w), 685 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C26H33N4O6]+: 497.2400, found: 497.2391 ([M+H]+). 
 
Synthesis of (3R,5R)-3,5-dicarboxy-1-(4-phenyldiazenyl)benzyl)pyrrolidin-3-aminium 
formate (p-Azo-APDC) 
 
 
 
Boc-protected dimethyl ester 5.8 (145 mg, 0.290 mmol) was dissolved in THF (5 mL) and a 2 M 
solution of LiOH (1 mL) was added. The mixture was stirred at room temperature for 16 h. The 
phases were separated and the aqueous layer was acidified to pH = 1 with 1 M HCl and then 
extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine 
(10 mL), dried over MgSO4 and concentrated under reduced pressure. The crude product was 
used without further purification in the following step. 
The residue was suspended in EtOAc (5 mL) and freshly prepared HCl gas (from NaCl and 
conc. H2SO4) was bubbled through the mixture for 1 h. The solvent was removed in vacuo and 
the residue suspended in Et2O (10 mL). After centrifugation, the supernatant liquid was 
removed. The procedure was repeated and the crude product purified by reversed-phase silica 
gel column chromatography (H2O/MeOH/HCO2H, gradient from 100:0:0.1 to 0:100:0.1), 
yielding p-Azo-APDC as its formate salt (67 mg, 0.18 mmol, 62%) as orange crystals. 
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[α]D22: +9.6 (c = 0.08, H2O). M.p.: 78 °C (decomp.). 1H NMR (D2O/KOD, 600 MHz, 27 °C): 
δ = 7.61–7.49 (m, 4H, ArH), 7.41–7.26 (m, 5H, ArH), 3.78 (d, J = 12.6 Hz, 1H, CH), 3.23 (d, 
J = 12.6 Hz, 1H, CH), 2.97 (dd, J = 8.4, 8.4 Hz, 1H, CH), 2.60 (d, J = 9.6 Hz, 1H, CH), 
2.54−2.47 (m, 2H, 2 x CH), 1.54–1.48 (m, 1H, CH) ppm. 13C NMR (D2O/KOD, 100 MHz, 
25 °C): δ = 182.0, 180.8, 151.9, 151.0, 141.5, 131.6, 130.6, 130.0, 129.4, 128.9, 128.2, 122.2, 
122.2, 120.6, 120.5, 68.9, 65.3, 63.1, 57.7, 43.6 ppm.[jj] IR (neat, ATR): ṽ = 3186 (m), 2916 
(s), 2850 (m), 1574 (vs), 1467 (m), 1445 (m), 1386 (s), 1303 (m), 1251 (w), 1155 (w), 1069 
(m), 928 (w), 880 (w), 834 (m), 788 (w), 765 (w), 686 (m) cm-1. HRMS (ESI-): m/z calcd. for 
[C19H19N4O4]-: 367.1406, found: 367.1412 ([M-H]-). UV/Vis: λmax = 323, 420 nm. 
 
Synthesis of (2R,4R)-dimethyl 4-((tert-butoxycarbonyl)amino)-1-(3-(phenyldiazenyl)-
benzyl)pyrrolidine-2,4-dicarboxylate (5.9) 
 
 
 
To a solution of amine 5.7 (22 mg, 0.073 mmol, 1.0 equiv.) in DCM (1.5 mL) were added 
DIPEA (25 µL, 0.15 mmol, 2.0 equiv.) and a solution of bromide 4.21 (40 mg, 0.15 mmol, 
2.0 equiv.) in DCM (1.5 mL). Bu4NI (27 mg, 0.073 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred at room temperature for 16 h. 1 M NaOH (3 mL) was added and the 
phases were separated. The aqueous phase was extracted with Et2O (2 x 10 mL) and the 
combined organic layers were washed with brine (15 mL), dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash silica gel chromatography (hexanes/EtOAc, 
10:1 → 2:1), affording tertiary amine 5.9 (23 mg, 0.046 mmol, 63%) as an orange oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.39. [α]D22: –46.0 (c = 0.10, DCM). 1H NMR (CDCl3, 
300 MHz, 27 °C): δ = 7.96–7.94 (m, 1H, ArH), 7.94–7.92 (m, 1H, ArH), 7.87 (s, 1H, ArH), 
7.86−7.81 (m, 1H, ArH), 7.58–7.48 (m, 5H, ArH), 5.41 (br s, 1H, NH), 4.16 (d, J = 12.9 Hz, 
                                                
[jj]  Additional signals in the aromatic region in the 13C NMR spectrum were observed due to 
cis/trans isomerization of p-Azo-APDC. 
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1H, CH), 3.75 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.72–3.68 (m, 1H, CH), 3.59 (dd, J = 9.3, 
6.0 Hz, 1H, CH), 3.15 (d, J = 10.2 Hz, 1H, CH), 3.00–2.88 (m, 2H, 2 x CH), 2.33 (dd, J = 13.8, 
6.0 Hz, 1H, CH), 1.41 (s, 9H, (CH3)3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 173.3, 
172.4, 155.1, 152.7, 152.6, 138.8, 131.5, 131.0, 129.1, 129.1, 123.2, 122.8, 121.9, 80.1, 64.0, 
63.4, 61.8, 57.7, 52.7, 52.1, 39.8, 28.2 ppm. IR (neat, ATR): ṽ = 3369 (w), 2976 (w), 2951 (w), 
2839 (w), 1739 (vs), 1711 (vs), 1586 (w), 1505 (m), 1472 (m), 1448 (m), 1435 (m), 1391 (w), 
1366 (m), 1274 (m), 1247 (s), 1200 (s), 1167 (vs), 1075 (m), 1046 (w), 1021 (w), 1000 (w), 915 
(w), 871 (w), 830 (w), 799 (w), 766 (m), 734 (m), 694 (s), 668 (w) cm-1. HRMS (ESI+): m/z 
calcd. for [C26H33N4O6]+: 497.2400, found: 497.2393 ([M+H]+). 
 
Synthesis of (3R,5R)-3,5-dicarboxy-1-(3-phenyldiazenyl)benzyl)pyrrolidin-3-aminium 
formate (m-Azo-APDC) 
 
 
 
Boc-protected dimethyl ester 5.9 (23 mg, 0.046 mmol) was dissolved in THF (1 mL) and a 2 M 
solution of LiOH (0.2 mL) was added. The mixture was stirred at room temperature for 16 h. 
The phases were separated and the aqueous layer was acidified to pH = 1 with 1 M HCl and then 
extracted with EtOAc (3 x 2 mL). The combined organic layers were washed with brine (5 mL), 
dried over MgSO4 and concentrated under reduced pressure. The crude product was used 
without further purification in the following step. 
The crude residue was suspended in EtOAc (2 mL) and freshly prepared HCl gas (from NaCl 
and conc. H2SO4) was bubbled through the mixture for 1 h. The solvent was removed in vacuo 
and the crude product was purified by reversed-phase silica gel column chromatography 
(H2O/MeOH/HCO2H, gradient from 100:0:0.1 to 30:70:0.1), yielding m-Azo-APDC as its 
formate salt (16 mg, 0.043 mmol, 93%) as an orange solid. 
[α]D22: –36.0 (c = 0.05, DMSO). M.p.: 183 °C (decomp.). 1H NMR (DMSO-d6, 600 MHz, 
27 °C): δ = 8.24 (s, 1H, HCO2-), 7.92–7.86 (m, 2H, ArH), 7.80 (s, 1H, ArH), 7.76–7.71 (m, 1H, 
ArH), 7.60−7.52 (m, 3H, ArH), 7.52–7.47 (m, 2H, ArH), 3.92 (d, J = 13.2 Hz, 1H, CH), 3.78 (d, 
J = 13.2 Hz, 1H, CH), 3.33 (d, J = 9.0 Hz, 1H, CH), 2.97 (d, J = 8.4 Hz, 1H, CH), 2.81 (d, 
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J = 8.4 Hz, 1H, CH), 2.44–1.37 (m, 1H, CH), 1.81 (d, J = 12.6 Hz, 1H, CH) ppm. 13C NMR 
(DMSO-d6, 150 MHz, 27 °C): δ = 176.8, 171.0, 164.3, 152.4, 152.4, 141.3, 132.2, 131.9, 
129.9, 129.5, 123.1, 123.0, 121.4, 68.3, 64.9, 61.6, 57.5. 39.5 ppm. IR (neat, ATR): ṽ = 2978 
(m), 1652 (m), 1614 (s), 1506 (m), 1477 (m), 1439 (m), 1398 (m), 1380 (m), 1334 (s), 1283 
(m), 1260 (m), 1224 (w), 1194 (m), 1137 (m), 1092 (w), 1031 (w), 973 (w), 911 (w), 888 (w), 
823 (m), 796 (s), 772 (m), 717 (w), 692 (vs) cm-1. HRMS (ESI-): m/z calcd. for [C19H19N4O4]-: 
367.1406, found: 367.1409 ([M-H]-). UV/Vis: λmax = 324, 440 nm. 
 
 
5.5.3 SYNTHESIS OF AZO-3C5HPGS 
 
Synthesis of dimethyl 5-((4-(phenyldiazenyl)benzyl)oxy)isophthalate (5.10) 
 
 
 
Dimethyl 5-hydroxyisophthalate (1.27 g, 6.06 mmol, 1.0 equiv.) was dissolved in acetone 
(175 mL) at room temperature and K2CO3 (1.67 g, 12.1 mmol, 2.0 mmol) and Bu4NI (2.24 g, 
6.06 mmol, 1.0 equiv.) were added, followed by bromide 4.18 (2.00 g, 7.27 mmol, 1.2 equiv.). 
The mixture was stirred for 16 h at room temperature. The solvent was removed in vacuo and 
DCM (100 mL) was added and the mixture was washed with water (200 mL). The aqueous 
layer was extracted with DCM (2 x 50 mL) and the combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (hexanes/DCM, gradient from 3:1 to 1:9), giving rise to azobenzene ether 5.10 
(2.39 g, 5.91 mmol, 98%) as orange crystals. Moreover, bromide 4.18 (204 mg, 0.740 mmol, 
10%) was recovered. 
TLC (hexanes/DCM, 1:4): Rf = 0.78. M.p.: 179–181 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 8.34 (t, J = 1.5 Hz, 1H, ArH), 8.01–7.92 (m, 4H, ArH), 7.90 (s, 1H, ArH), 7.89 (s, 
1H, ArH), 7.64 (m, 1H, ArH), 7.61 (m, 1H, ArH), 7.58–7.50 (m, 3H, ArH), 5.26 (s, 2H, CH2), 
3.97 (s, 6H, 2 x OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 166.1, 158.6, 152.6, 
152.5, 139.0, 131.9, 131.1, 129.1, 128.0, 123.4, 123.2, 122.9, 120.2, 70.0, 52.5 ppm. IR (neat, 
ATR): ṽ = 1725 (vs), 1596 (m), 1454 (m), 1429 (m), 1344 (m), 1316 (m), 1250 (vs), 1114 (m), 
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1052 (m), 1004 (m), 877 (w), 827 (w), 757 (m), 682 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C23H21N2O5]+: 405.1450, found: 405.1444 ([M+H]+). 
 
Synthesis of methyl 3-(hydroxymethyl)-5-((4-(phenyldiazenyl)benzyl)oxy)benzoate (5.11) 
 
 
 
Dimethyl ester 5.10 (2.00 g, 4.95 mmol, 1.0 equiv.) was dissolved in THF (200 mL) and LiAlH4 
(94 mg, 2.5 mmol, 0.5 equiv.) was added. The mixture was stirred for 4 h at room temperature. 
H2O was added (0.10 mL), followed by aqu. NaOH (10%, 0.20 mL) and H2O (0.30 mL). The 
mixture was stirred for 1 h and then filtered. The filtrate was concentrated in vacuo. The crude 
product was purified by flash silica gel chromatography (hexanes/EtOAc, 2:1 → 1:1), affording 
alcohol 5.11 (1.13 g, 3.00 mmol, 61%) as orange crystals. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.26. M.p.: 131–132 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.96–7.90 (m, 4H, ArH), 7.66–7.64 (m, 1H, ArH), 7.60–7.57 (m, 3H, ArH), 
7.54−7.46 (m, 3H, ArH), 7.25–7.23 (m, 1H, ArH), 5.20 (s, 2H, CH2), 4.73 (s, 2H, CH2), 3.92 (s, 
3H, OCH3), 1.74 (br s, 1H, OH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 166.7, 158.8, 
152.6, 152.3, 142.9, 139.4, 131.7, 131.1, 129.1, 128.0, 123.1, 122.9, 120.6, 118.3, 114.4, 69.7, 
64.6, 52.3 ppm. IR (neat, ATR): ṽ = 3493 (w), 1715 (s), 1598 (m), 1450 (m), 1435 (m), 1377 
(w), 1307 (s), 1234 (vs), 1158 (m), 1108 (m), 1049 (s), 1011 (m), 988 (m), 954 (w), 906 (w), 
853 (m), 838 (w), 825 (w), 798 (w), 770 (vs), 733 (w), 714 (w), 691 (s), 669 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C22H21N2O4]+: 377.1501, found: 377.1494 ([M+H]+). 
 
Moreover, unreacted dimethyl ester 5.10 (500 mg, 1.25 mmol, 25%) was recovered and the 
doubly reduced diol 5.41 (84 mg, 0.24 mmol, 5%) was obtained as orange crystals. 
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TLC (hexanes/EtOAc, 1:3): Rf = 0.33. M.p.: 108 °C (dec.). 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.95–7.91 (m, 4H, ArH), 7.59 (s, 1H, ArH), 7.57 (s, 1H, ArH), 7.54–7.51 (m, 2H, 
ArH), 7.50−7.46 (m, 1H, ArH), 6.98 (s, 1H, ArH), 6.95 (s, 2H, ArH), 5.17 (s, 2H, CH2), 4.68 (s, 
4H, 2 x CH2), 1.64 (br s, 2H, 2 x OH) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 159.2, 
152.6, 152.3, 142.9, 139.9, 131.1, 129.1, 127.9, 123.1, 122.9, 117.9, 112.5, 69.5, 65.1 ppm. IR 
(neat, ATR): ṽ = 3311 (m), 1600 (m), 1454 (m), 1298 (m), 1165 (m), 1019 (s), 832 (s), 769 
(m), 709 (w), 692 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C21H21N2O3]+: 349.1552, 
found: 349.1546 ([M+H]+). 
 
Synthesis of methyl 3-formyl-5-((4-(phenyldiazenyl)benzyl)oxy)benzoate (5.12) 
 
 
 
To a solution of alcohol 5.11 (1.12 g, 2.98 mmol, 1.0 equiv.) in DCM (65 mL), MnO2 (2.59 g, 
29.8 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered  through Celite and the residue washed 
thoroughly with DCM. The filtrate was concentrated under reduced pressure to give aldehyde 
5.12 (990 mg, 2.64 mmol, 89%) as an orange solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.67. M.p.: 147–148 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 10.04 (s, 1H, CHO), 8.17 (dd, J = 1.4, 1.4 Hz, 1H, ArH), 8.02–7.91 (m, 5H, ArH), 
7.70 (dd, J = 2.7, 1.4 Hz, 1H, ArH), 7.63 (s, 1H, ArH), 7.60 (s, 1H, ArH), 7.58–7.50 (m, 3H, 
ArH), 5.26 (s, 2H, CH2), 3.99 (s, 3H, OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 191.1, 165.7, 159.2, 152.6, 152.5, 138.7, 138.0, 132.6, 131.2, 129.1, 128.1, 124.8, 123.2, 
122.9, 122.2, 117.7, 70.0, 52.6 ppm. IR (neat, ATR): ṽ = 1732 (s), 1699 (s), 1595 (m), 1461 
(m), 1436 (m), 1394 (m), 1339 (m), 1302 (m), 1227 (vs), 1149 (m), 1110 (m), 1048 (m), 999 
(w), 866 (w), 832 (w), 802 (w), 764 (m), 684 (m), 668 (w) cm-1. HRMS (EI+): m/z calcd. for 
[C22H19N2O4]+: 375.1345, found: 375.1340 ([M+H]+). 
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Synthesis of methyl 3-(amino(cyano)methyl)-5-((4-(phenyldiazenyl)benzyl)-oxy)benzoate 
(5.13) 
 
 
 
To a solution of aldehyde 5.12 (678 mg, 1.81 mmol, 1.0 equiv.) in DCM (13 mL), a 7 M 
solution of NH3 in MeOH (13 mL) was added. The mixture was stirred for 10 min and TMSCN 
(0.36 mL, 2.9 mmol, 1.6 equiv.) was added dropwise. The reaction mixture was stirred for 36 h 
at room temperature, followed by removal of the solvent in vacuo. The crude product was 
purified by flash silica gel chromatography (hexanes/EtOAc, gradient from 4:1 to 1:1), 
affording aminonitrile 5.13 (557 mg, 1.39 mmol, 77%) as a red viscous oil. As a side product, 
cyanohydrin 5.15 (111 mg, 0.280 mmol) was obtained in 15% yield.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.28. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.96–7.94 
(m, 1H, ArH), 7.93–7.90 (m, 3H, ArH), 7.82 (ddd, J = 1.6, 1.6, 0.8 Hz, 1H, ArH), 7.65 (dd, 
J = 2.4, 0.6 Hz, 1H, ArH), 7.59 (s, 1H, ArH), 7.56 (s, 1H, ArH), 7.52–7.46 (m, 3H, ArH), 7.38 
(ddd, J = 2.4, 1.6, 0.8 Hz, 1H, ArH), 5.18 (s, 2H, CH2), 4.91 (s, 1H, CH), 3.91 (s, 3H, OCH3), 
2.05 (br s, 2H, NH2) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 166.1, 159.0, 152.6, 152.4, 
139.0, 138.3, 132.4, 131.2, 129.1, 128.0, 123.2, 122.9, 120.5, 120.4, 118.3, 115.7, 69.8, 52.5, 
46.9 ppm. IR (neat, ATR): ṽ = 1710 (vs), 1657 (w), 1596 (m), 1485 (w), 1434 (m), 1361 (m), 
1331 (m), 1299 (vs), 1221 (vs), 1154 (m), 1106 (w), 1042 (m), 1012 (w), 1000 (w), 859 (w), 
830 (m), 765 (vs), 688 (s) cm-1. HRMS (ESI+): m/z calcd. for [C23H21N4O3]+: 401.1614, found: 
401.1608 ([M+H]+). 
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Synthesis of methyl 3-(1-amino-2-methoxy-2-oxoethyl)-5-((4-(phenyl-diazenyl)benzyl)-
oxy)benzoate (5.14) 
 
 
 
Aminonitrile 5.13 (154 mg, 0.385 mmol) was dissolved in MeOH (4 mL) and cooled to 0 °C. A 
4 M solution of HCl in dioxane (4 mL) was added slowly. The solution was stirred for 1 h at 
0 °C. H2O (0.08 mL) was added and the mixture was warmed to room temperature and stirred 
for 16 h. The mixture was diluted with EtOAc (20 mL) and washed with NaHCO3 (3 x 20 mL; 
gas evolution!). The organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (DCM/MeOH/HOAc/H2O, 
90:10:0.6:0.6), affording dimethyl ester 5.14 (87 mg, 0.20 mmol, 52%) as a red oil. 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.42. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.96–7.95 (m, 1H, ArH), 7.95–7.94 (m, 1H, ArH), 7.94–7.93 (m, 1H, ArH), 
7.93−7.92 (m, 1H, ArH), 7.70 (dd, J = 1.2, 1.2 Hz, 1H, ArH), 7.61 (dd, J = 2.4, 1.2 Hz, 1H, 
ArH), 7.59 (s, 1H, ArH), 7.58 (s, 1H, ArH), 7.54–7.47 (m, 3H, ArH), 7.26–7.25 (m, 1H, ArH), 
5.19 (s, 2H, CH2), 4.66 (s, 1H, CH), 3.92 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 1.95 (br s, 2H, 
NH2) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 173.8, 166.5, 158.8, 152.6, 152.4, 142.1, 
139.3, 132.0, 131.1, 129.1, 128.0, 123.1, 122.9, 120.9, 118.7, 114.8, 69.8, 58.4, 52.6, 52.3 ppm. 
IR (neat, ATR): ṽ = 3369 (w), 2951 (w), 1720 (s), 1596 (m), 1539 (w), 1485 (w), 1435 (m), 
1333 (m), 1299 (vs), 1226 (vs), 1154 (m), 1106 (m), 1037 (m), 1013 (m), 929 (w), 875 (w), 830 
(m), 807 (w), 767 (s), 710 (w), 687 (s), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C24H24N3O5]+: 434.1716, found: 434.1710 ([M+H]+). 
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Synthesis of carboxy(3-carboxy-5-((4-(phenyldiazenyl)benzyl)oxy)phenyl)methanaminium 
formate (p-Azo-3C5HPG) 
 
 
 
Dimethyl ester 5.14 (59 mg, 0.14 mmol) was dissolved in THF (3 mL) and a 2 M solution of 
LiOH in water (0.5 mL) was added. The solution was stirred for 16 h at room temperature. The 
pH was adjusted to pH = 1 with 2 M HCl and the solvent was removed in vacuo. The crude 
product was purified by reversed-phase silica gel column chromatography 
(H2O/MeOH/HCO2H, gradient from 100:0:0.1 to 20:80:0.1), yielding p-Azo-3C5HPG as its 
formate salt (33 mg, 0.073 mmol, 54%) as orange solid. 
M.p.: 201 °C (dec.). 1H NMR (CD3OD/KOD/D2O, 600 MHz, 27 °C): δ = 7.80–7.75 (m, 4H, 
ArH), 7.62–7.60 (m, 1H, ArH), 7.55 (s, 1H, ArH), 7.54 (s, 1H, ArH), 7.51–7.48 (m, 1H, ArH), 
7.47–7.43 (m, 3H, ArH), 7.18 (dd, J = 2.4, 2.4 Hz, 1H, ArH), 5.15 (s, 2H, CH2), 4.39 (s, 1H, 
CH) ppm. 13C NMR (CD3OD/KOD/D2O, 150 MHz, 27 °C): δ = 179.6, 173.7, 169.1, 158.2, 
152.2, 151.8, 145.0, 140.4, 139.3, 129.4, 128.5, 128.4, 127.5, 122.8, 122.6, 122.3, 122.1, 69.2, 
61.1 ppm. IR (neat, ATR): ṽ = 3595 (w), 3084 (m), 2013 (w), 1675 (s), 1653 (m), 1611 (s), 
1594 (s), 1559 (w), 1500 (s), 1472 (m), 1399 (m), 1337 (m), 1302 (s), 1257 (s), 1167 (m), 1117 
(w), 1106 (w), 1062 (m), 1035 (w), 1013 (w), 961 (w), 930 (w), 900 (w), 872 (w), 834 (m), 812 
(w), 777 (m), 723 (w), 710 (w), 688 (vs), 668 (w) cm-1. HRMS (ESI-): m/z calcd. for 
[C22H18N3O5]-: 404.1246, found: 404.1250 ([M-H]-). UV/Vis: λmax = 322, 425 nm. 
 
Synthesis of methyl 3-(cyano(hydroxy)methyl)-5-((4-(phenyldiazenyl)benzyl)-oxy)benzoate 
(5.15) 
 
 
 
To a solution of aldehyde 5.12 (100 mg, 0.270 mmol, 1.0 equiv.) in DCM (2 mL), a 7 M 
solution of NH3 in MeOH (2 mL) was added. The mixture was stirred for 10 min at room 
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temperature and TMSCN (54 µL, 0.43 mmol, 1.6 equiv.) was added dropwise. The reaction 
mixture was stirred for 1 h at room temperature, followed by removal of the solvent in vacuo. 
The crude product was purified by flash silica gel chromatography (hexanes/EtOAc, 4:1), 
affording cyanohydrin 5.15 (82 mg, 0.20 mmol, 74%) as a red oil.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.50. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.96–7.94 
(m, 1H, ArH), 7.94–7.92 (m, 2H, ArH), 7.92–7.90 (m, 1H, ArH), 7.79–7.77 (m, 1H, ArH), 7.67 
(dd, J = 2.5, 1.3 Hz, 1H, ArH), 7.59 (s, 1H, ArH), 7.56 (s, 1H, ArH), 7.55–7.48 (m, 3H, ArH), 
7.37 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 5.56 (d, J = 6.4 Hz, 1H, CH), 5.19 (s, 2H, CH2), 3.92 (s, 
3H, OCH3), 3.53 (d, J = 6.4 Hz, 1H, OH) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): 
δ = 166.2, 159.1, 152.5, 152.4, 138.8, 137.2, 132.4, 131.2, 129.1, 128.0, 123.2, 122.9, 120.3, 
118.3, 118.0, 116.5, 69.9, 63.0, 52.6 ppm. IR (neat, ATR): ṽ = 3418 (m), 1721 (s), 1598 (m), 
1436 (m), 1335 (s), 1302 (vs), 1232 (m), 1155 (m), 1111 (m), 1044 (m), 831 (w), 766 (m), 689 
(m) cm-1. HRMS (ESI+): m/z calcd. for [C23H20N3O4]+: 402.1454, found: 402.1448 ([M+H]+). 
 
Synthesis of methyl 3-(1-hydroxy-2-methoxy-2-oxoethyl)-5-((4-(phenyldiazenyl)-benzyl)-
oxy)benzoate (5.20) 
 
 
 
Cyanohydrin 5.15 (29 mg, 0.072 mmol) was dissolved in MeOH (4 mL) and freshly prepared 
HCl gas (from the addition of conc. H2SO4 to NaCl) was bubbled through the solution for 
45 min at room temperature. The mixture was diluted with EtOAc (20 mL) and washed with 
NaHCO3 (2 x 25 mL; gas evolution!). The organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, 4:1 → 2:1) to yield dimethyl ester 5.20 (5.0 mg, 0.012 mmol, 17%) as a red 
oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.38. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 7.96–7.95 
(m, 1H, ArH), 7.95–7.94 (m, 1H, ArH), 7.94–7.93 (m, 1H, ArH), 7.92–7.91 (m, 1H, ArH), 7.74 
(dd, J = 1.5, 1.5 Hz, 1H, ArH), 7.63 (dd, J = 2.5, 1.4 Hz, 1H, ArH), 7.59 (s, 1H, ArH), 7.58 (s, 
1H, ArH), 7.54–7.47 (m, 3H, ArH), 7.29 (dd, J = 1.8, 1.8 Hz, 1H, ArH), 5.21–5.19 (m, 3H, CH, 
CH2), 3.92 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.52 (d, J = 5.1 Hz, 1H, OH) ppm. 13C NMR 
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(CDCl3, 150 MHz, 27 °C): δ = 173.6, 166.5, 158.7, 152.6, 152.4, 140.1, 139.2, 131.9, 131.1, 
129.1, 128.0, 123.1, 122.9, 120.7, 118.2, 115.3, 72.3, 69.8, 53.3, 52.3 ppm. IR (neat, ATR): 
ṽ = 3467 (w), 1720 (vs), 1596 (m), 1435 (m), 1331 (m), 1300 (vs), 1223 (s), 1153 (m), 1108 
(m), 1046 (m), 1012 (m), 831 (w), 769 (m), 689 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C24H23N2O6]+: 435.1556, found: 435.1552 ([M+H]+). 
 
Synthesis of dimethyl 5-((tert-butyldimethylsilyl)oxy)isophthalate (5.21) 
 
 
 
To a solution of dimethyl 5-hydroxyisophthalate (2.00 g, 9.52 mmol, 1.0 equiv.) in DMF 
(50 mL), imidazole (2.59 g, 38.1 mmol, 4.0 equiv.) and TBSCl (3.59 g, 23.8 mmol, 2.5 equiv.) 
were added. The reaction mixture was stirred at room temperature for 3 h. The mixture was 
diluted with H2O (100 mL) and extracted with Et2O (3 x 50 mL). The combined organic phases 
were washed with H2O (7 x 75 mL) and brine (75 mL) and then dried over MgSO4. The solvent 
was removed in vacuo and the crude product was purified by flash silica gel chromatography 
(hexanes/EtOAc, 20:1) to give TBS protected alcohol 5.21 (2.90 g, 8.94 mmol, 94%) as 
colorless crystals. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.69. M.p.: 68–70 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.31 (t, J = 1.5 Hz, 1H, ArH), 7.69 (d, J = 1.5 Hz, 2H, ArH), 3.95 (s, 6H, 2 x OCH3), 1.03 
(s, 9H, C(CH3)3), 0.26 (s, 6H, 2 x SiCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 166.1, 
155.9, 131.8, 125.4, 123.7, 52.4, 25.6, 18.2, –4.5 ppm. IR (neat, ATR): ṽ = 2953 (m), 2931 
(w), 2859 (w), 1727 (vs), 1593 (m), 1434 (m), 1336 (s), 1236 (s), 1190 (w), 1111 (m), 1024 (m), 
1005 (m), 938 (w), 902 (w), 874 (w), 835 (s), 783 (m), 760 (m), 721 (w), 668 (w) cm-1. HRMS 
(EI+): m/z calcd. for [C16H24O5Si]+: 324.1393, found: 324.1386 ([M]+). 
 
Synthesis of methyl 3-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)benzoate (5.22) 
 
 
 
Diester 5.21 (2.85 g, 8.78 mmol, 1.0 equiv.) was dissolved in THF (300 mL) and LiAlH4 
(167 mg, 4.39 mmol, 0.5 equiv.) was added. The mixture was stirred for 3 h at room 
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temperature. H2O was added (0.17 mL), followed by aqu. NaOH (10%, 0.34 mL) and H2O 
(0.51 mL). The mixture was stirred for 1 h and then filtered. The filtrate was concentrated in 
vacuo. The crude product was purified by flash silica gel chromatography (hexanes/EtOAc, 
4:1), affording alcohol 5.22 (1.46 g, 4.93 mmol, 56%) as a colorless oil. Diester 5.21 was 
recovered in 31% yield (870 mg, 2.68 mmol). 
TLC (hexanes/EtOAc, 4:1): Rf = 0.24. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.65 (ddt, 
J = 1.4, 1.4, 0.6 Hz, 1H, ArH), 7.44–7.41 (m, 1H, ArH), 7.08 (ddt, J = 2.3, 1.4, 0.6 Hz, 1H, 
ArH), 4.70 (d, J = 0.6 Hz, 2H, CH2), 3.92 (s, 3H, OCH3), 1.81 (br s, 1H, OH), 1.02 (s, 9H, 
C(CH3)3), 0.24 (s, 6H, 2 x SiCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 166.8, 156.0, 
142.8, 131.6, 123.1, 120.8, 120.1, 64.7, 52.2, 25.6, 18.2, –4.4 ppm. IR (neat, ATR): ṽ = 3430 
(w), 2952 (w), 2930 (w), 2885 (w), 2858 (w), 1724 (m), 1595 (m), 1448 (m), 1434 (m), 1390 
(w), 1362 (w), 1323 (s), 1253 (m), 1230 (m), 1190 (w), 1153 (m), 1106 (m), 1025 (m), 980 (w), 
939 (w), 895 (w), 836 (vs), 817 (w), 782 (m), 772 (m), 739 (w), 684 (w), 671 (w) cm-1. HRMS 
(EI+): m/z calcd. for [C15H24O4Si]+: 296.1444, found: 296.1446 ([M]+). 
 
Synthesis of methyl 3-((tert-butyldimethylsilyl)oxy)-5-formylbenzoate (5.23) 
 
 
 
To a solution of alcohol 5.22 (1.40 g, 4.72 mmol, 1.0 equiv.) in DCM (100 mL), MnO2 (4.10 g, 
47.2 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered  through Celite and the residue was washed 
thoroughly with DCM. The filtrate was concentrated under reduced pressure to give aldehyde 
5.23 (1.29 g, 4.38 mmol, 93%) as a colorless solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.65. M.p.: 32–33 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 10.02 (s, 1H, CHO), 8.14 (dd, J = 1.5, 1.5 Hz, 1H, ArH), 7.76 (dd, J = 2.5, 1.5 Hz, 1H, 
ArH), 7.53 (dd, J = 2.5, 1.5 Hz, 1H, ArH), 3.97 (s, 3H, OCH3), 1.02 (s, 9H, C(CH3)3), 0.26 (s, 
6H, 2 x SiCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 191.1, 165.8, 156.6, 138.0, 
132.5, 127.0, 124.8, 123.4, 52.5, 25.6, 18.2, –4.5 ppm. IR (neat, ATR): ṽ = 2953 (w), 2931 (w), 
2886 (w), 2858 (w), 1728 (m), 1704 (s), 1594 (m), 1458 (m), 1440 (m), 1386 (m), 1362 (w), 
1323 (s), 1232 (s), 1190 (w), 1145 (m), 1106 (w), 1024 (m), 1005 (w), 939 (w), 898 (m), 834 
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(vs), 783 (m), 770 (m), 738 (w), 689 (w), 677 (w) cm-1. HRMS (EI+): m/z calcd. for 
[C15H22O4Si]+: 294.1287, found: 294.1272 ([M]+). 
 
Synthesis of dimethyl 5-((3-(phenyldiazenyl)benzyl)oxy)isophthalate (5.25) 
 
 
 
Dimethyl 5-hydroxyisophthalate (1.27 g, 6.06 mmol, 1.0 equiv.) was dissolved in acetone 
(175 mL) at room temperature and K2CO3 (1.67 g, 12.1 mmol, 2.0 mmol) and Bu4NI (2.24 g, 
6.06 mmol, 1.0 equiv.) were added, followed by bromide 4.21 (2.00 g, 7.27 mmol, 1.2 equiv.). 
The mixture was stirred for 16 h at room temperature. The solvent was removed in vacuo and 
EtOAc (100 mL) was added. The organic phase was washed with H2O (200 mL) and dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
chromatography (hexanes/DCM, gradient from 3:1 to 1:9) to yield azobenzene ether 5.25 
(2.12 g, 5.24 mmol, 86%) as a red oil.  
TLC (hexanes/EtOAc, 10:1): Rf = 0.13. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 8.33 (dd, 
J = 1.5, 1.5 Hz, 1H, ArH), 8.05–8.01 (m, 1H, ArH), 7.98–7.90 (m, 3H, ArH), 7.89 (d, 
J = 1.5 Hz, 2H, ArH), 7.60–7.49 (m, 5H, ArH), 5.26 (s, 2H, CH2), 3.95 (s, 6H, 2 x OCH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 166.0, 158.7, 152.9, 152.6, 137.3, 131.9, 131.2, 129.7, 
129.4, 129.1, 123.4, 122.9, 122.9, 121.5, 120.2, 70.0, 52.4 ppm. IR (neat, ATR): ṽ = 2950 (w), 
1720 (s), 1594 (m), 1454 (m), 1432 (m), 1336 (m), 1312 (m), 1239 (vs), 1189 (w), 1150 (w), 
1116 (m), 1103 (w), 1040 (m), 1003 (m), 910 (w), 882 (w), 875 (w), 791 (m), 756 (s), 721 (m), 
693 (m), 672 (w) cm-1. HRMS (EI+): m/z calcd. for [C23H20N2O5]+: 404.1372, found: 404.1376 
([M]+). 
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Synthesis of methyl 3-(hydroxymethyl)-5-((3-(phenyldiazenyl)benzyl)oxy)benzoate (5.26) 
 
 
 
Dimethyl ester 5.25 (1.98 g, 4.90 mmol, 1.0 equiv.) was dissolved in THF (200 mL) and LiAlH4 
(93 mg, 2.5 mmol, 0.5 equiv.) was added. The mixture was stirred for 2 h at room temperature. 
H2O was added (0.10 mL), followed by aqu. NaOH (10%, 0.20 mL) and H2O (0.30 mL). The 
mixture was stirred for 30 min and then filtered. The filtrate was concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (hexanes/EtOAc, 3:1 → 2:1), 
affording alcohol 5.26 (1.09 g, 2.90 mmol, 59%) as a red oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.35. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 8.00–7.97 
(m, 1H, ArH), 7.94–7.90 (m, 2H, ArH), 7.88 (ddd, J = 6.4, 2.4, 2.4 Hz, 1H, ArH), 7.65 (s, 1H, 
ArH), 7.59 (dd, J = 2.4, 1.5 Hz, 1H, ArH), 7.55–7.46 (m, 5H, ArH), 7.24–7.23 (m, 1H, ArH), 
5.20 (s, 2H, CH2), 4.71 (s, 2H, CH2), 3.90 (s, 3H, OCH3), 1.87 (br s, 1H, OH) ppm. 13C NMR 
(CDCl3, 150 MHz, 27 °C): δ = 166.7, 158.8, 152.8, 152.5, 142.9, 137.7, 131.7, 131.1, 129.7, 
129.4, 129.1, 122.9, 122.8, 121.5, 120.6, 118.3, 114.3, 69.7, 64.6, 52.2 ppm. IR (neat, ATR): 
ṽ = 3414 (m), 2949 (w), 2873 (w), 1716 (s), 1595 (m), 1447 (m), 1433 (m), 1329 (m), 1301 (vs), 
1224 (s), 1150 (m), 1106 (m), 1044 (m), 998 (m), 924 (w), 887 (m), 796 (m), 785 (m), 767 (s), 
732 (w), 692 (vs), 657 (w) cm-1. HRMS (ESI+): m/z calcd. for [C22H21N2O4]+: 377.1501, found: 
377.1496 ([M+H]+). 
 
Synthesis of methyl 3-formyl-5-((3-(phenyldiazenyl)benzyl)oxy)benzoate (5.27) 
 
 
 
To a solution of alcohol 5.26 (990 mg, 2.63 mmol, 1.0 equiv.) in DCM (60 mL), MnO2 (2.29 g, 
26.3 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at room 
temperature for 2 d. The mixture was filtered through Celite and the residue was washed 
thoroughly with DCM. The filtrate was concentrated under reduced pressure to give aldehyde 
5.27 (920 mg, 2.46 mmol, 94%) as a red oil. 
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TLC (hexanes/EtOAc, 2:1): Rf = 0.81. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 10.01 (s, 1H, 
CHO), 8.13 (dd, J = 1.4, 1.4 Hz, 1H, ArH), 8.00 (s, 1H, ArH), 7.95–7.88 (m, 4H, ArH), 7.68 
(dd, J = 2.7, 1.4 Hz, 1H, ArH), 7.57–7.54 (m, 2H, ArH), 7.53–7.46 (m, 3H, ArH), 5.25 (s, 2H, 
CH2), 3.95 (s, 3H, OCH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 191.0, 165.7, 159.2, 
152.9, 152.5, 137.9, 137.0, 132.6, 131.2, 129.7, 129.5, 129.1, 124.6, 123.0, 122.9, 122.1, 121.5, 
117.7, 70.1, 52.5 ppm. IR (neat, ATR): ṽ = 1722 (m), 1698 (s), 1593 (m), 1458 (m), 1447 (m), 
1433 (m), 1334 (m), 1304 (vs), 1223 (s), 1195 (w), 1146 (m), 1106 (m), 1041 (m), 991 (m), 951 
(w), 906 (m), 883 (m), 787 (m), 765 (s), 730 (m), 691 (vs), 671 (m) cm-1. HRMS (EI+): m/z 
calcd. for [C22H19N2O4]+: 375.1345, found: 375.1340 ([M+H]+). 
 
Synthesis of methyl 3-(amino(cyano)methyl)-5-((3-(phenyldiazenyl)benzyl)oxy)benzoate 
(5.28) 
 
 
 
To a solution of aldehyde 5.27 (819 mg, 2.19 mmol, 1.0 equiv.) in DCM (16 mL), a 7 M 
solution of NH3 in MeOH (16 mL) was added at 0 °C. The mixture was stirred for 10 min and 
TMSCN (0.46 mL, 3.5 mmol, 1.6 equiv.) was added dropwise. The reaction mixture was slowly 
warmed to room temperature and stirred for 20 h, followed by removal of the solvent in vacuo. 
The crude product was purified by flash silica gel chromatography (hexanes/EtOAc, gradient 
from 10:1 to 1:1), affording aminonitrile 5.28 (274 mg, 0.680 mmol, 31%) as a red oil.  
TLC (hexanes/EtOAc, 2:1): Rf = 0.57. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 8.02–7.99 
(m, 1H, ArH), 7.95–7.89 (m, 3H, ArH), 7.84–7.82 (m, 1H, ArH), 7.69 (dd, J = 2.3, 1.4 Hz, 1H, 
ArH), 7.57–7.49 (m, 5H, ArH), 7.41 (ddd, J = 2.3, 1.7, 0.7 Hz, 1H, ArH), 5.23 (s, 2H, CH2), 
4.93 (s, 1H, CH), 3.93 (s, 3H, OCH3), 1.98 (br s, 2H, NH2) ppm. 13C NMR (CDCl3, 100 MHz, 
27 °C): δ = 166.1, 159.1, 152.9, 152.5, 138.2, 137.3, 132.4, 131.2, 129.8, 129.5, 129.1, 122.9, 
122.9, 121.5, 120.4, 120.4, 118.4, 115.7, 69.9, 52.4, 46.9 ppm. IR (neat, ATR): ṽ = 3382 (w), 
1716 (s), 1596 (m), 1447 (m), 1433 (m), 1332 (m), 1304 (s), 1227 (s), 1195 (w), 1152 (m), 1110 
(w), 1084 (w), 1042 (m), 999 (w), 907 (w), 888 (w), 798 (m), 786 (m), 767 (m), 731 (m), 693 
(vs) cm-1. HRMS (ESI+): m/z calcd. for [C23H21N4O3]+: 401.1614, found: 401.1609 ([M+H]+). 
 
Moreover, aldehyde 5.27 was recovered in 20% yield (162 mg, 0.430 mmol) and cyanohydrin 
5.30 was obtained as a side product in 40% yield (354 mg, 0.880 mmol) as a red oil. 
CO2Me
O CN
NH2
NN
5     STUDIES TOWARD PHOTOSWITCHABLE MGLUR6 AGONISTS AS A POTENTIAL 
        APPROACH TO VISION RESTORATION 
 
 
 
381 
 
 
TLC (hexanes/EtOAc, 2:1): Rf = 0.70. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 7.97–7.94 
(m, 1H, ArH), 7.92–7.85 (m, 3H, ArH), 7.75 (ddd, J = 1.6, 1.6, 0.6 Hz, 1H, ArH), 7.64 (dd, 
J = 2.4, 1.4 Hz, 1H, ArH), 7.53–7.45 (m, 5H, ArH), 7.35 (ddd, J = 2.4, 1.6, 0.6 Hz, 1H, ArH), 
5.53 (d, 1H, J = 6.9 Hz, CH), 5.16 (s, 2H, CH2), 3.96 (d, J = 6.9 Hz, 1H, OH), 3.88 (s, 3H, 
OCH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 166.3, 159.1, 152.8, 152.5, 137.3, 
137.2, 132.2, 131.2, 129.8, 129.5, 129.1, 122.9, 122.9, 121.5, 120.3, 118.5, 118.0, 116.4, 69.9, 
62.9, 52.6 ppm. IR (neat, ATR): ṽ = 3410 (w), 1719 (m), 1596 (m), 1447 (m), 1434 (m), 1381 
(w), 1334 (m), 1301 (s), 1226 (s), 1195 (w), 1151 (m), 1110 (m), 1040 (m), 999 (m), 908 (m), 
787 (m), 765 (s), 730 (m), 710 (w), 692 (vs) cm-1. HRMS (ESI+): m/z calcd. for [C23H20N3O4]+: 
402.1454, found: 402.1448 ([M+H]+). 
 
Synthesis of methyl 3-(1-amino-2-methoxy-2-oxoethyl)-5-((3-(phenyl-diazenyl)benzyl)oxy)-
benzoate (5.29) 
 
 
 
Aminonitrile 5.28 (174 mg, 0.430 mmol) was dissolved in MeOH (4.5 mL) and cooled to 0 °C. 
A 4 M solution of HCl in dioxane (4.5 mL) was added slowly. The solution was stirred for 1 h at 
0 °C. H2O (0.09 mL) was added and the mixture was warmed to room temperature and stirred 
for 16 h. The mixture was diluted with EtOAc (25 mL) and washed with NaHCO3 (2 x 25 mL; 
gas evolution!). The organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (hexanes/EtOAc (+1% TEA), 
gradient from 1:1 to 1:3), yielding dimethyl ester 5.29 (111 mg, 0.260 mmol, 60%) as a red oil. 
TLC (hexanes/EtOAc (+1% TEA), 1:3): Rf = 0.42. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 8.05–8.00 (m, 1H, ArH), 7.97–7.90 (m, 3H, ArH), 7.73 (dd, J = 1.4, 1.4 Hz, 1H, ArH), 7.65 
(dd, J = 2.5, 1.4 Hz, 1H, ArH), 7.59–7.49 (m, 5H, ArH), 7.31–7.28 (m, 1H, ArH), 5.23 (s, 2H, 
CH2), 4.67 (s, 1H, CH), 3.93 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 1.91 (br s, 2H, NH2) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 173.8, 166.5, 158.9, 152.9, 152.6, 142.2, 137.6, 132.0, 
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131.2, 129.8, 129.4, 129.1, 122.9, 122.8, 121.6, 120.9, 118.7, 114.7, 69.8, 58.4, 52.6, 52.3 ppm. 
IR (neat, ATR): ṽ = 2949 (w), 1721 (vs), 1594 (m), 1446 (m), 1434 (m), 1372 (w), 1331 (m), 
1301 (s), 1228 (s), 1164 (m), 1109 (w), 1043 (w), 998 (w), 879 (w), 792 (w), 768 (m), 694 
(m) cm-1. HRMS (ESI+): m/z calcd. for [C24H24N3O5]+: 434.1716, found: 434.1709 ([M+H]+). 
 
 
Synthesis of carboxy(3-carboxy-5-((3-(phenyldiazenyl)benzyl)oxy)phenyl)methan-
aminium formate (m-Azo-3C5HPG) 
 
 
 
Dimethyl ester 5.29 (82 mg, 0.19 mmol) was dissolved in THF (4 mL) and a 2 M solution of 
LiOH in water (0.67 mL) was added. The solution was stirred for 16 h at room temperature. The 
pH was adjusted to pH = 1 with 2 M HCl and the solvent was removed in vacuo. The crude 
product was purified by reversed-phase silica gel column chromatography (H2O/MeOH (+0.1% 
HCO2H), gradient from 10:0 to 4:6), giving rise to m-Azo-3C5HPG as its formate salt (54 mg, 
0.12 mmol, 63%) as an orange solid. 
RP-TLC (H2O/MeOH, 1:1): Rf = 0.19. M.p.: 154 °C (dec.). 1H NMR (DMSO-d6, 600 MHz, 
27 °C): δ = 7.98–7.96 (m, 1H, ArH), 7.90–7.87 (m, 2H, ArH), 7.85 (ddd, J = 7.6, 1.7, 1.7 Hz, 
1H, ArH), 7.64–7.55 (m, 6H, ArH), 7.47 (dd, J = 2.5, 1.3 Hz, 1H, ArH), 7.36–7.34 (m, 1H, 
ArH), 5.27 (s, 2H, CH2), 4.31 (s, 1H, CH) ppm. 13C NMR (DMSO-d6, 150 MHz, 27 °C): 
δ = 167.8, 167.5, 163.9, 158.4, 154.1, 154.0, 152.5, 152.3, 139.9, 138.9, 132.1, 130.8, 130.1, 
129.9, 123.0, 122.8, 121.5, 120.2, 113.9, 69.4, 58.3 ppm. IR (neat, ATR): ṽ = 3055 (w), 2907 
(w), 2607 (w), 1689 (m), 1596 (s), 1483 (m), 1394 (m), 1332 (m), 1301 (m), 1243 (m), 1173 
(m), 1060 (m), 972 (w), 922 (w), 883 (w), 790 (m), 767 (m), 690 (vs) cm-1. HRMS (ESI-): m/z 
calcd. for [C22H18N3O5]-: 404.1246, found: 404.1252 ([M-H]-). UV/Vis: λmax = 323, 433 nm. 
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Synthesis of methyl 3-(1-hydroxy-2-methoxy-2-oxoethyl)-5-((3-(phenyldiazenyl)benzyl)-
oxy)benzoate (5.31) 
 
 
 
Cyanohydrin 5.30 (60 mg, 0.15 mmol) was dissolved in MeOH (1.5 mL) and cooled to 0 °C. A 
4 M solution of HCl in dioxane (1.5 mL) was added slowly. The solution was stirred for 1 h at 
0 °C. H2O (0.03 mL) was added and the mixture was warmed to room temperature and stirred 
for 16 h. The mixture was diluted with EtOAc (20 mL) and washed with NaHCO3 (2 x 20 mL; 
gas evolution!). The organic layers were dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel chromatography (hexanes/EtOAc, 4:1 → 2:1), 
affording dimethyl ester 5.31 (40 mg, 0.092 mmol, 61%) as an orange oil. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.35. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 8.00–7.98 
(m, 1H, ArH), 7.94–7.88 (m, 3H, ArH), 7.73 (ddd, J = 1.5, 1.5, 0.6 Hz, 1H, ArH), 7.64 (dd, 
J = 2.5, 1.4 Hz, 1H, ArH), 7.55–7.47 (m, 5H, ArH), 7.30–7.28 (m, 1H, ArH), 5.21–5.18 (m, 3H, 
CH, CH2), 3.91 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.53 (d, J = 5.4 Hz, 1H, OH) ppm. 
13C NMR (CDCl3, 150 MHz, 27 °C): δ = 173.6, 166.5, 158.8, 152.8, 152.5, 140.1, 137.5, 
131.8, 131.1, 129.8, 129.1, 128.7, 122.9, 122.8, 121.6, 120.6, 118.2, 115.2, 72.3, 69.8, 53.3, 
52.3 ppm. IR (neat, ATR): ṽ = 3467 (w), 2951 (w), 1719 (s), 1595 (m), 1380 (w), 1334 (m), 
1331 (m), 1300 (vs), 1223 (vs), 1150 (m), 1111 (m), 1044 (m), 999 (m), 913 (m), 797 (m), 768 
(m), 733 (w), 693 (s) cm-1. HRMS (ESI+): m/z calcd. for [C24H23N2O6]+: 435.1556, found: 
435.1551 ([M+H]+). 
 
 
5.5.4 SYNTHESIS OF AZO-DCPG 
 
Synthesis of dimethyl 4-(hydroxymethyl)phthalate (5.32) 
 
 
 
1,2,4-Benzenetricarboxylic anhydride (10.0 g, 52.0 mmol, 1.0 equiv.) was dissolved in 
1,4-dioxane (160 mL). BH3 ! THF (1 M solution; 52.0 mL, 52.0 mmol, 1.0 equiv.) was added 
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dropwise via a dropping funnel over a period of 1.5 h at room temperature. The reaction mixture 
was stirred for 16 h and then poured into a mixture of sat. aqu. NH4Cl (120 mL) and DCM 
(200 mL). The phases were separated and the aqueous layer was extracted with DCM 
(2 x 50 mL). The combined organic layers were dried over MgSO4 and the solvent was removed 
under reduced pressure. The crude product was used in the next step without further 
purification. 
The residue was dissolved in methanol (200 mL) and conc. H2SO4 (1 mL) was added dropwise. 
The reaction mixture was heated under reflux for 18 h. After cooling to room temperature, the 
mixture was poured into a mixture of H2O (100 mL) and Et2O (200 mL). The two phases were 
separated and the aqueous layer was extracted with Et2O (2 x 100 mL). The combined organic 
layers were washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash silica gel column chromatography (hexanes/EtOAc, 
gradient from 4:1 to 1:1) to give alcohol 5.32 (5.92 g, 26.4 mmol, 51% over two steps) as a 
colorless oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.38. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.65 (d, 
J = 7.8 Hz, 1H, ArH), 7.62–7.58 (m, 1H, ArH), 7.48–7.42 (m, 1H, ArH), 4.69 (s, 2H, CH2), 
3.87 (s, 6H, 2 x OCH3), 3.38 (br s, 1H, OH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 168.4, 167.9, 145.0, 132.3, 130.2, 129.2, 128.8, 126.6, 63.8, 52.7, 52.6 ppm. IR (neat, 
ATR): ṽ = 3432 (w), 1717 (vs), 1610 (w), 1435 (m), 1283 (vs), 1197 (s), 1126 (s), 1070 (s), 977 
(m), 959 (m), 913 (w), 845 (w), 821 (w), 786 (m), 764 (m), 732 (w), 707 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C11H13O5]+: 225.0763, found: 225.0757 ([M+H]+). 
 
Synthesis of dimethyl 4-formylphthalate (5.33) 
 
 
 
To a solution of alcohol 5.32 (5.75 g, 25.6 mmol, 1.0 equiv.) in DCM (300 mL), MnO2 (22.3 g, 
256 mmol, 10 equiv.) was added in one portion. The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered through Celite and the residue was washed 
thoroughly with DCM. The filtrate was concentrated under reduced pressure to give aldehyde 
5.33 (5.11 g, 23.0 mmol, 90%) as a colorless oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.71. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 10.11 (s, 1H, 
CHO), 8.30 (dd, J = 1.8, 0.6 Hz, 1H, ArH), 8.08 (dd, J = 7.8, 1.8 Hz, 1H, ArH), 7.85 (ddd, 
O
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J = 7.8, 0.6, 0.6 Hz, 1H, ArH), 3.97 (s, 6H, 2 x OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 190.4, 167.4, 166.5, 137.7, 137.5, 132.1, 131.8, 130.5, 129.5, 53.0, 53.0 ppm. IR 
(neat, ATR): ṽ = 1729 (vs), 1707 (s), 1608 (m), 1437 (m), 1289 (s), 1198 (m), 1181 (m), 1125 
(m), 1070 (m), 959 (w), 901 (w), 849 (w), 822 (w), 805 (w), 771 (w), 710 (w) cm-1. HRMS 
(EI+): m/z calcd. for [C11H10O5]+: 222.0528, found: 222.0530 ([M]+). 
 
Synthesis of dimethyl 4-(1,3-dioxolan-2-yl)phthalate (5.34) 
 
 
 
Aldehyde 5.33 (535 mg, 2.41 mmol, 1.0 equiv.) was dissolved in benzene (10 mL) and ethylene 
glycol (0.66 mL, 12 mmol, 4.9 equiv.) and a catalytic amount of p-TsOH monohydrate (20 mg, 
0.11 mmol, 0.05 equiv) were added. The mixture was heated to reflux for 18 h in a Dean-Stark 
apparatus. After cooling, the solvent was removed in vacuo and the crude product was purified 
by flash silica gel column chromatography (hexanes/EtOAc, gradient from 5:1 to 2:1) to give 
1,3-dioxolane 5.34 (642 mg, 2.41 mmol, 100%) as a colorless oil. 
TLC (hexanes/EtOAc, 1:1): Rf = 0.73. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.87 (ddd, 
J = 1.7, 0.5, 0.5 Hz, 1H, ArH), 7.76 (d, J = 8.0 Hz, 1H, ArH), 7.65 (ddd, J = 8.0, 1.7, 0.5 Hz, 
1H, ArH), 5.88 (s, 1H, CH), 4.13–4.06 (m, 4H, 2 x OCH2), 3.94 (s, 3H, OCH3), 3.93 (s, 3H, 
OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 167.8, 167.7, 141.6, 132.5, 132.1, 129.1, 
129.0, 127.0, 102.4, 65.4, 52.7, 52.7 ppm. IR (neat, ATR): ṽ = 1721 (vs), 1434 (m), 1273 (s), 
1206 (s), 1124 (m), 1085 (s), 1069 (s), 1026 (m), 989 (m), 959 (m), 942 (m), 851 (m), 821 (m), 
791 (m), 767 (m), 723 (w), 709 (w), 692 (w), 664 (w) cm-1. HRMS (EI+): m/z calcd. for 
[C13H13O6]+: 265.0712, found: 265.0705 ([M-H]+). 
 
Synthesis of 4-(1,3-dioxolan-2-yl)phthalic acid (5.35) 
 
 
 
Dimethyl ester 5.34 (300 mg, 1.13 mmol, 1.0 equiv.) was dissolved in a mixture of THF (6 mL) 
and MeOH (2 mL). LiOH (108 mg, 4.52 mmol, 4.0 equiv.) in H2O (2 mL) was added and the 
reaction mixture was stirred for 4 h at room temperature. The mixture was diluted with H2O 
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(20 mL) and extracted with EtOAc (15 mL) to remove unreacted starting material. The aqueous 
phase was then acidified to pH = 1 with 1 M HCl and extracted with CHCl3/i-PrOH (1:1; 
3 x 20 mL). The combined organic layers were washed with H2O (30 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by flash silica gel column 
chromatography (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6 → 80:20:0.6:0.6) to give 
dicarboxylic acid 5.35 (167 mg, 0.700 mmol, 62%) as a colorless solid. 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.03. M.p.: 148 °C (dec.). 1H NMR 
(CDCl3, 300 MHz, 27 °C): δ = 10.63–10.17 (br s, 2H, 2 x CO2H), 8.01 (d, J = 1.7, 1H, ArH), 
7.91 (d, J = 8.0 Hz, 1H, ArH), 7.76 (dd, J = 8.0, 1.7 Hz, 1H, ArH), 5.94 (s, 1H, CH), 4.18–4.04 
(m, 4H, 2 x OCH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 173.4, 173.3, 142.5, 131.6, 
131.4, 129.8, 129.6, 127.5, 102.2, 65.4 ppm. IR (neat, ATR): ṽ = 2891 (m), 1693 (s), 1575 (m), 
1495 (m), 1359 (m), 1260 (vs), 1205 (s), 1143 (m), 1090 (vs), 1074 (s), 1024 (m), 986 (m), 943 
(m), 912 (w), 849 (m), 796 (s), 770 (m), 729 (w), 695 (w), 682 (w), 654 (w) cm-1. HRMS (EI+): 
m/z calcd. for [C11H9O6]+: 237.0399, found: 237.0392 ([M-H]+). 
 
Synthesis of 4-formyl-2-((4-(phenyldiazenyl)phenyl)carbamoyl)benzoic acid (5.37) and 5-
formyl-2-((4-(phenyldiazenyl)phenyl)carbamoyl)benzoic acid (5.38) 
 
 
 
Dicarboxylic acid 5.35 (1.82 g, 7.64 mmol, 1.0 equiv.) was dissolved in Ac2O (18 mL) and 
heated to 80 °C for 3 h. The reaction mixture was cooled to room temperature and the solvent 
was removed in vacuo to give quantitatively the crude anhydride 5.36 (1.31, 7.64 mmol) as a 
colorless solid. 
Without further purification, 5.36 (1.31 g, 5.95 mmol, 1.0 equiv.) was dissolved in THF 
(60 mL) and 4-aminoazobenzene (1.17 g, 5.95 mmol, 1.0 equiv.) was added. The mixture was 
heated under reflux for 16 h. The solvent was evaporated under reduced pressure and the crude 
product purified by a quick flash silica gel column chromatography (DCM/MeOH/HOAc/H2O, 
98:2:0.6:0.6) to give a mixture of the two regioisomers 5.37 and 5.38 (2.48 g, 5.94 mmol, 
100%) as a red solid. 
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This crude mixture was then dissolved in THF (120 mL) and 1 M HCl (11.9 mL, 2.0 equiv.) was 
added. The reaction mixture was stirred for 16 h at room temperature. 2 M NaOH (5.95 mL, 
2.0 equiv.) was added and the organic layer was washed with brine (75 mL), dried over MgSO4 
and concentrated under reduced pressure. The crude product was purified by flash silica gel 
column chromatography (DCM/MeOH/HOAc/H2O, 98:2:0.6:0.6), obtaining analytical samples 
of both regioisomers. 
4-Formyl-2-((4-(phenyldiazenyl)phenyl)carbamoyl)benzoic acid (5.37): 
 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.35. 1H NMR (DMSO-d6, 400 MHz, 
27 °C): δ = 13.96–12.96 (br s, 1H, CO2H), 10.88 (s, 1H, NH), 10.12 (s, 1H, CHO), 8.40 (d, 
J = 1.2 Hz, 1H, ArH), 8.15 (dd, J = 8.0, 1.2 Hz, 1H, ArH), 7.91–7.88 (m, 4H, ArH), 7.87–7.84 
(m, 2H, ArH), 7.80 (d, J = 8.0 Hz, 1H, ArH), 7.57–7.54 (m, 2H, ArH), 7.53 (dd, J = 1.6, 1.6 Hz, 
1H, ArH) ppm. 13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 192.9, 167.3, 166.9, 152.5, 148.2, 
143.5, 142.8, 137.0, 132.6, 131.5, 131.2, 131.2, 129.9, 129.4, 124.1, 122.8, 120.2 ppm. IR 
(neat, ATR): ṽ = 3313 (m), 3057 (m), 1677 (s), 1663 (s), 1597 (vs), 1545 (vs), 1505 (m), 1464 
(w), 1441 (w), 1408 (m), 1313 (s), 1263 (s), 1184 (m), 1154 (m), 1071 (m), 965 (w), 895 (w), 
841 (s), 758 (m), 721 (w), 680 (m), 667 (w) cm-1. HRMS (ESI-): m/z calcd. for [C21H14O4N3]-: 
372.0984, found: 372.0999 ([M-H]-). 
 
5-Formyl-2-((4-(phenyldiazenyl)phenyl)carbamoyl)benzoic acid (5.38): 
 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.28. 1H NMR (DMSO-d6, 400 MHz, 
27 °C): δ = 11.12 (s, 1H, NH), 10.12 (s, 1H, CHO), 8.14 (d, J = 1.2 Hz, 1H, ArH), 8.08 (dd, 
J = 8.0, 1.2 Hz, 1H, ArH), 8.04 (d, J = 8.0 Hz, 1H, ArH), 7.93–7.91 (m, 4H, ArH), 7.88–7.85 
(m, 2H, ArH), 7.58–7.55 (m, 2H, ArH), 7.54 (dd, J = 1.6, 1.6 Hz, 1H, ArH) ppm. 13C NMR 
(DMSO-d6, 100 MHz, 27 °C): δ = 192.9, 167.7, 167.0, 152.5, 148.2, 142.8, 138.7, 138.0, 
136.7, 131.5, 130.8, 130.6, 129.9, 129.5, 124.1, 122.8, 120.2 ppm. IR (neat, ATR): ṽ = 3293 
(m), 3059 (m), 1700 (vs), 1595 (s), 1539 (vs), 1499 (m), 1439 (w), 1407 (m), 1325 (m), 1262 
(m), 1188 (m), 1153 (m), 1070 (w), 1020 (w), 844 (m), 767 (m), 688 (m), 668 (w) cm-1. HRMS 
(ESI-): m/z calcd. for [C21H14O4N3]-: 372.0984, found: 372.1003 ([M-H]-). 
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Synthesis of carboxy(3-carboxy-4-((4-(phenyldiazenyl)phenyl)carbamoyl)phenyl)methan-
aminium formate (Azo-DCPG) and carboxy(4-carboxy-3-((4-(phenyldiazenyl)phenyl)-
carbamoyl)phenyl)methanaminium formate (5.39) 
 
 
 
A mixture of both regioisomeric aldehydes 5.37 and 5.38 (525 mg, 1.41 mmol, 1.0 equiv.) was 
dissolved in 7 M NH3 in MeOH (27 mL) and TMSCN (0.28 mL, 2.3 mmol, 1.6 equiv.) was 
added. The mixture was stirred at room temperature for 20 h. The solvent was removed under 
reduced pressure and the crude product was used without further purification in the next step. 
The crude residue was dissolved in MeOH (70 mL) and conc. H2SO4 (2 mL) was added 
dropwise. The reaction mixture was then heated to reflux for 3 h. After cooling to room 
temperature, the solvent was removed in vacuo and the residue was taken up in EtOAc (50 mL). 
The organic phase was washed with sat. aqu. NaHCO3 (2 x 50 mL) and brine (50 mL), dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by a quick flash silica 
gel column chromatography (DCM/MeOH/HOAc/H2O, 100:0:0:0 → 98:2:0.6:0.6) to yield a 
mixture of two isomers which was used directly in the next step. 
The crude products were dissolved in MeOH (9 mL) and cooled to 0 °C. A 4 M solution of HCl 
in dioxane (9 mL) was added slowly. The solution was stirred for 1 h at 0 °C. H2O (0.10 mL) 
was added and the mixture was warmed to room temperature and stirred for 16 h. The mixture 
was washed with sat. aqu. NaHCO3 (25 mL; gas evolution!) and extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4 
and concentrated in vacuo.  
The crude product was then dissolved in THF (24 mL) and a 2 M solution of LiOH (4 mL) was 
added. The mixture was stirred at room temperature for 2 d. 2 M HCl (5 mL) was added and the 
solvent was removed under reduced pressure. The crude product was purified by reversed-phase 
flash silica gel column chromatography (H2O/MeOH, 0.1% HCO2H, gradient from 100:0 to 
50:50), affording a mixture of both regioisomers Azo-DCPG and 5.39. The two regioisomers 
were then separated by HPLC (H2O/MeOH, 0.1% HCO2H, gradient from 95:5 to 30:70) to yield 
the two products in 75 mg (0.18 mmol, 13% over 4 steps; Rt = 50 min) and 25 mg (0.060 mmol, 
4% over 4 steps; Rt = 52 min) both as orange solids. Their identity was confirmed by HRMS 
and NMR but it was not possible to assign the corresponding structure to each compound.  
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Rt = 50 min: 1H NMR (CD3OD, 400 MHz, 27 °C): δ = 8.07–8.01 (m, 1H, ArH), 7.93–7.83 (m, 
6H, ArH), 7.70–7.65 (m, 2H, ArH), 7.54–7.47 (m, 3H, ArH), 4.74 (s, 1H, CH) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 171.0, 169.0, 152.7, 148.9, 141.6, 139.3, 130.6, 130.5, 128.8, 
128.7, 127.0, 124.7, 123.3, 122.2, 121.6, 120.1, 113.7, 57.9 ppm. HRMS (ESI-): m/z calcd. for 
[C22H17O5N4]-: 417.1199, found: 417.1202 ([M-H]-). 
 
Rt = 52 min: 1H NMR (DMSO-d6, 600 MHz, 27 °C): δ = 11.04 (br s, 1H, CO2H), 7.93–7.92 
(m, 1H, ArH), 7.91–7.87 (m, 4H, ArH), 7.86–7.85 (m, 1H, ArH), 7.85–7.84 (m, 1H, ArH), 
7.63–7.60 (m, 1H, ArH), 7.58–7.57 (m, 1H, ArH), 7.56–7.54 (m, 2H, ArH), 7.54–7.51 (m, 1H, 
ArH), 4.75 (s, 1H, CH) ppm. 13C NMR (DMSO-d6, 150 MHz, 27 °C): δ = 167.9, 167.8, 152.5, 
147.9, 143.3, 139.4, 131.4, 129.8, 129.6, 128.8, 128.3, 124.1, 124.1, 122.8, 122.1, 120.1, 120.0, 
58.1 ppm. HRMS (ESI-): m/z calcd. for [C22H17O5N4]-: 417.1199, found: 417.1202 ([M-H]-). 
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5.6 NMR SPECTRA 
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6.1 DEVELOPMENT OF AZO-SEN12333, A PCL FOR NICOTINIC 
ACETYLCHOLINE RECEPTORS 
 
Alpha 7 nicotinic acetylcholine receptors (α7 nAChRs) are implicated in the modulation of 
many cognitive functions, such as attention, working memory and episodic memory. For this 
reason, α7 nAChR agonists are promising therapeutic candidates for the treatment of cognitive 
impairment associated with a variety of disorders including Alzheimer’s disease and 
schizophrenia.[1]  
In a recent study by Wyeth Research (now part of Pfizer) novel α7 nAChR agonists were 
developed.[1] Among various candidates, SEN12333 was found to be a selective agonist of α7 
nAChRs (EC50 = 1.65 µM) with excellent in vitro and in vivo profiles, excellent brain 
penetration and oral bioavailability. Moreover, it demonstrated in vivo efficacy in multiple 
behavioural cognition models.[1] The authors add that most α7 agonists are based on 
quinuclidine scaffolds which recently had often failed clinical trials due to toxicological 
reasons.[1,2] Therefore, the α7 agonists developed by the authors based on a different class of 
compounds could avoid toxicity issues of quinuclidines. 
The extensive SAR studies[1] and two even more recent follow-up studies by the same 
authors[3,4] suggested a relatively high tolerance toward substitution of the phenylpyridine amide 
anchor for large biaromatic substituents. Consequently, a photoswitchable azobenzene 
derivative of SEN12333 was designed (Fig. 6.1). 
 
 
Figure	  6.1.	   Structures	  of	  SEN12333	  and	  Azo-­‐SEN12333.	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Synthesis of Azo-SEN12333 
 
The synthesis of Azo-SEN12333 commenced with an amide coupling of 5-bromovaleryl 
chloride with 4-aminoazobenzene to give amide 6.1 in 94% yield. Compound 6.1 was reacted 
with morpholine to furnish Azo-SEN12333 in 88% yield (Scheme 6.1). 
 
 
Scheme	  6.1.	   Synthesis	  of	  Azo-­‐SEN12333.	  
 
Biological Evaluation of Azo-SEN12333 
 
Azo-SEN12333 (among other compounds) was tested in a quick screening assay on Lymnaea 
stagnalis (Ls), Aplysia californica (Ac) and Aplysia californica Y55W (AcY55W) for their 
ability to reduce epibatidine binding (Epi, a high-affinity nAChR agonist) to α7 nAChR (Fig. 
6.2; Prof. Palmer Taylor, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla). 
In this assay, Azo-SEN12333 reduced Epi binding by 20-40%. 
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Figure	  6.2.	   Binding	   studies	   of	   10	  µM	   Azo-­‐SEN12333	   (among	   other	   compounds)	   on	   Ls,	   Ac,	   and	  
AcY55W.	  Nicotine	  (Nic;	  right)	  was	  used	  as	  an	  internal	  standard	  to	  verify	  proper	  functioning	  of	  the	  assay	  
(Prof.	  Palmer	  Taylor,	  Skaggs	  School	  of	  Pharmacy	  and	  Pharmaceutical	  Sciences,	  La	  Jolla).	  
 
Analysis of the photoswitching properties by UV/Vis spectroscopy revealed maximum 
absorption peaks for Azo-SEN12333 of λ = 361 nm and λ = 446 nm (Fig. 6.3a). The compound 
was then tested in HEK 293 cells transiently transfected with an α7 nAChR/glycine receptor 
chimera using the patch-clamp technique (Arunas Damijonaitis, LMU Munich). 
Azo-SEN12333 turned out to be a potent agonist of α7 nAChRs, being slightly more active in 
its trans configuration. However, both isomers of Azo-SEN12333 appear to be highly active, 
resulting in only limited amount of light-dependent current. The optimum photoswitching 
wavelengths were determined in a screening to be λ = 367 nm and λ = 449 nm (Fig. 6.3b and 
d). Kinetic measurements showed that photoswitching of nAChR currents with Azo-SEN12333 
occurs very rapidly (τ = 70 ms at λ = 449 nm; Fig. 6.3c).  
Despite these in part promising results, the limited amount of light-dependent current as well as 
a certain degree of receptor desensitization, which was observed during application of 
Azo-SEN12333, led to the conclusion to not follow up on these results. 
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Figure	  6.3.	   a)	   UV/Vis	   spectrum	   of	   Azo-­‐SEN12333.	   The	   peak	   absorption	   wavelengths	   are	  
λ	  =	  361	  nm	  and	  λ	  =	  446	  nm	  (DMSO).	  b)	  –	  d)	  Electrophysiological	  analysis	  of	  Azo-­‐SEN12333	   (100	  µM)	  in	  
HEK	  293	  cells	  transiently	  transfected	  with	  an	  α7	  nAChR/glycine	  receptor	  chimera	  (Arunas	  Damijonaitis,	  
LMU	  Munich).	  b)	  Wavelength	  screening.	  Irradiation	  with	  λ	  =	  367	  nm	  is	  used	  to	  generate	  the	  less	  active	  
cis	   isomer,	  alternated	  by	  different	  wavelength	  pulses	   to	   isomerize	  Azo-­‐SEN12333	   to	   the	   trans	   isomer.	  
λ	  =	  449	  nm	  was	  obtained	  as	  the	  most	  efficient	  photoswitching	  wavelength.	  c)	  Determination	  of	  τ.	  The	  
fastest	   photoswitching	   was	   observed	   for	   λ	  =	  449	  nm	   with	   τ	  =	  70	  ms.	   d)	   Representative	  
electrophysiological	  trace	  from	  b).	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6.2 DEVELOPMENT OF RED DAD, A RED-SHIFTED, NON-
PERMANENTLY CHARGED PCL FOR VOLTAGE-GATED POTASSIUM 
CHANNELS 
 
QAQ stands for a linear sequence of quaternary ammonium – azobenzene – quaternary 
ammonium and resembles the known local anesthetics lidocaine and its derivative QX-314 (Fig. 
6.4). QAQ enables rapid and selective optical control of nociception and neuronal excitability.[5] 
Due to its doubly charged nature, QAQ is membrane-impermeant but it is able to infiltrate pain-
sensing neurons through TRPV1 channels. From the intracellular site QAQ blocks voltage-
gated ion channels (NaV, KV, CaV) in the trans form but not the cis form.[5] Whereas QX-314 is 
also charged and therefore unable to cross the membrane, lidocaine is a tertiary amine which is 
able to permeate the membrane in its neutral state but functions as a channel blocker for NaV, 
KV and CaV channels from the cytoplasmic side in its protonated state.[6] Following this logic, a 
non-permanently charged and moreover red-shifted version of QAQ named Red DAD was 
designed and synthesized (Fig. 6.4). Having three basic nitrogen atoms in the molecule, 
Red DAD should exist in an equilibrium of positively charged and neutral molecules under 
physiological conditions and therefore be able to permeate membranes. Once Red DAD has 
crossed the membrane, it could be protonated and accumulate in the cytosol. Hence, it could 
function as photochromic blocker of voltage-gated ion channels, like QAQ does, without 
requiring noxious stimuli to open TRPV1 channels to allow the molecule to cross the 
membrane. 
 
 
Figure	  6.4.	   Structures	  of	  lidocaine	  (in	  its	  protonated	  form),	  QX-­‐314,	  QAQ	  and	  Red	  DAD.	  	  
 
Synthesis of Red DAD 
 
The synthesis of Red DAD is depicted in Scheme 6.2: The commercially available dye Disperse 
Red 1 (6.2) was treated under Appel conditions, affording bromide 6.3 in 95% yield. The 
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bromide was then replaced with diethyl amine by heating the two compounds together in a 
pressure tube. Thus, tertiary amine 6.4 was obtained in 91% yield. The nitro group was reduced 
using sodium sulfide, giving aniline 6.5 in 99% yield. Compound 6.5 was then converted to 6.6 
following a protocol used for the synthesis of lidocaine:[7] The aniline was reacted with 
chloroacetyl chloride which yielded α-chloro amide 6.6 quantitatively. The α-chloride was then 
replaced with diethyl amine by heating in a pressure tube, affording Red DAD in 69% yield. 
 
 
Scheme	  6.2.	   Synthesis	  of	  Red	  DAD.	  
 
The absorption maximum of Red DAD was determined by UV/Vis spectroscopy to be at 
λ = 454 nm (Fig. 6.5a). Whole-cell voltage-clamp recordings of layer 2/3 cortical neurons in an 
acute murine brain slice preparation (Laura Laprell, LMU Munich) revealed that Red DAD acts 
as a light-dependent blocker of K+ currents. Intrinsic KV channels were activated by voltage 
jumps from –70 mV to +50 mV in the presence of Red DAD (200 µM) while blocking NaV 
channels using TTX (1 µM). Currents elicited in the dark (Fig. 6.5b, left) were significantly 
smaller than in the presence of light of different wavelengths ranging from λ = 380 nm to 
λ = 520 nm (Fig. 6.5b, right), indicating that trans-Red DAD is a more potent KV channel 
blocker than cis-Red DAD. Statistical analyses showed that the highest relative change in 
current amplitude is obtained with λ = 460 nm (Fig. 6.5c) which is in good agreement with the 
absorption spectrum of Red DAD (Fig. 6.5a).  
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Figure	  6.5.	   a)	  UV/Vis	   spectrum	  of	  Red	  DAD	   (DMSO).	  The	  maximum	  absorption	  peak	   is	   found	  at	  
λ	  =	  454	  nm.	  b)	  Whole-­‐cell	  voltage-­‐clamp	  recording	  of	  layer	  2/3	  cortical	  neurons	  in	  presence	  of	  200	  µM	  
Red	   DAD	   and	   1	   µM	   TTX.	   Voltage	   jumps	   from	   –70	  mV	   to	   +50	  mV	   induce	   large	   K+	   outward	   currents.	  
Currents	   in	   darkness	   are	   compared	   to	   currents	   in	   the	   presence	   of	   light	   (λ	  =	  380–520	  nm).	   c)	  
Quantification	  of	  experiments	  as	  performed	   in	  b).	   Induced	  currents	  by	  voltage	   jump	   in	  darkness	  were	  
normalized	   to	   1.	  Note	   that	   all	  wavelengths	   induce	   larger	   currents	   compared	   to	   darkness.	  d)	   Current-­‐
voltage	   relationship	   in	   layer	   2/3	   cortical	   neurons	   in	   the	   presence	   of	   200	  µM	  Red	   DAD	   and	   1	  µM	   TTX	  
compared	  in	  darkness	  and	  in	  the	  presence	  of	  light	  (black:	  dark,	  blue:	  λ	  =	  460	  nm).	  e)	  Top:	  Raster	  plot	  of	  
a	   multielectrode	   array	   (MEA)	   recording	   of	   a	   Red	   DAD	   treated	   blind	   retina	   (cngA3-­‐/-­‐,	   rho-­‐/-­‐,	   opn4-­‐/-­‐)	  
stimulated	  with	  light	  (black	  bars:	  dark,	  blue	  bars:	  λ	  =	  480	  nm).	  Retina	  was	  mounted	  on	  a	  200	  µm/30	  µm	  
MEA	  (Multichannel	  Systems)	  after	  short	   incubation	  with	  200	  µM	  Red	  DAD.	  During	   the	  experiment	   the	  
retina	  was	  perfused	  with	  Normal	  Ringer’s	   solution	   at	   32–34	  °C	   at	   a	   flow	   rate	  of	   2–3	  ml/min.	   Bottom:	  
Average	   histogram	   of	   all	   cells	   detected	  with	   spiking	   rate	   in	   Hz	   (spikes/s;	  b)	   –	   e):	   Laura	   Laprell,	   LMU	  
Munich).	  
 
The current-voltage relationship in layer 2/3 cortical neurons in the presence of Red DAD and 
TTX confirmed that mostly outward rectifying currents are modulated by Red DAD in the 
presence of light (λ = 460 nm; Fig. 6.5d). Multielectrode array (MEA) experiments in retinae of 
blind mice (cngA3-/-, rho-/-, opn4-/-; Laura Laprell, LMU Munich) revealed that short incubation 
with Red DAD (200 µM) prior to the recording leads to light-dependent spiking of retinal 
ganglion cells (RGCs). Illumination with light (λ = 480 nm) more than doubles the spiking rate 
in RGCs compared to darkness. This light-dependent change in spiking frequency occurs 
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relatively fast and is fully reversible (Fig. 6.5e). Taken together, Red DAD is the most 
promising tool for our vision restoration approach. 
 
 
6.3 DEVELOPMENT OF A NEW DISULFIDE CONTAINING CLASS OF PTLS 
 
Maleimide containing PTLs, such as MAQ or MAG, have been used in the past to optically 
control various functions such as neuronal activity,[8–10] locomotor behavior in zebrafish[11] and 
the restoration of visual responses.[12] However, the usage of the highly reactive maleimides in 
in vivo experiments might be accompanied with various undesired side effects. Moreover, high 
concentrations of thiol containing molecules, such as serum albumin, might react with the 
maleimide moiety before it can reach its intended target. Therefore, new ways to covalently 
attach PTLs to ion channels or receptors are desired. 
Sunesis Pharmaceuticals, Inc. has developed a concept called Tethering® for fragment-based 
drug discovery which is based on reversible covalent bond formation reactions between the 
protein target and the fragment(s) to be evaluated.[13] It is based on sulfide exchange reactions of 
a fragment which contains a thiol functional group that is coupled to 2-aminothioethanol in 
order to increase solubility and a (genetically introduced) cysteine on the protein (Fig. 6.6). 
 
 
 
Figure	  6.6.	   Schematic	  illustration	  of	  the	  concept	  of	  Tethering®.	  Illustration	  adapted	  from	  Erlanson	  
et	  al.,[13]	  reprinted	  with	  permission	  from	  ANNUAL	  REVIEWS.	  Copyright	  2004.	  	  
 
Formation of the disulfide bond is extremely mild and occurs under equilibrium conditions, 
given a similar reduction potential of the thiol moieties engaged. As a result, a fragment with 
increased affinity to the target will lead to a thermodynamic sink and shift the equilibria toward 
this product (Fig. 6.7). 
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Figure	  6.7.	   Schematic	   illustration	   of	   some	   equilibra	   reactions	   in	   Tethering®.	   If	   a	   fragment	   has	  
inherent	  affinity	  for	  the	  target	  (here	  square	  B),	  equilibra	  will	  be	  shifted	  toward	  this	  complex.	  Illustration	  
adapted	  from	  Erlanson	  et	  al.,[13]	  reprinted	  with	  permission	  from	  ANNUAL	  REVIEWS.	  Copyright	  2004.	  
	  
Importantly, these disulfides are extracellularly stable and have no effect on other biological 
molecules. Therefore, they are potential candidates to replace the highly reactive maleimide 
moieties on previously used PTLs. Consequently, two disulfide analogues of the established 
PTL MAQ for voltage-gated potassium channels were designed which differ only in their 
distance between the azobenzene and the thiol moiety in order to screen for the optimum spacer 
length (Fig. 6.8).  
 
 
Figure	  6.8.	   Structures	  of	  MAQ	  and	  MS2	  and	  MS3.	  
 
Synthesis of MS2 and MS3 
 
Firstly, the Boc-protected disulfide precursors 6.10 and 6.11 were synthesized via a sulfide 
exchange reaction from commercially available di-Boc cystamine 6.7 and the corresponding 
mercaptocarbxylic acids thioglycolic acid (6.8) and 3-mercaptopropionic acid (6.9) in 56% and 
30% yield, respectively (Scheme 6.3). 
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Scheme	  6.3.	   Synthesis	  of	  disulfide	  precursors	  6.10	  and	  6.11.	  
 
After some unsuccessful amide coupling attempts using oxalyl chloride and DMF to form the 
acid chloride of 6.10 or EDCI as coupling reagent, HBTU and TEA allowed for amide 
formation of 4,4’-azodianiline 6.12 and carboxylic acid 6.10 to give amide 6.13 in 54% yield. 
Oxalyl chloride and DMF were used to convert the betaine to its acid chloride which was 
subsequently reacted with aniline 6.13 to give bisamide 6.15 in 19% yield. Deprotection of the 
Boc group using HCl gave MS2 in 67% yield (Scheme 6.4). 
The same reaction sequence was repeated with the elongated disulfide precursor 6.11 to obtain 
MS3 accordingly. HBTU-mediated amide coupling of 6.12 and 6.11 provided 6.14 in 30% 
yield. Compound 6.14 was then coupled with the acid chloride of the betaine to give bisamide 
6.16 in 52% yield. Finally, removal of the Boc group with HCl provided MS3 in 66% yield 
(Scheme 6.4). 
 
 
Scheme	  6.4.	   Synthesis	  of	  MS2	  and	  MS3.	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The maximum absorption wavelengths of MS2 and MS3 were determined to be at λ = 377 nm 
and λ = 456 nm (MS2, Fig. 6.9a), as well as at λ = 376 nm and λ = 455 nm (MS3, Fig. 6.9b). 
The compounds will be tested by Dr. Martin Sumser (LMU Munich) on their ability to act as 
PTLs on voltage-gated potassium channels in due time. 
 
 
Figure	  6.9.	   UV/Vis	  spectra	  (DMSO)	  of	  a)	  MS2	  and	  b)	  MS3.	  The	  maximum	  absorption	  wavelengths	  
are	  λ	  =	  377	  nm	  and	  λ	  =	  456	  nm	  (MS2),	  as	  well	  as	  λ	  =	  376	  nm	  and	  λ	  =	  455	  nm	  (MS3).	  
 
 
6.4 SYNTHESIS OF A PEGYLATED PHOTOCLEAVABLE O-NITROBENZYL 
PROTECTING GROUP  
 
In cooperation with the group of Prof. Herwig Baier (University of California, San Francisco, 
now Max-Planck-Institute Munich), a PEGylated photolytically cleavable o-nitrobenzyl 
protecting group (PG) was synthesized starting from vanillin (Scheme 6.5). The goal of this 
project was to increase the solubility of otherwise commercially available o-nitrobenzyl PGs 
(e.g. 4,5-dimethoxy-2-nitrobenzylbromide). The Baier group genetically engineered cysteine 
residues into a region on the cell surface which is responsible for cell-cell recognition and 
aggregation. By blocking these regions, interaction of cells would be prevented and therefore no 
cell aggregation could take place. If a photolytically cleavable PG is used, cell aggregation 
could be reinitiated by cleaving the PG with light in a high spatial and temporal precision. 
Firstly, vanillin was reacted with benzyl bromide to give benzyl ether 6.17 in 96% yield. 
Nitration of 6.17 with 100% nitric acid yielded 6.18 in 88%. The benzyl ether was cleaved with 
HBr in acetic acid in 79% yield (6.19), followed by propargylation using propargyl bromide, 
affording alkine 6.20 in 95% yield. Aldehyde 6.20 was then reduced to primary alcohol 6.21 
with NaBH4 (97% yield), followed by an Appel-type reaction with PBr3, furnishing bromide 
6.22 in 44% yield. Finally, the PEG azide 6.23 was attached via formation of a 1,2,3-triazole 
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using “click chemistry”.[14] The PEGylated light-sensitive o-nitrobenzyl protecting group PEG 
was obtained in 82% yield. 
 
 
Scheme	  6.5.	   Synthesis	  of	  PEGylated	  o-­‐nitrobenzyl	  PG	  PEG	  from	  vanillin.	  
 
First results in an N-Cadherin adhesion assay (Dr. Anna Lisa Lucido, University of California, 
San Francisco) showed that PEG appears to be effective in preventing cell aggregation, 
however lacks specifity for the D1C mutant (it also perturbs Ca2+-mediated binding in the 
wildtype; Fig. 6.10 top). Illumination with UV light slightly increases the average particle size 
due to cell aggregation. However, the difference is relatively small compared to the particle size 
without PEG, suggesting that a significant proportion of PEG was not cleaved by UV 
illumination (Fig. 6.10 bottom). Since o-nitrobenzyl protecting groups are well established as 
light-cleavable PGs in biological systems,[15] the conditions of UV illumination (wavelength, 
light intensity, duration of illumination) probably need to be further evaluated. 
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Figure	  6.10.	   N-­‐Cadherin	  adhesion	  assay	  of	  the	  PEGylated	  PG	  PEG	  (Dr.	  Anna	  Lisa	  Lucido,	  University	  
of	   California,	   San	   Francisco).	   PEG	   appears	   to	   bind	   to	   the	   cell	   surface	   and	   therefore	   prevents	   cell	  
aggregation.	  However,	  no	  significant	  specifity	  for	  the	  D1C	  mutant	  over	  the	  wildtype	  (top)	  was	  achieved.	  
Illumination	   with	   light	   only	   led	   to	   a	   small	   increase	   in	   aggregation,	   suggesting	   that	   the	   PG	   was	   not	  
removed	  completely	  (bottom).	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6.5 EXPERIMENTAL PROCEDURES AND ANALYTICAL DATA 
 
6.5.1 GENERAL EXPERIMENTAL DETAILS AND INSTRUMENTATION 
 
All reactions were carried out with magnetic stirring and if air or moisture sensitive in oven-
dried glassware under an atmosphere of nitrogen or argon. Syringes used to transfer reagents 
and solvents were purged with nitrogen or argon prior to use. Reagents were used as 
commercially supplied unless otherwise stated. Thin layer chromatography was performed on 
pre-coated silica gel F254 glass backed plates and the chromatogram was visualized under UV 
light and/or by staining using aqueous acidic vanillin or potassium permanganate, followed by 
gentle heating with a heat gun. Flash column chromatography was performed using silica gel, 
particle size 40–63 µm (eluants are given in parenthesis). The diameter of the columns and the 
amount of silica gel were calculated according to the recommendations of W. C. Still et al.[16] 
IR spectra were recorded on a Perkin Elmer Spectrum Bx FT-IR instrument as thin films with 
absorption bands being reported in wave number (cm-1). UV/Vis spectra were obtained using a 
Varian Cary 50 Scan UV/Vis spectrometer and Helma SUPRASIL precision cuvettes (10 mm 
light path).  
 1H and 13C NMR spectra were measured on Varian VNMRS 300, VNMRS 400, INOVA 400 or 
VNMRS 600 instruments. The chemical shifts are quoted as δ-values in ppm referenced to the 
residual solvent peak (CDCl3: δH 7.26, δC 77.2; CD3OD: δH 3.31, δC 49.0; DMSO-d6: δH 2.50, 
δC 39.5).[17] Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, 
q = quartet, quint = quintet, sext = sextet, sept = septet, m = multiplet. High resolution mass 
spectra (EI, ESI) were recorded by LMU Mass Spectrometry Service using a Thermo Finnigan 
MAT 95, a Jeol MStation or a Thermo Finnigan LTQ FT Ultra instrument. Melting points were 
obtained using a Stanford Research Systems MPA120 apparatus and are uncorrected. 
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6.5.2 SYNTHESIS OF AZO-SEN12333 
 
Synthesis of 5-bromo-N-(4-(phenyldiazenyl)phenyl)pentanamide (6.1) 
 
 
 
4-Aminoazobenzene (2.00 g, 10.1 mmol, 1.0 equiv.) was dissolved in DCM (40 mL) at 0 °C 
and TEA (1.40 mL, 10.1 mmol, 1.0 equiv.) was added. To this solution, 5-bromovaleryl 
chloride (1.49 mL, 11.1 mmol, 1.1 equiv.) was added dropwise and the reaction mixture was 
stirred for 1 h at 0 °C. The organic phase was washed with sat. aqu. NaHCO3 (100 mL) and 
brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash silica gel chromatography (DCM/MeOH, gradient from 100:0 to 4:1) to afford amide 6.1 
(3.42 g, 9.49 mmol, 94%) as an orange solid. 
TLC (DCM): Rf = 0.17. M.p.: 135–136 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 7.97−7.86 (m, 4H, ArH), 7.73–7.65 (m, 2H, ArH), 7.55–7.42 (m, 4H, ArH), 3.49–3.40 (m, 
2H, CH2), 2.49–2.39 (m, 2H, CH2), 2.02–1.87 (m, 4H, 2 x CH2) ppm. 13C NMR (CDCl3, 
75 MHz, 27 °C): δ = 170.7, 152.6, 149.0, 140.3, 130.8, 129.0, 124.0, 122.7, 119.8, 36.6, 33.1, 
32.0, 23.9 ppm. IR (neat, ATR): ṽ = 3320 (m), 3069 (w), 2948 (w), 2871 (w), 1669 (vs), 1594 
(s), 1526 (vs), 1463 (m), 1442 (m), 1406 (m), 1384 (m), 1308 (m), 1266 (m), 1256 (m), 1211 
(w), 1180 (m), 1152 (m), 1118 (w), 1106 (w), 1070 (w), 1020 (w), 962 (w), 920 (w), 888 (w), 
853 (m), 836 (m), 768 (m), 732 (w), 718 (m), 685 (m), 668 (w) cm-1. HRMS (ESI+): m/z calcd. 
for [C17H19N3OBr]+: 360.0711, found: 360.0710 ([M+H]+). 
 
Synthesis of 5-morpholino-N-(4-(phenyldiazenyl)phenyl)pentanamide (Azo-SEN12333) 
 
 
 
Bromide 6.1 (1.00 g, 2.78 mmol, 1.0 equiv.) was dissolved in MeCN (40 mL) and morpholine 
(0.51 mL, 5.8 mmol, 2.1 equiv.) was added. The mixture was heated to reflux for 12 h. The 
cooled suspension was diluted with EtOAc (50 mL), washed with sat. aqu. NaHCO3 (100 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
N
N
N
H
O
Br
N
N
N
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chromatography (CHCl3/MeOH, 20:1 → 15:1), yielding Azo-SEN12333 (896 mg, 2.45 mmol, 
88%) as an orange solid. 
TLC (DCM/MeOH, 10:1): Rf = 0.38. M.p.: 171–172 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.95–7.85 (m, 4H, ArH), 7.72–7.64 (m, 2H, ArH), 7.55–7.41 (m, 4H, ArH), 3.71 (t, 
J = 4.8 Hz, 4H, 2 x CH2), 2.46–2.35 (m, 8H, 4 x CH2), 1.86–1.72 (m, 2H, CH2), 1.66–1.53 (m, 
2H, CH2) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 171.2, 152.6, 149.0, 140.4, 130.7, 
129.0, 124.0, 122.7, 119.7, 66.9, 58.5, 53.7, 37.5, 26.0, 23.3 ppm. IR (neat, ATR): ṽ = 3341 
(w), 2946 (w), 2853 (w), 2811 (w), 1700 (m), 1684 (m), 1670 (s), 1654 (m), 1601 (m), 1576 
(m), 1559 (m), 1540 (s), 1522 (vs), 1507 (s), 1473 (m), 1458 (m), 1437 (m), 1407 (m), 1340 
(m), 1302 (m), 1272 (m), 1247 (m), 1177 (w), 1155 (m), 1116 (m), 1068 (m), 1003 (m), 908 
(w), 866 (w), 851 (w), 835 (w), 804 (w), 769 (w), 718 (w), 685 (w), 668 (w) cm-1. HRMS 
(ESI+): m/z calcd. for [C21H27N4O2]+: 367.2134, found: 367.2131 ([M+H]+). UV/Vis: 
λmax = 361, 446 nm. 
 
 
6.5.3 SYNTHESIS OF RED DAD 
 
Synthesis of N-(2-bromoethyl)-N-ethyl-4-((4-nitrophenyl)diazenyl)aniline (6.3) 
 
 
 
Disperse Red 1 (6.2; 2.00 g, 6.36 mmol, 1.0 equiv.) was dissolved in THF (40 mL) and CBr4 
(2.42 g, 7.31 mmol, 1.15 equiv.) and PPh3 (1.92 g, 7.31 mmol, 1.15 equiv.) were added at 0 °C. 
The reaction mixture was warmed to room temperature and stirred for 1.5 h. The solvent was 
removed under reduced pressure and the crude product was purified by flash silica gel column 
chromatography (hexanes/EtOAc, 6:1), yielding bromide 6.3 (2.28 g, 6.04 mmol, 95%) as a 
deep red solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.60. M.p.: 142–143 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 8.38–8.29 (m, 2H, ArH), 7.98–7.87 (m, 4H, ArH), 6.82–6.72 (m, 2H, ArH), 3.81 (t, 
J = 7.8 Hz, 2H, CH2), 3.62–3.45 (m, 4H, 2 x CH2), 1.27 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (CDCl3, 75 MHz, 27 °C): δ = 156.6, 150.4, 147.6, 144.1, 126.3, 124.7, 122.7, 111.4, 
52.3, 45.8, 27.6, 12.6 ppm. IR (neat, ATR): ṽ = 2974 (w), 1601 (m), 1559 (w), 1516 (vs), 1465 
N N
NO2
NBr
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(w), 1424 (w), 1406 (w), 1390 (m), 1354 (m), 1340 (m), 1311 (w), 1271 (w), 1254 (w), 1218 
(w), 1202 (w), 1155 (m), 1141 (m), 1106 (m), 1077 (w), 1002 (w), 858 (m), 823 (m), 756 (w), 
724 (w), 686 (w), 668 (w) cm-1. HRMS (ESI+): m/z calcd. for [C16H18N4O2Br]+: 377.0613, 
found: 377.0610 ([M+H]+). 
 
Synthesis of N1,N1,N2-triethyl-N2-(4-((4-nitrophenyl)diazenyl)phenyl)ethane-1,2-diamine 
(6.4) 
 
 
Bromide 6.3 (300 mg, 0.800 mmol, 1.0 equiv.) was dissolved in EtOH (4 mL) in a pressure tube 
and diethyl amine (0.83 mL, 8.0 mmol, 10 equiv.) was added. The reaction mixture was heated 
to 100 °C for 12 h. The solvent was removed under reduced pressure and the crude product was 
purified by flash silica gel column chromatography (DCM/MeOH, gradient from 100:0 to 2:1) 
to give diamine 6.4 (268 mg, 0.730 mmol, 91%) as a deep red oil. 
TLC (DCM/MeOH, 20:1): Rf = 0.30. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 8.33–8.28 (m, 
2H, ArH), 7.92–7.85 (m, 4H, ArH), 6.76–6.71 (m, 2H, ArH), 3.53–3.47 (m, 4H, 2 x CH2), 
2.68−2.61 (m, 2H, CH2), 2.59 (q, J = 7.2 Hz, 4H, 2 x CH2), 1.24 (t, J = 7.1 Hz, 3H, CH3), 1.05 
(t, J = 7.2 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 156.9, 151.4, 
147.2, 143.4, 126.3, 124.6, 122.5, 111.1, 50.4, 49.7, 47.6, 45.9, 12.4, 12.0 ppm. IR (neat, 
ATR): ṽ = 2969 (m), 1602 (s), 1557 (w), 1513 (vs), 1470 (w), 1423 (w), 1407 (w), 1390 (m), 
1340 (m), 1255 (w), 1201 (w), 1156 (m), 1142 (m), 1105 (m), 1072 (w), 998 (w), 859 (m), 824 
(m), 755 (w), 721 (w), 687 (w), 666 (w) cm-1. HRMS (ESI+): m/z calcd. for [C20H28N5O2]+: 
370.2243, found: 370.2238 ([M+H]+). 
 
Synthesis of N1-(4-((4-aminophenyl)diazenyl)phenyl)-N1,N2,N2-triethylethane-1,2-diamine 
(6.5) 
 
 
Nitroarene 6.4 (288 mg, 0.780 mmol, 1.0 equiv.) was dissolved in 1,4-dioxane (12 mL) and 
water (1 mL) and Na2S (106 mg, 1.36 mmol, 1.7 equiv.) was added. The reaction mixture was 
N N
NO2
NN
N N
NH2
NN
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heated to 90 °C for 2 h. As TLC analysis indicated remaining starting material, more Na2S 
(53 mg, 0.68 mmol, 0.9 equiv.) was added and the mixture was heated to 90 °C for another 
1.5 h. Sat. aqu. NaHCO3 (30 mL) was added and the aqueous phase was extracted with DCM 
(3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4 
and the solvent was concentrated in vacuo. The crude product was purified by flash silica gel 
column chromatography (DCM/MeOH, gradient from 20:1 to 10:1) to give azoaniline 6.5 
(260 mg, 0.770 mmol, 99%) as a deep red oil. 
TLC (DCM/MeOH, 10:1): Rf = 0.30. 1H NMR (CDCl3, 300 MHz, 27 °C): δ = 7.83–7.74 (m, 
2H, ArH), 7.75–7.68 (m, 2H, ArH), 6.77–6.67 (m, 4H, ArH), 3.90 (br s, 2H, NH2), 3.58–3.39 
(m, 4H, 2 x CH2), 2.73–2.55 (m, 6H, 3 x CH2), 1.21 (t, J = 7.1 Hz, 3H, CH3), 1.08 (t, J = 7.8 Hz, 
6H, 2 x CH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 149.3, 148.0, 146.1, 143.5, 124.5, 
124.0, 114.8, 111.1, 50.2, 49.2, 47.6, 45.6, 12.5, 11.7 ppm. IR (neat, ATR): ṽ = 3337 (w), 3209 
(w), 2968 (m), 2932 (w), 2811 (w), 1619 (m), 1591 (vs), 1561 (m), 1511 (m), 1468 (w), 1450 
(w), 1395 (m), 1350 (m), 1294 (m), 1276 (m), 1245 (m), 1201 (w), 1149 (s), 1071 (w), 998 (w), 
944 (w), 834 (m), 821 (m), 730 (w) cm-1. HRMS (ESI+): m/z calcd. for [C20H30N5]+: 340.2501, 
found: 340.2497 ([M+H]+). 
 
Synthesis of 2-chloro-N-(4-((4-((2-(diethylamino)ethyl)(ethyl)amino)-phenyl)diazenyl)- 
phenyl)acetamide (6.6) 
 
 
 
Aniline 6.5 (181 mg, 0.530 mmol, 1.0 equiv.) was dissolved in THF (25 mL) and cooled to 
0 °C. DIPEA (0.11 mL, 0.64 mmol, 1.2 equiv.) and chloro acetylchloride (64 µL, 0.80 mmol, 
1.5 equiv.) were added. The reaction mixture was slowly warmed to room temperature and 
stirred for 1.5 h. The solvent was removed under reduced pressure and the crude product was 
purified by flash silica gel column chromatography (DCM/MeOH, gradient from 15:1 to 10:1) 
to yield amide 6.6 (226 mg, 0.530 mmol, 100%) as a deep red oil. 
TLC (DCM/MeOH, 10:1): Rf = 0.34. 1H NMR (CDCl3, 400 MHz, 27 °C): δ = 8.31 (br s, 1H, 
NH), 7.87–7.79 (m, 4H, ArH), 7.68–7.64 (m, 2H, ArH), 6.74–6.70 (m, 2H, ArH), 4.20 (s, 2H, 
CH2), 3.54–3.43 (m, 4H, 2 x CH2), 2.71–2.55 (m, 6H, 3 x CH2), 1.21 (t, J = 7.1 Hz, 3H, CH3), 
1.07 (t, J = 7.1 Hz, 6H, 2 x CH3) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): δ = 163.6, 150.3, 
150.1, 143.2, 137.4, 125.2, 123.1, 120.1, 111.0, 50.2, 49.4, 47.6, 45.7, 42.9, 12.5, 11.8 ppm. IR 
N N
H
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(neat, ATR): ṽ = 3249 (w), 2969 (m), 2810 (w), 1675 (m), 1596 (vs), 1541 (m), 1514 (s), 1446 
(w), 1422 (m), 1393 (m), 1350 (m), 1313 (w), 1276 (w), 1248 (m), 1198 (w), 1154 (s), 1139 (s), 
1073 (w), 998 (w), 844 (m), 821 (m), 731 (w), 696 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C22H31ClN5O]+: 416.2217, found: 416.2215 ([M+H]+). 
 
Synthesis of 2-(diethylamino)-N-(4-((4-((2-(diethylamino)ethyl)(ethyl)amino)-phenyl)-
diazenyl)phenyl)acetamide (Red DAD) 
 
 
 
Chloride 6.6 (218 mg, 0.520 mmol, 1.0 equiv.) was dissolved in EtOH (5 mL) in a pressure tube 
and diethyl amine (0.54 mL, 5.2 mmol, 10 equiv.) was added. The reaction mixture was heated 
to 100 °C for 16 h. The solvent was removed under reduced pressure and the crude product was 
purified by flash silica gel column chromatography (DCM/MeOH, 30:1 → 25:1) to give 
Red DAD (161 mg, 0.360 mmol, 69%) as a deep red oil. 
TLC (DCM/MeOH, 10:1): Rf = 0.41. 1H NMR (CDCl3, 600 MHz, 27 °C): δ = 9.53 (br s, 1H, 
NH), 7.86–7.79 (m, 4H, ArH), 7.70–7.65 (m, 2H, ArH), 6.75–6.68 (m, 2H, ArH), 3.53–3.43 (m, 
4H, 2 x CH2), 3.16 (s, 2H, CH2), 2.68–2.62 (m, 6H, 3 x CH2), 2.59 (q, J = 7.0 Hz, 4H, 2 x CH2), 
1.21 (t, J = 7.1 Hz, 3H, CH3), 1.09 (t, J = 7.2 Hz, 6H, 2 x CH3), 1.06 (t, J = 7.1 Hz, 6H, 
2 x CH3) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): δ = 170.1, 150.0, 149.5, 143.3, 138.7, 
125.0, 123.1, 119.3, 111.0, 58.2, 50.3, 49.4, 48.9, 47.6, 45.7, 12.5, 12.4, 11.9 ppm. IR (neat, 
ATR): ṽ = 3276 (w), 2967 (m), 2932 (w), 2813 (w), 1692 (m), 1597 (s), 1560 (m), 1510 (vs), 
1447 (m), 1420 (m), 1393 (m), 1350 (m), 1299 (m), 1276 (m), 1247 (m), 1202 (m), 1152 (s), 
1139 (s), 1070 (m), 998 (m), 905 (w), 845 (m), 820 (m), 730 (w), 668 (w) cm-1. HRMS (ESI+): 
m/z calcd. for [C26H41ON6]+: 453.3342, found: 453.3337 ([M+H]+). UV/Vis: λmax = 454 nm. 
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6.5.4 SYNTHESIS OF MS2 AND MS3 
 
Synthesis of 2-((2-((tert-butoxycarbonyl)amino)ethyl)disulfanyl)acetic acid (6.10) 
 
 
 
Di-Boc-cystamine 6.7 (3.53 g, 10.0 mmol, 1.0 equiv.) was dissolved in CHCl3 (60 mL) and 
TEA (8.73 mL, 63.0 mmol, 6.3 equiv.) was added. To this solution, thioglycolic acid 6.8 
(0.69 mL, 10 mmol, 1.0 equiv.) was added in portions. The reaction mixture was stirred at room 
temperature for 2 h. The organic phase was washed with 0.5 M KHSO4 (3 x 60 mL) and dried 
over MgSO4. The solvent was removed under reduced pressure and the residue was dissolved in 
Et2O (300 mL). The organic phase was extracted with sat. aqu. NaHCO3 (3 x 150 mL) and the 
combined aqueous phases were washed with Et2O (200 mL), followed by acidification with 
0.5 M KHSO4 to pH = 3. The aqueous phase was extracted with CHCl3 (3 x 150 mL), washed 
with brine (300 mL), dried over MgSO4 and concentrated in vacuo. Disulfide 6.10 was obtained 
in 56% yield (1.49 g, 5.57 mmol) as colorless oil. 
TLC (CHCl3/MeOH, 9:1): Rf = 0.49. 1H NMR (DMSO-d6, 400 MHz, 27 °C): δ = 12.53 (br s, 
1H, CO2H), 6.95 (t, J = 5.5 Hz, 1H, NH), 3.54 (s, 2H, CH2), 3.21–3.15 (m, 2H, CH2), 2.81–2.72 
(m, 2H, CH2), 1.35 (s, 9H, C(CH3)3) ppm. 13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 171.0, 
155.9, 78.2, 41.4, 39.6, 37.7, 28.7 ppm. IR (neat, ATR): ṽ = 3344 (w), 2977 (m), 2929 (w), 
1699 (s), 1516 (m), 1479 (w), 1454 (w), 1393 (m), 1366 (m), 1344 (w), 1272 (m), 1252 (m), 
1162 (vs), 1050 (w), 1001 (w), 950 (w), 862 (m), 778 (w), 664 (w) cm-1. HRMS (ESI-): m/z 
calcd. for [C9H16NO4S2]-: 266.0521, found: 266.0521 ([M-H]-). 
 
Synthesis of tert-butyl (2-((2-((4-((4-aminophenyl)diazenyl)phenyl)amino)-2-oxoethyl)di-
sulfanyl)ethyl)carbamate (6.13) 
 
 
 
4,4’-Azodianiline 6.12 (301 mg, 1.42 mmol, 1.0 equiv.), carboxylic acid 6.11 (380 mg, 
1.42 mmol, 1.0 equiv.) and HBTU (1.61 g, 4.25 mmol, 3.0 equiv.) were dissolved in THF 
(19 mL) and TEA (0.59 mL, 4.3 mmol, 3.0 equiv.) was added. The reaction mixture was then 
heated to reflux for 20 h. EtOAc (40 mL) was added to the cooled mixture and the organic 
OH
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phase was washed with sat. aqu. NaHCO3 (2 x 30 mL), brine (30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by reversed-phase flash column 
chromatography (H2O/MeOH, gradient from 10:0 to 3:7) to yield amide 6.13 in 54% (349 mg, 
0.760 mmol) as an orange oil. 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.55. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.77–7.67 (m, 6H, ArH), 6.74–6.70 (m, 2H, ArH), 3.37–3.31 (m, 4H, 2 x CH2), 
2.79–2.75 (m, 2H, CH2), 1.43 (s, 9H, C(CH3)3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 168.5, 156.9, 152.0, 149.4, 144.3, 139.4, 124.6, 122.4, 119.9, 113.7, 78.8, 39.3, 39.1, 37.6, 
27.3 ppm. IR (neat, ATR): ṽ = 3355 (w), 2976 (w), 2930 (w), 2488 (w), 1677 (s), 1624 (m), 
1597 (s), 1505 (m), 1477 (m), 1404 (m), 1365 (m), 1299 (m), 1248 (m), 1152 (vs), 1041 (w), 
985 (w), 946 (w), 845 (m), 762 (vs), 666 (m) cm-1. HRMS (ESI+): m/z calcd. for 
[C21H28N5O3S2]+: 462.1639, found: 462.1634 ([M+H]+). 
 
Synthesis of 2-((4-((4-(2-((2-((tert-butoxycarbonyl)amino)ethyl)disulfanyl)acetamido)-
phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-aminium formate (6.15) 
 
 
 
2-(Triethylammonio)acetate (239 mg, 1.50 mmol, 5.0 equiv.) was dissolved in MeCN (10 mL) 
and oxalyl chloride (0.75 mL, 2 M in DCM, 1.5 mmol, 5.0 equiv.) was added, followed by DMF 
(3 drops). The mixture was stirred for 1 h at room temperature. The solvent was removed in 
vacuo and dried under high vacuum for 30 min. The crude product was redissolved in DMF 
(7 mL) and slowly added to a solution of aniline 6.13 (138 mg, 0.300 mmol, 1.0 equiv.) and 
DIPEA (0.26 mL, 1.5 mmol, 5.0 equiv.) in DMF (13 mL) at 0 °C. The reaction mixture was 
slowly warmed to room temperature and stirred for 16 h. The solvent was removed under 
reduced pressure and the crude product was purified by reversed-phase flash column 
chromatography (H2O/MeOH (+ 0.1% HCO2H), gradient from 100:0 to 55:45) to yield amide 
6.15 as its formate salt in 19% (35 mg, 0.058 mmol) as an orange oil. 
1H NMR (CD3OD, 600 MHz, 27 °C): δ = 8.36 (br s, 1H, HCO2-), 7.94–7.88 (m, 4H, ArH), 
7.82−7.76 (m, 4H, ArH), 4.21 (s, 2H, CH2), 3.69 (q, J = 7.2 Hz, 6H, 3 x CH2), 3.62–3.57 (m, 
2H, CH2), 3.37–3.33 (m, 2H, CH2), 2.87–2.83 (m, 2H, CH2), 1.45–1.38 (m, 18H, C(CH3)3, 
3 x CH3) ppm. 13C NMR (CD3OD, 150 MHz, 27 °C): δ = 168.6, 166.5, 161.8, 156.9, 149.4, 
148.9, 141.1, 139.8, 123.3, 123.3, 120.1, 119.8, 78.8, 56.1, 54.4, 43.0, 39.1, 37.6, 27.3, 6.5 ppm. 
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IR (neat, ATR): ṽ = 3263 (w), 2980 (w), 1691 (m), 1595 (vs), 1549 (s), 1501 (m), 1454 (w), 
1413 (w), 1362 (w), 1326 (m), 1254 (m), 1158 (m), 1009 (w), 948 (w), 853 (m), 782 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C30H46N6O4S2]+: 604.2865, found: 604.2846 ([M-HCO2+H]+). 
 
Synthesis of 2-((4-((4-(2-((2-ammonioethyl)disulfanyl)acetamido)phenyl)diazenyl)phenyl)-
amino)-N,N,N-triethyl-2-oxoethan-1-aminium formate (MS2) 
 
 
 
Boc-protected amine 6.15 (26 mg, 0.043 mmol) was dissolved in 1,4-dioxane (2 mL) and DMF 
(0.4 mL). A 4 M solution of HCl in 1,4-dioxane (2 mL) was added and the reaction mixture was 
stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the 
crude product was purified by reversed-phase flash column chromatography (H2O/MeOH 
(+ 0.1% HCO2H), gradient from 10:0 to 8:2) to yield MS2 as its formate salt in 67% (17 mg, 
0.029 mmol) as an orange oil. 
1H NMR (CD3OD, 400 MHz, 27 °C): δ = 8.43 (br s, 2H, 2 x HCO2-), 7.93–7.86 (m, 4H, ArH), 
7.81–7.76 (m, 4H, ArH), 4.27–4.14 (m, 2H, CH2), 3.74–3.57 (m, 8H, 3 x CH2, CH2), 3.34–3.30 
(m, 2H, CH2), 3.07–2.99 (m, 2H, CH2), 1.38 (t, J = 7.2 Hz, 9H, 3 x CH3) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 168.4, 167.4, 161.8, 149.4, 149.0, 141.0, 139.9, 126.4, 123.3, 
123.2, 122.7, 120.1, 119.8, 119.5, 119.2, 56.2, 54.4, 42.3, 37.8, 34.4, 6.5 ppm. IR (neat, ATR): 
ṽ = 2989 (m), 1687 (m), 1591 (vs), 1549 (s), 1500 (s), 1458 (m), 1412 (m), 1377 (m), 1329 (m), 
1255 (m), 1156 (m), 1112 (w), 1010 (w), 953 (w), 900 (w), 852 (m), 764 (w), 732 (w) cm-1. 
HRMS (ESI+): m/z calcd. for [C24H36N6O2S2]+: 504.2341, found: 504.2331 ([M-2 HCO2+H]+). 
UV/Vis: λmax = 377, 456 nm. 
 
Synthesis of 3-((2-((tert-butoxycarbonyl)amino)ethyl)disulfanyl)propanoic acid (6.11) 
 
 
 
Di-Boc-cystamine 6.7 (1.76 g, 5.00 mmol, 1.0 equiv.) was dissolved in CHCl3 (30 mL) and 
TEA (4.37 mL, 31.5 mmol, 6.3 equiv.) was added. To this solution, 3-mercaptopropionic acid 
6.9 (0.44 mL, 5.0 mmol, 1.0 equiv.) was added in portions. The reaction mixture was stirred at 
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room temperature for 2.5 h. The organic phase was washed with 0.5 M KHSO4 (3 x 30 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure and the residue was 
dissolved in Et2O (100 mL). The organic phase was extracted with sat. aqu. NaHCO3 
(3 x 50 mL) and the combined aqueous phases were washed with Et2O (100 mL), followed by 
acidification with 0.5 M KHSO4 to pH = 3. The aqueous phase was extracted with CHCl3 
(5 x 30 mL), washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. 
Disulfide 6.11 was obtained in 30% yield (419 mg, 1.49 mmol) as colorless oil.  
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.54. 1H NMR (DMSO-d6, 400 MHz, 
27 °C): δ = 12.36 (br s, 1H, CO2H), 6.96 (t, J = 5.4 Hz, 1H, NH), 3.27–3.11 (m, 2H, CH2), 
2.94−2.83 (m, 2H, CH2), 2.80–2.68 (m, 2H, CH2), 2.66–2.55 (m, 2H, CH2), 1.37 (s, 9H, 
C(CH3)3) ppm. 13C NMR (DMSO-d6, 100 MHz, 27 °C): δ = 173.1, 155.9, 78.2, 38.1, 34.1, 
34.0, 33.5, 33.4, 28.7 ppm. IR (neat, ATR): ṽ = 3345 (w), 2978 (m), 2931 (w), 1708 (vs), 1517 
(m), 1480 (w), 1454 (w), 1394 (m), 1367 (m), 1251 (s), 1164 (vs), 1046 (w), 1029 (w), 949 (w), 
863 (w), 779 (w) cm-1. HRMS (ESI-): m/z calcd. for [C10H18NO4S2]-: 280.0677, found: 
280.0679 ([M-H]-). 
 
Synthesis of tert-butyl (2-((3-((4-((4-aminophenyl)diazenyl)phenyl)amino)-3-oxopropyl)di-
sulfanyl)ethyl)carbamate (6.14) 
 
 
 
4,4’-Azodianiline 6.12 (189 mg, 0.890 mmol, 1.0 equiv.), carboxylic acid 6.11 (250 mg, 
0.890 mmol, 1.0 equiv.) and HBTU (1.01 g, 2.67 mmol, 3.6 equiv.) were dissolved in THF 
(12 mL) and TEA (0.37 mL, 2.7 mmol, 3.6 equiv.) was added. The reaction mixture was then 
heated to reflux for 24 h. EtOAc (25 mL) was added to the cooled mixture and the organic 
phase was washed with sat. aqu. NaHCO3 (2 x 20 mL), brine (20 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by reversed-phase flash column 
chromatography (H2O/MeOH, gradient from 10:0 to 1:9) to yield amide 6.14 in 30% (130 mg, 
0.270 mmol) as a red oil. 
TLC (DCM/MeOH/HOAc/H2O, 90:10:0.6:0.6): Rf = 0.74. 1H NMR (CD3OD, 400 MHz, 
27 °C): δ = 7.79–7.73 (m, 2H, ArH), 7.72–7.65 (m, 4H, ArH), 6.76–6.70 (m, 2H, ArH), 
3.07−3.01 (m, 2H, CH2), 2.85–2.78 (m, 4H, 2 x CH2), 1.42 (s, 9H, C(CH3)3) ppm. 13C NMR 
(CD3OD, 100 MHz, 27 °C): δ = 170.7, 157.0, 151.9, 149.2, 144.3, 139.8, 124.6, 122.4, 119.8, 
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113.8, 78.8, 39.3, 37.7, 36.2, 33.6, 27.3 ppm. IR (neat, ATR): ṽ = 3354 (m), 3041 (w), 2977 
(w), 2930 (w), 1680 (m), 1622 (m), 1597 (vs), 1534 (s), 1506 (s), 1456 (w), 1425 (m), 1402 (m), 
1366 (m), 1300 (m), 1253 (m), 1160 (m), 1141 (m), 1045 (w), 950 (w), 844 (m), 780 (w), 754 
(w) cm-1. HRMS (ESI-): m/z calcd. for [C22H28N5O3S2]-: 474.1634, found: 474.1633 ([M-H]-). 
 
Synthesis of 2-((4-((4-(3-((2-((tert-butoxycarbonyl)amino)ethyl)disulfanyl)propanamido)-
phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-aminium formate (6.16) 
 
 
 
2-(Triethylammonio)acetate (215 mg, 1.35 mmol, 5.0 equiv.) was dissolved in MeCN (10 mL) 
and oxalyl chloride (0.68 mL, 2 M in DCM, 1.4 mmol, 5.0 equiv.) was added, followed by DMF 
(3 drops). The mixture was stirred for 1 h at room temperature. The solvent was removed in 
vacuo and dried under high vacuum for 30 min. The crude product was redissolved in DMF 
(13 mL) and slowly added to a solution of aniline 6.14 (130 mg, 0.270 mmol, 1.0 equiv.) and 
DIPEA (0.24 mL, 1.4 mmol, 5.0 equiv.) in DMF (7 mL) at 0 °C. The reaction mixture was 
slowly warmed to room temperature and stirred for 16 h. The solvent was removed under 
reduced pressure and the crude product was purified by reversed-phase flash column 
chromatography (H2O/MeOH (+ 0.1% HCO2H), gradient from 100:0 to 55:45) to yield amide 
6.16 as its formate salt in 52% (94 mg, 0.14 mmol) as an orange oil. 
1H NMR (CD3OD, 600 MHz, 27 °C): δ = 8.34 (br s, 1H, HCO2-), 7.93–7.85 (m, 4H, ArH), 
7.83−7.74 (m, 4H, ArH), 4.22 (s, 2H, CH2), 3.68 (q, J = 7.2 Hz, 6H, 3 x CH2), 3.37–3.34 (m, 
2H, CH2), 3.08–3.03 (m, 2H, CH2), 2.87–2.83 (m, 2H, CH2), 2.83–2.80 (m, 2H, CH2), 1.43 (s, 
9H, C(CH3)3), 1.39 (t, J = 7.2 Hz, 9H, 3 x CH3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): 
δ = 170.8, 165.7, 161.8, 156.9, 149.4, 148.7, 141.3, 139.8, 123.2, 123.2, 120.1, 119.7, 78.8, 
56.2, 54.4, 39.3, 37.8, 36.2, 33.5, 27.3, 6.6 ppm. IR (neat, ATR): ṽ = 3257 (w), 2979 (w), 1692 
(m), 1594 (vs), 1546 (s), 1501 (m), 1455 (m), 1412 (m), 1366 (m), 1345 (m), 1302 (m), 1254 
(m), 1210 (w), 1157 (m), 1011 (w), 982 (w), 950 (w), 853 (m), 784 (w) cm-1. HRMS (ESI+): 
m/z calcd. for [C30H46N6O4S2]+: 618.3022, found: 618.3001 ([M-HCO2+H]+). 
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Synthesis of 2-((4-((4-(3-((2-ammonioethyl)disulfanyl)propanamido)phenyl)diazenyl)-
phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-aminium formate (MS3) 
 
 
 
Boc-protected amine 6.16 (40 mg, 0.065 mmol) was dissolved in 1,4-dioxane (2.5 mL) and 
DMF (0.5 mL). A 4 M solution of HCl in 1,4-dioxane (2.5 mL) was added and the reaction 
mixture was stirred at room temperature for 16 h. The solvent was removed under reduced 
pressure and the crude product was purified by reversed-phase flash column chromatography 
(H2O/MeOH (+ 0.1% HCO2H), gradient from 100:0 to 85:15) to yield MS3 as its formate salt in 
66% (26 mg, 0.043 mmol) as an orange oil. 
1H NMR (CD3OD, 400 MHz, 27 °C): δ = 8.43 (br s, 2H, 2 x HCO2-), 7.93–7.83 (m, 4H, ArH), 
7.83–7.69 (m, 4H, ArH), 4.21 (s, 2H, CH2), 3.67 (q, J = 7.2 Hz, 6H, 3 x CH2), 3.34–3.29 (m, 
2H, CH2), 3.14–3.05 (m, 2H, CH2), 3.01–2.93 (m, 2H, CH2), 2.90–2.81 (m, 2H, CH2), 1.38 (t, 
J = 7.2 Hz, 9H, 3 x CH3) ppm. 13C NMR (CD3OD, 100 MHz, 27 °C): δ = 170.7, 167.3, 161.8, 
149.4, 148.7, 141.2, 139.8, 126.4 (cis isomer), 123.2, 123.2, 122.7 (cis isomer), 120.1, 119.7, 
119.5 (cis isomer), 119.1 (cis isomer), 56.1, 54.4, 37.8, 36.0, 33.9, 32.9, 6.5 ppm. IR (neat, 
ATR): ṽ = 2990 (m), 1690 (m), 1593 (vs), 1501 (m), 1412 (m), 1375 (m), 1346 (m), 1302 (m), 
1257 (m), 1156 (m), 852 (m), 766 (w) cm-1. HRMS (ESI+): m/z calcd. for [C25H37N6O2S2]+: 
517.2419, found: 517.2416 ([M-2 HCO2+H]+). UV/Vis: λmax = 376, 455 nm. 
 
 
6.5.5 SYNTHESIS OF PEG 
 
Synthesis of 4-(benzyloxy)-3-methoxybenzaldehyde (6.17) 
 
 
 
Vanillin (20.0 g, 131 mmol, 1.0 equiv.) was dissolved in acetone (300 mL) and K2CO3 (9.10 g, 
65.5 mmol, 0.5 equiv.) and benzyl bromide (15.6 mL, 131 mmol, 1.0 equiv.) were added. The 
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mixture was heated under reflux for 20 h and then poured into water (300 mL). The resulting 
yellowish oil was extracted with DCM (3 x 75 mL). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by flash silica gel 
column chromatography (hexanes/EtOAc, gradient from 20:1 to 6:1) to yield benzyl ether 6.17 
(30.5 g, 126 mmol, 96%) as a colorless solid. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.36. M.p.: 63–64 °C. 1H NMR (CDCl3, 300 MHz, 27 °C): 
δ = 9.86 (s, 1H, CHO), 7.49–7.31 (m, 7H, ArH), 7.01 (d, J = 8.2 Hz, 1H, ArH), 5.27 (s, 2H, 
CH2), 3.96 (s, 3H, OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 190.8, 153.6, 150.1, 
136.0, 130.3, 128.7, 128.2, 127.2, 126.6, 112.4, 109.4, 70.9, 56.1 ppm. IR (neat, ATR): 
ṽ = 1680 (s), 1585 (s), 1507 (s), 1464 (m), 1454 (m), 1424 (m), 1396 (w), 1340 (w), 1265 (vs), 
1236 (m), 1194 (w), 1158 (m), 1135 (s), 1081 (w), 1022 (m), 919 (w), 866 (w), 809 (w), 782 
(w), 733 (m), 698 (m), 658 (w) cm-1. HRMS (EI+): m/z calcd. for [C15H14O3]+: 242.0943, found: 
242.0939 ([M]+). 
 
Synthesis of 4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde (6.18) 
 
 
 
Compound 6.17 (14.6 g, 60.1 mmol) was added in 5 portions to aqu. 65% HNO3 (75 mL) at 
0 °C. The reaction mixture was stirred at 0 °C for 30 min, followed by 2 h at room temperature. 
The mixture was poured onto ice water (500 mL) and the solids were filtered and dried under 
high vacuum, yielding ortho-nitro aldehyde 6.18 (15.1 g, 52.6 mmol, 88%) as yellow crystals. 
TLC (hexanes/EtOAc, 4:1): Rf = 0.38. M.p.: 122–124 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 10.46 (s, 1H, CHO), 7.69 (s, 1H, ArH), 7.51–7.34 (m, 6H, ArH), 5.29 (s, 2H, CH2), 
4.04 (s, 3H, OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 187.7, 153.7, 151.4, 143.6, 
134.8, 128.9, 128.7, 127.6, 125.7, 110.0, 108.9, 71.6, 56.7 ppm. IR (neat, ATR): ṽ = 1678 (m), 
1568 (m), 1511 (s), 1456 (w), 1402 (w), 1329 (m), 1281 (s), 1222 (m), 1165 (m), 1058 (vs), 978 
(s), 872 (m), 849 (m), 802 (w), 752 (s), 699 (m) cm-1. HRMS (EI+): m/z calcd. for 
[C15H13NO5]+: 287.0794, found: 287.0802 ([M]+). 
 
 
 
 
OBn
OMe
OH
O2N
6     MISCELLANEOUS PROJECTS 
 
 
 
456 
Synthesis of 4-hydroxy-5-methoxy-2-nitrobenzaldehyde (6.19) 
 
 
 
Benzyl ether 6.18 (15.1 g, 52.6 mmol) was dissolved in a mixture of HOAc (100 mL) and aqu. 
48% HBr (33 mL) at 85 °C. The mixture was stirred for 2.5 h at this temperature and then 
cooled to room temperature. The solids were filtered, washed with water and dried under high 
vacuum for 12 h. Phenol 6.19 (8.15 g, 41.3 mmol, 79%) was obtained as a yellow solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.33. M.p.: 206–208 °C. 1H NMR (CDCl3, 200 MHz, 
27 °C): δ = 10.40 (s, 1H, CHO), 7.68 (s, 1H, ArH), 7.45 (s, 1H, ArH), 6.20 (s, 1H, OH), 4.07 (s, 
3H, OCH3) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): δ = 187.4, 150.3, 149.6, 144.8, 125.0, 
111.2, 109.7, 56.9 ppm. IR (neat, ATR): ṽ = 3120 (m), 1670 (s), 1583 (s), 1512 (vs), 1460 (w), 
1439 (w), 1421 (m), 1368 (m), 1326 (m), 1297 (vs), 1276 (vs), 1210 (s), 1180 (s), 1159 (s), 
1056 (s), 990 (m), 914 (m), 900 (w), 883 (m), 809 (m), 735 (s), 720 (s), 681 (m) cm-1. HRMS 
(EI+): m/z calcd. for [C8H7NO5]+: 197.0324, found: 197.0304 ([M]+). 
 
Synthesis of 5-methoxy-2-nitro-4-(prop-2-yn-1-yloxy)benzaldehyde (6.20) 
 
 
 
Phenol 6.19 (1.55 g, 7.86 mmol, 1.0 equiv.) was dissolved in DMF (20 mL) and K2CO3 (1.41 g, 
10.2 mmol, 1.3 equiv.) was added, followed by propargyl bromide (80% in toluene; 0.910 mL, 
10.2 mmol, 1.3 equiv.). The mixture was heated to 50 °C for 3 h. Water (50 mL) was added and 
the mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed 
with aqu. 5% NaOH (3 x 50 mL) and brine (3 x 50 mL). The organic phase was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash silica 
gel column chromatography (hexanes/EtOAc, 4:1) to give proparyl ether 6.20 (1.75 g, 
7.44 mmol, 95%) as a yellow solid. 
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TLC (hexanes/EtOAc, 4:1): Rf = 0.33. M.p.: 133–136 °C. 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 10.49 (s, 1H, CHO), 7.82 (s, 1H, ArH), 7.46 (s, 1H, ArH), 4.94 (d, J = 2.4 Hz, 2H, 
CH2), 4.05 (s, 3H, OCH3), 2.68–2.61 (m, 1H, CH) ppm. 13C NMR (CDCl3, 75 MHz, 27 °C): 
δ = 187.6, 153.7, 149.9, 143.4, 126.4, 110.3, 109.5, 77.7, 76.4, 57.2, 56.8 ppm. IR (neat, 
ATR): ṽ = 1688 (m), 1570 (m), 1508 (s), 1460 (m), 1396 (m), 1328 (m), 1284 (vs), 1222 (vs), 
1168 (m), 1059 (s), 1012 (m), 972 (m), 880 (m), 814 (m), 765 (w), 738 (m), 710 (w), 688 
(m) cm-1. HRMS (EI+): m/z calcd. for [C11H9NO5]+: 235.0481, found: 235.0482 ([M]+). 
 
Synthesis of (5-methoxy-2-nitro-4-(prop-2-yn-1-yloxy)phenyl)methanol (6.21) 
 
 
 
A solution of aldehyde 6.20 (1.73 g, 7.36 mmol, 1.0 equiv.) in MeOH (100 mL) at 0 °C was 
added to a solution of NaBH4 in MeOH (50 mL) at 0 °C. The reaction mixture was stirred at this 
temperature for 1 h and then concentrated under reduced pressure. A sat. aqu. solution of NH4Cl 
(100 mL) was added and the aqueous phase was extracted with DCM (5 x 30 mL). The 
combined organic layers were washed with brine (75 mL), dried over MgSO4 and concentrated 
in vacuo, affording alcohol 6.21 (1.69 g, 7.12 mmol, 97%) as a yellow solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.42. M.p.: 137–138 °C. 1H NMR (CDCl3, 400 MHz, 
27 °C): δ = 7.87 (s, 1H, ArH), 7.20 (s, 1H, ArH), 4.96 (s, 2H, CH2), 4.85–4.80 (m, 2H, CH2), 
3.99 (s, 3H, OCH3), 2.68–2.47 (m, 2H, CH, OH) ppm. 13C NMR (CDCl3, 100 MHz, 27 °C): 
δ = 154.5, 145.5, 139.5, 133.3, 111.4, 111.0, 77.1, 76.9, 62.8, 57.1, 56.5 ppm. IR (neat, ATR): 
ṽ = 3287 (m), 3264 (m), 1579 (w), 1515 (s), 1494 (m), 1453 (w), 1427 (w), 1383 (m), 1320 (m), 
1254 (s), 1215 (m), 1164 (m), 1066 (vs), 1024 (w), 985 (w), 973 (w), 882 (m), 817 (m), 758 
(w), 706 (w), 685 (w) cm-1. HRMS (EI+): m/z calcd. for [C11H11NO5]+: 237.0637, found: 
237.0644 ([M]+). 
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Synthesis of 1-(bromomethyl)-5-methoxy-2-nitro-4-(prop-2-yn-1-yloxy)benzene (6.22) 
 
 
 
Alcohol 6.21 (200 mg, 0.840 mmol, 1.0 equiv.) was suspended in Et2O (30 mL) at 0 °C. PBr3 
(1 M in DCM; 2.02 mL, 2.02 mmol, 2.4 equiv.) was added and the mixture was stirred at 0 °C 
for 20 min, followed by 5 h at room temperature. The reaction was quenched by the addition of 
MeOH (2 mL) and then poured into water (100 mL). The aqueous phase was extracted with 
EtOAc (5 x 30 mL), dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by flash silica gel column chromatography (hexanes/EtOAc, gradient from 
6:1 to 4:1) to give bromide 6.22 (111 mg, 0.370 mmol, 44%) as a yellowish solid. 
TLC (hexanes/EtOAc, 2:1): Rf = 0.56. M.p.: 120 °C (dec.). 1H NMR (CDCl3, 300 MHz, 
27 °C): δ = 7.86 (s, 1H, ArH), 7.00 (s, 1H, ArH), 4.89 (s, 2H, CH2), 4.86 (d, J = 2.4 Hz, 2H, 
CH2), 4.01 (s, 3H, OCH3), 2.62 (t, J = 2.4 Hz, 1H, CH) ppm. 13C NMR (CDCl3, 75 MHz, 
27 °C): δ = 153.7, 146.5, 140.0, 128.4, 114.1, 111.2, 77.2, 76.9, 57.1, 56.6, 29.9 ppm. IR (neat, 
ATR): ṽ = 3286 (w), 1611 (w), 1581 (m), 1515 (vs), 1463 (m), 1398 (w), 1329 (s), 1271 (vs), 
1212 (s), 1179 (m), 1123 (w), 1062 (s), 1024 (m), 987 (m), 928 (w), 871 (m), 817 (w), 793 (m), 
760 (w), 732 (w), 676 (w) cm-1. HRMS (EI+): m/z calcd. for [C11H10BrNO4]+: 298.9793, found: 
298.9768 ([M]+). 
 
Synthesis of 23-(4-((4-(bromomethyl)-2-methoxy-5-nitrophenoxy)methyl)-1H-1,2,3-triazol-
1-yl)-3,6,9,12,15,18,21-heptaoxatricosan-1-ol (PEG) 
 
 
 
PEG azide 6.23 (26 mg, 0.066 mmol, 2.0 equiv.) was dissolved in THF (1 mL) and H2O (1 mL). 
CuSO4 ! 5 H2O (1.0 mg, 0.0040 mmol, 0.1 equiv.) and sodium ascorbate (1.6 mg, 0.0080 mmol, 
0.2 equiv.) were added, followed by alkine 6.22 (10 mg, 0.033 mmol, 1.0 equiv.). The mixture 
was stirred at room temperature for 16 h. H2O (10 mL) was added and the aqueous phase was 
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extracted with CHCl3 (5 x 5 mL). The combined organic layers were washed with brine 
(20 mL), dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash silica gel column chromatography (CHCl3/MeOH, 50:1 → 25:1) to give 
triazole PEG (19 mg, 0.027 mmol, 82%) as a yellowish oil.  
TLC (DCM/MeOH/H2O/HOAc, 90:10:0.6:0.6): Rf = 0.37. 1H NMR (CDCl3, 600 MHz, 
27 °C): δ = 7.89 (s, 1H, ArH), 7.86 (s, 1H, ArH), 6.93 (s, 1H, ArH), 5.29 (s, 2H, CH2), 4.83 (s, 
2H, CH2), 4.55–4.52 (m, 2H, CH2), 3.94 (s, 3H, OCH3), 3.87–3.83 (m, 2H, CH2), 3.70–3.67 (m, 
3H), 3.65−3.56 (m, 37H, CH2), 2.68 (br s, 1H, OH) ppm. 13C NMR (CDCl3, 150 MHz, 27 °C): 
δ = 153.7, 147.5, 142.2, 140.1, 127.9, 124.7, 114.0, 110.9, 72.5, 70.6, 70.6, 70.6, 70.5, 70.5, 
70.5, 70.5, 70.5, 70.4, 70.3, 70.2, 70.0, 69.3, 63.1, 61.6, 56.5, 50.6, 50.4, 30.0 ppm. IR (neat, 
ATR): ṽ = 3434 (m), 2873 (m), 1581 (m), 1523 (vs), 1465 (m), 1346 (m), 1333 (m), 1280 (vs), 
1217 (m), 1102 (s), 1063 (s), 986 (w), 949 (w), 829 (w) cm-1. HRMS (ESI+): m/z calcd. for 
[C27H44BrN4O12]+: 695.2139, found: 695.2134 ([M+H]+). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6     MISCELLANEOUS PROJECTS 
 
 
 
460 
6.6 NMR SPECTRA 
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7 LIST OF ABBREVIATIONS 
 
Δ 
3C5HPG 
 
ABCTC 
Ac 
Ac 
AC 
AChBP 
ACPT-I 
  
ACRO 
AETD 
AFM 
AI 
ALCM 
ALTG 
AMPA 
 
AP 
AP 
APDC 
 
aqu. 
Ar 
ATP 
ATR 
AUC 
Bn 
Boc 
brsm 
 
Bt 
Bu 
BZ 
heating under reflux 
3-carboxy-5-hydroxyphenyl-
glycine 
Azo-BCTC 
acetyl 
aplysia californica  
Azo-Capsazepine 
acetylcholine binding proteine 
(1S,3R,4S)-1-aminocyclopentane-
1,3,4-tricarboxylic acid 
Azo-Crobenetine 
Azo-Etomidate 
atomic force microscopy 
Azo-Icilin 
Azo-Lacosamide 
Azo-Lamotrigine 
2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl)propanoic acid 
action potential 
Azo-Propofol 
4-aminopyrrolidine-2,4-di-
carboxylate 
aqueous 
aryl 
adenosine triphosphate 
attenuated total reflectance 
area under curve 
benzyl 
tert-butyloxycarbonyl 
based on recovered starting 
material 
benzotriazole 
butyl 
benzodiazepine 
ca. 
calcd. 
cat. 
CAP 
CaM 
CaMBD 
CaV 
cDNA 
ChARGe 
 
 
CHO 
ChR 
CL 
conc. 
CPZ 
cRNA 
CSA 
Cys 
d 
d 
DAG 
DCM 
DCPG 
DHPG 
DIC 
DIPEA 
DMAP 
DMF 
DMSO 
DNA 
DRG 
E+ 
e.g. 
circa 
calculated 
catalyzed/catalytic 
capsaicin 
calmodulin 
calmodulin binding domain 
voltage-gated calcium (channel) 
complementary DNA 
optochemical tool consisting of 
arrestin-2, rhodopsin and a  
G-protein 
chinese hamster ovary 
channelrhodopsin 
caged ligand 
concentrated/concentration 
capsazepine 
complementary RNA 
camphorsulfonic acid 
cysteine 
day(s) 
doublet 
diacyl glycerol 
dichloromethane 
dicarboxyphenylglycine 
dihydroxyphenylglycine 
N,N-diisopropylcarbodiimide 
N,N-diisopropylethylamine 
4-dimethylaminopyridine 
N,N-dimethylformamide 
dimethyl sulfoxide 
deoxyribonucleic acid 
dorsal root ganglion 
electrophile 
for example 
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EC50 
 
Ed. 
ED50 
EDCI 
 
EEG 
EGTA 
EI 
Epi 
equiv. 
ESI 
Et 
ETD 
FBS 
FDA 
GABA 
GIRK 
 
Glu 
GPCR 
h 
HATU 
 
 
HBS 
HBTU 
 
 
HCN1 
 
HEK 
HEPES 
 
HMDS 
 
half maximal effective 
concentration 
editor 
median effective dose 
N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride 
electroencephalogram 
ethylene glycol tetraacetic acid 
electron impact ionization 
epibatidine 
equivalent(s) 
electrospray ionization 
ethyl 
etomidate 
fetal bovine serum 
Food and Drug Administration 
γ-aminobutyric acid 
G-protein-coupled inwardly-
rectifying potassium (channel) 
glutamate 
G-protein-coupled receptor 
hour(s) 
O-(7-azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HEPES buffered saline 
O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluoro- 
phosphate 
hyperpolarization-activated 
cyclic nucleotide-gated channel 1 
human embryonic kidney 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  
hexamethyldisilazane 
 
HPLC 
 
HRMS 
 
i.e. 
I-RTX 
IC50 
 
ICK 
iGluR 
im 
IR 
J 
kB 
KcsA 
 
KV 
LC 
LCE 
LCM 
LED 
LiGluR 
 
LimGluR 
 
LORR 
Ls 
LTG 
m 
m- 
m.p. 
m/z 
Me 
MES 
mGluR 
min 
high-performance liquid 
chromatography 
high resolution mass  
spectrometry 
that is 
iodoresiniferatoxin 
half maximal inhibitory 
concentration 
inhibitor cysteine knot 
ionotropic glutamate receptor 
imidazole 
infrared 
coupling constant 
Boltzmann constant 
potassium crystallographically-
sited activation (channel) 
voltage-gated potassium (channel) 
liquid crystal(s) 
liquid crystal elastomer(s) 
lacosamide 
light-emitting diode 
light-gated ionotropic glutamate 
receptor 
light-gated metabotropic 
glutamate receptor 
loss of righting reflex(es) 
lymnaea stagnalis 
lamotrigine 
multiplet 
meta- 
melting point 
mass to charge ratio 
methyl 
maximum electroshock seizure 
metabotropic glutamate receptor 
minute(s) 
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Ms 
MS 
nAChR 
NaV 
NavAb 
 
Nic 
NMR 
NPC 
NpHR 
 
Nu 
o- 
P 
p- 
PCL 
PEG 
PG 
Ph 
phen 
PIP2 
 
PKC 
PLC 
PPCG-2 
 
ppm 
Pr 
PTL 
py 
q 
quint 
R 
Rf 
RGC 
RNA 
mesyl 
molecular sieves(s) 
nicotinic acetylcholine receptor 
voltage-gated sodium (channel) 
voltage-gated sodium channel 
from arcobacter butzleri 
nicotine 
nuclear magnetic resonance 
4-nitrophenyl chloroformate  
halorhodopsin from 
natronomonas 
nucleophile 
ortho- 
pore 
para- 
photochromic ligand 
polyethylene glycol 
protecting group 
phenyl 
phenantroline 
phosphatidylinositol 4,5-
biphosphate  
protein kinase C 
phospholipase C 
(2S)-2-(2'-phosphono-3'-
phenylcyclopropyl)glycine 
parts per million 
propyl 
photoswitchable tethered ligand 
pyridine 
quartet 
quintet 
organic rest 
retention factor 
retinal ganglion cell 
ribonucleic acid 
rt 
RTX 
s 
s 
SAR 
sat. 
SD 
SEM 
sept 
sext 
SHU 
SM 
T 
t 
TBS 
TCDP 
 
TEA 
Tf 
THF 
TLC 
TM 
TMS 
TP 
TRP 
TRPA 
TRPC 
TRPM 
TRPML 
TRPN 
 
TRPP 
TRPV 
Ts 
TTX 
US 
room temperature 
resiniferatoxin 
second(s) 
singlet 
structure–activity relationship(s) 
saturated 
standard deviation 
standard error of the mean 
septet 
sextet 
scoville heat unit(s) 
starting material 
temperature(s) 
triplet 
tert-butyldimethylsilyl 
1,1’-thiocarbonyldi-2(1H)-
pyridone 
triethylamine 
triflyl 
tetrahydrofuran 
thin layer chromatography 
transmembrane 
tetramethylsilyl/ or -silane 
typical procedure 
transient receptor potential 
TRP ankyrin 
TRP canonical or classical 
TRP melastatin 
TRP mucolipin 
TRP no mechanoreceptor 
potential C 
TRP polycystin 
TRP vanilloid 
tosyl 
tetrodotoxin 
United States 
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UV 
VChR 
Vis 
VSD 
YFP 
ultraviolet 
volvox channelrhodopsin 
visible 
voltage-sensing domain 
yellow fluorescent protein 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Wir stehen selbst enttäuscht und sehn betroffen 
Den Vorhang zu und alle Fragen offen.” 
 
(Bertolt Brecht in Der gute Mensch von Sezuan) 
 
